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Hypothermic machine perfusion (HMP) is a dynamic method of preserving kidneys ex 
vivo with established clinical benefits over static cold storage (SCS). The aim of the 
first part of this thesis was to determine whether HMP influences clinical outcomes in 
the United Kingdom via registry analysis of a national dataset.  
In the second part of this thesis, metabolic changes during HMP are explored using 
nuclear magnetic resonance (NMR) spectroscopy. Chapter 5 describes differences 
between HMP and SCS conditions using 1D 1H NMR in a porcine donation after 
circulatory death (DCD) model. 
Further experimental chapters use perfusion fluid supplemented with the metabolic 
tracer universally labelled [U13-C] glucose to describe de novo aerobic and anaerobic 
metabolism in ex vivo kidneys during HMP. Novel developments in tracer-based NMR 
methodology are discussed early in the thesis. 
In Chapter 6, perfusion fluid supplemented with [U13-C] glucose was used to 
demonstrate several benefits of supplementing perfusion fluid with oxygen during 
HMP in a porcine DCD model.  
In the final section, modified [U13-C] glucose perfusion fluid demonstrated differences 
in de novo metabolism in sub-types of cadaveric kidneys prior to transplantation in a 
clinical study which also aimed to correlate metabolism with clinical outcome.  
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Chapter 1 : Introduction 
Current practice in the field of Renal Transplantation is explored prior to description and 
discussion of hypothermic storage modalities, namely static cold storage and hypothermic 
machine perfusion. Following this, NMR spectroscopy and metabolism are discussed 
independently prior to exploring how NMR plays a role in the field of tracer-based 






Renal Transplantation  
Chronic Kidney Disease and the role of transplantation  
Renal transplantation is considered the optimal treatment for patients with or approaching 
end stage renal disease (ESRD). The necessity to commence renal replacement therapy 
(RRT), including haemodialysis and peritoneal dialysis, defines ESRD (1, 2) with such 
dialysis modalities resulting in negative implications for quality of life (3, 4).  
Renal transplantation confers several significant benefits compared to other forms of RRT 
including improvements to quality of life (5-7). Cohort studies also show a significant 
increase in patient survival (8-11), although such improvement in life expectancy is not 
consistently demonstrated for those over the age of 65 (12, 13). From a health economics 
perspective, renal transplantation is also cost-effective (14, 15) with the cost-benefit of 
renal transplantation estimated at £24,100 for every year a patient has a functioning graft 
compared to dialysis (16).  
The first successful renal transplant was performed in 1954 between monozygotic twins 
(17) with the graft lasting for 8 years. Since then, transplantation outcomes have benefited 
from multiple medical advances (18) including advances in immunosuppression, donation 
from blood group incompatible donors, donation from circulatory death donors and 
laparoscopic donor nephrectomy being established as a surgical technique.  
Cadaveric donation 
Within the National Health Service Blood and Transplantation (NHSBT) framework in the 
United Kingdom, organs for transplantation are retrieved from both live donors and 






donors, formerly known as heart-beating donors, and donation after circulatory death 
(DCD) donors, formerly known as non-heart beating donors.  
The number of renal transplants performed every year continues to increase with 3,596 
renal transplants being performed in the UK between 1st April 2017 and 31st March 2018. 
Recent years have seen a near consistent increase in the number of organs transplanted 
from both DBD and DCD donors, yet despite these increasing numbers, the number of 
patients waiting for a renal transplant remains high. In April 2018, 5,011 patients were on 
the waiting list for a renal transplant (19).  
Significant differences between DBD and DCD donors impact on graft quality, mainly as 
a result of exposure to warm ischaemia inherent to the retrieval of DCD organs but avoided 
in DBD donors.  
DBD donors are those with an identifiable neurological insult causing damage such that 
patients are in an irreversible apnoeic coma, confirmed on brainstem testing. Such 
patients are considered dead from an ethical and legal perspective (20). The retrieval 
operation is commenced with an intact donor circulation. After gaining proximal and distal 
control, major blood vessels are cannulated prior to perfusion of abdominal viscera with 
chilled perfusion fluid and venting of perfusate through the inferior vena cava. Such rapid 
perfusion with chilled fluid, usually <10°C, cools organs whilst also clearing vasculature of 
blood products, thus preventing clots from forming within the organ. The aims of inducing 
hypothermia will be further discussed later in this chapter. The cold ischaemic time (CIT) 
extends from the initiation of cold perfusion until the restoration of warm circulation at the 
time of implantation (20). Figure 1a shows the DBD retrieval processes. DBD organs are 







Figure 1. Schematic representation of the retrieval process for DBD(a) and DCD(b) kidneys showing the differences 
in visceral perfusion, starting with withdrawal of organ support for DCD organs, until graft reperfusion. Following 
withdrawal of organ support, kidneys experience a variable duration of functional warm ischaemic time (fWIT) prior 
to a period of warm ischaemic time (WIT) including a non-touch period prior to the retrieval operation commencing. 
The cold ischaemic time (CIT) for both DBD and DCD organs commences when abdominal viscera are cold 
perfused in-situ.      
DCD organs are sub-classified as defined by the Maastricht criteria (21) which has been 
modified in recent years (22). This updated classification refers to the location of cardiac 
arrest and manner in which asystole is reached. In the UK, nearly all DCD organs are 
retrieved from Maastricht category III donors where circulatory arrest is expected. These 
donors have usually suffered severe irrecoverable neurological insult to the extent where 
further medical intervention is not thought to be of benefit, although such donors do not 
meet the criteria of brainstem death.  
Following cessation of life-supporting treatment, typically inotropic and ventilatory support 
(23), organs are exposed to states of hypoxia and hypoperfusion before the donor reaches 
asystole. In the UK, once death is confirmed, the retrieval operation can commence 
following a five minute mandatory non-touch period although the duration of this period 























varies internationally. The priority during subsequent laparotomy, performed according to 
national protocol (24), is arterial cannulation prior to re-perfusion of organs with chilled 
preservation fluid.  
In countries such as Spain (25), France (26) and USA (27), additional DCD organs may 
be procured from uncontrolled donors in whom circulatory death was not expected but the 
cause of cardiac arrest is deemed to be non-reversible. 
The warm ischaemic time (WIT) is defined as the time without perfusion and oxygen 
elapsed from the beginning of circulatory death to the start of organ perfusion either with 
cold flush or in situ normothermic perfusion (22). However, this does not reflect the period 
in which in situ organs are hypoperfused prior to asystole and therefore still exposed to 
warm ischaemic conditions. The definition of functional WIT (fWIT) makes reference to 
this period; fWIT begins when the systolic blood pressure drops below 50mmHg for at 
least two minutes after withdrawal of life sustaining treatment, continuing until the start of 
organ perfusion. Figure 1b shows the DCD retrieval processes with reference to asystole, 
WIT and fWIT. 
As a result of the initial warm ischaemic insult during procurement, DCD organs are less 
tolerant of longer periods of cold ischaemia (28).This is reflected in the allocation system. 
Currently, one of each pair of DCD kidneys is allocated locally within 4 regions within the 
UK in an attempt to reduce CIT (19). In contrast DBD organs are allocated nationally via 
the NHSBT Kidney Allocation Scheme (19).  
In contrast to organs such as the pancreas and lungs, the kidneys are surprisingly resilient 
to warm ischaemia, influencing the maximum recommended fWIT (30min and 60min vs 






causes a degree of long-term functional damage with less than 20 minutes of warm 
ischaemia resulting in superior outcomes (30-32).  
All cadaveric organs, whether DBD or DCD, vary in terms of quality with several factors 
identified to be independently associated with graft loss, namely donor age, 
cerebrovascular accident as the cause of death, renal insufficiency (serum creatinine >132 
μmol/L) and a history of hypertension (33). These form the criteria for classification of sub-
types of cadaveric donor as expanded criteria donors (ECD), also referred to as marginal 
organs or extended criteria donor organs (34). Organs are classified as ECD if the donor 
is aged over 60 or aged 50 to 59 with at least two of the other three co-morbidities 
(cerebrovascular cause of death, renal insufficiency, hypertension) (33). The simplicity of 
the dichotomous ECD classification benefits its use in the clinical setting to risk stratify 
organs.  
Analysis of UK registry data determined donor risk factors determining graft outcome and 
patient survival following renal transplantation: donor age, history of hypertension, donor 
weight, length of stay in hospital and use of adrenaline. The risk factors were used to 
develop the UK Kidney Donor Risk Index (UK KDRI), a risk stratification tool to predict 
outcome for deceased donor kidneys. In the UK recent years have seen an increase in 
the number of organs transplanted from DCD and higher risk donors defined by UK KDRI 
(19, 35).  
Outcomes following transplantation 
Grafts are subject to a multitude of physiological insults during the transplantation process.  
As a consequence, a graft may exhibit immediate graft function (IGF) or delayed graft 






When a graft fails to function immediately, patients may require dialysis in order to treat 
complications of renal failure, primarily hyperkalaemia, hyperuraemia and fluid overload. 
The requirement for dialysis in the first week following transplantation is most commonly 
used to define delayed graft function (DGF) (36) with the main benefit of this definition 
being the simplicity and relevance to everyday clinical practice.  A minority of patients will 
remain reliant on dialysis due to primary non-function (PNF) of the graft. As with DGF, 
PNF includes non-functioning kidneys due to any cause. Figure 2 shows the development 
of possible outcomes following renal transplantation.  
Long term outcomes following transplantation are described by rates of graft survival and 
patient survival. Graft survival is commonly defined as the time from transplantation until 
commencing renal replacement therapy or death (37).   
 







Consequences of DGF  
In contrast with live donor kidneys which have a DGF rate of 4-9% (39), the rate of DGF 
in cadaveric kidneys is up to 56% (40). The presence of DGF has implications for patient, 
clinician and healthcare provider. In addition to post-operative dialysis sessions, DGF 
precipitates the need for transplant imaging and renal transplant biopsies, increasing the 
duration of hospital admission as a result. Aside from shorter-term concerns, the 
development of DGF is thought to have more serious implications including the 
development of acute rejection, negative implications for long term renal function, graft 
loss (41, 42) and death with a functioning graft (43). However, in DCD kidneys such 
association with longer term consequences does not hold true (44, 45). 
Clinical course following transplantation from cadaveric donors  
In keeping with other populations such as the USA (27), UK registry analyses have shown 
DCD organs experience nearly double the incidence of DGF compared to DBD organs 
with incidences of 48.5% and 24.9% reported respectively (28). This is perhaps 
unsurprising given the warm ischaemic insult these organs are subject to. Despite these 
higher rates of DGF compared to kidneys from DBD donors, DCD kidneys have 
comparable long-term outcomes with similar rates of graft survival and patient survival 
reported (46, 47). The same cannot be said for ECD organs. Such organs are associated 
with a worse long-term outcome regardless of whether the deceased donor sub-type is 
DBD or DCD (28). Despite this, due to the demand for cadaveric organs, the utilisation of 
ECD kidneys is increasing (19).  
Of note, cold ischaemic time in static hypothermic conditions is a major determinant of 






especially in ECD and DCD organs (46). Such detrimental effects are particularly 
detrimental if CIT is prolonged (49). 
Live donor transplantation involves a short CIT compared to cadaveric donation as a result 
of planned, usually same-site transplantation from relatively healthy individuals with low 
rates of DGF as a consequence (39). In contrast, donor factors, the retrieval process and 
logistical complexities in combination with the nature of emergency operating contribute 







Organ Preservation  
Since early work by Carrel and Lindbergh (50) performed even prior to the first successful 
renal transplant there has been interest in ex vivo organ perfusion. Initial interest in 
normothermic (51) and hypothermic methods of organ preservation faded away with the 
advent of static cold storage, a cheap, effective method of storing and transporting organs. 
In this chapter, hypothermic methods of organ preservation, namely static cold storage 
and hypothermic machine perfusion, are discussed. Normothermic perfusion is discussed 
later in Chapter 8.   
Static Cold Storage  
  
 
Figure 3 (a) Insulated box for transport of kidneys with attached tag showing laterality and transport information 
with (b) kidney contained internally surrounded by crushed ice  
Static cold storage (SCS), the most common method of organ preservation worldwide 
(52), involves placing a kidney into an impermeable bag surrounded with chilled 
preservation fluid. This inner bag is surrounded by two bags, each containing chilled 
preservation fluid, then surrounded by ice in an insulated box (Figure 3). As a preservation 







The maintenance of hypothermia at 4°C reduces metabolism and enzyme activity within 
cells. At lower temperatures, freezing can occur resulting in coagulative necrosis on 
reperfusion. Whilst initial organ flush via the renal artery cools the kidney internally, 
subsequent maintenance of hypothermia occurs via heat transfer to surrounding fluid and 
ice.  
In addition to the effects of hypothermia, the efficacy of SCS is in part due to changes 
effected by constituents of the surrounding preservation fluid, some of which attempt to 
counteract the detrimental effects of hypothermia and hypoxia. These effects, namely cell 
swelling, acidosis and the formation of reactive oxygen species (ROS), are key 
components of Ischaemia Reperfusion injury (IRI) discussed in more depth later in the 
introductory chapters.  
Commercially available static cold storage preservation fluids  
The composition of SCS preservation fluids varies widely yet the aims remain the same; 
to maintain intra-cellular fluid composition and prevent cell swelling using a combination 
of impermeants and colloids, to neutralise acidosis using buffers and to scavenge ROS. 
Table 1 shows the composition of key fluids used in SCS.    
The elimination of magnesium from the first described Collins solution (53, 54) lead to the 
development of EuroCollins (EC) solution (55), commonly used in clinical practice for SCS 
until the early 1990’s when it was replaced by Belzer’s University of Wisconsin (UW) 
solution. Collins and EC solutions relied on glucose to maintain a high osmotic pressure 
with a Na+/K+ electrolyte composition reflecting intra-cellular fluid in an attempt to stop 
sodium influx which is responsible for cell swelling. However, the high glucose composition 






impermeant. UW solution, now the commonly used industry gold standard for SCS (56), 
replaced glucose with the impermeants lactobionate and raffinose whilst maintaining a 
similar composition of electrolytes. Notably, UW includes ROS scavengers such as 
glutathione and allopurinol and hydroxyethyl starch (HES) as a colloid to provide 
significant oncotic pressure. However the choice of HES as a colloid within UW solution 
is contentious as it increases viscosity (57), consequently increasing aggregation of red 
blood cells (58, 59) which may contribute to patchy reperfusion patterns in the clinical 
setting (60). An alternative colloid, Polyethylene glycol (PEG), has been suggested as a 
less viscous alternative to HES (61).    
Hyperosmolar citrate (HOC) in contrast, uses mannitol which acts as both a buffer and 
ROS scavenger. HOC also has an electrolyte composition which is dissimilar to both intra 
and extra-cellular fluid.   
Several trials have compared the outcomes following the use of different SCS fluids, with 
one systematic review concluding that EC solution is associated with a higher incidence 
of DGF compared to preservation with UW or histidine-tryptophan-ketoglutarate solution 
(HTK) (62). In the UK, almost organs are transported to transplant centres in SCS 







Table 1. Composition of SCS preservation fluids (table adapted from Maathius et al. 2008(66)). All 
concentrations in mM unless otherwise stated 
 EC (55) HOC (63) UW (64) HTK (65) 
Colloids     
HES (g/l) - - 50 - 
PEG-35 (g/l) - - - - 
     
Impermeants     
Citrate - 80 - - 
Glucose 195 - - - 
Histidine - - - 198 
Lactobionate - - 100 - 
Mannitol - 185 - 38 
Raffinose - - 30 - 
Sucrose - - - - 
     
Buffers     
Citrate - 80 - - 
Histidine - - - 198 
K2HPO4 15 - - - 
KH2PO4 43 - 25 - 
NaHCO3 10 - - - 
NaH2PO4 - - - - 
Na2HPO4 - - - - 
     
Electrolytes     
Calcium - - - 0.0015 
Chloride 15 - 20 32 
Magnesium - - - 4 
Magnesium sulphate - 40 5 - 
Potassium 115 79 120 9 
Sodium 10 84 25 15 
     
ROS Scavengers      
Allopurinol - - 1 - 
Glutathione - - 3 - 
Mannitol - 185 - 38 
Tryptophan - - - 2 
     
Additives     
Adenosine - - 5 - 
Glutamic acid - - - - 
Ketoglutarate - - - 1 







Hypothermic Machine Perfusion  
Hypothermic machine perfusion (HMP) preceded SCS as a means of preserving ex-vivo 
kidneys but due to claims of equivalence of clinical outcome and higher costs, declined in 
usage, prior to its resurgence in the last 2 decades. As the name suggests, the key benefit 
of HMP is similar to SCS in that metabolism and other enzymatic pathways within cells 
are reduced by maintaining hypothermia.  
The simple principle of HMP is the constant recirculation of chilled perfusion fluid through 
the kidney (67) at 1-8°C via a cannulated renal artery. Fluid leaves via the renal vein, 
flowing back into a reservoir. Organ Recovery System’s LifePort® Kidney Transporter 
(Itasca, IL, USA, seen in Figure 4) is a non-oxygenating pressure-controlled device 
whereby a desired systolic pressure is maintained. The RM3 (Waters Medical Systems, 
Birmingham, AL, USA), a flow-controlled system, is another such device which delivers 
HMP. All HMP devices are small and portable with a simple user-friendly interface making 
them ideal for storage of kidneys within and during transport to transplant centres.   
Debate remains over which device to use. One trial observed better short-term functional 
outcomes with less histological damage with Organ Recovery System’s LifePort® Kidney 
Transporter compared to kidneys perfused with Waters RM3 flow-driven system (68). 
Since a NICE technology appraisal in 2009 (69), the LifePort® Kidney Transporter remains 
the only machine recommended for HMP in the UK. Standard clinical practice is to keep 
the systolic pressure constant at 30mmHg (40, 70-72), although some units change 
pressure settings dependant on perfusion parameters (73). This sub-physiological 
pressure is enough to re-instigate flow in capillary beds but not high enough to result in 







Figure 4. Schematic diagram of a LifePort® Kidney Transporter  
Temperature regulation of perfusate at hypothermic temperatures is dependent on heat 
transfer between a reservoir of crushed ice/water and the disposable cartridge which sits 
within it which houses the kidney. The cartridge is covered with an inner sterile and outer 
plastic lid and connects to tubing which passes through the peristaltic pump, filter, 
sampling port, bubble chamber and pressure sensor. Measurements are provided for flow, 
resistance and actual pressure within the perfusion circuit. Figure 4 shows a schematic 
diagram showing the key components.   
Two versions of the LifePort® Kidney Transporter are in clinical use with the newer version 
(1.1) updated with a few key features. The LifePort® 1.0 measures perfusate temperature 
at the interface between cartridge and ice reservoir, although this not the true temperature 
of circulating perfusate. The updated LifePort® 1.1 measures the temperature of the 
circulating perfusate itself. Added benefits include a more user-friendly interface enabling 
easier retrieval of perfusion parameters onto USB device and the measurement of systolic 
and diastolic pressure readings in the in-flow limb. Both devices are small and contains 4 


























Figure 5. A range of portable devices commonly used for HMP: LifePort® Kidney Transporter 1.0 (a) and 1.1 (b), 
Kidney Assist, Organ Assist (c), Waters RM3 (d), and Waters Waves® (e). 
 
Oxygenating HMP devices  
The LifePort® Kidney Transporter v1.0 (Organ Recovery Systems, Itasca, IL, USA) and 
RM3 (Waters Medical Systems, Birmingham, AL, USA) featured in earlier research into 
















base for optimisation of HMP. Newer machines such as the Waves® preservation system 
(Waters Medical System, LLC; Rochester, MN, USA) and the Kidney Assist-transport 
(Organ Assist, Groningen, the Netherlands) incorporate a means of oxygenating 
circulating perfusion fluid into the HMP circuit.  
Preservation fluids used for HMP  
The solution most commonly used for HMP was formulated by Belzer and Southard at the 
University of Wisconsin (75). The solution, University of Wisconsin Machine Preservation 
Solution (UW-MPS), is a gluconate based solution incorporating the complex starch 
molecule HES similar to UW. The solution has a lower potassium content than UW, as the 
sodium/potassium ratio is reversed, in an attempt to reduce vasoconstriction. Notably UW-
MPS includes 10mM glucose.   
The constituents of UW-MPS are shown in Table 2. The perfusion fluid is available 
commercially as Belzer MPS® solution (Bridge to Life (Europe) ltd, London, UK) and 
Kidney Perfusion Solution (KPS-1, Organ Recovery Systems, Itasca, IL, USA). 
 Table 2. Constituents of UW-MPS (75) 
Constituent Amount in 1L (g) Concentration (mM) 
Calcium chloride (dehydrate) 0.068 0.5 
Sodium hydroxide 0.70 n/a 
HEPES (free acid) 2.38 10 
Potassium phosphate (monobasic) 3.4 25 
Mannitol (USP) 5.4 30 
Glucose, beta D (+) 1.80 10 
Sodium Gluconate 17.45  80 
Magnesium Gluconate (D (-) gluconic acid, 
hemimagnesium salt) 1.13 5 
Ribose, D (-) 0.75 5 
Hydroxyethyl starch (HES) 50.0 n/a 
Glutathione (reduced form) 0.92 3 
Adenine (free base) 0.68  5 






Other solutions have been used during machine perfusion such as HTK (76), UW solution 
(77) and even cell culture medium (78) with varying results but UW-MPS is the standard, 
accepted perfusion fluid used in clinical practice. 
Mechanisms of action of HMP  
Early work on hypothermic machine perfusion focused on its functional benefits without 
full understanding of the mechanisms of action (50). However, such mechanisms are now 
better understood (79, 80).  
Considering flow dynamics, HMP acts to reverse the vasospasm caused by hypothermia. 
Prior to initiating HMP there is an absence of flow in capillary beds with stasis of initial cold 
flush perfusion fluid. Increasing recruitment of these glomerular capillary beds with 
subsequent amelioration of vasospasm is likely to be the underlying mechanism by which 
intra-renal resistance decreases and flow increases (80). However, the presence of flow 
alone is not the only method by which flow dynamics change during HMP; the low 
potassium content of UW-MPS avoids the vasoconstriction seen in SCS solutions such 
as UW (81).  
Figure 6 shows a typical graph of changes to flow and resistance parameters over the 
duration of a period of HMP. The majority of these changes to perfusion parameters 







Figure 6. Typical changes in flow (a) and resistance (b) parameters during HMP using the LifePort Kidney 
Transporter.  
On a cellular level, HMP is beneficial to both vasculature and renal parenchyma. Pulsatile 
flow induces shear stress and has been proposed to decrease endothelial damage 
through upregulation of the endothelial protective gene Kruppel-like factor 2 (KLF-2) (82, 
83). KLF-2 is critical for the production of vasodilators including nitric oxide and the 
expression of anti-thrombogenic genes whilst potentially inhibiting pro-inflammatory 
responses (84-86). Vasorelaxation, proposed to be due to greater endothelial nitric oxide 
synthase (eNOS) phosphorylation has been observed in the HMP setting (87).  
Increased cortical microcirculation on re-perfusion decreases the exposure of those areas 
to warm ischaemia thus kidneys with an improved circulation should have a lower 
incidence of DGF following implantation as a result of more uniform perfusion. This is 
reflected in the observation that renal resistance at the end of HMP is a risk factor for 






It is not only the presence of perfusion but also the nature of the perfusion which may 
promote benefit (89-91). The simulated arterial waveform during pulsatile perfusion may 
facilitate the re-opening of capillary beds collapsed during cold storage. In doing so, low 
flow rates continually wash out metabolic waste products, such as lactate, and by-products 
of cellular damage from the kidney. Buffers within UW-MPS prevention of the 
accumulation of lactate serve to maintain homeostatic pH levels within the kidney (75).  
Perfusion fluid is circulated via rollator pump at low sub-physiological pressures 
(<30mmHg), much below the range of pressures in which ultra-filtration occurs. 
Conventional urine production does not occur although it is likely that the collecting system 
receives a small amount of fluid from upstream parts of the nephron as a consequence of 
damage to Bowman’s capsule. However, low perfusion pressures are beneficial during 
HMP as they result in a lower activation of Von Willebrand factor, less damage to the 
proximal tubule and improved cortical microcirculation resulting in better functional 
recovery after transplantation (92). Unlike normothermic perfusion, Urine production 
cannot be used to assess graft quality during HMP.  
For every 10°C reduction in temperature, metabolic rates are thought to halve (93). Hence 
hypothermia reduces metabolism, yet it does not cease completely. The extent to which 
metabolic pathways remain active during HMP has not been fully described although one 
would suspect it is anaerobic pathways that remain active given the largely hypoxic 
hypothermic environment of HMP. The 10mM glucose is readily available to cells as a 
metabolic substrate as it passes through vascular beds during HMP with evidence of both 
anaerobic and aerobic metabolism such that HMP kidneys consume more oxygen and 
restore ATP levels compared to SCS kidneys (94). Metabolism during HMP is further 






Opportunities for graft assessment and optimisation  
A major advantage of HMP over static storage methods is the potential to assess organ 
viability and potentially predict post-transplant outcomes. Perfusion parameters, perfusate 
biomarkers and histological scoring systems have all been evaluated as markers of 
outcome.  
Perfusate biomarkers  
Aside from a plausible biological basis, properties of a good biomarker include  sensitivity 
and specificity for a particular outcome. Identifying such a biomarker for use during HMP 
would provide a multitude of benefits including preparation and counselling for DGF, and 
information regarding patient and graft function and longevity. With the advent of 
technologies such as oxygenated HMP and normothermic perfusion as a means of 
potentially reconditioning organs, the identification of targets which would benefit from 
such reconditioning would be beneficial.  
Substances expelled from functioning cells or products of cell damage are washed out 
from the kidney during HMP. Hence the circulating perfusate can be readily sampled with 
changes in composition reflecting both cell damage and ongoing cell metabolism. Thus, 
the sampling port of the LifePort® offers a non-invasive means of monitoring changes in 
perfusate composition.  
In recent years a weak association has been demonstrated between several biomarkers 
sampled during HMP and post-transplantation outcome (95, 96) demonstrating potential 
clinical utility. However, no one marker has or can be used in isolation for such purpose 
reflecting a lack of specificity and sensitivity of any one detrimental biological pathway in 






Biomarkers of note showing promise are lactate dehydrogenase (LDH) (96), glutathione 
s transferase (GST) (97) and aspartate transaminase (AST) (96). Their role is further 
discussed in Chapter 7.   
Perfusion parameters 
Given that HMP recruits capillary beds and causes vasorelaxation with beneficial 
reperfusion patterns, it would seem logical that renal resistance (RR) should decline over 
the duration of HMP. Should renal resistance start and remain high, one would speculate 
that irreversible ischaemic damage has occurred, therefore renal resistance should 
correlate with post-transplant function.     
Several papers have assessed the prognostic significance of renal resistance during 
HMP. Two studies by Jochmans et al (88) and de Vries et al (98) are commonly quoted 
as showing an association between renal resistance and DGF, PNF and 1-year graft 
survival. However statistical analyses of the study populations showed only a limited 
predictive value. Hence RR should not be used to discard kidneys as described by other 
groups (99) where conclusions drawn are subject to bias due to the discard rates of those 
organs with a higher renal resistance. 
Cost effectiveness of HMP  
Particularly in the current economic climate from a health economics perspective, 
demonstration of clinical benefit must be off-set against the cost of HMP. Interestingly the 
National Institute for Health and Care Excellence guidance published in January 2009 (69) 
was based on evidence preceding the full report of the Machine Preservation Trial and 
other research since then. The guidance states kidney preservation with the LifePort® 






storage with UW solution. Of the 2 cost-benefit analyses cited, the UK based analysis 
preceded the main evidence base of HMP (38).  
Following the longer-term follow-up data of the Machine Preservation Trial, an 
accompanying cost-benefit analysis (100) determined there were major cost benefits in 
addition to the gain in life-years and quality adjusted life years (QALYs). Similar 
conclusions were drawn from an analysis observing the outcomes of ECD kidneys in a 
single centre in Spain (101). Perhaps in the wake of a lack of positive finding in UK-based 
HMP trials, a cost-benefit analysis of HMP in the UK has not been repeated.  
Outcomes of HMP vs SCS  
The clinical benefits of HMP over SCS have been analysed using case-control studies, 
single centre observational studies, registry analyses, randomised control trials (40, 70) 
and meta-analyses (102, 103). Of the evidence base, a handful of well-designed RCTs 
provide compelling evidence for the short-term benefits of HMP with longer term benefits 
in some sub-populations. 
The Machine Preservation Trial, often quoted as the evidence for the benefits of HMP over 
SCS, was performed within the European Transplant zone observing the differences in 
the outcomes of 336 pairs of kidneys retrieved from both DBD and DCD donors. 
Importantly, HMP was initiated by a perfusionist at the time of retrieval. The trial itself 
recruited subjects over a one year period ending in November 2006 before being reported 
in 2009 (70), with a further follow-up commentary published in 2012 (71).   
Donor pairs of kidneys were randomised to receive HMP or SCS prior to implantation into 






secondary endpoints included patient and graft survival. The Machine Preservation Trial 
observed a statistically significant difference (p=0.03) in the incidence of delayed graft 
function in kidneys undergoing hypothermic machine perfusion (n=77, 22.9%) compared 
with static cold storage (n=101, 30.1%). For DBD kidneys, HMP was associated with 
improved graft survival at 1 year (hazard ratio of 0.52, p=0.03).   
Of the 336 pairs of kidneys included in the study, DCD kidneys made up an eighth of the 
sample size (12.5%); machine perfusion was associated with lower rates of DGF for DCD 
kidneys but it was not associated with improved 3-year graft survival. The study was not 
without criticism. For example, kidneys with multiple arteries, often rendering HMP difficult, 
are known to be associated with inferior graft outcomes (104). Organs with such anatomy 
were allocated to the SCS arm in the Machine Preservation Trial which may have 
contributed to the observed differences.  
An analysis of the outcomes from all DCD kidneys in Belgium and the Netherlands which 
were part of the Machine Preservation Trial showed HMP significantly reduced the rate of 
DGF compared to SCS (69.5% vs 53.7%) but did not improve patient or graft survival. 
Interestingly the study did show some functional improvement with HMP; creatinine 
clearance was improved 1 month post-op compared to SCS kidneys (105).  
A randomised controlled trial funded by the NHSBT was conducted in DCD (Maastricht 
category 3) donors within the UK between August 2006 and October 2007 (40). DCD 
donors were selected due to higher rates of DGF. In contrast to the Eurozone study, 
clinicians had the choice of when to initiate HMP following organ retrieval.  
Results from this UK based RCT contrasted with the Eurozone transplant study. The study 






between the rate of delayed graft function in HMP kidneys compared with those in SCS 
(58% vs 56%). Not all HMP was commenced at the time of retrieval, although the authors 
did not find a difference between those kidneys which did and did not undergo HMP from 
source.  
The lack of significant difference may be attributed to a small sample size, but may also 
have been in part due to the delay in initiating HMP, plausible given the aforementioned 
mechanisms of action of HMP. Within the study however, there was no difference in 
outcome between those kidneys where HMP was initiated at retrieval or at arrival in 
transplant centre. The contrasting evidence for the European and UK experiences is 
interesting, particularly in the context of differences in timing of initiation of HMP. Timing 
of initiation is further discussed in Chapter 4.  
Results of the Machine Preservation Trial suggest that HMP is most beneficial for ECD 
kidneys with a lower rate of DGF (106), lower rate of PNF and improved 1-year and 3-
year graft survival compared with ECD kidneys stored in static cold storage.  
Two meta-analyses collating the results of the above RCTs concluded that kidneys 
preserved with HMP had a lower incidence of DGF yet no consistent association with 1-
year graft survival was observed (102, 103).   
Concluding remarks 
The last decade has seen a resurgence in interest in hypothermic machine perfusion with 








Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance (NMR) Spectroscopy is used to analyse the abundance and 
structure of organic compounds. In this section, key concepts relating to NMR 
spectroscopy are discussed including spin, chemical shift, j-coupling, the NMR 
spectrometer and pulse sequences.    
Basic NMR concepts   
Spin and the Boltzmann distribution  
NMR spectroscopy takes advantage of the magnetic properties of certain nuclei in order 
to study their physical and chemical characteristics thereby determining the structure of 
molecules which they contribute to (107).  
Isotopes of an element share the same number of protons, defining the atomic number of 
that element. Differing numbers of neutrons give rise to different isotopes of an element, 
with the summation of nucleons giving rise to the atomic mass of that element’s isotope. 
For example, the isotopes of carbon include 12C, 13C and 14C. The latter isotope is 
radioactive whilst 12C and 13C are stable isotopes which are considered in this thesis.  
Nuclei of these isotopes possess a quantum mechanical property known as ‘spin’ which 
determines whether they are observable by NMR spectroscopy or not. Nuclei can have 
zero spin, such as 12C, integer spin, such as 14N, and half-integer spin such as 1H or 13C. 
Spin ½ nuclei occupy one of two possible spin states. Most biologically relevant nuclei 
have stable (i.e. non-radioactive) spin ½ isotopes (e.g. 1H, 13C, 15N, 31P). The magnetic 
moment of these nuclei is a consequence of nuclear mass, charge and spin; this magnetic 






In the absence of an external magnetic field, the magnetic moment of nuclei usually does 
not possess an orientational preference (Figure 7a). However, when nuclei inside a 
sample are exposed to an external, oriented, static magnetic field (B0), as depicted in 
Figure 7b, nuclei with spin ½ orientate themselves either with or against the direction of 
the external magnetic field.   
 
Figure 7. The orientation of the magnetic moments of nuclei in a magnetic field before and after the 
application of an external magnetic field (B0) 
Considering energy states, nuclei can adopt a high energy state in an anti-parallel (b) 
direction to the external magnetic field or a low energy state which is parallel to the 
external magnetic field (a) (Figure 8).  
 
 






The proportion of nuclei occupying high and low energy states is described by the 




Equation 1. The Boltzmann distribution. N1 and N2 represent the number 
of nuclei in spin up (a) and spin down (b) configurations. ΔE is the 
difference in energy between the two states, k is the Boltzmann constant 
(1.381 x 10-23 joules/K) and T is the absolute temperature in Kelvin.   
At high temperatures, almost equal numbers of nuclei occupy the high and low energy 
state respectively. At low temperatures, a higher proportion of nuclei occupy low energy 
state.  
Spin is an angular momentum around the axis of the external magnetic field. The Larmor 
frequency is the term used to describe the frequency of precession- the frequency at which 
the magnetic moment precesses around the unique axis of the external magnetic field. 
The precession frequency ($)) of a nucleus is proportional to the strength of the magnetic 
field (B0) and the gyromagnetic ratio (γ; a constant physical property for each isotope) as 




Equation 2. Calculation of the Lamor frequency/ frequency of precession (!!) of a nucleus. B0 
represents the strength of the magnetic field. γ represents the gyromagnetic ratio.   
Therefore, for a given magnetic field strength, the magnitude of the gyromagnetic ratio 






Chemical shift  
In order to understand how 1H NMR spectra differentiate molecules, it is necessary to 
understand two key concepts; shielding of the nucleus by the surrounding electron cloud, 
leading to what is known as chemical shift, and scalar coupling between different nuclei 
in the same molecule (also known as J-coupling) (107, 108).  
Given Equation 2, it would seem that all protons in a molecule have the same resonance 
frequency. However, the magnetic field experienced by an individual nucleus is a 
combination of both the externally applied field B0 and a small magnetic field produced by 
their electrons surrounding the nucleus. The net magnetic field (Blocal) experienced by a 
nucleus is given by the equation below where * denotes a shielding constant.   
)*+,-* = ))(1 − *) 
Equation 3. Calculation of the local magnetic field (Blocal) experienced by a nucleus 
where " denotes a shielding constant and B0 represents the external magnetic field.    
A proton experiences less of the external magnetic field as a result of orbiting electrons 
and is therefore considered to be shielded from the effects of the external magnetic field. 
Electronegative groups attached to a carbon atom within a molecule draw electrons away 
from protons. Protons are then more exposed to the external magnetic field hence are 
said to be de-shielded. Thus, chemically distinct nuclei in a molecule all experience a 
slightly different external magnetic field strength due to differences in local chemistry.  
The frequency at which a nucleus resonates is proportional to the experienced field 
strength. It should also be noted that differences in frequency are proportional to the 
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Equation 4. Calculation of the Lamor frequency (!) using B0 (the external 
magnetic field), " (a shielding constant) and γ (the gyromagnetic ratio).  
According to the above equation, the frequency difference between two signals in the 
spectrum is proportional to the strength of the external magnetic field. For example, if two 
signals from one molecule were 500 Hz apart on a 11.7 T magnet, they would be 900 Hz 
apart from each other on a 21.4 T magnet. Thus, there is a requirement for an x axis where 
corresponding signals from the same molecule resonate at the same ‘frequency’ 
independent of the strength of the external magnetic field.  
The chemical shift axis is such a scale in which corresponding signals remain at the same 
position independent of external magnetic field strength. By referencing the absolute 
resonance frequency of a nucleus to the absolute resonance frequency of a reference 
molecule and by dividing that frequency difference by the absolute resonance frequency 
of the reference compound, the dependency on the external magnetic field strength is 
eliminated (Equation 5). The resultant chemical shift is calculated in parts per million (ppm) 
relative to a reference molecule. 
 
Chemical shift = (frequency of signal – frequency of reference) x 106 
                    frequency of reference 
 
Equation 5. Calculation of chemical shift. 
A reference molecule must be chemically inert, such that it does not react with compounds 
within the sample, in addition to displaying simple, predictable signals which can be easily 
attributed on NMR spectra. The molecule 4,4-dimethyl-4-silapentane-1-sulfonic acid 






d6-DSS results in a high intensity proton signal which defines the origin of the chemical 
shift axis.  
 
 
Figure 9. d6-DSS (4,4-dimethyl-4-silapentane-1-
sulfonic acid).  
Figure 10 shows the consequences of shielding on chemical shift.  
 
 
Figure 10. The effect of shielding on chemical shift. 
The presence of the same electronegative group on a neighbouring carbon has a lesser 
effect on the magnetic field experienced by that proton as it is further away, thus the 
chemical shift experienced is less. Figure 11 shows the resultant chemical shift 

















within the molecule. If more than one electronegative group acts to draw electrons away 
from a proton, the effect is cumulative. 
 
Figure 11. The effect of neighbouring electronegative groups on observed chemical shift. Blue boxes 
denote the position at which signals for protons appear on the chemical shift axis according to the 









Two adjacent nuclei in a magnetic field which both possess the property of spin will 
interact. The interaction, or coupling, recognises the change in magnetic field a nucleus 
experiences due the spin state of a nearby nucleus. Two types of coupling exist: J-
coupling (or scalar coupling) and dipolar coupling (or magnetic dipole-dipole interaction), 
although only J-coupling will be explained here as dipolar coupling is not relevant to the 
work presented in this thesis (107, 108).  
J-coupling is mediated via the electrons of chemical bonds, not by the spatial distance 
between the interacting nuclei. NMR active nuclei, in this case protons, exert the biggest 
influence when they are three chemical bonds or less away. Most couplings observed in 
1D-1H NMR spectra are either vicinal (i.e. protons attached to neighbouring carbon atoms 
or three chemical bonds apart from each other) or geminal (i.e. protons attached to the 
same carbon atom or two chemical bonds apart from each other) in the absence of 13C 
labelling. 
A neighbouring proton increases or decreases the net magnetisation experienced by a 
group dependant on whether this neighbouring proton is in the a or b configuration. As a 
single neighbouring proton can exist in either a or b state, but approximately 1016 
molecules contribute to the same signal in the spectrum where the protons are almost 
equally distributed between a and b state, the signal of a group is split into two peaks due 
to the effect of that neighbouring proton with equal areas under each peak (1:1). The 
splitting of the signal for a group with two equivalent neighbouring protons is determined 
by the four combinations of spin states (aa, ab, ba and bb) of those two protons which 
results in three unique combinations. The areas under the three resultant peaks therefore 






equivalent neighbouring protons is split into four peaks with areas under each peak in the 
ratio 1:3:3:1.  
A signal with n number of equivalent neighbouring protons is split into (n+1) peaks with 
intensities according a Pascal triangle (Figure 12). Complex splitting patterns are 
encountered where neighbouring protons are non-equivalent. The distance between 
peaks in a signal which has been split is determined by the J-coupling constant, measured 
in Hz, as J-coupling is independent of the external magnetic field strength. The J-coupling 
constant is a measure of the interaction between a pair of non-zero net spin nuclei.  
Regarding J-coupling nomenclature, the number of bonds between the two nuclei are 
usually indicated as leading suffix, e.g. 3JHH for a 1H-1H coupling three chemical bonds 
apart. Signal multiplets in 1D-1H NMR spectra are usually dominated by 2JHH and 3JHH, in 
the absence of 13C enrichment, as the coupling constants are typically in the range of 4-
15Hz. If 13C nuclei are present in the sample, the 1JCH coupling will usually be the largest 
coupling with typical values between 120 and 165Hz. 
 
 







Basic NMR concepts applied to 1D spectra of lactate  
Chemical shift, splitting patterns and area under each signal are characterised by the 
chemical environment of NMR active nuclei. Therefore, NMR spectra of unknown 
compounds can be utilised to derive structural information about the molecule under 
investigation. Let us apply the aforementioned concepts to the 1D-1H NMR spectra 
acquired of lactate which is annotated in Figure 13. The proton attached to the second of 
three carbons is de-shielded due to the adjacent hydroxyl group therefore experiences a 
larger chemical shift. The signal of C(2) seen at 4.10 ppm is split into four resonance lines 
(quartet) due to the combination of spin states of the three protons in the adjacent methyl 
group. The signal at 1.32 for the methyl group, or C(3), is split into two peaks (doublet) 
due to the two possible spin states of the adjacent proton attached to C(2). Signals from 
the oxygen bound protons are usually not observed as they are in fast exchange with the 
solvent, the resonance of which will be suppressed. 
 








The NMR Spectrometer 
The Henry Wellcome Building at the University of Birmingham houses several NMR 
spectrometers varying in magnetic field strength and probe type. An NMR spectrometer 
is constructed from three components: The NMR magnet, the probe and the spectrometer 
console (107). 
NMR Magnet 
The homogenous magnetic field is produced by a large superconducting electromagnet. 
In order to reach the very large magnetic field strengths required for NMR, the magnet coil 
needs to be cooled down to temperatures below 6K, which is usually achieved by placing 
the magnet coil into a bath of liquid helium (T = 4.2K). At these temperatures the coil 
material becomes superconducting and hence electrical resistance of the coil is reduced 
to zero. Therefore, the current in the coil continues to flow in a closed system without need 
for further electrical power after the initial charge.  
However, the field generated by such a large magnet is not homogenous enough and as 
a result several smaller coils known as shim coils surround the sample in order to generate 
the field homogeneity required. The combination of the larger magnetic field and these 
smaller shim coils, when calibrated, results in a homogenous magnetic field (field 
disturbances < 1:6*108) corresponding to a linewidth less than 1Hz.  
Probe  
The probe is the part of the spectrometer closest to the sample. The probe in itself consists 
of several parts. The most important parts of a probe are the transmitter and receiver coils. 






sample, whereas the receiver coil, usually the same as of the transmitter coils, detects 
radiofrequency emitted by the sample. In order to maximise the signal-to-noise ratio in the 
resulting NMR spectrum, the receiver coil is positioned as close to the sample as possible.  
Calibration of the probe involves tuning, the process in which the circuit resonates at the 
Larmor frequency, and matching, the process by which the impedance of the probe is 
adjusted to match that of the transmitter. The probes used in this thesis also contained a 
pre-amplifier cooled down to 25K to minimise spectral noise originating from electronic 
noise in the console. On Bruker spectrometers, this type of probe is known as a 
CryoProbe™. 
Spectrometer Console  
Following application of a pulse sequence, nuclei return to equilibrium and in doing so, 
release absorbed energy thereby re-orientating themselves in B0, returning to the 
Boltzmann distribution regarding occupancy of alpha and beta states. It is during this time 
where the radiofrequency signals generated by the change in nuclei orientation are 
recorded, as a consequence of change in transverse magnetisation. In the acquisition 
phase of the pulse sequence, transient oscillations in the receiver probe are the basis of 
an analogue signal known as free induction decay (FID).   
The spectrometer console contains all the electronic components to generate 
radiofrequencies, receiving the signals from the probe and digitising the analogue signal. 
The generated FID is further amplified and sent to the acquisition computer for data 
processing. The FID is converted from the time domain to the frequency domain via 






The console also contains microcontroller and real-time computers which allow the 
execution of pulse sequences and therefore the performance of various NMR 
experiments. In the following section we will discuss different pulse sequences used 











In order to understand the types of pulse sequence used in this thesis it is necessary to 
discuss a few key concepts relating to NMR, namely the vector model and the rotating 
frame concept (109, 110).   
The vector model, chemical shift and quadrature detection  
In simple terms, NMR spectrometers first orientate nuclei in the direction of a strong 
magnetic field prior to the transient application of a smaller oscillating magnetic field in the 
form of a radiofrequency (RF) pulse. The net magnetisation can be described as a vector 
in terms of the x, y and z-axes.  
 
Figure 14. The effect of application of a 90-degree pulse along the y-axis on 
nuclei in the equilibrium state where M0 denotes the net magnetisation, B0 shows 
the direction of the external magnetic field, B1 represents a pulse which results in 
a magnetic field causing an element of transverse magnetisation  
The vector model refers to the changes in net magnetisation experienced as a result of 
the application of an RF pulse. The model assumes that the net magnetisation behaves 
like a classical, not quantum mechanical, magnetic field vector and can therefore be 
described by the Bloch equations (107). Nuclei exposed to an external magnetic field B0 






to the main axis of the external magnetic field  (Figure 14a). In the equilibrium state, nuclei 
do not possess any net transverse magnetisation, which occurs along the x- or y-axis in 
the vector model.  
The application of a radiofrequency pulse at the Larmor frequency along the y-axis 
changes the net magnetisation resulting in a transverse component of magnetisation seen 
in Figure 14b. This angle of change of the magnetisation vector is dependent on the 
direction, length and duration of RF pulse applied.  
The concept of rotating frame is necessary to simplify the description of changes in net 
magnetisation during the application of RF pulses or delays within pulse sequences. This 
is achieved by viewing the above vector model from the top of the z-axis much like an 
observation deck rotating in the xy plane at the Larmor frequency (see Figure 15a). The 
effect of an RF pulse on net magnetisation is visualised relative to the Lamor frequency in 
one or two axes. Figure 15a shows observation from the y-axis.    
Despite consideration of precession at the Larmor frequency using the rotating frame 
concept, net magnetization continues to rotate due to chemical shift dispersion of 
resonance frequencies. The transmitter frequency remains in the middle of the spectrum, 
an apparent frequency of zero, therefore discrimination is required between positive and 
negative frequencies.  
The concept of quadrature detection is used to describe detection of signals along two 
axes in the xy plane in order to differentiate between positive and negative frequencies. 
In Figure 15a, both rotations (positive and negative frequencies) will generate identical 
signals. Therefore, FT will generate the same spectrum for both as shown in Figure 15b. 






generate the same signal again but as they start on opposite sides, FT will lead to a 
spectrum as displayed in Figure 15d. Summation of both spectra leads to frequency 




Figure 15. Pictoral representation of quadrature detection showing the effects of observation 
along x and y axes resulting in output spectra (b) and (d) following fourier transformation, prior 
to frequency discrimination. This is achieved as negative frequencies are eliminated following 
summation of (b) and (d) as shown in panel (e) 
J-coupling occurs in addition to chemical shift. The transmitter frequency remains centred 
on the chemical shift in question (i.e. the centre of the multiplet generated by the coupled 
spin system). Initially after a 90-degree pulse, net magnetization vectors can be 
considered in the rotating frame shown in Figure 16, similar to Figure 15. Hence two 
signals are generated displayed on a spectrum separated by the J coupling constant.   
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Figure 16. Representation of J-coupling showing in-phase (b) and anti-phase (d) 
magnetisation. J represents the J-coupling constant. The multiplet generated is centred 
around the chemical shift in question (w0) 
Initially, after spin excitation through a RF pulse, magnetic moments from both spins with 
neighbouring spins in alpha or beta state, point in the same direction. However, because 
of their difference in rotation frequency, if the spins are allowed to develop their J-coupling, 
at some point magnetisation from spins next to neighbouring spins in alpha state will point 
in the opposite direction compared to the magnetisation originating from spins next to 
neighbouring spins in beta state. The former state is known as in-phase magnetisation, 
while the latter represents anti-phase magnetisation. Because the two coupled spins are 
in a coherent state when they are in anti-phase state, this state can be used to transfer 
magnetisation in pulse sequences such as the 1H,13C-HSQC pulse sequence. Figure 16a 
represents in-phase magnetisation whilst Figure 16b represents anti-phase magnetisation 
which can be used to transfer magnetisation in pulse sequences such as HSQC.   
Characteristics of pulses  
The characteristics of a pulse include length, strength, frequency, shape and axis (109, 
110).  Pulse notation thus describes the effect of the applied magnetic field strength (gB1 
[Hz]), time the pulse is applied for (µs -ms) and the axis in which the pulse is applied at 
the frequency (⍵). The most commonly used pulse is a 90-degree pulse (p/2) which 
results in transferring magnetisation from the z axis into the xy plane or vice versa. A 180-






A hard pulse (a pulse with a very large B1 field strength), usually square in shape, acts to 
indiscriminately excite a large bandwidth of frequencies using a high-power pulse applied 
for a short amount of time. A soft pulse (a pulse with a much smaller B1 field strength) acts 
to excite only a small bandwidth of frequencies, as narrow as a single peak, classically 
using lower power pulses are applied for a longer duration to achieve the same rotation 
angle. Adiabatic pulses, a type of shaped pulse, are able to excite a much larger 
bandwidth than hard pulses.  
Decoupling  
Decoupling simplifies an NMR spectrum as signal splitting due to J-coupling is not 
observed. This is of particular importance in spectra where signals from 1H nuclei are split 
due to 13C-1H coupling. Decoupling is of particular use in heteronuclear single-quantum 
coherence (HSQC) spectra which selectively observe protons bound to 13C atoms. 
Without decoupling, in HSQC spectra, every signal would be observed twice leading to 
crowded spectra. Decoupling removes signal splitting, aiding interpretation of spectra.  
1D pulse sequences   
1D-1H NMR spectroscopy is the most commonly used high resolution experiment due to 
its simplicity, speed and sensitivity. Chemical shift is used to define the presence of 
different functional groups whilst integration of proton signals provides information on the 
number of protons within each signal. Due to overlap of signals there is frequently 
uncertainty relating to the identity of molecules and concentrations of those molecules 
within the sample.   
The simplest 1D-1H NMR experiment comprises of a preparation period and a detection 






pulse. This is followed by the acquisition period in which FID occurs as the magnetisation 
of the nucleus returns to equilibrium. In reality, several transients are acquired of a sample 
in order to enhance the signal to noise ratio. While true signals accumulate proportionally 
to the number of transients, noise signals only accumulate proportionally to the square 
root of the number of transients. Therefore, the overall signal to noise ratio in a NMR 
spectrum increases with the square root of the number of transients (e.g. the signal to 
noise ratio will double if the number of transients is quadrupled).  
The pulse sequence starts with a recycling delay followed by a 90 degree pulse (p/2) prior 
to acquisition time (see Figure 17). In practice, 2.2 seconds is a typical value for the time 
it takes to acquire the FID. Typical relaxation delays are 4-5 seconds, so that the total time 
it takes to acquire one transient (also known as the repetition time) is about 7 seconds. 
 
Figure 17. 1D 1H NMR experiment with a relaxation period 
prior to a 90 degree pulse depicted by a black rectangle. Blue 
arrow depicts transfer of magnetization subsequent to 
acquisition of an FID. 
 
Figure 18. The NOESY pulse sequence incorporates a period of pre-saturation 
prior to three 90 degree pulses.  
The high concentration of protons within water (approximately 110 mol/L) relative to that 
of any metabolite within the sample (typically 50 µM – 5 mM) warrants the signal from the 
solvent protons to be suppressed. Several methods for solvent suppression exist, the 






the frequency of the solvent resonance, known as pre-saturation. The 1D-1H NMR 
experiments in this thesis were acquired with a slightly modified pulse sequence known 
as NOESY pre-saturation which results in an improved saturation of the water resonance 
over a simple 1D pre-saturation pulse sequence.  
In the NOESY pulse sequence (Figure 18), pre-saturation is followed by a sequence of 
three 90 degree pulses, collectively known as a 90 degree composite pulse which leads 
to more even excitation across the entire spectrum than a single 90 degree pulse and 
enhances water suppression. It should be noted that while this pulse sequence can be 
used to transfer magnetisation between different protons in the same molecule, this 
requires the mixing time (tm in the pulse sequence shown above) to be on the order of 
450ms for small molecules. If the pulse sequence is used for enhanced water suppression, 
the mixing time is reduced to 10ms, so that magnetisation transfer via the nuclear 
Overhauser enhancement (NOE) is negligible. 
A 1D spectrum targeting 13C nuclei would suffer from a low signal to noise ratio due to the 
low abundance and low gyromagnetic ratio of this nucleus.  
2D pulse sequences  
2D NMR serves to give extra information that cannot be displayed on a single 1D spectrum 
by introducing an independent second frequency axis. A series of 1D spectra is acquired 
with a systematic variation of one parameter, usually a time delay during the pulse 
sequence. The introduction of a second dimension helps with signal overlap by increasing 
the signal dispersion. This aids signal assignment reducing ambiguity when assigning 






Types of 2D NMR experiments include correlation experiments and Overhauser effect 
experiments. Correlation experiments rely on J-coupling between nuclei connected by 
chemical bonds. The two sub-types of correlation experiments are termed either 
homonuclear when the two nuclei used to create the two different spectral dimensions are 
the same, such as 1H-1H, or heteronuclear when the two nuclei are different, such as 1H-
13C. 
2D NMR experiments consist of a sequence of pulses with variation of one parameter. In 
addition to the preparation and acquisition periods which make up 1D pulse sequences, 
additional steps include an evolution time (t1) and potentially a mixing period prior to or 
after the evolution period. As the duration of the evolution time t1 is systematically varied 
to create an indirect time axis, this resulting in two independent time axes which can be 
Fourier transformed independently to form a 2D spectrum.  
2D-1H,13C HSQC NMR experiment is an example of an inverse NMR experiment, an 
experiment which studies insensitive nuclei via magnetisation transfer from a high-
sensitivity nucleus, usually 1H. As previously mentioned, 13C nuclei have a lower 
gyromagnetic ratio compared to protons, which have a gyromagnetic ratio approximately 
four times higher than 13C nuclei. The 2D-1H,13C HSQC NMR experiment therefore 
overcomes the poor sensitivity of the 1D-13C NMR spectrum which is vital for NMR 
experiments conducted as part of this thesis, as metabolite concentrations are usually too 
low to allow the acquisition of a 1D-13C NMR experiment in a reasonable time frame.  
HSQC is an example of an inverse NMR experiment, an experiment which studies 
insensitive nuclei from a high-sensitivity nucleus, usually 1H. As previously mentioned, 13C 
nuclei have a lower gyromagnetic ratio compared to protons, which have a  gyromagnetic 






experiments to overcome the poor signals generated from 13C nuclei when observed in 
isolation (1D-13C NMR).  
The 2D-1H,13C HSQC NMR pulse sequence utilises the INEPT (Insensitive Nuclei 
Enhanced by Polarization Transfer) pulse sequence element to transfer 1H magnetisation 
to 13C nuclei (shown in Figure 19) before the magnetisation which has undergone a period 
of evolution, is transferred back to the 1H nucleus for observation (108). Thin lines 
represent p/2 pulses whilst thicker lines represent p pulses.  
 
 
Figure 19. The INEPT pulse sequence during which 
magnetisation is transferred from 1H to 13C nuclei. 
 
The FID of such 1H nuclei in this scenario are classically acquired with 13C decoupling 
such that 1H,13C J-coupling is not active during the FID acquisition in the direct time 
domain.  
Figure 20 depicts the HSQC pulse sequence with RF pulses targeting 1H and 13C nuclei 
and a blue arrow depicting magnetisation transfer. Evolution of J-coupling occurs during 








Figure 20. 1H,13C HSQC pulse sequence with 1H and 13C decoupling elements highlighted. The blue arrow 
depicts transfer or magnetisation from 1H to 13C nuclei before transfer back to 1H nuclei. 
The spectrum produced is a result of plotting spectral frequency due to variations in the t1 
domain against the spectra acquired from the FID, similar to 1D experiments. The output 
spectra for 2D HSQC is a 3-dimensional plot with chemical shift for the two nuclei of 
interest (1H and 13C) displayed on the two axes. Analysis of 2D HSQC spectra is discussed 
in Chapter 2.    
Acquisition and Fourier transformation  
In the acquisition phase of a pulse sequence, the raw output signal is the summation of 
multiple signals, the amplitude of which decreases with time with a half-life decay pattern 
(107). This raw output observed analogue signal produced during an NMR experiment is 
known as free induction decay (FID).  Two types of relaxation occur, both showing 
exponential decay.  
Transverse relaxation or T2 relaxation, is responsible for interaction of spins with other 
nuclei. The signal decay of an FID is dominated by this T2 relaxation which results in loss 







Longitudinal (spin-lattice) relaxation, known as T1, is responsible to restore the Boltzmann 
distribution in order for a subsequent transient acquisition in the case of 1D spectra, or 
increment acquisition if 2D spectra are being acquired.  
Before processing of this signal occurs, the analogue signal is converted to a digital signal 
by analogue-digital convertors. This is achieved by sampling the signal at regular points 
along the analogue signal prior to conversion to a data point in the form of a binary value. 
The sampling rate used is determined by the maximum frequency (fmax) which can be 
represented correctly. The below equation is used to calculate this maximum frequency 




Equation 6. Calculation of the Nyquist frequency (fmax) where Δt represents the 
interval between data points.  
The same equation is rearranged to calculate the sampling interval, or dwell time, from 
the Nyquist frequency. 
∆= 121.-/
 
Equation 7. Calculation of the sampling interval (∆) using the Nyquist frequency 
(fmax). 
An analogue signal is thus converted to a good quality digital signal which accurately 
represents the original signal. Subsequently, Fourier transformation permits 
decomposition of a complex signal, composed of a number of exponentially decaying 
sinusoidal functions, its constituent frequencies. The Fourier transformation is required to 






(x-axis) against amplitude (y-axis). Peaks seen on NMR spectra commonly have a 
Lorentzian shape which can be expressed in terms of peak height, spectral width at half 
height and frequency at the centre of each peak.  
A signal with a pattern not showing much exponential decay, resulting in a long FID, leads 
to a spectral peak of narrow width. A signal showing fast exponential decay, resulting in a 
short FID, leads to a wide peak in the NMR spectrum with a smaller signal height to noise 
ratio as a result. If the analogue FID signal contains detected frequencies higher than fmax, 
these frequencies will be aliased inside the spectra at different frequencies following 
digitisation and Fourier transform.  
Modern spectrometers overcome this by oversampling the FID and applying a digital filter 
to remove any signal contribution from outside the spectra. It should be noted that this 
process, known as oversampling, is only possible for the direct dimension.  
Conclusion  
NMR is a sensitive modality which can be used to identify a profile of metabolites 
containing NMR active nuclei with spin 1/2; commonly 1H and 13C nuclei. In a latter section 
we will explore the utility of NMR in the detection of molecules containing 13C atoms within 







Ischaemia Reperfusion Injury and the Kidney 
The ongoing ischaemic injury prior to implantation, in addition to the collective damage 
inflicted on the kidney due to a second ‘hit’ following reperfusion, is known collectively as 
Ischaemia Reperfusion Injury (IRI). All transplanted kidneys experience IRI to varying 
degrees. Major insults occur during procurement and storage of organs as a result of both 
warm and cold ischaemia despite hypothermic conditions with IRI continuing following re-
perfusion. The pathological changes which occur determine clinical outcome following 
transplantation.  
In this section, anatomy and physiology of the kidney is reviewed, prior to exploring key 
metabolic pathways which are active in normal physiological conditions. The 
consequences of ischaemia during the transplantation process are discussed with the 
consequential pathological effects and clinical consequences of IRI.  
The Kidney 	
Renal Anatomy 
The kidneys are paired organs lying in the retroperitoneum either side of the vertebral 
column with arterial blood flow originating directly from the abdominal aorta via renal 
arteries (111). Despite accounting for less than one percent of body mass the kidneys 
receive roughly 25 percent of cardiac output, roughly 1.2L/min. Venous blood flow reaches 
the vena cava via a main renal vein whilst urine leaves the kidney via the renal pelvis 
forming the ureter shortly afterwards. In addition to the divisions and tributaries of these 
structures, lateral bisection reveals an outer cortex in addition to inner medullary pyramids 







Figure 21. Schematic diagram of a laterally bisected left kidney with a patch 
of aorta still attached to renal artery. 
A main renal artery divides sequentially into progressively smaller arteries with the 
smallest afferent arterioles supplying the nephron, the functional unit of the kidney. Each 
kidney contains roughly 1.2 million nephrons. A nephron consists of a hollow tube in which 
filtered fluid enters via ultrafiltration within the glomerulus and changes composition 
constantly throughout the length of the nephron prior to entering the collecting system. 
Each part of the nephron shown in Figure 22 plays a role in electrolyte and water 
homeostasis.  
Renal Physiology  
Primarily, the kidneys are key regulatory organs responsible for electrolyte and water 
homeostasis. In addition, the kidney has 3 key endocrine functions, namely secretion of 
renin, calcitriol and erythropoietin. It is also responsible for the excretion of some 
substances including metabolic waste products and some toxins (74).  
Electrolyte homeostasis involves several active and passive processes in different regions 
of the nephron. Along with being structurally and functionally heterogenous, these regions 












regional disparity in oxygen availability.  In terms of renal parenchymal oxygenation, the 
cortex experiences the highest oxygen levels with progressive reduction in the outer 
medulla and the lowest levels in the papillae (112).  
Cells in the proximal convoluted tubule (PCT) are the most metabolically active, 
accounting for roughly two thirds of the volume of the renal cortex. Given the greater 
abundance of oxygen in the renal cortex, compared with the renal medulla, it is 
unsurprising that cortical cells are more dependent on aerobic metabolism and are 
consequently more sensitive to ischaemia. A high metabolic rate is required to meet the 
energy demands of PCT cells. This is largely due to their many resorptive mechanisms 
which are coupled to transport of sodium ions which occurs via a Na+/K+ ATPase pump 
on the basal membrane in tandem with a Na+/H+ cotransporter on the luminal side of 
epithelial cells.  
Proximal tubule cells, along with tubular cells in the thick ascending limb of the loop of 
Henlé and distal tubule, have an abundance of mitochondria in order to meet high energy 
requirements. It is estimated that 90 percent of the oxygen consumption of a cell is 
mitochondrial with 80 percent of this linked to ATP generation via oxidative 
phosphorylation (113).  
In contrast, the inner medulla has a lower energy requirement. Medullary blood flow is 
relatively lower (114, 115) due to shunting of blood flow in the cortex resulting in 
permanently hypoxic environment in which reliance is on anaerobic means of ATP 







Figure 22. Schematic diagram showing the components of the nephron and their 
position with relation to cortex and medulla. 
Metabolic Pathways    
Energy stores such as glycogen are low within the kidney, in contrast to the liver. The 
kidney utilises substrates for metabolism within the bloodstream including glucose, 
lactate, and free fatty acids. In the following section aerobic and anaerobic metabolic 
pathways will be described in more detail (116, 117).  
In addition to variation in energy requirements and oxygen delivery to different regions of 
the kidney in normal physiological conditions, metabolic pathway activity is affected at 
different stages of the transplantation process due to conditions of hypothermia and 
hypoxia. In this section key metabolic pathways are explored prior to introducing the 
concept of ischaemia reperfusion injury.  
Glucose is metabolised within cells to produce adenosine triphosphate (ATP), the cell’s 
‘energy currency’ from adenosine diphosphate (ADP), CO2 and water. The conversion of 
ADP to ATP occurs during 2 processes; substrate-level phosphorylation and oxidative 






















from carbohydrates within the cell (117); glycolysis, the Tricarboxylic acid (TCA) cycle and 
the electron transport chain.  
Glycolysis and the fate of pyruvate  
Glycolysis is the main metabolic pathway using glucose (Figure 23) as a substrate to 
generate ATP. Over a series of ten reactions catalysed by enzymes, glucose, a 6-carbon 
molecule, is converted to 2 pyruvate molecules, each consisting of a 3-carbon atom 
backbone. Glycolysis is a primitive pathway, releasing free energy in the form of 
adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH).  
Pyruvate molecules can either undergo transamination, forming alanine, or are reduced 
to form lactate under anaerobic conditions. Both alanine and lactate concentrations are 
thus markers of glycolytic pathway activity. Lactate concentrations are commonly used in 
the clinical environment as a marker of anaerobic metabolism in a range of clinical 
conditions, all the result of inadequate end-organ perfusion such as septic shock and 
hypovolaemic shock.  
In aerobic conditions, pyruvate undergoes decarboxylation via the enzyme pyruvate 
dehydrogenase to form acetyl co-enzyme A (acetylCoA), resulting in energy production 
via NADH, or alternatively undergoes carboxylation via the enzyme pyruvate carboxylase 
to form oxaloacetate, filling in additional intermediates in the tri-carboxylic acid cycle for 








Tri-carboxylic acid (TCA) cycle 
Relative to the TCA cycle, glycolysis is responsible for only a small amount of ATP 
production. The TCA cycle, also referred to as the Krebs cycle or the citric acid cycle, is a 
cyclical metabolic pathway. The cycle takes place in the mitochondrial matrix under the 












glucose, approximately 32 ATP can be generated using the TCA cycle and its 
accompanying electron transport chain (117). Whilst it is not directly dependant on 
oxygen, it is linked to oxygen consumption via NADH/FADH2 and the electron transport 
chain.  
Pyruvate dehydrogenase, is considered the gatekeeper of the TCA cycle as it regulates 
the incoming flux of glycolytic products, converting pyruvate into acetyl-CoA. The 2-carbon 
acetyl group from this molecule is transferred to the 4-carbon molecule oxaloacetate 
forming citrate, a 6-carbon molecule (Figure 24). In subsequent reactions in the TCA cycle, 
citrate loses 2 carboxyl groups as carbon dioxide, giving rise to 5-carbon (alpha-
ketoglutarate) then 4-carbon molecules (succinate, fumarate, malate, oxaloacetate). 
 
Figure 24. The TCA cycle metabolites and entry points of pyruvate into the cycle. The TCA cycle is shown in 
green. 
Pyruvate can also enter the TCA cycle as oxaloacetate via carboxylation, but this tends to 
happen when the energy requirement of cells increases acutely, such as during exercise, 






cycle, acetyl-CoA is oxidised to produce NADPH and FADH2 for energy generation via the 
electron transport chain. 
The 2 carbon atoms entering the TCA cycle as acetyl-CoA as part of the pyruvate 
dehydrogenase are not the same 2 carbons lost from citrate when it forms alpha-
ketoglutarate and subsequently succinate. Instead, these carbons are incorporated into 
the newly formed backbone of the succinate molecule.  
The electron transport chain 
The electron transport chain, sited in the inner mitochondrial membrane, is a series of 
reactions whereby electrons are sequentially transferred between electron donors and 
acceptors. The transfer of electrons pumps protons into the inter-membrane space, 
generating an electrochemical gradient. At the end of the chain, electrons are passed to 
oxygen, the most electronegative acceptor in the chain. Energy generated in the presence 
of oxygen via the phosphorylation of ADP to form ATP; the process is termed oxidative 
phosphorylation.  
During oxidative phosphorylation, the reduced forms of hydrogen carriers NADH and 
FADH2 are oxidised to NAD+ and FAD. Oxidative phosphorylation is an oxygen dependent 
process and generates much higher levels of ATP in contrast to glycolysis.  
The pentose phosphate pathway  
Whilst the majority of glucose entering cells is utilised for glycolysis, breakdown products 
of glucose can also be used to facilitate pentose phosphate pathway (PPP) activity. The 






key component of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) nucleotides. 
There are 2 parts to the cycle, an oxidative and a non-oxidative phase.  
During the oxidative phase, glucose-6-phosphate, the second intermediate of glycolysis, 
is oxidised to form ribose-5-phosphate, a 5-carbon sugar. During this phase, 2 
nicotinamide adenine dinucleotide phosphate (NADP+) molecules accept electrons to form 
2 molecules of the molecule’s reduced form (NADPH). These NADPH molecules are 
required in multiple reductive reactions throughout the cell including fatty acid 
biosynthesis, cholesterol biosynthesis and nucleotide biosynthesis.  
The non-oxidative phase sees the interconversion of phosphorylated sugars to 6-carbon 
intermediates of the glycolytic pathway and 5-carbon sugars used in the synthesis of 
nucleotides.   
Beta-oxidation of fatty acids   
Energy release from fatty acids occurs via beta-oxidation in the mitochondria. This 
catabolic process releases acetyl-CoA, which supplies the TCA cycle, in addition to 
electron carriers NADH and FADH2. NADH and FADH2 generate ATP via the electron 






Ischaemia Reperfusion Injury  
Ischaemia reperfusion injury (IRI) describes cellular damage after reperfusion of 
previously viable ischemic tissues (119). Such injury is thought to be a key non-
immunological cause of delayed graft function as it is responsible for the development of 
post-ischaemic acute tubular necrosis (120). IRI occurs in 2 phases, the first ischaemic 
phase due to interruption of blood flow with changes invoked setting the scene for further 
damage to be inflicted during the second reperfusion phase. Both phases are 
characterised by disruption of regulatory functions at a cellular level. In this section, the 
major deleterious processes central to IRI will be discussed, including reduction in ATP 
stores, accumulation of intracellular calcium ions, propagation of reactive oxygen species 
and subsequent mitochondrial dysfunction.  
Reduction of ATP stores  
Cessation of blood supply promptly results in whole organ ischaemia due to exhaustion of 
oxygen supply by aerobic tissue. During ischaemia, the lack of oxygen supresses 
oxidative phosphorylation, decreasing ATP synthesis. Cellular ATP stores are thus quickly 
depleted with consequences for energy dependant processes within the cell and a 
resultant switch from aerobic to anaerobic metabolism. Following the switch, ATP is 
produced almost exclusively by glycolytic pathway activity with a consequent build-up of 
lactate resulting in a decrease in intracellular pH. However, this switch ultimately fails to 
meet the high energy demands of aerobic tissue due to the lower yield of ATP per glucose 
molecule. Once ATP stores have been exhausted, phosphorylation of fructose-6-







Energy dependant processes responsible for electrolyte homeostasis, such as the crucial 
membrane bound Na+/K+ ATPase, fail following depletion of ATP stores. The effect of this 
is a net accumulation of intracellular Na+ ions with a consequent rise in Cl- ion 
concentration.  The accumulation of intracellular Na+ ions results in cellular oedema due 
to hydrostatic effects. Furthermore, the dephosphorylation of ATP to adenosine and 3 
particles of inorganic phosphate is a contributor to the hyperosmolarity of the intracellular 
compartment which further attracts water via diffusion, aquaporin and the glucose 
transporter (121).  
Oedema disrupts organelles including lysosomes, mitochondria and the endoplasmic 
reticulum. The latter is responsible for an initial rise in intracellular Ca2+ which is particularly 
detrimental. Destabilisation of lysosomal membranes leads to release of lysosomal 
enzymes causing damage to cell structure (122) whilst mitochondrial oedema results in 
disruption of oxidative phosphorylation.  
Intracellular calcium excess 
Several adverse events are a result of the disruption to intracellular calcium homeostasis 
during IRI. The increase in intra-cellular Ca2+ ions occurs due to several mechanisms. 
Early accumulation of intracellular Ca2+ is thought to be due to redistribution of stores from 
the endoplasmic reticulum (123). Following longer periods of ischaemia, intracellular Ca2+ 
ions are no longer actively pumped out of cells by the ATP dependant Na+/Ca2+ antiporter 
with possible reversal of flow leading to Ca2+ accumulation in the cytoplasm. Reperfusion 
is responsible for a further increase in intra-cellular calcium concentration.  
The increase in cytosolic Ca2+ activates calcium dependent enzymes such as proteases 






towards apoptosis on reperfusion. Proteases such as calpains and caspases, have 
numerous targets including the cytoskeleton, proteins within plasma membranes, 
lysosomes, mitochondria and the nucleus whilst Phospholipase A2 cleaves phospholipids 
(121).  
Reactive Oxygen Species 
Oxidative damage is inflicted by ROS, a term which incorporates free radicals and non-
radical species. Oxidative damage commences during ischaemia due to intracellular ROS 
formation (124), although only a small amount of ROS are produced during this initial 
ischaemic phase. The electron transport chain of mitochondria is the main source of intra-
cellular ROS but several other sources are implicated in the production of ROS. 
Membrane and cytosolic oxidases, such as xanthine oxidases and NADPH oxidases, are 
upregulated during ischaemic insult although they may remain inactive due to low 
intracellular pH prior to reactivation when pH is normalised at reperfusion.  
Re-oxygenation on reperfusion is responsible for significant ROS production as the kidney 
lies vulnerable with such upregulated enzymes lying inactive. Chemokines are responsible 
for attracting neutrophils, macrophages and eosinophils which also release ROS, 
contributing to this second ‘wave’ of damage as part of reperfusion injury.  
The presence of unpaired electrons within a molecule confers a high degree of reactivity. 
Such molecules are known as free radicals. Non-radical species do not contain unpaired 
electrons. At high concentrations, ROS are detrimental to cell structures inflicting 
widespread damage to lipids, proteins and nucleic acids (125). It should be mentioned 






pathways which act to promote cell proliferation, differentiation and migration thereby 
promoting tissue remodelling and angiogenesis (126).  
The superoxide anion, a free radical species, is considered the “primary” ROS but does 
not itself react with proteins or nucleic acids (127). Superoxide undergoes a dismutation 
reaction, catalysed by the enzyme superoxide dismutase, producing hydrogen peroxide 
and oxygen. Hydrogen peroxide is removed by 2 enzymes, catalase and glutathione 
peroxidase, both of which work in conjunction with superoxide dismutase. Catalase, 
located in peroxisomes, promotes the conversion of hydrogen peroxide to water and 
molecular oxygen. Glutathione peroxidase decomposes hydrogen peroxide forming 
water, whilst oxidising glutathione.  
The enzymes superoxide dismutase, catalase and glutathione peroxidase are the cell’s 
most effective enzymatic defence against low levels of ROS, limiting ROS accumulation. 
Non-enzymatic anti-oxidants include thiol anti-oxidants such as glutathione. 
The Fenton reaction describes the conversion of hydrogen peroxide to the highly reactive 
hydroxyl free radical during conditions of oxidative stress. For this reaction to occur, the 
superoxide radical reacts with iron containing molecules to release free intracellular iron 
which then reacts with hydrogen peroxide to form the hydroxyl free radical (128). The 
hydroxyl free radical is highly reactive and has a short half-life within the cell, reacting with 
substrate close to its site of production.  
Mitochondrial dysfunction 
Mitochondria are both a major source of ROS via the disrupted electron transport chain 
and are also a major target of ROS. The mitochondrial permeability transposition pore 






during certain pathological conditions. High levels of mitochondrial Ca2+ are responsible 
for opening of the mPTP which allows molecules <1,500 Daltons to pass through (121).  
Calcium and reactive oxygen species (ROS) are the most important triggers for opening 
of the mPTP (129); its opening results in mitochondrial swelling and release of caspase 
dependant co-factors into the cytosol (130). During reperfusion these caspase dependant 
co-factors activate executioner caspase enzymes which are responsible for cell death via 
energy dependant processes such as apoptosis.  
Microvascular dysfunction and the contribution of the immune system  
The detrimental sequelae of ischaemic insults are not limited to renal parenchyma. 
Vascular endothelium experiences a multitude of changes which are more evident on 
reperfusion.  Endothelial cells swell via the mechanisms described above. In addition, loss 
of glycocalyx and breakdown of the actin cytoskeleton are observed (131)leading to 
interstitial fluid aggregation.  
Ischaemia promotes expression of pro-inflammatory gene products such as leucocyte 
adhesion molecules and cytokines. In addition, ischaemia promotes increased levels of 
vasoconstrictor substances such as platelet derived growth factor-B, endothelins and 
thromboxane A2 (132) and a decreased production of vasodilatory substances such as 
nitric oxide. These mechanisms create unfavourable conditions for reperfusion (119). 
Complement activation also results in the formation of several pro-inflammatory mediators 
(133). The ensuing proinflammatory state is more evident on reperfusion.  
Increased expression of adhesion molecules recruits both leucocytes and neutrophils into 
tissues. At reperfusion, leucocytes enter the interstitial compartment following a sequence 






adhesion and transmigration (134, 135). Further damage occurs at this stage as a result 
of the release of toxic ROS, proteases and elastases by leucocytes whilst neutrophils in 
post-ischaemic tissue also release ROS, cytokines and proteases.  
In combination, endothelial cell swelling, leucocyte-endothelial cell adhesion, interstitial 
fluid accumulation and decreased endothelial cell mediated vasorelaxation result in 
mechanical obstruction to blood flow resulting in a well described ‘no-reflow’ phenomenon 
(119).  
The effects of hypothermia  
Hypothermia is well known to reduce metabolic activity with an accompanying decrease 
in oxygen consumption forming the basis of organ preservation. However, not all effects 
of such decrease in temperature are beneficial (136); the use of hypothermia is a trade-
off between beneficial and deleterious effects (137).  
The difference between hypothermia inflicted in the clinical setting, and the physiology of 
hibernating animals demonstrate during hypothermic conditions, is the control of 
suppression of metabolism. The desired effect of hypothermia in the clinical setting, for 
example during organ preservation, cardiac-pulmonary bypass and neurosurgical 
procedures, is a suppression in metabolism. In contrast, in hibernating mammals, a 
regulated metabolic depression is observed in which ATP supply and demand is balanced 
(138). Regulated metabolic depression is not limited to cold-adapted mammals and has 
infact been observed in primates such as fat-tailed dwarf lemurs in which body 
temperature can decrease as low as 5°C to match ambient surroundings during 






Hypothermic injury is largely attributed to loss of cell ion homeostasis, in particular sodium 
homeostasis. This occurs as a result of differential temperature effects on ion channels 
compared to ATP driven pumps such as the Na+/K+ ATPase pump. Reduced efflux of Na+ 
from cells is observed due to decrease in Na+/K+ pump activity (140) in addition to passive 
influx of Na+ via ion channels (141). Both mechanisms of increasing Na+ ions result in 
dissipation of ion gradients, cell swelling and inhibition of ATP generation (142). In 
addition, ROS are also thought to contribute to damage inflicted due to hypothermia (143).   
Several processes also increase cytosolic Ca2+ during hypothermia including efflux of Ca2+ 
in exchange for Na+, membrane depolarisation leading to opening of voltage gated Ca2+ 
channels and loss of Ca2+ from the sarcoplasmic reticulum (140). As a result, increased 
phospholipase activity leads to cell membrane hydrolysis which results in further increases 
in cell membrane permeability and ultimately cell death (140). 
Manifestation of ischaemia reperfusion injury in cadaveric kidneys 
The mechanisms of damage resulting in DGF in cadaveric donors differs between donor 
sub-types. DBD and DCD donor organs are susceptible to different physiological insults. 
Brainstem death results in inflammatory immunological signals such as upregulation of 
cell adhesion molecules leading to leucocyte and neutrophil localisation to donor organ 
(136, 144, 145). The attraction of such immune cells amplify damage during the 
reperfusion phase of IRI (146).  
In contrast, the period of warm ischaemia which DCD organs are subject to results in 
pathological processes central to depletion of ATP stores, such as cell swelling and 






during reperfusion, leading to a further period of warm ischaemia. This observed 
microvascular ‘no-reflow’ phenomenon contributes to reperfusion injury (147).   
The pathological changes seen on biopsy of cadaveric kidneys with DGF are known as 
acute tubular injury or acute tubular necrosis (148) with the observed spectrum of 
histological changes seen reflecting the timing and nature of IRI. Changes in metabolism 
during ischaemic and hypothermic insults are detrimental to regulatory functions within 
the cell, damaging kidneys during the preservation period but also setting the scene for 








Metabolomic studies aim to comprehensively and quantitatively analyse the wide array of 
metabolites present in biological samples (149). Metabolomics is the endpoint of the -
omics cascade occupying a niche which separates itself from genomics, the study of the 
genome, and proteomics, the study of proteins produced by an organism, tissue or cell. 
Whilst the genome is a static entity, the proteome and metabolome undergo dynamic 
changes; both proteomics and metabolomics complement genomics as phenotypic 
molecular markers revealing the effects of environmental changes on biological systems 
(150). Metabolomics in particular measures the short-term chemical response of cells and 
tissues to a biological event, thereby linking protein and gene expression (151).   
Metabolomic studies can be divided into untargeted studies, which aim to 
comprehensively analyse all measurable analytes in a sample, and targeted studies, 
which aim to measure defined groups of chemically characterized and biochemically 
annotated ‘labelled’ metabolites (152).  
Investigative techniques  
NMR spectroscopy and mass spectrometry are the two most successful and widely used 
analytical techniques in the field of metabolomics. Mass spectrometry measures the mass 
to charge ratio of ions within a sample. Molecules are ionized then continually fragmented 
with the mass to charge ratio measured for each ion. Their relative abundance within the 
sample is measured with the potential to calculate absolute concentrations. Gas 
chromatography and liquid chromatography are two techniques by which molecules can 
be separated prior to mass spectrometry. One limitation inherent to mass spectrometry is 






spectrometry as not all samples readily undergo ionization and due to the differing 
ionisation of different metabolites.  
NMR spectroscopy takes advantage of the magnetic properties of nuclei with the property 
of spin in order to study their physical and chemical characteristics thereby determining 
the structure of molecules which they contribute to. Quantification of metabolites in a 
sample is permitted by 1D 1H NMR spectroscopy, although the accuracy of such 
quantification depends on the overlap of spectral pattern of such a metabolite.  
Compared with mass spectrometry, NMR is able to analyse samples with a high 
throughput, requiring minimal sample preparation, simple methods of quantifying 
metabolites and non-destructive acquisition of data (153-155). NMR also allows more 
accurate description of a metabolite as it is able to determine chemical structure and also 
distinguish between metabolites with identical masses. However, NMR is less sensitive 
than mass spectrometry.  
The majority of metabolomic studies use either analytical technique in isolation however 
the distinct limitations described apply to such a unilateral approach. Several approaches 
to combining the two techniques have been described with respect to both ‘conventional’ 
metabolomics and incorporation of a metabolic tracer (156) in an attempt to overcome the 
limitations of each technique in isolation.  
Metabolic isotope tracers  
Cellular metabolism involves a complex network of pathways resulting in metabolite 
production from different substrates, or perhaps even the same substrate from different 






NMR and mass spectrometry, do not allow differentiation of such pathways. A metabolic 
isotope tracer permits such observations. Techniques such as NMR spectroscopy and 
mass spectrometry follow the fate of a metabolic tracer molecule, thereby providing 
information regarding the metabolism of the molecule of interest (157). Molecules used as 
metabolic tracer must be biologically and functionally identical to the naturally occurring 
molecule of interest known as the tracee (157).  
Metabolic tracers can be either stable or radioactive isotopes. A stable isotope tracer can 
be defined as a molecule with one or more isotopes with a different mass than the most 
abundantly occurring mass incorporated somewhere in the molecule (157).  
For the purpose of this thesis, we will consider incorporation of 13C into a glucose 
molecule. With respect to carbon, 12C is the most frequently observed isotope containing 
6 protons and 6 neutrons within its nucleus. The isotope 13C is a non-radioactive and 
therefore stable isotope of carbon containing 6 protons and 7 neutrons in its nucleus, 
accounting for 1.07% of all carbon. The third isotope 14C is found within the atmosphere, 
containing 8 neutrons within its nucleus and is therefore unstable resulting in radioactive 
decay.  
Figure 25 shows standard 12C glucose and [U-13C] glucose, a synthetically produced 
glucose molecule in which each of the six 12C atoms within the glucose molecule has been 







Figure 25. Standard 12C glucose (a) and [U-13C] glucose (b). 
With regards to glycolytic pathway activity, universally 13C labelled glucose as the 
substrate for glycolysis produces universally 13C labelled pyruvate which undergoes 
conversion to universally 13C alanine and universally 13C labelled lactate as shown in 
Figure 26. 
 
Figure 26. [U-13C] pyruvate (a), [U-13C] alanine (b) and [U-13C] lactate (c).  
Different labelling patterns occur in metabolites within, and as a product of, the TCA cycle 
depending on whether universally labelled 13C pyruvate enters via the pyruvate 
dehydrogenase or less commonly, the pyruvate carboxylase pathway. The TCA cycle 
does not transfer carbon atoms to hydrogen carriers, thus no 13C labelled compounds are 
seen as a result of electron transport chain activity.    
As discussed, 2D 1H,13C HSQC NMR experiments exploit the spin properties of 1H and 
the 13C isotope such that [U-13C glucose] and some of its associated metabolites are 






nuclei results in differentiation between isotopes using mass spectrometry. The two 
approaches can be combined by first simulating 13C multiplets in NMR spectra and utilizing 
mass increments to obtain long range information prior to combining this information to 
derive isotopomer distributions for metabolites of interest (158). This combined use of both 
2D 1H,13C HSQC NMR and mass spectrometry aids isotopomer distribution determination.   
Metabolomic studies in renal transplantation 
Metabolomic studies have a key role in describing metabolic mechanisms in addition to 
helping identify biomarkers of disease (159) with several reported studies specific to renal 
transplantation (160-167).  
Studies to date have aimed to demonstrate several roles for metabolomics in the field of 
renal transplantation including the ability to localise kidney damage, assess organs at risk 
of rejection and assess the extent of damage to kidneys as a result of IRI (160). Each of 
these studies have focused on discovering a biomarker, or biomarkers, of either function 
or representation of an insult inflicted during the transplantation process. The properties 
of an ideal biomarker include ease of measurement with samples taken in a non-invasive 
manner, reliable measurement with a rapid turn-around time, sensitivity for early detection 
and risk stratification at low cost (161). Both NMR and mass spectrometry fulfil several of 
these characteristics and can thus be used to identify potential biomarkers.  
Studies have observed significant differences in the urinary metabolome of kidneys with 
immediate and delayed graft function with three studies suggesting trimethylamine-N-
oxide, a marker of medullary injury, is a prognostic marker of functional outcome post-
transplantation (162-164). One study examining the urine metabolome described the 






acids/pyroglutamate which adequately predict prolonged duration of DGF with AUC 0.85 
(165). Furthermore, with respect to immunological causes of DGF, the urinary 
metabolome may be predictive of types of cellular rejection in both adult (166) and 
paediatric recipients (167). Given the kidneys alone produce urine, it would seem logical 
that metabolites detected in the urine reflect metabolic processes occurring in 
transplanted organs although concentrations of such metabolites in the urine may be 
confounded by the existing urine output of native kidneys.  
To a lesser extent, metabolomics studies have also investigated changes in the serum in 
animal (162) studies post-transplantation in an attempt to predict outcomes including DGF 
and rejection. However, blood and its constituents represent an average of several 
homeostatic processes in the body. This may be viewed as an advantage but difficulties 
lie in attributing changes to transplanted organs alone. Studies using serum are also 
subject to interference from extra-corporeal haemolysis which greatly affects analysis of 
samples in untargeted studies (168-170).  
In addition to blood and urine metabolites, examination of whole organs preserved with 
HTK solution using 31P NMR suggested the energy status of kidneys could be calculated 
using the ratio of phosphomonoesters and inorganic phosphate (171). In the study 
performed by Hené et al, energy status correlated with type of donor kidney and incidence 
of acute tubular necrosis.  
Metabolomics studies involving ex vivo kidneys during the organ 
preservation period  
Metabolomic studies in transplantation have investigated the changing composition of 






et al (171), the organ preservation period between retrieval and implantation of an organ 
allows a period of observation during which time metabolomics studies can be performed.  
During hypothermic machine perfusion, single kidneys are isolated and remain in a 
temperature regulated environment in which perfusion fluid circulates. In this closed 
system, the kidney alone effects a change in the constituents of the circulating fluid. It 
would therefore seem logical that identification of a biomarker in perfusion fluid adds value 
to HMP as a tool for identifying damage and therefore predicting function post-
transplantation.  
Indeed several studies and meta-analyses have discussed the use of proteomic 
biomarkers in such a context. These are discussed further in Chapter 7. Studies by our 
unit and others (172, 173) have described the evolving role of metabolomics in 
identification of a biomarker.  
Using a purely 1D 1H NMR approach, Guy et al. (173) aimed to describe the metabolic 
profile of human kidneys awaiting transplantation by analysing changes in circulating 
perfusate. In this study the perfusate of 26 cadaveric kidneys was analysed with perfusate 
concentrations of glucose, inosine and leucine identified as potential indicators of graft 
function post-transplantation. However, concentrations of glucose determined by 1H 1D-
NMR did not correlate with those measured by blood glucometer.  
Bon et al (172) showed how changing metabolite levels in circulating perfusate correlated 
with functional outcome in a porcine DCD auto-transplantation model. An increase in 
several metabolites including lactate, choline and amino acids including valine, glycine 






duration of perfusion. The NMR sample processing turnaround period of 2 hours showed 
the potential application of NMR analysis of HMP perfusate samples to the clinical setting.   
Previous research has demonstrated the validity of the pig model as similar metabolic 
profiles of pig kidneys and human kidneys were observed during hypothermic machine 
perfusion using a 1D-NMR approach (174). Discussion of the pig model with relevance to 
renal transplantation is discussed further in Chapter 5.  
Using the porcine DCD model described in depth in Chapter 2, six porcine kidneys were 
perfused with fluid enriched with [U-13C] glucose for 24 hours. Kidneys were subject to 24 
hours of perfusion during which time sequential perfusate samples were taken with cortex 
samples taken at the end of the perfusion period (175). 
Analysis of tissue and perfusate samples identified metabolites including [U-13C] lactate 
and [U-13C] alanine in all end point cortex samples representing de novo anaerobic 
activity. Of note, several samples of renal cortex revealed the presence of [4,5-13C] 







Metabolomics studies possess the ability to detect in excess of a thousand metabolites. 
Yet given this ability, and the observation that most metabolomics studies are conducted 
on small samples sizes of less than 100 (176), the risk of false positives is high. Thus, any 
significant relationships in untargeted studies should be approached with a degree of 
skepticism, including the identification of individual metabolites as biomarkers.    
In the context of organ preservation, metabolomic studies displays changes within 
transplanted organs which occur quickly in relation to ever changing environmental stimuli 
such as ischaemia and hypothermia. The use of a metabolic tracer enables direct 
interrogation of metabolic pathways of choice, accurately attributing changes in metabolite 
levels to these particular pathways. In doing so the risk of identifying false positive 
relationships is reduced. When used ex vivo in hypothermic machine perfusion, both 
targeted and untargeted studies demonstrate a changing metabolome with the potential 









Chapter 2 : Methods  
In this chapter the process of acquiring, preparing and initiating hypothermic machine 
perfusion for porcine and human kidneys is described. Metabolomic analytical techniques 
including NMR and mass spectrometry methods are described along with methods for 
histological analysis and biochemical assays. The porcine model is appraised in Chapter 







Porcine model of Donation after Circulatory Death  
Porcine kidneys were procured from 22 to 26 week-old male English White pigs weighing 
between 80 and 85 kg from a local abattoir (F.A. Gill, Wolverhampton, UK) in a model 
previously used by our group (174) designed to simulate a Maastricht category III DCD 
donor (22). 
Pigs were hung from their hind legs following electrical stunning to permit exsanguination 
via transected jugular veins. Sternopubic laparotomy and bilateral nephrectomy followed 
14-15 minutes later following a series of hair removal procedures with this time period 
between exsanguination and nephrectomy considered the warm ischaemic time. En-bloc 
nephrectomy was performed by abattoir staff with requests that maximal lengths of 
vasculature and ureter be preserved prior to transfer of organs to a sterile bench set up 
as described below.   
To permit fair comparison, pairs of kidneys were only included if both kidneys were 
supplied by a single artery at the point of origin from the abdominal aorta. However, no 
organs were discarded on this basis. No animals were killed solely for experimental 
purposes; all were due for human consumption, therefore no ethical approval was 
required. 
A sterile set up was used on site at the abattoir with reusable surgical equipment washed 
and autoclaved prior to usage. Disposable equipment was discarded via appropriate 







Figure 27. Abbatoir set-up for assessment and flush of porcine kidneys showing a 1L bag of Soltran (A) 
attached to giving standard giving set (B) attached to a 14G cannula resting in sterile metal bowl filled 
with crushed ice (C).Syringe containing 5,000iU heparin (D) prepared next to two 8mm T-connectors (E), 
straight clips (F), 3/0 Vicryl ties (H), tissue scissors (I) and two pairs of non-toothed forceps (J) on a 
sterile blue drape (K).  
On receipt of a pair of porcine kidneys, each kidney was quickly checked for anatomical 
damage to cortex and for adequate length of vasculature prior to identification, placement 
of a surgical clip and cannulation of main renal artery with 14G cannula.   
Kidneys were flushed with 500ml Soltran® (Baxter, UK) kept at 2-4°C at a pressure of 120-
150mmHg in order to removed blood from renal vasculature, thereby preventing 
thrombosis prior to initiation of HMP, and to promote rapid cooling of organs. Soltran® 
(Baxter, UK) fluid bags were placed on a drip stand as shown in Figure 27. In some sets 
of experiments flush solution was supplemented with an additional 0.93 g [U-13C] labelled 










a large bore cannula held in place by hand. During flush kidneys were observed for 
changes in flow rate of flush solution, indicated by drip rate in flow chamber, and change 
in colour of renal cortex and flow of effluent flush solution from renal vein. In all cases by 
the end of initial flush, effluent was noted to be clear. Following flush, excess perinephric 
fat was removed from the kidney with major vessels and ureter identified prior to 
placement in cold storage.  
For the purpose of transport both kidneys were placed in a sterile autoclave bag containing 
500ml Soltran® (Baxter, UK) and 20ml PenStrep (ThermoScientific Fisher, UK). Air was 
expelled from this bag prior to closure with autoclave tape. The bag was surrounded by 
crushed ice in a polystyrene box for transport back to the laboratory. Kidneys were 
commonly kept in such static cold storage for 2 hours prior to initiation of HMP in order to 
simulate transport of organs to transplantation centres.   
Preparation of human cadaveric kidneys in the clinical setting  
Human cadaveric organs were received in static cold storage conditions (Figure 3). Sterile 
equipment was set up as show in Figure 28 prior to opening of the three Aldon bags which 
kidneys are commonly stored in during transfer.   
Following removal from static cold storage, arterial and venous anatomy was identified 
and dissected free from surrounding peri-hilar tissue, tying non-essential arterial and 
venous branches securely to ensure haemostasis on reperfusion. The aortic patch was 
divided to leave a wide circumference of aorta around the renal artery ostium which 
permitted attachment of a RingSeal connector as described below. Main renal vein and 
inferior vena cava, when present, were not divided to allow transplanting surgeon to 






dissected free from surrounding tissue whilst ensuring immediate peri-ureteric tissue 
remained intact to minimise ureteric ischaemic insult. Excess perinephric tissue was 
removed so as to expose the renal cortex with attention not to incise capsule. Anatomical 
variants and pathology such as renal cysts and tumours were identified. Main renal artery 
and main renal vein were checked for leakage with a non-traumatic Tibbs cannula 
attached to a 20ml syringe filled with Ringer’s lactate.  
Following this, the kidney was prepared for attachment to the hypothermic machine 
perfusion circuit.  
 
Figure 28. Theatre backbench set-up for preparation of human cadaveric kidneys. On a sterile operating 
theatre trolley, crushed ice in chilled fluid (3L frozen, 3L chilled Ringer’s lactate solution) (A) were placed in a 
metal bowl accompanied by equipment for preparation of grafts including small swabs (B), straight clips (C), 
3/0 Vicryl ties (D), non-toothed and fine toothed forceps (E), Potts scissors (F), needle holders (G) next to a 
sharps discarder pad, in addition to Watson Cheyne probe (H), 20ml syringe with Tibbs cannula attached, 
















Figure 29 shows a cadaveric kidney retrieved en-bloc complete with aortic patch. Main 
renal artery ostium is positioned to the left of the patch. Note atherosclerotic disease of 
patch. Perinephric fat surrounds the cortex which is visible in places.   
  









Hypothermic Machine Perfusion  
LifePort® Kidney Transporter 
A LifePort® Kidney Transporter (Organ Recovery Systems, Chicago, USA) was used to 
provide hypothermic machine perfusion with key design features as described in Chapter 
1. One of two versions of the LifePort® Kidney Transporter were used for experiments in 
this thesis. Experiments performed in the clinical setting were performed on either version 
1.1 (Figure 30) or version 1.0 (Figure 31). All laboratory experiments were performed on 
the original version 1.0. Function and mechanism of action was identical between both 
versions.   
Figure 31 shows version 1.0 in use in the laboratory setting perfusing a porcine kidney 
connected via a 5mm T-connector. Note this circuit includes a membrane oxygenator used 
for experiments in Chapter 6. Figure 30 shows a human kidney perfused on version 1.1 
in the clinical setting via a RingSeal connector.  
 














Figure 31. LifePort® Kidney Transporter 1.0 perfusing a porcine kidney with a membrane 
oxygenator incorporated into the perfusion circuit. 
Preparation of renal artery prior to initiation of HMP 
Pulsatile perfusion via the renal artery during machine perfusion requires the renal artery 
to be cannulated. Aside from an occlusive seal, the connection should also be non-
traumatic to the intima of the artery to avoid pre-disposition to thrombosis post-operatively.   
As per manufacturer instructions this is achieved via a RingSeal connector or a T-
connector. A RingSeal connector requires a single main renal artery with an appropriate 
circumference of aortic patch in order to allow 2 overlapping plastic rings to seal the 
circumference of the patch. One ring covered in a rubber seal provides a view of the ostium 
via a transparent window whilst the exterior side of the artery/patch passes through the 
second ring as shown in Figure 32. This does not damage the intima of the renal artery or 
the aortic patch but does require a single renal artery and an appropriate circumference 













To attach the RingSeal connector, the edge of aortic patch was grasped gently and 
brought through lower ring. The overlying ring with viewing window was lowered into place 
ensuring a circumference of patch lay between upper and lower ring resulting in a water-
tight seal. Two rubber ties were then used to secure the Ringseal in place. Flushing with 
a 20ml syringe with distal end of the connector open was used to check for an intact seal 
and also expel air from the viewing chamber. If the seal was not intact, the above steps 
were repeated. The distal end cap was then replaced with the viewing chamber full of 
fluid.  
To attach the T-connector, a surgical clip was attached to the cut edge of the renal artery. 
An appropriate sized connector, either 3mm/ 5mm/ 7mm T-connector, was lowered into 
the lumen. The connector was secured with a 2/0 or 3/0 Vicryl tie (Ethicon, UK) lying in 
the fixation groove. Additional securing sutures were placed as required. As with the 
RingSeal connector, the connector was then flushed with 20ml syringe prior to placement 
of distal cap.  
 
Figure 32. Attachment of the kidney to the LifePort® inflow limb using a T-connector (a) and RingSeal 
connector (b).  
Figure 33 shows a prepared cadaveric kidney prior to insertion into the pre-prepared 









Figure 33. Cadaveric kidney prepared for hypothermic machine perfusion.  
Set up of HMP 
Kidneys were preserved using the LifePort® Kidney Transporter version 1.0 or 1.1 (Organ 
Recovery Systems, Chicago, USA). The following steps were performed as per 
manufacturer’s instructions to prepare the cartridge prior to insertion of the kidney and 
attachment of T-connector/ RingSeal connector to perfusion tubing.  
The ice reservoir was loaded with non-sterile crushed ice and agitated to ensure as much 
ice as possible filled the reservoir. The reservoir was then filled with tap water until enough 
ice had melted to permit further filling of crushed ice at which point ice was filled again. 
This latter step was repeated until ice/water level reached the brim of the reservoir at 
which point the reservoir lid was secured in place.  
A disposable cassette was filled with 1 litre of UW-MPS on the sterile back-bench 
preparation table before replacing the internal and external cassette lids. The cassette 






the cartridge were secured in place with gentle pressure prior to placing rubber tubing 
over peristaltic mechanism. Rubber tubing of the peristaltic pump mechanism was 
secured in place with hinged lever. The cartridge lock was rotated into place prior to 
attachment of pressure/temperature sensing cable.  
The ‘flush’ function was initiated for a pre-determined time, usually 5 minutes, allowing 
perfusion fluid to circulate through the tubing of the cassette.  After placing sterile drape 
over LifePort® cassette, the outer lid and inner lid were removed and placed on backbench 
preparation table.  
Following cessation of the ‘flush’ function by pressing ‘stop’, the pre-prepared kidney was 
placed on supporting platform of the LifePort® cassette covered by netting. Attention was 
paid to placing the artery and associated connector in the supporting jig so as not to place 
the renal artery under tension in order to avoid traction injury. This was always a vertical 
orientation which permitted direct visualization of the ostium via the transparent viewing 
chamber on Ringseal connector. Where possible, the kidney was placed with renal vein 
anteriorly to permit view of effluent. 
The inflow limb of the perfusion circuit was connected to the T-connector/ Ringseal. The 
distal end cap was kept loose.  At this point an assistant should press ‘prime’ in order to 
fill the inflow limb of the perfusion circuit, expelling any air via the distal end of the 
connector. Once all air is removed the cap should be tightened after pressing ‘stop’. The 
‘start’ button was then pressed to initiate perfusion.  
Following initiation of perfusion, flow parameters were observed, the perfusion circuit 
checked for leaks and the kidney examined for leakage around T-connector/ RingSeal 






removed. The outer insulating covering lid of the LifePort® machine was placed on the 
LifePort® when sampling was not in progress.  
Perfusion pressure for all kidneys should be set at 30mmHg as a default, the pressure 
used in the initial Machine Preservation Trial (70) forming the evidence base for the use 
of HMP. Perfusion fluid used in all experiments was an identical composition to UW-MPS 
as originally described by Belzer (75) with formulation as described in Chapter 1. The 
solution is supplied by 2 manufacturers with product names Kidney Perfusion Solution 
(KPS-1®, Organ Recovery Systems limited) and Belzer Machine Perfusion Solution 
(Belzer MPS®, Bridge to Life Europe limited). The formulation is identical regardless of 
supplier.  
  
Figure 34. Custom made Kidney Perfusion 
Solution containing U-13C glucose. 
In some experiments the 10mM glucose in a standard 1L bag of perfusion fluid was 
supplemented with an additional 0.93g U-13C glucose resulting in a concentration of 
15mM. In Chapter 7 human cadaveric kidneys were perfused with a specially made batch 
of clinical grade KPS-1 in which all glucose was U-13C labelled supplied in bottles as 






Sampling of perfusate from the LifePort® 
Timing and volume of perfusate sampled from the LifePort® varied according to 
experiment protocol. However, the aseptic technique for sampling remained the same. 
Before sampling, perfusion parameters and temperature were noted. Such data was noted 
prior to sampling as disturbance of flow in the perfusion tubing resulted in the LifePort® 
machine recalibrating flow and resistance parameters.  
Wearing sterile gloves, the cap was removed from the sampling port. Following this a fresh 
sterile 5ml syringe was inserted firmly into the sampling port creating a water-tight seal 
and kept vertical. The desired volume of fluid was aspirated into the syringe prior to 
removal from the sampling port.  
Fluid was then expelled into 2ml cryovials then placed in -20°C freezer storage prior to 
transfer to -80°C freezer storage until sample analysis. In Chapter 7 where experiments 
were performed in the clinical setting, cryovials were placed directly in dry ice prior to 
freezer storage at -80°C.  
Where perfusion fluid was sampled to be run in a Point of Care blood gas analyser, 1ml 
was retrieved in a blood gas syringe. Samples were run in a calibrated Point of Care 
analysis machine (Cobasâ b221, Roche Diagnostics Limited) to provide pH, pO2, pCO2, 
lactate and glucose readings level in real time. At no point was any perfusion fluid returned 
to the perfusion circuit or reservoir.   
End-point tissue sampling  
At the end of the perfusion period, kidneys were removed from the LifePort® and quickly 






exposure. Following this, sections of cortex and medulla no larger than 1cm3 were 
dissected out and placed in 50ml Falcon tubes then flash frozen in liquid nitrogen prior to 
storage at -80°C. Figure 35 shows a laterally bisected porcine kidney with dotted lines 
indicating where tissue would be sampled for cortex and medulla samples.   
 
Figure 35. Laterally bisected porcine kidney following hypothermic machine 
perfusion with examples of areas of renal cortex (C ) and medulla (M) 
highlighted from which tissue was sampled.   
NMR and MS sample preparation  
Preparation of perfusate samples  
Perfusate samples were either extracted for analysis or run ‘neat’. When samples were 
extracted, perfusate samples for 1D 1H NMR, 2D 1H,13C HSQC NMR and GC-MS analysis 
were taken from the upper layer of a biphasic solution containing polar metabolites, formed 
from a vigorously mixed solution of equal amounts of neat perfusate, methanol (-80°C) 









When analysed ‘neat,’ perfusates were thawed and vortexed before 430μl was added to 
an Eppendorf in addition to 230μl NMR buffer. Contents were mixed by vortexing for ten 
minutes before being sonicated for ten minutes to break up any microparticles. 
Preparation of end-point tissue samples  
Cortex and medulla samples were cryo-homogenised manually using a Cryo-cup grinder 
(Biospec Products, Bartlesville, OK, USA). From this, 0.5g was suspended in 5.1ml 
methanol (-80°C) and homogenised in 7ml Tissue homogenizing CK28 tubes (Bertin 
Technologies, Montigny-le-Bretonneux, France) using a Precellys® 24 Dual homogeniser 
(Bertin Technologies, Montigny-le-Bretonneux, France) at low speeds in short intervals 
(5000 RPM for 8x10 s) to prevent samples from heating. Following this, 5.1ml Chloroform 
(-20°C) and 4.65ml de-ionised water were then added and the resultant solution mixed 
vigorously. From the upper polar layer of the sample, 1.5ml was aspirated and dried at 
35°C overnight in a vacuum drier.  
Re-suspension of extracted tissue samples  
The composition of standard NMR Buffer solution is as follows: 100 mM phosphate buffer, 
containing 0.5 mM DSS, 2mM Imidazole and 10% D2O.  In the case of extracted samples, 
dried polar residue was resuspended in 600μl of standard NMR buffer.  
Neat perfusate samples were prepared using a four-fold concentrated NMR buffer solution 
with the following composition: 400 mM phosphate buffer containing 2 mM DSS and 8 mM 
imidazole. 150μl of four-fold buffer was mixed with 390μl of each fluid sample and 60μl of 






For all neat samples and resuspended polar extracts, 600μl of sample was added to a 
5mm NMR tube and then hand-centrifuged to remove air bubbles before being wiped with 
methanol using a lint free cloth. Sample cassettes were then loaded into the Bruker 








NMR data was acquired using a 600 MHz Bruker Avance III NMR spectrometer at the 
Henry Welcome Building for Biomolecular NMR Spectroscopy, University of 
Birmingham. One-dimensional proton NMR spectroscopy (1D-1H NMR) and two- 
dimensional proton-carbon Heteronuclear Single Quantum Coherence spectroscopy 
(2D-1H,13C HSQC) were used with a 5mm inverse Cryoprobe.  
1D 1H NMR acquisition protocols 
Acquisition time per sample was 15 minutes. Sample temperature was set to 300 K. Water 
resonance was suppressed using NOESY-presat. The spectral width was set to 7288.6 
Hz (12 ppm). For 1D-1H spectra, 32768 data points were acquired using a 4 second 
relaxation delay and 128 transients. Automated tuning, matching and shimming to a DSS 
line width of <1Hz was performed prior to acquisition of each spectrum.  
1D 1H NMR analysis   
Following acquisition, 1D-1H Spectra were read into MetaboLab, a MATLAB based NMR 
software (177) where manual phase correction and spline baseline correction were 
performed before data export into Chenomx NMR Suite 8.3 (Chenomx INC, Edmonton, 
AB, Canada) where spectra were once again visualised with the area under each peak 
corresponding to the concentration of each metabolite. Where multiple peaks at different 
chemical shift positions related to a particular metabolite, metabolite concentration was 






One function of Chenomx software is automated peak assignment for a pre-selected 
group of metabolites, also allowing for signal shift. Following automatic peak assignment, 
the allocation of each metabolite was checked/ re-allocated in each spectrum where 
allocation was deemed to be incorrect. All samples were effectively blinded from point of 
NMR experimentation when they were assigned a sample number until after spectral 
analysis.   
To ensure reproducibility and consistency of analysis, the same peak annotation was 
performed at one area of chemical shift for all experiments. A reference table for 
metabolites was created with corresponding areas of chemical shift where peak 
annotation was performed (Table 3).  
For metabolites where more than one peak appears in the same chemical shift area, 
Chenomx software shows peak assignment for each metabolite in addition to a summation 
spectral line for all metabolites which have been assigned. The reported concentrations 
























3-Hydroxybutyrate  1.204 Hippurate  7.82 
3-Methylxanthine  8.02 Hypoxanthine  8.20 
Acetate  1.91 Inosine  6.055 
Adenine  8.11 Isoleucine  0.997 
Alanine  1.46 Isopropranolol  1.162 
Citrate  2.67 Lactate  1.40 
Ethanol  1.17 Leucine  0.948 
Formate  8.44 Malonate  3.11 
Fumarate  6.51 Mannitol  3.840 
Gluconate  4.12 N-Phenylacetylglycine  7.412 
Glucose  3.524 Ribose  2.21 
Glutamate  2.341 Tyrosine  6.877 
Glutathione  2.97 Uracil  7.52 
Glycine  3.54 Valine  1.029 
2D -1H,13C HSQC acquisition protocols 
For 2D-1H,13C HSQC experiments, spectral widths were set to either 7,288.6 Hz (1H, 12 
ppm) or 24,155 Hz (13C, 160 ppm). 512 complex data points were acquired for the 1H 
dimension of 2D-1H, 13C-HSQC NMR spectra. 30% of 2048 complex data points (614 
complex data points) were acquired for the 13C dimension. The spectra were zero-filled to 
1024 (1H) times 16384 (13C) real data points prior to multiplet simulation analysis. 
Acquired spectra were reconstructed with compressed sensing using the MDDNMR and 
NMRpipe software (178-180) prior to analysis using MetaboLab, which uses pyGamma 






2D -1H,13C HSQC analysis  
Chemical shift was first calibrated using the methyl group of lactate as per its assignment 
in the human metabolome database (182) resulting in a 2D spectrum display shown in 
Figure 36 where 1H chemical shift is shown on the x-axis and 13C chemical shift is shown 
in the y-axis. 
 
 
Figure 36. 2D 1H-13C HSQC spectrum of perfusate sample using KPS-1 supplemented with universally 
labelled glucose. Axes denote chemical shift of 13C nuclei (y-axis) and 1H nuclei (x-axis).  
Spectral peaks were manually allocated to the nuclei of carbon atoms with an attached 
proton within metabolites from the metabolite library available in Metabolab (Figure 37). 






were then matched to observed splitting patterns of each carbon nucleus (Figure 38, 
Figure 39).  
 
Figure 37. Spectral peaks attributed to C(2)  and C(3) of lactate  
 







Figure 39. Splitting of C(2) and C(3) of alanine. 
Where mass spectrometry was also used to analyse samples, MetaboLab was used to 
integrate data from 2D 1H,13C HSQC NMR and GCMS using a model free approach (158) 
to derive isotopomer distributions for key metabolites of interest.  
Firstly, a set of isotopomers to be fitted was proposed including an estimation of how much 
isotopomer was present. Following this, Metabolab software back-calculated multiplet 
percentages as well as MID percentages. The software then compared the back-
calculated percentages with experimental data. A simplex fitting algorithm was then used 
to determine the optimum percentages of proposed isotopomers to fit the experimental 
data. After fitting, any major discrepancy between simulated and experimental data 









Figure 40. Calculation of isotopomer combinations of lactate using imputed 2D NMR and MS data on 
Metabolab software. 
 
Gas Chromatography-Mass Spectrometry  
Mass spectrometry samples were analysed by Alpesh Thakker in the metabolic tracer 
analysis core (MTAC) facility in the Institute of Metabolism and Systems Research. GC-
MS was performed on a standard volume of sample described for each set of experiments.  
Sample derivatisation  
In order to derivatize proteinogenic amino acids, organic acids and glycolytic 
intermediates for GC-MS analysis, the dried extract was incubated at 95°C for 60 minutes 
in open tubes in order to remove any residual moisture in the samples. The dried polar 
extract was dissolved in 40μl 2% methoxyamine HCL in pyridine (Sigma-Aldrich, 
Dorset,UK) followed by incubation for 60 minutes at 60°C. Subsequently, 60μl N-
tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) with 1% (w/v) 
tertbutyldimethyl-chlorosilane (TBDMSCI) (Sigma-Aldrich, Dorset, UK) derivatization 






well-sealed tube which prevented evaporation. Samples then underwent centrifugation at 
13,000 rpm for 5 minutes. The clear supernatant was transferred to a chromatography vial 
with a glass insert (ThermoFisher, Scientific, Chromacol, Hertfordshire, UK) and 
proceeded immediately to GC-MS analysis. 
Analysis of derivatised samples  
GC-MS was performed using an Agilent 7890B Series GC/MSD gas chromatograph with 
a polydimethylsiloxane GC column coupled, with a mass spectrometer (Agilent 
Technologies UK Limited, Stockport, UK). Prior to sample analysis the GC-MS was tuned 
to a full width at half maximum (FWHM) peak width of 0.60 atomic mass units (a.m.u) in 
the mass range of 50 to 650 mass to charge ratio (m/z) using PFTBA tuning solution. A 
total of 1μl of each sample was injected into the GC-MS in split mode 1:10 with helium 
carrier gas at a rate of 1.0 ml/min. The inlet liner containing glass wool was set to a 
temperature of 270°C. Oven temperature was set at 100°C for 1 minute before ramping 
to 280°C at a rate of 5°C/min. Temperature was further ramped to 320°C at a rate of 10 
°C min/min held at 320°C for 5 minutes. Compound detection was carried out in full scan 
mode in the mass range 50 to 650 m/z, with 2-4 scans/sec, a source temperature of 
250°C, a transfer line temperature of 280°C and a solvent delay time of 6.5 minutes. The 
injector needle was cleaned with acetonitrile three times before measurement 
commencement and three times following every measurement thereafter. 
Raw GC-MS data was converted to common data format (CDF) using the acquisition 
software.  For determination of the mass isotopomer distributions (MIDs), spectra were 
corrected for natural isotope abundance. Data processing from raw spectra to MID 







Calculation of the concentration of labelled metabolites  
The area of chemical shift at which peak annotation was performed in 1D spectra 
corresponded to the chemical environment of a proton, group or neighbouring protons. 
This chemical environment is influenced by the presence of a neighbouring 13C atom. 
Hence when quantifying the concentration of lactate using 1D 1H NMR, the quantification 
is based on the 1H signal neighbouring a 12C atom in the position of carbon 2 in the lactate 
molecule.  
Combined analysis using 2D NMR and GCMS data using Metabolab details isotopomer 
distributions, enabling a calculation to be performed to determine the proportion of 
isotopomers of lactate, for example, with an unlabelled 12C atom at the position of the 
second carbon in the lactate molecule. Using this information and the concentration of 
lactate determined using 1H signal adjacent to 12C atom at the carbon 2 position, the 
concentration of U-13C lactate can be determined by scaling concentrations according to 
the isotopomer distribution. Similar calculations were performed to determine the absolute 
concentration of U-13C alanine.  
Histology 
Light Microscopy 
Wedges of renal cortex and medulla from 3 pairs of HMP/O2 and HMP/Air kidneys and 
renal arteries were fixed in formalin and processed to a paraffin block. Following this, 4µm 
sections of renal cortex and medulla were stained with Haematoxylin and Eosin (H&E) 







Photomicrographs of 10 random glomeruli (40x magnification), 10 random areas 
containing predominantly tubules (5 subcapsular and 5 mid-cortex at 20x magnification) 
and 5 transverse sections of intra-parenchymal arteries (20x magnification) were 
assessed. Image J 1.05i software (National Institute of Health, USA) was used for 
morphometric assessment.   
Images were assessed for evidence of injury using glomerular shrinkage, interstitial 
oedema and perivascular oedema as indicators of damage. To calculate glomerular 
shrinkage, the percent glomerular area occupied by glomerular tuft was determined for 
each glomerulus. The mean distance between 25 random tubules for each 
photomicrograph was used as a surrogate marker of interstitial oedema. The proportion 
(%) of vessel area to adventitia was calculated to determine the extent of perivascular 
oedema; lower percentages indicated more perivascular oedema. 
The injury of extra-parenchymal renal arteries were semi-quantitatively graded: 
endothelial denudation: 0 nil, 1 minimal, 2, moderate, 3 extensive; Intimal oedema: 0 nil, 
1 focal, 2 moderate to extensive; medial oedema and vacuolation of smooth muscle cells: 
0 normal, 1 minimal, 2 moderate to extensive. 
Electron Microscopy 
Standard protocols of the Electron Microscopy Laboratory, University Hospitals 
Birmingham, Birmingham, UK were followed. For electron microscopy (EM), biopsies 
(2mm x 2mm x 5mm) of renal cortex were fixed in 2.5% glutaraldehyde in 0.1 M phosphate 
buffer, pH 7.4 then postfixed in osmium tetroxide and en-bloc stained with uranyl acetate 






were stained with toluidine blue and ultrathin sections stained with lead citrate and 
examined by a Joel JEM1200-EX 11 electron microscope.  
Random photomicrographs were taken of glomeruli, tubules and arteries/arterioles at 
6800x to include mesangial areas and glomerular capillary loops. Of the total mitochondria 
present, the percent of glomeruli of normal morphology, condensed and containing 
flocculent densities were determined for each kidney. Both the pathologist and technician 
who acquired and analysed images with light and electron microscopy were blinded to the 
kidney allocation groups. 








Biochemical Assays  
Glutathione assay  
Samples were prepared by adding 0.2g powdered renal cortex to 5ml ice cold cell lysis 
buffer (0.1 % Triton X-100 in PO4-EDTA assay buffer) prior to mixing via vortex. PO4-
EDTA assay buffer consisted of 5 mM EDTA, 100 mM NaH2PO4, adjusted to pH 8.0. At 
this point 200 µL was removed for protein estimation, performed using the Bradford assay.  
In a new tube, 900 µl of the sample was added to 100 µL ice-cold 50% trichloroacetic acid 
(TCA). Protein-free supernatants containing reduced glutathione (GSH) were prepared by 
centrifugation of the samples at 20,000 rpm for 20 minutes at 4°C. Of the supernatant, 10 
µL was used as the sample in the GSH assay.  
The GSH assay, first described by Hissin and Hilf (184), was used to calculate GSH 
concentrations. Samples prepared as above were transferred to a 96 well plate with prior 
addition of 180 µL PO4-EDTA assay buffer to each well. A standard curve was constructed 
(0.1-1.2 µg GSH) using a freshly made GSH stock solution (0.1 mg/ml in ice-cold assay 
buffer), which was added to wells containing 180µL of PO4-EDTA assay buffer and 10µl 
5% TCA.   
Following addition of 10 µl o-phthalaldehyde solution (1 mg/ml in 100% methanol), 
samples were mixed thoroughly via agitation. Fluorescence was measured using a 
microplate reader (Infinite 200 Pro, Tecan) at an excitation wavelength of 355 nm and an 
emission wavelength of 420 nm. Total GSH (nmol) was determined from the standard 






ThioBarbituric Acid Reducing Substances (TBARS) assay 
Samples were prepared by adding 0.1g powdered renal cortex to 1ml KCl buffer (1.15% 
KCl and 1% DMSO) prior to mixing via vortex. At this point 200µL was removed for protein 
estimation, performed using the Bradford assay. 
In a new tube, 200 µL of the sample was added to 200µL 8.1 % (w/v) sodium dodecyl 
sulphate, 1.5ml 20% (v/v) acetic acid (pH 3.5), 900µl thiobarbituric acid (TBA) solution, 
and 1.2ml distilled water. TBA was prepared as a 25mg/ml solution in 0.2M NaOH and the 
final TBA solution was prepared by mixing TBA, trichloroacetic acid and 12M HCl at a 
6:5:1 ratio. The sample was heated at 95°C for 45 minutes, allowed to cool in a room 
temperature water bath, and centrifuged at 2000 g for 10 minutes. 250µl of each samples 
was transferred into triplicate wells in a 96-well plate. A standard curve was constructed 
for malondialdehyde (MDA) (0.5-5mM) using an MDA standard solution (500mM). Varying 
volumes of the MDA standard were added to wells containing 250µL of the TBA solution 
described above.  The absorbance was measured at 532nm using a microplate reader 
(CLARIOstar, BMG Labtech) and total MDA (nmol) was determined from the standard 
curve and normalised to protein mass.  
TBA and GSH were purchased from Sigma-Aldrich, UK. TCA and BSA were purchased 
from Fisher Scientific, UK. OPT was purchased from MP Biomedicals, UK. The MDA 









Glutathione S Transferase Pi assay  
A glutathione s transferase pi (GST Pi) enzyme-linked immunosorbent assay (ELISA) was 
performed as per manufacturer’s instructions (Oxford Biomedical Research, UK). 
Following thawing of perfusate samples, 100µL of perfusate sample was added to a 
corresponding well on the 96 well microplate provided prior to incubation at room 
temperature for 1 hour. A standard curve was prepared for GST Pi (0-10ng/mL) using a 
GST Pi standard solution (10ng/mL) prior to the same incubation period.  
The contents of each well was then washed. This involved the contents of the microplate 
being shaken out prior to washing of each well three times with 300µL wash buffer. The 
microplate was then tapped on a lint free towel to ensure no solution remained in the well. 
The microplate was then incubated at room temperature for 1 hour following addition of 
100µL of detection antibody prior to repeating the wash step as described. The microplate 
was then incubated again at room temperature for 30 minutes following addition of 100µL 
HRP conjugate to each well. The wash step was then repeated.  
After addition of 100µL TMB substrate (stabilised TMB reagent), colour was allowed to 
develop in the plates. The reaction was stopped with the addition of 25µL 3N sulphuric 
acid to each well. The base of each microplate was wiped with a lint free cloth prior to 
insertion into the plate reader. Plates were read at 450nm in a microplate reader.  The 
change in standard concentration was plotted against the concentration of GST Pi, in order 
to determine final concentrations of GST Pi in each perfusate sample, with a standard 








Neutrophil Gelatinase-Associated Lipocalin assay  
Human Lipocalin-2/ neutrophil gelatinase-associated lipocalin (NGAL) ELISA was 
performed as per manufacturer instructions (R&D Systems, UK). A standard curve was 
prepared for NGAL (0-10ng/mL) using the calibrated diluent RD5-24 supplied (100ng/ml).  
To begin with, 100µL of assay diluent RD1-52 was added to each well of the 96 well 
microplate provided. Either 50µL standard or 50µL sample was then added to each well. 
Wells were covered with adhesive tape prior to incubation for 2 hours at 2-8°C in a 
laboratory fridge. Each well was then aspirated and washed with wash buffer solution 
400µL using a squirt bottle. This wash step was performed 4 times. Following the 4th wash, 
any remaining liquid was removed by decanting then blotting against a lint free towel.  
Following addition of 200µL cold Human Lipocalin-2 conjugate to each well the plate was 
covered with adhesive strips and incubated for 2-8°C in a laboratory fridge for 2 hours. 
The plate was washed 4 times as described above. Following addition of 200µL of 
substrate solution to each well, the plate was then incubated at room temperature for 30 
minutes protected from light.  
A total of 50µL of stop solution was then added to each well following observation of colour 
change from yellow to blue. The base of each microplate was wiped with a lint free cloth 
prior to insertion into the plate reader. Plates were read at 450nm in a microplate reader. 
The change in standard concentration was plotted against the concentration of NGAL, in 
order to determine its final concentration in each perfusate sample, with a standard curve 







Lactate Dehydrogenase assay  
Lactate dehydrogenase assay was performed according to manufacturer’s instructions 
(Sigma-Aldrich, St. Louis, USA). A standard curve was prepared by adding 0, 2, 4, 6, 8 
and 10µL of 1.25mM NADH generating 0 to 12.5nmol. 25µL of perfusate samples was 
added to each well of a 96 well plate in addition to 25µL of assay buffer. The contents of 
each plate was mixed via horizontal shaking for 1 minute.  
The base of each microplate was wiped with a lint free cloth prior to insertion into the plate 
reader. After 2 minutes, plates were read at 450nm in a microplate reader. The plate was 
then incubated in the dark at 37°C for 5 minutes prior to a second absorbance reading 
taken at 450nm.  
Further absorbance readings were taken at 450nm until the most active sample was near 
the end of the linear range of the standard curve. To analyse results, the absorbance 
reading from the blank 0nmol NADH reference sample was subtracted from the final 
absorbance reading from each sample for plates read at each time point. The change in 
absorbance measurement between initial and end point plates was calculated for each 
sample and for standard concentrations.  The change in standard concentration was 
plotted against the concentration of NADH, in order to determine final concentrations of 
NADH in each perfusate sample, with a standard curve plotted using linear regression and 







Chapter 3 : Developments in NMR 
spectroscopy techniques: 13C spectral 
filters and J-Coupling based splitting 
enhancement  
 
In this Chapter, two advances in NMR methodology are described with their utility 
demonstrated for analysing perfusate and tissue samples following HMP. The techniques 
were written up and submitted in the form of a manuscript which was published in 
Wellcome Open Research in September 2018 (185). 
The techniques were developed in conjunction with my supervisor Christian Ludwig. I 
wrote and refined the manuscript in addition to performing porcine kidney experiments to 
demonstrate the utility of 13C spectral filters and J-Coupling based splitting enhancement 















Advances in NMR methodology including modification and development of pulse 
sequences are key to improving sensitivity of such experiments with shorter sample run 
time. The combination of NMR and mass spectrometry data is useful to determine 
isotopomer distribution when both techniques are combined in a model-free approach 
(158). However, such methodology does not readily aid quantification of labelled 
metabolites as 2D 1H,13C HSQC pulse sequences also require 1D 1H NMR pulse 
sequences to allow metabolite quantification. The time taken to analyse one sample using 
such pulse sequences is around 4 hours.  
For the purposes of identifying labelled metabolites which are a product of universally 
labelled glucose, the ideal pulse sequence would be permit quantification of labelled 
metabolites in a short time enabling multiple samples to be run in a short period. Bon et 
al suggested simple 1D 1H NMR pulse sequences may be useful to analyse perfusate 
samples during HMP in the clinical setting (172).  
In this Chapter, quantitative spectral filters were developed and used to analyse the 
perfusate of kidneys undergoing HMP. In addition, the attached publication describes J-
Coupling based splitting enhancement in 2D-NMR spectra. This technique was applied to 
extracted renal cortex samples acquired from a kidney which underwent oxygenated HMP 
as part of experiments described in Chapter 7.  
Quantitative spectral filters  
It is not possible to determine whether the singlet component in the multiplet is present 






consequence, the quantitative multiplet analysis needs additional information to scale the 
multiplet percentages. Such information could be mass isotopomer distribution data. In 
the absence of such data, the additional information can either be created by preparing 
paired samples (labelled/ unlabeled), albeit at the risk of incorporating biological noise into 
the data, or by the use of quantitative spectral filters, which allow the determination of 
absolute per carbon percentages of 13C incorporation. Quantitative spectral filters 
therefore provide a quick test for 13C incorporation with the limitations that 1D spectra are 
subject to signal overlap restricting the extent to which signals can be assigned accurately.  
Enhancement of J-coupling based splitting  
The manuscript describes pulse sequences which enhance J-coupling based splitting with 
the main advantage being a reduction in the number of increments which need to be 
acquired as a result of the pulse sequence reducing NMR data acquisition times.  
This was used routinely for NMR experiments conducted during this thesis with a resultant 
four-fold decrease in acquisition times. When used in conjunction with non-uniform 
sampling, this permitted a further four-fold decrease in acquisition time meaning 
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      Amendments from Version 1
This version addresses all major and most minor criticisms of the 
reviewers. We simplified the biological models and concentrated 
mostly on renal metabolism, by adding new experimental data. 
We also removed 900 MHz data and are now using NMR data 
acquired at 600 MHz only. We redesigned most figures to exclude 
spectral overlays to improve clarity and added line shape 
simulations. We also added a new figure, which is now Figure 5, 





Investigations of metabolism in health and disease increas-
ingly rely on tracing the use of stable isotope-enriched nutrients 
through the cell’s metabolic pathways. The most widely utilised 
technology platform to analyse the resulting complex patterns 
of labelling in multiple cellular metabolites is mass spectrom-
etry (MS), due to its high sensitivity, short run times and a 
resulting low-cost operation1–12. Conversely, NMR spectros-
copy is relatively under-utilised, despite being able to provide 
higher resolution information on the conversion of synthetically 
produced stable isotopes of nutrients are incorporated into 
cellular metabolites12–19. This is because NMR spectroscopy has 
historically suffered from low sensitivity, long acquisition times 
and the need for complex analytical tools.
NMR spectroscopy is, however, ideally suited to answering 
some of the more pressing questions about metabolic control in 
health and disease. We currently have limited knowledge about 
the compartmentalisation of metabolic pathways in metaboli-
cally-active organelles, such as mitochondria, and therefore 
whether the same metabolite is selectively utilised for distinct 
purposes in different compartments20. Given the recent drive to 
target metabolism in various diseases, understanding the control 
of metabolism by different tissues is critical to the ability to 
select specific therapies which target the desired pathways 
within appropriate cellular compartments. While sample 
analysis by high-resolution NMR spectroscopy is performed 
ex vivo or in vitro, the data obtained provide information on 
metabolic pathways in vivo.
Stable isotope-enriched metabolic precursors, such as glu-
cose or glutamine, are employed as metabolic tracers. These 
synthetically produced nutrients are enriched in isotopes with a 
low natural abundance, such as 13C or 15N. Despite the fact that 
metabolites can arise from multiple sources, the contribution of 
the different metabolic pathways to the synthesis of this metabo-
lite can be determined through the analysis of the 13C and/or 15N 
distribution within the metabolite (Figure 1). The couplings 
Figure 1. Tracing of metabolic pathways. The labelling patterns arising from [1,2-13C] glucose (A & B) as well as from [U-13C,15N] glutamine 
(C for 13C labelling and A–C for 15N labelling) are shown. Metabolism of [1,2-13C] glucose leads to distinctive labelling patterns in lactate 
and alanine ([2,3-13C] lactate/alanine when using glycolysis and [3-13C] lactate/alanine when using the pentose phosphate shunt, PPP) 
(Panel A). Similarly, glutamate and aspartate express different labelling patterns from [1,2-13C] glucose, depending whether they were 
synthesised via pyruvate dehydrogenase (PDH; resulting in [4,5-13C] glutamate) or via the pyruvate carboxylase (PC; resulting in [2,3-13C] 
aspartate) route (Panel B). Metabolisation of labelled glutamine can reveal other anaplerotic pathway activities such as reductive carboxylation 
(Panel C).
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are visualised in the indirect dimension of an HSQC spectrum 
allowing the determination of the percentage incorporation of 
isotopic label into adjacent nuclei. While MS data does not 
need a reference sample to distinguish between labelled and 
unlabelled metabolites, it is not always possible to derive the 
exact distribution of labelled nuclei within a molecule. In con-
trast, NMR spectroscopy data can resolve label distribution at the 
atomic level, enabling a clearer picture of the label distribution in 
metabolites.
Our recently published combined NMR spectroscopy and MS 
approach (CANMS) harnesses the strengths of both modalities 
to produce highly-resolved metabolism information in the form 
of metabolite isotopomers19. The detailed interpretation of MS 
isotopologue data, when using MS data in isolation, requires 
use of a pre-defined metabolic model. In contrast, the integrated 
analysis of NMR spectroscopy and MS data makes fewer 
assumptions about the metabolic network, providing a more 
accurate insight into relative pathway contributions than is 
possible with current established methods or the independent 
analysis of MS or NMR spectroscopy data alone. For example, 
proton-less carbon atoms do not give rise to a signal in 
2D-HSQC NMR spectra, although incomplete information 
on those carbons is available via splitting of adjacent carbon 
nucleus signals. The combination of NMR spectroscopy and 
MS analysis fills this gap as the MS data provides informa-
tion on the amount of single carbon labelling into those carbon 
nuclei via “m+x” isotopologues. [1,2-13C] glucose is the optimal 
tracer to assess metabolic flux through glycolysis vs pentose 
phosphate pathway (PPP) shunting back into glycolysis. While 
the glycolytically derived isotopomer of lactate is [2,3-13C] 
lactate, the PPP derived isotopomers can be [3-13C], [1-13C] or 
[1,3-13C] lactate. Although the first isotopomer can be assessed 
with NMR spectroscopy data, the other two isotopomers 
include labelling in C(1), which HSQC NMR spectroscopy 
is “blind” to. In these cases, MS data adds new information 
to the NMR spectroscopy data by contributing the isotopo-
logues NMR spectroscopy is not able to detect, while NMR 
spectroscopy adds to the MS data by differentiating between 
[1,3-13C] and [2,3-13C] lactate.
A major drawback of utilising 13C-13C scalar coupling informa-
tion to derive isotopomer distributions is the time required to 
acquire spectra. For example, around four hours are required 
for the acquisition of a 2D-HSQC NMR spectrum with high- 
resolution in the 13C dimension, even when using fast, 
state-of-the-art non-uniform sampling (NUS) techniques.
Here we describe two developments, quantitative spectral filters 
and signal splitting enhancement, to facilitate and speed-up the 
acquisition of NMR spectra for tracer-based analysis of 
metabolism. Such techniques permit high throughput metabolic 
pathway profiling, increasing access, affordability and sensitivity 
when using NMR spectroscopy as an investigative modality. 
Additionally, these developments facilitate fast detection of 15N 
labelling, especially when combined with 13C tracing, thus 
providing extra information allowing more accurate metabolic 
pathway profiling.
Methods and results
Quantitative spectral filters for 13C tracer observation: 1D 
Spectral filters
Experimental setup. A porcine kidney was procured from a 
slaughterhouse (FA Gill, Wolverhampton) following approximately 
14 minutes warm ischaemic time (WIT) as per previous 
experimental methodology18. No animal was killed solely for 
experimental purposes; all were due for human consumption, 
therefore no ethical approval was required. After 2 hours cold 
ischaemic time, kidneys were subject to 18 hours of hypother-
mic machine perfusion. The perfusate sample was collected 
after 6 hrs of perfusion and prepared for NMR analysis.
1D NMR spectra were acquired using a Bruker Avance III 
600 MHz NMR spectrometer equipped with a 5mm z-PFG TCI 
Cryoprobe. 128 transients were acquired for each spectrum with 
a 5 s interscan relaxation delay. A total of 32768 data points 
with a spectral width of 12 ppm was acquired for each FID 
using an adiabatic bi-level decoupling scheme to suppress 1H, 
13C J-coupling during acquisition21. While decoupling for this 
long (2.25 s) was possible because of the cryogenic probe and 
may potentially work with a room temperature probe, care must 
be taken as there will be significant sample heating. The sample 
heating can be significantly reduced, with only very minor 
reduction in resolution, by acquiring for only 1.125 s. In order 
to estimate whether a specific spectrometer with a cryoprobe can 
tolerate the power dissipation originating from the decoupling 
sequence specific attention should be paid to the cryogas heater 
current, which should never fall below its system specific lower 
limit.
The spectra were processed within the MetaboLab software 
package (version 2018.07182055)22. A 0.5 Hz line broadening 
was applied with zero-filling of the data up to 131072 real data 
points prior to Fourier transformation. The resulting spectra 
were referenced using DSS and manually phase corrected. 
Subsequently the spectral baseline was corrected using 
MetaboLab’s spline baseline correction before the spectra were 
exported to Bruker format for metabolites to be quantified in the 
Chenomx software package (version 8.2, http://www.chenomx.
com).
NMR methodology. Despite their relative simplicity and 
limited resolution, 1D-NMR spectra are highly sensitive tools 
with which to identify and quantify metabolites. Spectral filters 
enable the acquisition of spectra which filter out certain 
signals, thereby reducing ambiguity in 1D spectra associ-
ated with attributing peaks to nuclei within metabolites. For 
example, one can acquire 1D 1H NMR spectra of protons 
bound to 13C only, simplifying signal assignment and analysis 
of the acquired spectra. The simplest approach to collect such 
spectra would be to acquire the first increment of a 2D-1H, 
13C-HSQC spectrum. However, signal intensities are not 
directly comparable with those in standard 1D-1H NMR spectra. 
It is therefore not possible to directly derive 13C percentages 
based on a comparison of those spectra with standard proton 1D 
spectra unless only a small subset of molecules is labelled 
with 13C and one accompanying spectrum is scaled so that 
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the majority of signals within the two spectra are of same 
intensity23. Spectral filters such as BIRD, TANGO and 
POCE24–28 originated in protein NMR spectroscopy to filter out 
certain parts of the magnetisation and therefore quantitative 
data cannot be gained from resultant output spectra. Quantitative 
comparisons between unfiltered and filtered spectra are usually 
unnecessary, except for tracer-based analysis. Here we present a 
novel spectral filter which enables quantitative analysis of resultant 
spectra from single samples, enriched with 13C tracer.
Panels A-1 and B-1 in Figure 2 show the pulse sequences 
implementing the quantitative spectral filter. While the central 
Figure 2. Spectral Filters in 1D spectroscopy. To determine percentage 13C incorporation two spectra are acquired per sample. One 
spectrum (A) contains 1H signals originating from all protons (all 1H spectrum), while the second spectrum (B) only contains signals from 
protons attached to a 13C nucleus. The central 13C P−pulse with phase F3 is executed every second transient in both experiments. The 
proton magnetisation in the all 1H pulse sequence is the same for 12C and for 13C bound protons and as a consequence, all 1H magnetisation 
is longitudinal during the interval between 1H pulses with the phases F2 and F4. Because of the additional 13C P−pulses in the 13C bound 
1H pulse sequence, the magnetisation for the two different kinds of protons develops differently. Here only the 13C bound 1H magnetisation 
is longitudinal in the interval between the 1H pulses with the phases F2 and F4. Therefore, the 12C bound 1H magnetisation can be destroyed 
using the two pulse field gradients labelled gp1 and gp2. A recovery delay of 200 µs was used after each gradient. The central 
13C P−pulse 
with phase F4 improves magnetisation selection as it is accompanied by phase changes of the 1H pulses and the receiver. All 13C P-pulses 
are adiabatic Chirp pulses with GB1max = 10 kHz. 1H,13C J-coupling is suppressed during acquisition using adiabatic bilevel decoupling 
(ad-bilev)21. The pulse phases are: F1 = x, x, -x, -x; F2 = x, x, -x, -x for the all 1H spectrum (A-1) and y, y, y, y for the 13C bound 1H spectrum 
(B-1), F3 = x, y, -x, -y, F4 = x, -x, -x, x, y, -y, -y, y for the all 1H spectrum (A-1) and y, -y, -y, y, -x, x, x, -x for the 13C bound 1H spectrum 
(B-1). Panels A-2 and B-2 show the peaks from Alanine and Lactate methyl protons in the all 1H spectrum (A-2) and the 13C bound 
1H spectrum (B-2). The scaling of the two spectra is identical allowing easy determination of the percentage incorporation of 13C metabolites. 
Panels A-3 and B-3 demonstrate the complete removal of the 12C bound proton signal from the 13C edited spectrum (B-3) leaving only 
the natural abundance 13C signals to be observed.
Page 5 of 34
Wellcome Open Research 2018, 3:5 Last updated: 19 SEP 2018
13C P-pulse (phase F3) is used only in odd numbered transients 
and replaced with a delay of the same length during even 
numbered transients, the two other 13C P-pulses are only used 
in the 12C filtering experiment (B-1), where 1H magnetisation 
to 12C neighbours is filtered out, so that only 13C bound 1H 
magnetisation contributes to the signal intensities in the 1D 
spectrum. The phase cycle F1 changes as well between the 2 
experiments, as indicated in the figure legend.
Panels A-2 and B-2 in Figure 2 depict two sample spectra from 
a perfusate sample where a cadaveric porcine kidney was 
perfused with modified University of Wisconsin machine 
perfusion solution (UW MPS) during a period of hypothermic 
machine perfusion. The standard unlabelled glucose constituent 
(10 mM) within classical UW MPS was replaced with 10 mM 
universally labelled glucose, for use as a metabolic tracer during 
the 18 hour perfusion.
While filters such as BIRD utilise relaxation to minimise the 
unwanted part of the magnetisation, methods such as TANGO 
or POCE generate magnetisation where 12C bound 1H atoms 
possess either the same or the opposite phase compared to the 
magnetisation of 13C bound 1H atoms, generating two different 
spectra. By subtraction of these two spectra, the magnetisation 
of 13C bound 1H atoms can then be calculated. In case of low 13C 
incorporation, as with any difference technique, subtracting 
two very large signals in presence of a small signal can lead to 
substantial artefacts. The quantitative spectral filter works 
slightly differently compared to TANGO and POCE as the pulse 
sequence depicted in Figure 2, panel B-1 makes use of two 
gradient pulses (gp1 and gp2) to destroy unwanted magnetisation. 
As an example, panels A-3 and B3 in Figure 2 show a variant 
of the pulse sequences where the adiabatic bilevel decoupling 
(ad-bilev)21 has been omitted, so that the 12C and the 13C bound 
1H signals appear separated in the spectrum. The 12CH3 signal 
in A-3 has been truncated to be able to visualise the 13C 
satellites, which appear with 0.5% of the peak height of the 
12CH3 signal. As can be seen in panel B-3, the 
12CH3 signal is 
completely suppressed without leaving an artefact, so that even 
signals from naturally occurring 13C alone are easily detectable in 
a 13C decoupled spectrum.
The quantitative spectral filter is invariant with respect to 
differential 1H relaxation rates or signal multiplicities. As with 
any J-coupling based filtering approach, the 12C filtered 
spectrum will be scaled with a factor that is proportional to 
sin(2PDJCH)2, where D is the delay during the first and last spin 
echo. D is usually set to ¼JCH with JCH = 145 Hz. Assuming a 
minimum JCH of 120 Hz and a maximum JCH of 165 Hz, results 
in a maximum downscaling of 7.2%.
J-Coupling based splitting enhancement in 2D-NMR 
spectra
Experimental setup. Slaughterhouse porcine kidneys (WIT-
15 minutes) were cannulated and flushed with chilled Soltran 
solution (Baxter) as performed in clinical practice. Kidneys were 
placed in static cold storage en route to our laboratory, where 
they were immediately perfused with modified KPS-1 using the 
Lifeport Kidney Transporter 1.0 (Organ Recovery Systems), 
which has been modified to include a paediatric oxygenator. 
Oxygen was supplied at a flow rate of 0.7 L/min for the duration 
of the 24 hours perfusion period.
At the end of the perfusion period, the kidney was removed 
from the perfusion circuit and laterally bisected. Sections of 
cortex and medulla were isolated and snap frozen in liquid 
nitrogen. These tissues were powdered, also under liquid 
nitrogen, and 0.5 g was placed in 7 ml homogenisation tube 
(Precellys, CK28), containing 5.1 ml of HPLC grade methanol 
(−80°C) to quench metabolism. These were homogenised using 
the Precellys 24 dual homogeniser (8x 5000 rpm for 15 s). The 
samples were mixed with 4.65 ml deionised water and 5.1 ml 
HPLC grade chloroform and vigorously agitated. Biphasic 
separation of polar and non-polar solvents was performed by 
centrifugation (1300 g, 15 minutes, 4°C), after which 4.5 ml of 
the polar layer was aspirated and dried overnight at 35°C.
The dried extracts were resuspended in 60 µl NMR buffer 
(0.1 M phosphate buffer, 0.5 mM 4,4-dimethyl-4-silapen-
tane-1-sulfonic acid, 2 mM imidazole and 10% D2O). These 
suspensions were sonicated to dissolve micro particles and then 
35 µl of this solution was added to 1.7 mm NMR tubes.
1H,13C-HSQC spectra were acquired using a Bruker Avance III 
600 MHz NMR spectrometer equipped with a 1.7 mm z-PFG 
TCI Cryoprobe. The HSQC spectra were acquired using 2 
transients per increment with echo/anti-echo gradient coher-
ence selection and an additional pre-saturation for suppressing 
the water resonance during the 1.5 s interscan relaxation delay. 
The 1H dimension was acquired with a spectral width of 13 
ppm using 512 complex data points. The 13C dimension was 
acquired with a spectral width of 160 ppm using 25% (2048) 
of 8192 data points using a non-uniform sampling scheme. 
The non-uniformly sampled spectra were reconstructed via 
the compressed sensing algorithm within the MDDNMR 
(version 2.5)29 and processed using NMRPipe (version 9.2)30. 
All spectra were processed without baseline correction to avoid 
complications in the multiplet analysis procedure.
NMR methodology. The relatively long acquisition times 
of 2D-HSQC spectra are necessary to generate the spectral 
resolution required to resolve complex multiplet patterns19. Here 
we present a technique to manipulate the appearance of NMR 
multiplets in the indirect dimension of 2D-HSQC spectra. 
The ability to expand the splitting caused by J-coupling has 
previously been reported31,32. Here we apply this technique 
in order to negate the requirement for the collection of large 
number of increments in the 13C dimension, which, together with 
methods such as non-uniform sampling29,33 and variation of 
the repetition time34 significantly reduces the time required to 
acquire 2D-HSQC spectra with sufficient resolution. It also 
means that at increasingly higher magnetic fields, the advan-
tages of extra sensitivity and increased 1H chemical shift reso-
lution are not negated by the increased 13C increments needed 
in in order to resolve J-couplings. Enhancement of the split-
ting due to J-coupling can be achieved by incrementing the spin 
echo delay after the period where chemical shift of 13C evolves in 
parallel with the chemical shift evolution (Figure 3). This spin 
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Figure 3. Splitting Enhanced HSQC Spectroscopy. The splitting enhancement due to J-coupling is achieved using an additional spin echo 
subsequent to the 13C evolution period. The delays in the spin-echo for the J-coupling enhancement are multiples of the dwell time (dw). While 
the chemical shift evolves with dw, which is determined by setting the spectral width of the spectrum, splittings are enhanced depending 
on the increment of the 13C gradient selection spin-echo. The HSQC spectrum is acquired using echo/anti-echo for quadrature detection to 
allow for efficient removal of artefacts in only two scans per increment. Optionally, the 13C,15N-couplings can be scaled by the introduction of 
the 15N P-pulse simultaneously with the 13C P-pulse (labelled p2). 1H,13C J-coupling is suppressed during acquisition using adiabatic bilevel 
decoupling (ad-bilev)21. The pulse phases are: F1 = y; F2 = x, -x; Frec = x, -x.
echo refocuses the 13C chemical shift and the 1H-13C coupling, 
but allows the 13C-13C coupling to evolve further. The delays in 
the spin echo are proportional to those in the Ω+JCC evolution 
period with the amount of extra coupling achieved being defined 
by the stretch of the JCC increment compared to the Ω+JCC 
increment. Thus, the 13C-13C J-couplings can be expanded as 
required (Figure 4). The ability to scale the signal splittings to 
varying extents means that the experiment can be tuned to the 
requirements of the sample and which metabolites are present, 
and of interest. Figure 4 demonstrates the effect of J-coupling 
splitting enhancement on 2D HSQC spectra, displaying C(6) of 
13C enriched glucose. The 13C trace through the left-most signal 
(Figure 4D), demonstrates clearly that while the singlet in the 
middle of the multiplet does not change, the splitting due 
to the 1JCC coupling increases and in fact splits into multiple 
signals as the splittings of previously unresolved long-range 
couplings are amplified so that they are large enough to become 
resolved in the spectrum. These splittings can easily be simulated 
(Figure 4E), thereby providing additional information with 
which to model metabolic pathways.
Large expansion of J-coupling also allows for rapid collec-
tion of data, as the resolution required to resolve them becomes 
diminished (Figure 5). However, this should be tempered by 
the need to avoid unnecessary overlap of signals. To date, the 
authors have acquired 2D spectra with up to eight fold 
enhanced 13C J-couplings, combined with shortening the 
acquisition by using variable pulse sequence repetition times34, 
leading to an overall decrease in acquisition time by a factor 
larger than 10 (Figure 5). Panels A to D show the spectral region 
of the methyl groups of lactate and alanine. Panel E shows a 
cross section, as marked in the 2D spectra, from alanine, whereas 
panel F shows the corresponding simulations of those 
multiplets. The acquisition times for the different spectra 
were 233, 110, 51 and 24 minutes (Table 1). Whilst the lines in 
the spectrum become broader due to the shorter acquisition 
times, this is negated by the increase in splittings, allowing 
the analysis of the multiplets with similar precision. Shorter 
acquisition times may be achieved by including spectral fold-
ing in the acquisition protocol or by incorporating new fast 
acquisition schemes such as ASAP- or ALSOFAST-HSQC35. 
15N tracing
Experimental setup. 2D 14 N spectral filter - Sample preparation 
is described elsewhere16. 2D 1H 13C-HSQC NMR spectra with 
and without 14N filtering were acquired using a Bruker Avance 
III 600 MHz NMR spectrometer equipped with a 1.7 mm 
z-PFG TCI Cryoprobe. The HSQC spectra were acquired using 
2 transients per increment with echo/anti-echo gradient 
coherence selection and an additional pre-saturation during the 
1.5 s interscan relaxation delay to suppress the water resonance. 
The 1H dimension was acquired with a spectral width of 13 ppm 
using 512 complex data points. The 13C dimension was acquired 
with a spectral width of 160 ppm using 2048 data points. The 
spectra were processed with quadratic cosine window functions 
and without baseline correction to avoid complications in the 
multiplet analysis procedure.
13 C, 15 N J-coupling splitting enhancement. The human Renal 
Proximal tubule cell line (RPTEC/TERT1, supplied by Evercyte 
GmBH, Austria) was used to investigate the metabolic fates 
of both carbon from glucose, and carbon and nitrogen from 
glutamine. Cells were expanded as described elsewhere36, 
with population doubling level (PDL) routinely tracked using 
in-house software (PDL calculator, EcoCyto). Cells with PDL 
between 43 and 45 were collated and seeded at a density of 
4×104/cm2 in 75 cm2 flasks containing 240 µl/cm2 flux media 
(Zenbio, cat DMEMf12-NGG002), supplemented as above with 
the addition of 17.5 mM [1,2-13C] D-Glucose (sigma 453188) 
and 2 mM [U-13C,U-15N] L-Glutamine (sigma, 607983). Cell 
Page 7 of 34
Wellcome Open Research 2018, 3:5 Last updated: 19 SEP 2018
Figure 4. J-coupling splitting enhancement HSQC spectroscopy. 1H,13C HSQC spectra showing the C(6) of glucose are shown 
(A, B and C). The spectrum with no J-coupling splitting enhancement is shown in blue (A), with an enhancement of two in green (B) and 
with an enhancement of four in red (C). The 13C trace of the HSQC spectra (D), taken from the 1H frequency as depicted by the dashed line, 
clearly shows the increase in observed splitting. The J-coupling splitting enhancement is achieved using an additional spin echo 
subsequent to the 13C evolution period. The delays to achieve the scaling of the splittings are multiples of dw such the use of a delay of 
3*dw will result in a J-coupling splitting enhancement of 4 (one from the t1 evolution and three from the J-coupling splitting enhancement 
spin echo). The observed splitting can be simulated (E) giving the following incorporation percentages. From the no J-coupling splitting 
enhancement spectrum 6.8% / 41.2% / 52 % for [6-13C] / [5,6-13C] / [U-13C], from the two-fold J-coupling splitting enhancement 6.3% / 41.4% 
/ 52.3 % for [6-13C] / [5,6-13C] / [U-13C] and from the four-fold J-coupling splitting enhancement 5.9% / 41.6% / 52.5 % for [6-13C] / [5,6-13C] / 
[U-13C].
culture was continued for 48 hours to allow isotopic labelling, 
after which cells were washed with ice-cold saline solution (0.9%) 
and collected by scraping into 2 ml pre-chilled methanol (-20°C), 
2 ml water (4°C) and 2 ml chloroform (-20°C). The solution 
was vigorously mixed for 10 minutes, after which lysates were 
centrifuged at 15,000 g for 15 min at 4°C. 1 ml of the sample 
was aspirated for NMR analysis. Samples were dried using a 
Savant (SPD1010) speedvac concentrator and then resuspended 
in 60 µL of 100 mM sodium phosphate buffer, containing 
0.5 mM DSS, 2 mM Imidazole in D2O, pH 7.0. The samples 
were vortexed and subsequently sonicated for 10 min and then 
centrifuged at 15000 g for 30 seconds to collate the fluid. Finally 
35 µl of the samples were transferred to 1.7 mm NMR 
tubes.
2D-1H,13C-HSQC and 2D-1H,15N-HSQC NMR spectra were 
acquired using a Bruker Avance III 600 MHz NMR spectrometer 
equipped with a 1.7 mm z-PFG TCI Cryoprobe. The HSQC 
spectra were acquired using 2 transients per increment with 
echo/anti-echo gradient coherence selection with an additional 
pre-saturation to suppress the water resonance during the 
1.5 s interscan relaxation delay. The 1H dimension of the 1H, 
13C-HSQC spectra was acquired with a spectral width of 
12 ppm using 512 complex data points. The 13C dimension was 
acquired with a spectral width of 160 ppm using 25% (2048) of 
8192 data points using a non-uniform sampling scheme. The 1H 
dimension of the 1H,15N-HSQC spectra was acquired with a 
spectral width of 12 ppm using 1024 complex data points. The 
15N dimension was acquired with a spectral width of 40 ppm 
using 256 data. All non-uniformly sampled spectra were 
reconstructed via the compressed sensing algorithm within 
MDDNMR (version 2.5)29 and processed using NMRpipe 
(version 9.2)30. All spectra were processed without baseline 
correction to avoid complications in the multiplet analysis 
procedure especially with regards to the negative peaks caused 
by the echo/anti-echo coherence selection with gradients.
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Table 1. Comparison of spectroscopic techniques. The acquisition time and signal to noise ratios of various 
experiments used in this study. A good signal to noise ratio can be achieved using the spectral filtering 
allowing rapid measurement of quantitative spectra. The signal to noise benefit of the HSQC over the 1D 13C 
acquisition is clearly seen. The effect of increasing the J-coupling splitting enhancement whilst simultaneously 
reducing the number of increments on the acquisition time of 1H,13C-HSQC spectra is also shown.
Experiment Acquisition time [mins]
Signal to noise 
ratio (CH3 of 
lactate)
Transients TD SW [ppm]
Splitting 
enhancement
1H 1D (all 1H) 2 327.31 8 16384 12 1
1H 1D (13C bound 1H) 2 66.13 8 16384 12 1
1H,13C-HSQC 233 823.86 2 1024/8192 12/160 1
1H,13C-HSQC 110 770.98 2 1024/4096 12/160 2
1H,13C-HSQC 51 426.41 2 1024/2048 12/160 4
1H,13C-HSQC 24 283.38 2 1024/1024 12/160 8
13C 1D (30n excitation) 1414 59.95 16384 65538 239 1
Figure 5. Simulation of J-coupling splitting enhanced spectra. 1H,13C HSQC spectra showing the C(3) of alanine are shown (A, B, C and 
D). The enhancement of J-coupling in the 1H,13C-HSQC spectra leads to increased separation of coupled peaks and allows the collection 
of data with reduced numbers of increments in the 13C dimension resulting in shorter acquisition times. The number of points collected 
in the 13C dimension can be reduced to match the increase in J-coupling enhancement as the loss of resolution will be counteracted by 
the increase in separation of the coupled peaks. Spectra with no enhancement (A), two-fold enhancement (B), four-fold enhancement 
(C) and eight-fold enhancement (D) were collected. The overlay of the differently enhanced spectra clearly shows the effect of the 
enhancement (E). The enhancement can be tailored to meet the need in order to maximise separation without significantly increasing 
signal overlap whilst achieving the maximum reduction in acquisition time possible. The splitting enhancement can easily be included in the 
simulation parameters (F) resulting in no adverse effects on the simulated spectra. The simulation gives the following incorporation 
percentages. From the no J-coupling splitting enhancement spectrum 12.1% / 87.9% for [3-13C] / [2,3-13C], from the two-fold 
J-coupling splitting enhancement 12.0% / 88.0% for [3-13C] / [2,3-13C], from the four-fold J-coupling splitting enhancement 12.0% / 88.0% 
for [3-13C] / [2,3-13C] and from the eight-fold J-coupling splitting enhancement 12.1% / 87.9% for [3-13C] / [2,3-13C].
All NMR spectra in this article were processed within 
the MetaboLab software package (version 2018. 07182055; 
http://metabolab.uk)22.
NMR methodology. Both aforementioned methods can be used 
to detect 15N labelling in metabolites, which alongside 13C isotope 
incorporation can provide additional much-needed information 
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on the overlapping activity of multiple metabolic pathways. 2D 
spectroscopic filters are an extension of the 1D concept and as 
such can be used to simplify increasingly complex 2D spectra by 
selectively observing a subset of metabolites in which nuclei of 
interest have been incorporated. For example, the analysis of the 
13C nuclei that are adjacent to 15N nuclei using 2D spectra permits 
a simplified unequivocal description of the nature in which two 
metabolic pathways converge.
Similar to the 1D method, the acquisition of two spectra is 
required in order to enable a quantitative analysis of the amount 
of 15N labelling in the presence of 13C labelling within the metab-
olite. If spectral simplification is the goal, a single spectrum is 
sufficient16. The pulse sequence (Figure 6) is a gradient selected 
1H,13C-HSQC spectrum with the spectral filter added once 
the 1H magnetisation has been transferred to the 13C nucleus. 
The spectrum collected with the 14N spectral filter (Panel C-2, 
Figure 6. Filtered HSQC spectroscopy. The application of a 15N filtering block in the 1H,13C-HSQC pulse sequence (A) allows the observation 
of 1H,13C groups directly coupled to 15N nuclei. In the sequence in panel B-1 no filtering will be observed and the resulting spectrum (C-1) 
will contain all 1H, 13C groups adjacent to either 14N or 15N nuclei. The use of a 15N filter (B-2) will result in only those 1H, 13C groups adjacent 
to a 15N nuclei being observed in the resulting 1H, 13C HSQC spectrum (C2). 1H,13C J-coupling is suppressed during acquisition using 
adiabatic bilevel decoupling (ad-bilev)21. The pulse phases are: F1 = y; F2 = x, -x; F3 = x for the no filter sequence (panel B-1) and y for the 
15N filtered sequence (panel B-2); F4 = y, –y for the no filter sequence and y, y for the 15N filtered sequence; F5 = y, -y for the no filter 
sequence x, -x for the 15N filtered sequence; F6 = x, x, -x, -x; F7 = x, x, x, x, -x, -x, -x, -x; F8 = x, x, x, x, y, y, y, y; Frec = x, -x, -x, x, y, -y, -y, y.
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Figure 6) contains only two visible NMR signals, corresponding 
to arginine and arginosuccinate, clearly showing how the filter 
can simplify complex spectra for easier analysis.
While 2D spectral filters serve a purpose, their quantitative 
usage is limited by the variability of the 1JCN constant. J-coupling 
splitting enhancement on the other hand can be easily extended 
to include 13C-15N J- coupling splitting enhancement. Indeed, the 
addition of a single 15N P–pulse simultaneous with the central 
13C P–pulse (Figure 3) is sufficient to enhance the apparent 
13C-15N J-coupling splitting in 1H,13C-HSQC spectra, an 
example of which is given in Figure 7. The 2D signals for the 
JCN splitting scaled spectrum are shown in panel A. Panels B 
and C show traces of the 13C multiplets for carbon atoms 2 and 
3 of alanine. While the JCC splittings are enhanced by a factor 
of 4 in both spectra, the apparent JCN splittings are unchanged 
in the spectrum in panel B, whereas they are enhanced by a 
factor of 4 in the spectra in panel C. Because the 2JCN coupling 
between C(3) and N is negligible, both traces for C(3) overlap 
perfectly. C(2) on the other hand experiences a 1JCN coupling, 
Figure 7. Splitting due to 15N and 13C incorporation. Regions of the 1H,13C-HSQC spectrum containing signals from alanine 
(panels A & B). The 13C traces of the alanine signals are shown with either no JCN-coupling splitting enhancement (B) or four-fold JCN-
coupling splitting enhancement (C). The signals are split by either 1JCC or 
1JCN coupling contributions. The long range 
1H,15N-HSQC 
spectrum (D) is composed of unlabelled alanine (central peak) and 13C/15N labelled alanine (6 outer signals, 4 split by 2JHC and 
1JNC 
couplings and 2 only split by 1JHC (values for the coupling constants are shown in panel E)).
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which is too small to be resolved when the JCN splitting is not 
enhanced and is only detectable in panel C.
JCN coupling, as any J-coupling, works in two directions, 
therefore a similar approach can be followed from the opposite 
direction. While amine groups of small molecules are notori-
ously difficult to observe due to chemical exchange of amine 
protons with solvent molecules, a long-range HSQC spectrum 
can be acquired. In such a spectrum proton magnetisation is 
transferred from HA (the proton bound to C(2)) via the 
2JHN 
coupling. The splitting due to the JNC coupling then can be 
enhanced to show the appearance of 13C labelling in molecules 
which contain 15N next to those labelled carbon nuclei. As in 
this case, where the 13C nucleus is also bound to the proton 
determining the chemical shift on the horizontal axis, that 
same proton signal will be split by the 1JCH coupling 
constant. The result in this case is therefore a signal split into 
7 2D components (Figure 7, panel D), demonstrating that 
alanine was either recycled from unlabelled alanine which was 
incorporated into proteins, synthesised de-novo from [U-13C] 
glucose and 15N labelled glutamate which originated from 
[U-13C, U-15N] glutamine that was added to the growth medium 
in addition to the [U-13C] glucose or just synthesised de novo 
from [U-13C] glucose with an unlabelled amino group trans-
ferred to form alanine. In conjunction with MS data, this com-
plementarity between the 2D-1H,13C- and the 2D- 1H,15N-HSQC 
spectra enables a model-free metabolism analysis using multiple 
nutrients as tracer sources in a single sample.
Discussion
Changes in metabolism are increasingly being recognised as 
central to the pathogenesis of a number of different diseases. 
Although metabolomic studies have helped determine aspects 
of disease phenotype, tracing the changing use of specific 
metabolic pathways using stable isotope-enriched nutrients 
provides higher resolution information on altered metabolic 
pathway activity that may lead to the identification of specific 
novel therapeutic targets. Over the last few years, development of 
magnet and probe technology, including innovative ultra- 
sensitive microprobes, has enabled the study of systems that 
were not previously amenable to NMR spectroscopy. Parallel 
advancement in the methods used to acquire and analyse data 
from samples will increase the amount of information we can 
gain from such samples.
In this paper, we describe how spectral filters and J-splitting 
enhancement can be used in tracer-based metabolism studies. 
These techniques overcome some of the major hurdles in the use 
of NMR spectroscopy. A challenge in the analysis of NMR 
HSQC spectroscopy data has been the need for an additional 
“unlabelled” sample in order to determine absolute per carbon 
13C incorporation percentages. However, samples cannot be 
assumed to be biologically identical, thus making analyses 
problematic due to the inability to determine accurate 13C isotope 
incorporation values. Systems that demonstrate greater inter- 
sample variation, such as in vivo tracer studies, are even more 
prone to these analytical issues. The use of spectral filters 
negates the requirement for two samples and instead a single 
sample can be used to determine absolute percentage 13C 
incorporation and thus allow the scaling of multiplets.
The 2D HSQC spectrum is a powerful tool in the study of 
metabolism as it takes advantage of the increased sensitivity of 
the 1H nucleus over 13C and using the splitting due to J-coupling 
in the 13C dimension allows the indirect visualisation of the 13C 
incorporation into quaternary carbons. However, long acqui-
sitions times, even when using the latest NUS techniques, 
limits the number of samples that can be acquired. Reducing the 
experimental time makes the use of HSQC spectra a much more 
attractive method in the study of tracer-based metabolism. 
The use of echo/anti-echo for quadrature detection ensures 
efficient elimination of unwanted artefacts, whilst using only 
two scans per increment in the indirect dimension. The changes 
observed in line shape due to the quadrature detection are 
predictable and can be easily incorporated into line fitting 
analysis. As described elsewhere19, the simulation procedure 
assumes weak coupling between the different carbon nuclei. The 
simulation is implemented as a spin echo before the acquisi-
tion of a 13C-FID to allow the evolution of 13C,13C spin coupling 
prior to the first increment.
The ability to scale the visualised splittings due to J-coupling 
allows HSQC spectra to be acquired in time equivalent to that of 
a 1D 1H spectrum, but the HSQC spectrum contains significantly 
more information. The reduced time required to acquire HSQC 
spectra means that it is feasible to apply 2D methods to in vivo 
tracer-based metabolism studies, as well as allowing the use of 
greater sensitivity of higher field spectrometers while avoiding 
longer experiment times (Table 1). Expansion of the splitting due 
to J-coupling can also bring out smaller long-range couplings that 
were not apparent in a normal HSQC spectrum. Thus, the scal-
ing of splittings can either be used to decrease acquisition imes by 
allowing data collection at lower resolution or to bring out smaller 
couplings not previously visible. These small couplings include the 
1JCN couplings that are found in many metabolites after the addition 
of metabolites labelled 15N in conjugation with 13C. This increases 
the information available and allows more in-depth analysis of 
complex metabolic pathways. In the example shown (Figure 6), 
the cells used for this experiment were deficient in the expression 
of fumarate hydratase16 and therefore contained high fumarate 
levels. One hypothesis was that argininosuccinate is synthesised 
from fumarate and arginine to minimise intracellular fumarate. In 
order to ascertain the signal assignment, we used [U-13C, U-15N] 
arginine and were able to show that 15N labelled argininosuccinate 
was being produced in the cells containing the knock out, but not in 
wild-type cells16. This shows the utility of using multiple labelled 
nutrients to answer fundamental questions in metabolism.
In summary, the spectroscopic tools presented here open up new 
avenues for tracer-based metabolism studies. Scaling of signal 
splittings due to J-coupling leads to faster data collection of 
samples supplemented with nutrients enriched in stable isotopes, 
such as 13C and 15N. This enables profiling of metabolic pathways 
and can also be used to enhance sensitivity beyond current 
technical developments whilst maintaining reasonable data 
acquisition times. Ultimately, the use of 1D spectral filters 
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as well as the fast acquisition of HSQC spectra leads to the 
possibility of tracing metabolism in real-time. In addition, 
simultaneous tracing with multiple nutrients will lead to unprec-
edented insight into the interplay of converging and intersecting 
metabolic pathways, both in vitro and in vivo37.
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a 30 degree excitation 1D 13C spectrum, acquired using a TXO 
Cryoprobe. The file jEnhanced_13C_HSQC.zip contains the 
1H, 13C-HSQC spectra with different J-coupling splitting 
enhancements. 
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Chapter 4 : Outcomes of cadaveric 
kidneys undergoing hypothermic machine 
perfusion: Analysis of registry data  
In this chapter, National Health Service Blood and Transfusion service registry data were 
analysed to assess the outcomes of cadaveric kidneys undergoing hypothermic machine 
perfusion compared to those stored in static cold storage alone.  
Data for DCD kidneys formed the basis of a study which was presented by myself as an 
oral presentation at the European Society of Transplantation Congress in Barcelona in 
September 2017 with accompanying abstract published in the journal Transplantation 
International (Appendix A).  
Data regarding DBD kidneys is discussed in this chapter in addition to a further 
commentary which appears alongside the main manuscript which reports data for DCD 
kidneys.  
I designed the study and was responsible for requesting data from NHSBT, initial data 
analysis and subsequent analysis, data interpretation and write-up of manuscript. I wrote 
the manuscript which was published in the American Journal of Transplantation in 2018 








Prior to commencing experimental research aiming to better understand and optimise 
hypothermic machine perfusion, a review of the evidence base for HMP revealed a lack 
of understanding of current practice in the UK. The current recommendations for the usage 
of HMP were a result of a technology appraisal conducted by the National Institute of 
Health and Care Excellence in 2009 (69) which pre-dated the main research widely quoted 
as the evidence for and against the use of HMP; namely the Machine Preservation Trial 
conducted by Moers et al. (70, 71, 187)  and the results of a multi-centre randomised 
controlled trial in the UK conducted by Watson et al. (40).    
The Machine Preservation Trial (70), which forms the majority of the evidence base for 
HMP, is the largest RCT describing short and long-term benefits of HMP for DBD 
cadaveric kidneys, including ECD kidneys (106) with an extended dataset from the same 
trial showing benefits for DCD kidneys (105). This extended dataset including only DCD 
kidneys reported a significant reduction in DGF rates for machine perfused kidneys but no 
longer-term benefits to graft survival.  
In contrast, Watson et al (40) reported no difference in outcomes between DCD kidneys 
stored using HMP and those stored purely in static cold storage in a five centre UK based 
study. The contrasting results from the two studies is interesting and the reasons for the 
differences in reported outcomes are speculative. A likely contributing factor is that the 
two studies varied in methodology; differences included choice of standardised 
immunosuppression regimes, storage fluid for static storage conditions and most notably 
the timing of initiation of HMP. In the Machine Preservation Trial, HMP was initiated at 
retrieval centre by a dedicated perfusionist in contrast with Watson et al’s RCT in which 






For DBD kidneys in the UK, the evidence is more contentious. No randomised controlled 
trials have assessed the benefits of HMP for such kidneys where HMP was not initiated 
from source.  
The aim of conducting this analysis of national registry data was to determine whether 
HMP confers any short or long-term benefits for DBD and DCD cadaveric kidneys in the 
UK. This is important given the lack of a logistical framework in which HMP can be initiated 
at source; for the majority of cadaveric organs, HMP would have been initiated following 
arrival to implanting centre. Secondary aims were to determine the usage of HMP for 















As described in the manuscript, demographic and clinical data for all renal transplants 
occurring in the United Kingdom are submitted by transplant centers to the UK Transplant 
Registry held by the NHSBT.  
Data were requested for all adult patients receiving a single-organ cadaveric renal 
transplant between January 2007 and December 2015 to allow sufficient follow-up to 
determine long-term functional outcome data. Kidneys which underwent normothermic 
perfusion, blood group and HLA antibody incompatible transplants were excluded. 
Creatinine was only recorded for those patients who were being followed up, and who 
remained dialysis independent at the time of follow up.  
Preliminary statistical analysis divided cadaveric organs into DBD and DCD sub-types. 
Survival outcomes were assessed using Kaplan-Meier curves, with Cox regression used 
to generate hazard ratios (HRs) and p-values. Patient survival was only considered from 
a patients first transplant. Rates of DGF were compared between the groups using 
Fisher’s exact test, whilst creatinine levels were reported as medians and interquartile 
ranges (IQRs), with comparisons performed using Mann-Whitney tests. Further statistical 
methods are described for DCD kidneys in the accompanying manuscript. Graft survival 
rates were death censored.  
All analyses were performed using IBM SPSS 22 (IBM Corp. Armonk, NY), with p<0.05 
deemed to be indicative of statistical significance throughout. Cases with missing data 







There were 11,302 renal transplants eligible for inclusion in the study. Of these, 6,773 
kidneys (59.9%) were from DBD donors with the remaining 4,529 (40.0%) from DCD 
donors.  
Outcomes following transplantation of DBD donor kidneys 
Of 6,773 DBD donor renal transplants, 6,721 (99.2%) underwent preservation using static 
cold storage alone with less than one percent undergoing hypothermic machine perfusion 
(n=52, 0.8%). Comparisons between outcomes by preservation modality are reported in 
Table 4. The rates of DGF were not found to differ significantly between the groups, with 
this occurring in 22.8% of SCS organs, compared to 28.3% of those preserved with HMP 
(p=0.380). Neither patient nor graft survival were found to differ significantly between the 
groups, with hazard ratios for HMP vs. SCS of 1.73 (95% CI: 0.89 – 3.33, p=0.100, Figure 
41) and 0.81 (95% CI: 0.36 – 1.80, p=0.601, Figure 42), respectively. Creatinine levels at 
follow up were also similar in the SCS and HMP groups, with medians of 130µmol/L vs. 
140µmol/L (p=0.166), 131µmol/L vs. 129µmol/L (p=0.912) and 130µmol/L vs. 150µmol/L 
(p=0.301) at 1, 3 and 5 years, respectively. 
The small number of DBD kidneys undergoing HMP precluded multivariate analysis as 










Table 4. Univariable analysis of patient outcomes by preservation modality for DBD kidneys. DGF: Data 
reported as N (%), with p-value from Fisher’s exact test. Survival: Data reported as Kaplan-Meier estimated 
rates at five years, with p-value from a log-rank test based on all available follow up. Creatinine: Data reported 
as median (IQR), with p-value from a Mann-Whitney test. Bold p-values are significant at p<0.05. 
 N SCS HMP p-Value 
DGF 6166 1398/6120 (22.8%) 13/46 (28.3%) 0.380 
5 year Graft Survival  6768 85.6% 87.3% 0.601 
5 year Patient Survival  5551 88.1% 81.3% 0.100 
12 month Creatinine (µmol/L) 5834 130 (104 – 167) 140 (115 – 179) 0.166 
36 month Creatinine (µmol/L)  4018 131 (104 – 172) 129 (104 – 164) 0.912 
60 month Creatinine (µmol/L)  2527 130 (103 – 170) 150 (112 – 202) 0.301 
 
 
Figure 41. Kaplan Meier curve of patient survival by preservation 
modality. 
 
Figure 42. Kaplan Meier curve of death-censored graft survival by 




Outcomes following transplantation of DCD donor kidneys 
In contrast to DBD organs, HMP was used in 19.1% (n=864) of the 4,529 DCD kidneys 
transplanted over the study period. Key findings for DCD kidneys included a significantly 
lower incidence of delayed graft function for organs preserved with HMP than for organs 
preserved with SCS (34.2% vs 42.0%, p<0.001), despite a slightly longer cold ischemic 
time (median: 14.8 vs 14.1 hours, p<0.001).  
Multivariable analysis found the effect of preservation modality to remain significant, with 
HMP organs having a significantly lower rate of DGF (odds ratio 0.65, 95% confidence 
interval 0.53-0.80, p<0.001) and significantly shorter times to DGF resolution (average 6.1 
vs 7.4 days, p=0.003) than SCS organs. Both patient (p=0.313) and graft (p=0.263) 
survival rates were similar in the two preservation groups. HMP was associated with a 
marginal functional benefit in 1-year creatinine values, with serum creatinine values of 
120µmol/L (HMP) vs 124µmol/L (SCS) (p=0.044). Serum creatinine values were 
converted for manuscript purposes to reflect the country of publication of the journal.  
HMP utilisation was found to decline over the study period, from being used in 25.6% of 
the transplants in 2007-2010, to 14.4% of transplants in 2014-2015 (p<0.001). HMP was 
most commonly used in organs that were perfused with the recipients’ blood during the 
daytime (08:00 - 16:59, p<0.001), and cases where HMP was used had significantly longer 
CIT than SCS organs (median 14.8 vs. 14.1 hours, p<0.001). Full results for DCD kidneys 






Differences in utilisation of HMP for DBD and DCD kidneys  
The utilisation of HMP almost exclusively for DCD kidneys in the UK is surprising given 
that the most convincing evidence to support HMP, the  Machine Preservation Trial, 
showed the most benefit in DBD with a reduction in DGF rates (26.5% in the cold storage 
group vs 20.8% HMP group) and significant improvement in 1 and 3 year graft survival 
(70, 71).   
It is well known that the incidence of DGF in DCD kidneys is higher than that of DBD 
kidneys (188). An extended dataset of solely DCD kidneys as an extension of the Machine 
Preservation Trial reported by Jochmans et al (105) described a decrease in the incidence 
of DGF from 69.5% to 53.7%. Hence a potential reason for the disparity in utilization of 
HMP for DBD and DCD kidneys may be the notable difference in absolute risk reduction 
in DGF for DCD kidneys compared with DBD kidneys (15.8% vs 5.7%) in these studies 
(70, 105). However, such findings were reported during the inclusion period for this study. 
One might suggest HMP is only used as a tool for reducing the incidence of DGF, 
explaining its preferential use for DCD kidneys.   
Outcomes of DCD kidneys undergoing HMP 
As discussed in the manuscript, key findings were a reduction in the incidence of DGF for 
kidneys which underwent HMP with a reduction in the duration of DGF for those kidneys 
preserved using HMP compared with those stored in static conditions alone. These 
findings were in contrast with the randomised controlled trial conducted by Watson et al 
(40) which included DCD kidneys included in this study. The study found no difference in 




reduction in the incidence of DGF from 69.5% to 53.7% for kidneys preserved in static 
conditions compared to HMP in an extension of the Machine Preservation Trial reflecting 
a larger absolute risk reduction compared to DCD kidneys in our cohort (42.0% static cold 
storage vs 34.2% kidneys preserved using HMP). One reason for this may be timing of 
initiation of HMP as all machine perfusion was initiated at source in contrast with kidneys 
in the UK. A clinical trial is underway in the UK in which HMP is initiated in DCD organs at 
source in order to address the effect of timing of initiation (189).   
DGF as an outcome measure  
The overall incidence of DGF in DCD kidneys was lower than that reported in trials by 
Jochmans et al (105) and Watson et al (40). However, DGF as an outcome measure 
indicates, but does not directly measure graft functional post transplantation. The now 
widely accepted definition of DGF is subject to criticism, with the contentious issue being 
the threshold for the use of dialysis between centres (36). Earlier transplantation research 
used alternative definitions of DGF (190) including variations in the dialysis-based 
definition of DGF (191, 192), a creatinine clearance-based definition of DGF (193-195) or 
a combination of both (196, 197).  
DGF includes patients who underwent dialysis for any reason, perhaps over-estimating 
the number of patients with non-functioning grafts. Importantly in our observational study, 
in addition to afore mentioned RCTs by Moers et al (70) and Watson et al (40), clinicians 
would not have been blinded to the use of HMP which may have influenced decision 
making regarding dialysis in the post-operative period. If clinicians view kidneys preserved 
with HMP as less likely to experience DGF, the threshold for dialysis may be higher 
resulting in a lower incidence of DGF compared with those organs in which the incidence 




The lack of consistency in the definition of DGF and the variation in clinical practice with 
respect to dialysing patients limits the extent to which results from different studies can be 
compared. For this reason, time to resolution of DGF was also included as an outcome 
measure to determine whether there were any further short-term benefits of HMP.  
Study design  
Although considered a lower level of evidence compared to well-designed randomised 
control trials (198, 199), one major criticism of cohort studies is the vulnerability of subjects 
to the influence of confounding factors with randomised controlled trials designed to 
isolate single interventions. Most randomised controlled trials assessing the benefits of 
HMP involve a relatively small number of transplants and are therefore may also be unable 
to control for multiple confounding factors. Hence one strength of a cohort study is the 
ability to control for multiple confounding factors due to a large sample size.  
Similar to other registry analyses (200), it would be false to assume any differences in 
outcomes are due to preservation modality alone. In a single centre study, Guy et al 
previously described explored a role of HMP in prolonging cold ischaemic time from a 
median 13 to 28 hours, reducing the incidence of DGF in kidneys preserved using HMP 
from 47 to 27%, without impacting on graft survival (72). This may have been the case 
with some DCD kidneys in our cohort as median CIT was increased and reperfusion time 
more likely to be in the daytime for kidneys preserved using HMP. However, such practice 
is unlikely to be widespread as the increase in CIT was less than one hour. Kidneys with 
multiple renal arteries, associated with inferior graft outcomes (104), may not have been 
preserved using HMP as such anatomy renders HMP difficult. In addition, kidneys placed 
on HMP may be have been discarded depending on perfusion parameters when using 




outcome for kidneys stored with HMP. The difference in DGF rates may therefore in part 
be due to graft assessment not due to the treatment effect of HMP.  
Limitations  
Cohort studies are subject to several disadvantages. First of all, as with any registry 
analysis, accuracy of data may be questioned. Several desired data fields were not fully 
populated in addition to a lack of some relevant data fields discussed within the manuscript 
and in this discussion.  
Duration and timing of initiation of HMP 
The primary aim of the study was to determine whether there were any benefits of HMP 
usage within the confines of current practice. One major limitation was the lack of data 
regarding initiation and cessation of HMP. Data regarding the mean duration and timing 
of initiation of HMP are not routinely collected in the United Kingdom. In kidneys preserved 
using HMP it is likely that those organs with a longer overall cold ischaemic time were 
preserved with HMP for longer. However, given this lack of data, our study does not 
describe a dose-response type relationship whereby the optimal timing of initiation and 
duration of HMP to promote the most clinical benefit is described.  
The duration and timing of initiation of HMP are likely to determine the extent to which 
HMP results in functional benefit for each individual kidney (81). Such functional benefits 
likely result from the several mechanisms of action of HMP discussed in Chapter 1 which 
act concurrently following its initiation. 
It is well known that renal vascular resistance falls during HMP with one study indicating 




of DGF and 1-year graft failure (88) and renal resistance at 4 hours approached statistical 
significance for the development of DGF.  
Concerning the duration of HMP, between 1 and 4 hours of HMP following a period of cold 
storage both improved renal resistance on reperfusion and resultant functional outcome 
in a porcine model (82) suggesting benefit even with such short durations of HMP. Yet 
such improvements in functional outcome with short durations of HMP contrasts with the 
results of a porcine study by Hosgood et al comparing 18 hours of cold storage, 18 hours 
of HMP and 4 hours of HMP following 14 hours of cold storage (201). In this study no 
functional benefit was seen with 4 hours of HMP after cold storage suggesting a 
deleterious effect in delaying the initiation of HMP with a period of static cold storage. It 
could be argued that the initial static cold storage period may continually damage organs 
resulting in ischaemia reperfusion injury which cannot be reversed by a short period of 
HMP. A retrospective analysis by Matos et al was performed in a centre where DBD 
kidneys are received after 22 hours static cold storage (202). In this study, a further 
increase in CIT with a mean HMP duration 11 hours resulted in a reduction in the incidence 
of DGF with a reduction in duration of DGF for those kidneys without immediate graft 
function compared with those implanted soon after arrival at the implanting centre. Such 
outcomes indicate HMP has a role to play in organ reconditioning even after a significant 
period of static cold storage.   
In the Machine Preservation Trial and associated studies which showed benefits for DBD 
(70, 71), DCD (105) and ECD kidneys (106), HMP was initiated at source resulting in a 
high proportion of the median CIT being accounted for by dynamic perfusion compared 
with static storage. Subsequent sub-group analysis of the Machine Preservation Trial data 
described the striking reduction in the incidence of DGF for those machine perfused 




(187). Similarly, a registry analysis in the USA observed a significant reduction in the 
incidence of DGF for all kidneys irrespective of cold ischaemic time, including those with 
a cold ischaemic time less than 6 hours (200). Interestingly in this large registry analysis, 
there was no such reduction in the incidence of DGF for DCD and ECD kidneys preserved 
with HMP for less than 6 hours suggesting such higher risk kidneys require a longer 
duration of HMP to translate into clinical benefit.  
Final comments  
This observational study demonstrates that HMP is used almost exclusively for DCD 
kidneys in the UK, acting to reduce the incidence and duration of DGF with the suggestion 
of a small functional benefit at 1 year. This study aids decision making regarding initiation 
of HMP in DCD kidneys in centres where organs are received following a period of SCS 
although findings do not clearly define the most beneficial timing of initiation or duration of 
HMP.  
Several influencing factors such as pre-HMP exposure to static storage conditions and 
the subtype of cadaveric kidney in question influence the minimum duration of HMP which 
promotes functional benefit following transplantation. In Chapter 5, metabolism during 
HMP is compared with SCS kidneys in order to explain how metabolism contributes to the 
development of ischaemia reperfusion injury which is known to influence post-
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Evidence is currently lacking regarding the outcomes of kidneys undergoing hypother-
mic machine perfusion (HMP) in patients in the United Kingdom. Using the National 
Health Service Blood and Transplant database, the authors compared outcomes for 
recipients of single- organ donation after circulatory death (DCD) kidneys preserved 
with HMP with those preserved using only static cold storage (SCS). Between 2007 
and 2015, HMP was used in 19.1% (864/4,529) of kidneys. Rates of delayed graft 
function (DGF) were significantly lower in organs preserved with HMP than for organs 
preserved with SCS (34.2% vs 42.0%, P < .001), despite a slightly longer cold ischemic 
time (median: 14.8 vs 14.1 hours, P < .001). Multivariable analysis found the effect of 
preservation modality to remain significant, with HMP organs having a significantly 
lower rate of DGF (odds ratio 0.65, 95% confidence interval 0.53- 0.80, P < .001) and 
significantly shorter times to DGF resolution (average: 6.1 vs 7.4 days, P = .003) than 
SCS organs. The patient (P = .313) and graft (P = .263) survival rates were similar in the 
2 preservation groups. HMP was associated with a marginal functional benefit in 
1- year creatinine values (P = .044), with adjusted averages of 1.36 mg/dL (HMP) 
 versus 1.40 mg/dL (SCS). This study supports the use of HMP and aids decision- 
making over its instigation, which may improve short- term patient outcomes.
K E Y W O R D S
clinical research/practice, kidney transplantation/nephrology, organ perfusion and preservation, 
organ procurement and allocation, registry/registry analysis
1  | INTRODUCTION
Hypothermic machine perfusion (HMP) has been shown to reduce 
the incidence of delayed graft function (DGF) after transplantation of 
deceased donor kidneys from brainstem death (DBD) and circulatory 
death (DCD) donors.1-5 DCD kidneys are now widely used, accounting 
for just under half of deceased donor kidneys transplanted in the United 
Kingdom.6 While longer- term outcomes for such kidneys are equivalent 
to those from DBD kidneys,7,8 the risk of developing DGF is increased.
Given the reduction in DGF rates demonstrated by multiple stud-
ies for HMP kidneys,9 DCD organs would seemingly have most to gain 
from a period of HMP. Yet, surprisingly, the evidence for HMP of DCD 
kidneys is less unilateral than that for DBD kidneys,1,2 with 1 UK- based 
randomized trial stopped prematurely after interim analysis found no 
difference in DGF rates between HMP and SCS- preserved organs.10
In the United Kingdom, HMP using the LifePort Kidney Transporter 
(Organ Recovery Systems, Itasca, IL) is permitted by the National 
Institute of Health and Care Excellence11 and has been used in clinical 
practice for over a decade, albeit with varying rates of uptake in indi-
vidual units. Such variation between centers may relate to the logistical 
challenges associated with the initiation of HMP but may also be due 
to a lack of evidence detailing the outcomes of kidneys undergoing 
Abbreviations: CIT, cold ischemia time; DBD, donation after brainstem death; DCD, donation 
after circulatory death; DGF, delayed graft function; HMP, hypothermic machine perfusion; 
NHSBT, National Health Service Blood and Transplant; SCS, static cold storage.
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HMP in the United Kingdom, particularly where the opportunity to 
commence HMP at the time of donation rarely exists. Hence, clinicians 
are required to decide whether HMP should be commenced only after 
the kidney has arrived at their units in SCS conditions.
Against this background, the aim of this study was to review 
current practices and outcomes for DCD kidneys in an attempt to 
strengthen future decision- making regarding commencing HMP when 
DCD kidneys arrive at the recipient unit.
2  | METHODS
2.1 | Study population
Demographic and clinical data for all renal transplants occurring 
in the United Kingdom are submitted by transplant centers to the 
UK Transplant Registry held by National Health Service Blood and 
Transplant (NHSBT) service. Reviewing the resulting database, all 
adult patients receiving a single- organ DCD donor kidney transplant 
between January 2007 and December 2015, where the preservation 
modality was hypothermic (SCS or HMP), were included in the study. 
Creatinine was only recorded for those patients still alive and being 
followed up at the time.
2.2 | Outcome measures
Primary outcome measures were rates of DGF and graft survival 
(death censored). DGF was defined as the need for dialysis in the first 
week after renal transplantation. Secondary outcome measures were 
time to resolution of DGF; serum creatinine values at 1, 3, and 5 years; 
and patient survival.
2.3 | Statistical methods
Initially, univariable analyses were performed to compare a range of 
factors and outcomes between the HMP and SCS groups. Ordinal and 
non- normally distributed variables were compared between groups by 
using Mann- Whitney tests, while nominal variables were compared by 
using the Fisher exact test where there were 2 categories and χ2 tests 
otherwise. Patient and graft survival rates were compared by using 
Kaplan- Meier curves with log- rank tests. Patient survival was consid-
ered only for patients receiving their first graft. Creatinine levels and 
the time to resolution of DGF both followed skewed distributions and 
so were log10- transformed before analysis. The resulting values were 
compared between groups by using independent- samples t-tests and 
summarized by using geometric means and 95% confidence intervals 
(CIs).
Multivariable analyses were then performed to assess the differ-
ences between the HMP and SCS groups, after accounting for the ef-
fects of potentially confounding factors. This analysis was based on 
binary logistic regression models for dichotomous outcomes, general 
linear models of log10- transformed data for continuous outcomes, 
and Cox regression for the survival outcomes. Before the analysis, 
the goodness of fit of each continuous factor was assessed, either 
using Hosmer- Lemeshow tests or by examination of the standardized 
or Martingale residuals, as applicable. Where poor model fit was de-
tected, continuous variables were divided into categories and treated 
as categorical in the analysis.
For each of these analyses, a backward stepwise approach was 
used to select independent predictors of outcome. Factors with sub-
stantial quantities of missing data that were not selected for inclusion 
in the final model were excluded, and the analysis was repeated to 
maximize the included sample size. Where the preservation method 
(HMP vs SCS) was not included in the final model due to nonsignifi-
cance, factors in the model were entered into a new model alongside 
the preservation method. For the analysis of creatinine levels and the 
time to resolution of DGF, adjusted averages were calculated for HMP 
and SCS groups by using values predicted when the same “average” 
patient had been in either preservation group. Adjusted averages were 
generated by multiplying coefficients for continuous variables by the 
mean of the cohort, and the coefficients for categorical variables were 
multiplied by the proportion of the cohort in each category.
A secondary analysis was performed for DGF to assess how the 
effect of preservation method varied according to duration of cold 
ischemia time (CIT). Initially, a binary logistic regression model was 
produced with the preservation method, CIT, and an interaction term 
as factors. Multivariable subgroup analyses were then performed for 
the SCS and HMP groups separately, as detailed previously.
All analyses were performed by using IBM SPSS 22 (IBM Corp., 
Armonk, NY), with P < .05 deemed to be indicative of statistical sig-
nificance throughout. Cases with missing data were excluded on an 
analysis- by- analysis basis.
3  | RESULTS
3.1 | Demographics
Data were available for a total of 4529 transplantations across 23 
centers (median 180 transplantations per center, range 30- 503 trans-
plantations). Overall, HMP was used in 864 (19.1%) cases, but usage 
rates varied by center, ranging from the 5 centers that did not use 
HMP in any transplantations during the period to 1 center that used 
HMP in 64.4% (197/306) of cases.
Comparisons for a range of factors between SCS and HMP kidneys 
are reported in Tables 1 and 2. Data for baseline factors were generally 
well populated (greater than 95%), with the exception of recipient hep-
atitis C virus infection, dialysis at transplantation, and donor terminal 
creatinine, which were recorded in only 77%, 88%, and 90% of cases, 
respectively. Organs preserved with HMP were from donors with a 
significantly higher body mass index than those in the SCS group (me-
dian 26.4 vs 26.1 kg/m2, P = .006) and were less likely to be from do-
nors with hypertension (24.2% vs 28.1%, P = .028). In addition, HMP 
use was found to differ by both donor and recipient ethnicity (both 
P < .001) and dialysis modality at time of transplantation (P = .008). 
HMP kidneys had a longer CIT (median 14.8 vs 14.1 hours, P < .001), 
and reperfusion more commonly took place during the daytime 
(P < .001). HMP use was also found to be in decline during the study 
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period, from being used in 25.6% of the transplantations in 2007- 2010 
to 14.4% of transplantations in 2014- 2015 (P < .001) (Table 2).
Patient outcomes were then compared between the HMP and SCS 
groups. The results of these analyses are summarized in Table 3, while 
the full multivariable models are reported in Tables S1- S5.
3.2 | Delayed graft function
DGF status was recorded in 4126 (91.1%) of transplantations. Overall 
rates of DGF were significantly lower for HMP kidneys compared with 
SCS kidneys (34.2% vs 42.0%, P < .001), with an odds ratio (OR) of 
0.72 (95% CI 0.61- 0.85, P < .001), translating into a number needed 
to treat of 12.9 (95% CI 8.7- 25.6). For those patients where DGF oc-
curred, the time to resolution was significantly shorter in HMP kid-
neys (P = .004), at a mean of 6.2 days (95% CI 5.4- 7.0 days) compared 
with 7.4 days (7.0- 7.8) in the SCS group.
After adjustment for confounding factors (Tables S1 and S2), mul-
tivariable analysis found the effect of preservation modality to remain 
significant, with HMP organs having a significantly lower rate of DGF 
(OR 0.65, 95% CI 0.53- 0.80, P < .001) and significantly shorter times 
to DGF resolution (17.7% shorter, 95% CI 6.2%- 27.8%, adjusted aver-
age: 6.1 vs 7.4 days, P = .003) than SCS organs.
3.3 | Patient and graft survival
There was no evidence of a significant association between preser-
vation modality (HMP or SCS) and either patient survival (P = .813) 
TABLE  1 Donor and recipient factors by use of hypothermic 
machine perfusion (HMP) vs static cold storage (SCS)
No. SCS cohort HMP cohort P- value
Donor
Age, y (IQR) 4529 54 (43- 63) 54 (41- 63) .656
Sex, n (%) .939
Female 1817 1469 (40.1) 348 (40.3)
Male 2712 2196 (59.9) 516 (59.7)
Ethnicity, n (%) <.001
White 4386 3534 (96.4) 852 (98.6)
Asian 76 75 (2.0) 1 (0.1)
Black 24 22 (0.6) 2 (0.2)
Mixed/other 43 34 (0.9) 9 (1.0)







Blood group, n (%) .173
A 1838 1475 (40.2) 363 (42.0)
AB 115 97 (2.6) 18 (2.1)
B 459 387 (10.6) 72 (8.3)




Negative 2175 1758 (49.2) 417 (50.2)
Positive 2231 1818 (50.8) 413 (49.8)
Hypertension, n (%) .028
No 3130 2528 (71.9) 602 (75.8)










Age, y (IQR) 4529 55 (46- 63) 56 (47- 64) .070
Sex, n (%) .659
Female 1507 1225 (33.5) 282 (32.6)
Male 3017 2435 (66.5) 582 (67.4)
Ethnicity, n (%) <.001
White 3531 2788 (76.3) 743 (86.5)
Asian 630 548 (15.0) 82 (9.5)
Black 290 267 (7.3) 23 (2.7)
Mixed/other 61 50 (1.4) 11 (1.3)
Blood group, n (%) .185
A 1799 1443 (39.4) 356 (41.2)
AB 180 150 (4.1) 30 (3.5)
B 555 466 (12.7) 89 (10.3)
O 1995 1606 (43.8) 389 (45.0)
Cytomegalovirus, n (%) .059
Negative 1991 1580 (45.4) 411 (49.0)
Positive 2328 1901 (54.6) 427 (51.0)
No. SCS cohort HMP cohort P- value
Hepatitis C virus, n (%) .305
Negative 3449 2753 (99.4) 696 (99.0)
Positive 24 17 (0.6) 7 (1.0)
Diabetes, n (%) .949
No 4096 3315 (90.5) 781 (90.4)




Not on dialysis 20 11 (0.3) 9 (1.2)
Hemodialysis 2831 2274 (71.0) 557 (72.5)
Peritoneal dialysis 1119 916 (28.6) 203 (26.4)
Graft number, n (%) .557a
1 4164 3374 (92.1) 790 (91.4)
2 327 259 (7.1) 68 (7.9)
>2 38 32 (0.9) 6 (0.7)





Data are reported as n (%), with P- values from Fisher exact/χ2 tests or as 
median (IQR), with P- values from Mann- Whitney tests, unless stated oth-
erwise. Bold P- values are significant at P < .05.
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or graft survival (death censored) (P = .452, Figure 1) on univariable 
analysis. These relationships remained nonsignificant after adjustment 
for confounding factors on multivariable analysis, with P = .313 and 
P = .263, respectively (Table S3- S4).
3.4 | Creatinine
Creatinine levels at follow- up were available at 12, 36, and 60 months 
in 87%, 59%, and 35% of the cohort, respectively. On univariable 
analysis, there was a tendency for creatinine levels to be lower in the 
HMP group compared to the SCS group, at 12 months (geometric 
mean: 1.36 vs 1.40 mg/dL, P = .055), 36 months (1.35 vs 1.40 mg/
dL, P = .072), and 60 months (1.35 vs 1.40 mg/dL, P = .133), al-
though none of these comparisons reached statistical significance. 
However, after accounting for confounding factors in a multivariable 
analysis (Table S5), a significant difference in 12- month creatinine 
levels was detected (P = .044), with levels found to be 2.8% lower 
in organs preserved using HMP compared with the use of SCS (95% 
CI 0.1%- 5.3%). Evaluating the model at the midpoints of the factors 
accounted for produced adjusted average 12- month creatinine levels 
of 1.36  and 1.40 mg/dL for HMP and SCS kidneys, respectively.
3.5 | Association between DGF and HMP by CIT
A set of analyses were then performed to assess whether the previ-
ously observed association between HMP and reduced rates of DGF 
varied with CIT. In a binary logistic regression model with CIT, the pres-
ervation modality and an interaction term as factors, the interaction 
was close to reaching statistical significance (P = .087). For this reason, 
separate multivariable analyses of DGF were produced for the HMP 
and SCS subgroups, to further assess the impact of CIT (Table S6). 
This found a tendency for the rate of DGF to increase with CIT in the 
SCS group (OR per 10 hours: 1.08, 95% CI 0.91- 1.28, P = .366) but to 
 decrease with CIT where HMP was used (OR per 10 hours: 0.76, 95% 
CI 0.52- 1.10, P = .142), although neither of these effects reached sta-
tistical significance. This relationship is depicted in Figure 2.
No. SCS cohort HMP cohort P- value
Year of transplantation, n (%) <.001b
2007- 2009 1051 782 (21.3) 269 (31.1)
2010- 2011 918 745 (20.3) 173 (20.0)
2012- 2013 1285 1046 (28.5) 239 (27.7)
2014- 2015 1275 1092 (29.8) 183 (21.3)
Time of day recipient’s blood 
perfused, n (%)
<.001
0:00- 7:59 924 776 (21.3) 148 (17.2)
8:00- 16:59 2059 1613 (44.4) 446 (51.7)
17:00- 23:59 1514 1246 (34.3) 268 (31.1)
CIT, h (IQR) 4470 14.1 (11.1- 17.2) 14.8 (11.4- 18.8) <.001
Chronic renal failure at 
transplantation, n (%)
.100b
0 3240 2646 (72.2) 594 (68.8)
1- 20 374 285 (7.8) 89 (10.3)
21- 80 694 555 (15.1) 139 (16.2)
81- 100 221 179 (4.9) 42 (4.9)




No 4504 3642 (99.4) 862 (99.8)
Yes 25 23 (0.6) 2 (0.2)
HLA mismatch level, n (%) .217a
1 140 109 (3.0) 31 (3.6)
2 1084 874 (23.8) 210 (24.3)
3 2667 2153 (58.7) 514 (59.8)
4 638 529 (14.4) 109 (12.6)
Data are reported as n (%), with P- values from Fisher exact/χ2 tests or as median (IQR), with P- values 
from Mann- Whitney tests, unless stated otherwise. Bold P- values are significant at P < .05.
aOrdinal factors were compared between the groups by using Mann- Whitney tests.
bThe ungrouped values were compared by using Mann- Whitney tests.
TABLE  2 Transplant and mismatch 
factors by hypothermic machine perfusion 
(HMP) vs static cold storage (SCS)
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3.6 | Association between DGF rates and HMP use 
by centers
A subgroup analysis was performed to assess whether the reduc-
tion in DGF rates with HMP varied by the HMP use strategy of the 
transplanting center. The 23 transplant centers were divided into 3 
groups: those that used HMP in less than 5%, 5% to 20%, and more 
than 20% of cases (Table 4). A binary logistic regression model was 
then produced to assess whether the effect of HMP on DGF dif-
fered between these groups. This found no significant interaction 
between these factors (P = .081), although there was a tendency for 
HMP to be more effective in reducing rates of DGF in centers where 
it was used more frequently (ie, in >20% of cases, OR 0.66, P < .001) 
than for the intermediate- use group (ie, in 5- 20% of cases, OR 1.08, 
P = .697).
4  | DISCUSSION
This review of a national NHSBT data set provides real- world data 
on outcomes after a period of HMP as used in clinical practice in the 
United Kingdom. This study describes the short- term and longer- term 
outcomes after a period of HMP, which is important, given the dis-
cordance between previous trial methodology and clinical practice in 
many countries where HMP is not routinely commenced at the re-
trieval center.
Kidneys undergoing a period of HMP had a clear reduction in the 
risk of developing DGF, compared with SCS kidneys, corroborating 
findings from previous studies1–3 and meta- analyses.4,5 These findings 
are in contrast to the previously reported trial in the United Kingdom10 
investigating the effects of HMP in DCD kidneys and highlight the 
TABLE  3 Univariable and multivariable analyses of outcomes by 






DGF 0.72 (0.61 to 
0.85)















0.92 (0.75 to 
1.14)





0.97 (0.78 to 
1.21)













DGF, delayed graft function. Statistics are quoted for HMP vs SCS. Bold 
P-values are significant at P < .05.
DGF: Results are reported as odds ratios from binary logistic regression 
models. The full multivariable analysis is reproduced in Table S1.
Time to DGF resolution: Results are reported as percentage differences 
between groups from general linear models of log10- transformed data. The 
full multivariable analysis is reproduced in Table S2.
Survival: Results are reported as hazard ratios from Cox regression models. 
Analysis of patient survival only includes those patients receiving their first 
graft. The full multivariable analyses are reproduced in Tables S3 and S4.
Creatinine: Results are reported as percentage differences between groups 
from general linear models of log10- transformed data. The full multivari-
able analysis is reproduced in Table S5.
F IGURE  1 Kaplan- Meier curve of graft survival by preservation 
modality
F IGURE  2 Associations between cold ischemia time (CIT) and 
delayed graft function (DGF) in the hypothermic machine perfusion 
(HMP) and static cold storage (SCS) cohorts. The points represent 
DGF rates and 95% confidence intervals within 4 hourly intervals 
of CIT, plotted at the midpoints of the interval. Trend lines are from 
univariable binary logistic regression models within the SCS and HMP 
subgroups, with CIT as a covariate
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strengths of a population- based analysis. The absolute risk reduction 
in DGF in this study (7.8%) was greater than that in the previously 
reported machine preservation trial1 (5.7%), where HMP was com-
menced at the retrieval center. Similar to previous studies,1,12 our 
results demonstrate a reduction in the duration of DGF for kidneys 
undergoing HMP, further reaffirming the short- term benefits of HMP, 
even following an initial storage period in SCS conditions. Yet, while 
lower rates of DGF after renal transplantation may infer improved 
graft survival in general,13 our data did not show the same benefit for 
HMP kidneys. In our cohort, as with previous studies,2,3 no longer- 
term benefit was observed for kidneys undergoing a period of HMP.
There has been little evidence to inform clinicians faced with the 
choice of whether to subject kidneys to a period of HMP once organs 
arrive at the transplant center and effectively increase the CIT or to 
implant expediently. Multiple studies have correlated increased CIT 
with inferior outcomes for SCS kidneys,14 yet the duration for which 
HMP can be safely used is not known. Our analysis of DGF rates by CIT 
clearly demonstrates that, at least in the short term and within a 24- 
hour window, the well- established detrimental effects of prolonged 
CIT for SCS kidneys is not applicable for HMP organs (Figure 2). For 
kidneys undergoing a period of HMP, the likelihood of developing DGF 
does not increase with prolonged CIT up to 24 hours.
While this study does not explicitly compare kidneys perfused 
overnight with those transplanted overnight, it does demonstrate 
that there appear to be no short- term adverse effects of increasing 
CIT with a period of HMP. This would appear to support the practice 
of overnight perfusion of DCD kidneys by using HMP as a bridging 
therapy, provided total CIT is projected to be less than 24 hours, as 
previously described in our unit.15 Furthermore, we found that HMP 
kidneys had a slightly longer CIT and were more likely to transplanted 
during daylight hours. This finding suggests, at least in some centers, 
that kidneys arriving overnight underwent HMP and were transplanted 
the following morning. Cost analysis should therefore consider the 
beneficial effects of transplantation during daylight hours in addition 
to the advantages of reduction in DGF rates (number needed to treat = 
12.9). Subgroup analyses of HMP use rates by transplant centers seem 
to support the regular use of HMP to achieve lower rates of DGF for 
those kidneys that undergo machine perfusion, although this analysis 
did not explore the nature of center- specific practices.
Kidneys undergoing HMP were generally higher risk than the SCS- 
alone group and, when such confounding factors were adjusted for, 
HMP kidneys demonstrated a small but significant benefit in creati-
nine at 1 year, for functioning grafts. While unlikely to be of any clinical 
significance, this may reflect some functional benefit of HMP past the 
immediate postoperative period, although this does not translate to 
longer- term creatinine improvements.
Conclusions drawn are limited by the nature of an observational 
study, including the absence of data regarding timing and duration of 
HMP, selection of organs for HMP, and discard rates. Because data 
regarding the mean duration and timing of initiation of HMP are not 
routinely collected for all transplantations in the United Kingdom, our 
study does not address the question of when HMP should be initiated 
and, further to this, does not define a possible dose- response relation-
ship between duration of HMP and DGF rates.
The presence of multiple renal arteries has been associated with 
higher rates of DGF16 and may have affected selection for HMP, given 
that organ anatomy changed allocation to preservation modality in 
the machine preservation trial.1 Pump perfusion parameters, such as 
renal resistance, may be predictive of posttransplantation outcome17 
thereby leading to discard of organs deemed worse quality although, 
conversely, the same characteristics may provide reassurance, lead-
ing to lower discard rates than those assessed by transplant surgeon 
alone.18
This large, well- populated data set does, however, enable robust 
statistical analysis. As part of this review, it was surprising to find 
that despite the demonstrable benefits of HMP, its use in the United 
Kingdom declined during the study period. The reasons for this are 
not clear and contrast with results of an analysis of transplant registry 
data in the United States that describes HMP being used in two- thirds 
of DCD kidneys.19 Nevertheless, the UK data may reflect a waning na-
tional interest, perhaps resulting from a lack of clear overall evidence 
supporting HMP use, combined with a lack of explicit guidance regard-
ing specific situations in which HMP is beneficial.
However, in an era of transplantation where DCD kidneys ac-
count for between one- fourth and one- third of all single- organ kid-
ney transplants in the United Kingdom, this study, using real- world 
data, supports the use of HMP, even after an initial period of SCS, 
and aids decision- making regarding its instigation. Applying HMP 
in these situations has the potential to improve short- term patient 
outcomes. Furthermore, recognizing the opportunity to perfuse kid-
neys overnight and increasingly perform transplantation during day-
light hours in an increasingly medically complex donor and recipient 
TABLE  4 Subgroup analysis of delayed graft function (DGF) in hypothermic machine perfusion (HMP) vs static cold storage (SCS) by HMP 
use rate of transplanting center
HMP rate Center Transplant
SCS HMP
Odds ratio (95% 
CI) P- valueNo. DGF No. DGF
<5% 11 1351 1337 499 (37.3%) 16 4 (25.0%) 0.56 (0.18- 1.75) .317
5- 20% 5 1088 972 484 (49.8%) 118 61 (51.7%) 1.08 (0.74- 1.58) .697
>20% 7 1682 1039 422 (40.6%) 644 201 (31.2%) 0.66 (0.54- 0.82) <.001
Odds ratios are from univariable binary logistic regression models within each subgroup, and are for HMP, relative to SCS. Bold P-values are significant at 
P < .05.
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population offers potential financial, logistical, and patient safety 
benefits.
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Supplementary Tables relating to manuscript  
 
Supplementary Table 1 – Multivariable analysis of DGF 
 
Odds Ratio  
(95% CI) p-Value 
Preservation Modality (HMP) 0.65 (0.53 - 0.80) <0.001 
Donor Age (per Decade) 1.17 (1.10 - 1.23) <0.001 
Donor Sex (Male) 1.27 (1.08 - 1.50) 0.004 
Donor BMI (per kg/m2) 1.03 (1.01 - 1.04) <0.001 
Donor Terminal Creatinine (per 0.1 mg/dL) 1.04 (1.02 - 1.06) <0.001 




White - - 
Asian 1.10 (0.88 - 1.38) 0.407 
Black 1.48 (1.10 - 2.01) 0.010 
Mixed/Other 0.95 (0.50 - 1.80) 0.870 
Dialysis at Transplant 
 
<0.001 
Haemodialysis - - 
Peritoneal Dialysis 0.40 (0.33 - 0.48) <0.001 




1 - - 
2 1.52 (1.12 - 2.07) 0.008 
>2 4.02 (1.55 - 10.43) 0.004 
HLA Mismatch Level 
 
0.027 
1 - - 
2 1.79 (1.06 - 3.01) 0.029 
3 1.53 (0.92 - 2.55) 0.099 
4 1.95 (1.14 - 3.34) 0.015 
Year of Transplant 
 
<0.001 
2007-2009 - - 
2010-2011 0.73 (0.57 - 0.93) 0.012 
2012-2013 0.57 (0.45 - 0.72) <0.001 




<18 Months - - 
18-35 Months 0.99 (0.81 - 1.20) 0.909 
36-59 Months 1.27 (1.04 - 1.56) 0.020 
60+ Months 1.08 (0.76 - 1.54) 0.654 
Results are from a multivariable binary logistic regression model and bold p-values are significant at 
p<0.05. Hazard ratios are relative to the reference category for categorical variables, or for an 
increase of the stated number of units for continuous variables. All factors from Tables 1a-c were 
originally considered for inclusion, but recipient HCV was subsequently excluded, due to the large 
quantity of missing data in the factor, and the fact that it was not selected for inclusion in the initial 
stepwise model. Waiting time was divided into categories, since a Hosmer and Lemeshow test 
indicated poor model fit when the factor was treated as continuous in univariable analysis. The 





Supplementary Table 2 – Multivariable analysis of time to resolution of DGF 
 Coefficient (95% CI) p-Value 
Preservation Modality  (HMP) -17.7% (-27.8%, -6.2%) 0.003 
Donor Age (per Decade) 4.7% (1.1%, 8.3%) 0.009 
Donor Sex (Male) 15.7% (4.8%, 27.7%) 0.004 
Year of Transplant  0.068 
2007-2009 - - 
2010-2011 -15.9% (-26.6%, -3.5%) 0.013 
2012-2013 -2.8% (-14.5%, 10.6%) 0.669 
2014-2015 -8.2% (-20.3%, 5.7%) 0.234 
Results are from a multivariable general linear model and bold p-values are significant at p<0.05. Due 
to the level of skew in the distribution, the times to resolution of DGF were log10-transformed, prior to 
analysis. The coefficients from the resulting model were then anti-logged, and converted into 
percentage differences. As such, the quoted values represent the estimated percentage difference in 
the time to resolution relative to the reference category for categorical variables, or for an increase of 
the stated number of units for continuous variables. All factors from Tables 1a-c were originally 
considered for inclusion, but recipient HCV, dialysis at transplant and donor terminal creatinine were 
subsequently excluded, due to the large quantities of missing data in these factors, and the fact that 






Supplementary Table 3 – Multivariable analysis of patient survival 
  Hazard Ratio (95% CI) p-Value 
Preservation Modality (HMP) 0.87 (0.67 -1.14) 0.313 
Donor BMI (per kg/m2) 1.02 (1.00 - 1.04) 0.019 
Donor Terminal Creatinine (per 0.1 mg/dL) 0.98 (0.95 -1.00) 0.093 
Recipient Age (per Decade) 1.77 (1.59 -1.97) <0.001 
Recipient Diabetes 1.55 (1.16 -2.07) 0.003 
Recipient Ethnicity  0.089 
White   
Asian 0.67 (0.46 -0.96) 0.031 
Black 0.72 (0.45 -1.15) 0.170 
Mixed/Other 1.25 (0.55 -2.83) 0.588 
Dialysis  <0.001 
Haemodialysis   
Peritoneal Dialysis 0.50 (0.39 -0.66) <0.001 
Not on Dialysis 0.99 (0.25 -4.00) 0.989 
HLAi 3.66 (1.16 -11.51) 0.027 
HLA Mismatch Level  0.083 
1   
2 1.97 (0.79 -4.90) 0.143 
3 1.90 (0.78 -4.63) 0.158 
4 2.53 (1.01 -6.31) 0.047 
CIT (per 10 Hours) 1.33 (1.07 -1.64) 0.009 
Time of Day Recipient’s Blood Perfused  0.080 
0:00 - 7:59   
8:00 - 16:59 1.40 (1.04 -1.89) 0.026 
17:00 - 23:59 1.24 (0.90 -1.71) 0.179 
Results are from a multivariable Cox regression model and bold p-values are significant at p<0.05. 
Hazard ratios are relative to the reference category for categorical variables, or for an increase of the 
stated number of units for continuous variables. All factors from Tables 1a-c were originally 
considered for inclusion, but recipient HCV was subsequently excluded, due to the large quantity of 
missing data and the fact that it was not selected for inclusion in the initial stepwise model. The 
preservation modality was not selected for inclusion by this analysis, and so was entered into a model 
alongside those factors that had been selected by the stepwise procedure. The final model was based 





Supplementary Table 4 – Multivariable analysis of graft survival 
  Hazard Ratio (95% CI) p-Value 
Preservation Modality  (HMP) 0.88 (0.70 - 1.10) 0.263 
Donor Age (per Decade) 1.21 (1.14 - 1.29) <0.001 
Dialysis (Peritoneal)* 0.75 (0.61 - 0.92) 0.006 
HLA Mismatch Level  0.008 
1 - - 
2 1.19 (0.66 - 2.15) 0.552 
3 1.68 (0.96 - 2.96) 0.071 
4 1.35 (0.74 - 2.49) 0.327 
CRF at Transplant (per 10 units) 1.06 (1.02 - 1.09) <0.001 
CIT (per 10 hours) 1.44 (1.21 - 1.71) <0.001 
Time of Day Recipient’s Blood Perfused  0.292 
0:00 - 7:59 - - 
8:00 - 16:59 1.08 (0.84 - 1.37) 0.563 
17:00 - 23:59 1.21 (0.94 - 1.55) 0.145 
Results are from a multivariable Cox regression model and bold p-values are significant at p<0.05. 
Hazard ratios are relative to the reference category for categorical variables, or for an increase of the 
stated number of units for continuous variables. All factors from Tables 1a-c were originally 
considered for inclusion, but recipient HCV and donor terminal creatinine were subsequently 
excluded, due to a large quantity of missing data in these factors, and the fact that they were not 
found to be significant in the initial stepwise model. The preservation modality was not selected for 
inclusion by this analysis, and so was entered into a model alongside those factors that had been 
selected by the stepwise procedure. *Patients not on dialysis (N=20) were excluded from this 
analysis, as there were no graft failures in this group making hazard ratios incalculable. The final 






Supplementary Table 5 – Multivariable analysis of 12 month creatinine 
  Coefficient (95% CI) p-Value 
Preservation Modality (HMP) -2.8% (-5.3%, -0.1%) 0.041 
Donor Age (per Decade) 10.7% (9.7%, 11.6%) <0.001 
Donor Ethnicity  0.014 
White - - 
Asian 12.2% (3.8%, 21.3%) 0.004 
Black 11.4% (-4.1%, 29.4%) 0.156 
Mixed/Other -2.8% (-12.2%, 7.5%) 0.577 
Donor Hypertension 4.2% (1.7%, 6.9%) 0.001 
Recipient Age (per Decade) -3.1% (-4.1%, -2.2%) <0.001 
Recipient Sex (Male) 22.6% (19.9%, 25.4%) <0.001 
Recipient Ethnicity  <0.001 
White - - 
Asian -10.3% (-13.0%, -7.5%) <0.001 
Black 11.9% (7.3%, 16.8%) <0.001 
Mixed/Other -5.6% (-13.7%, 3.2%) 0.206 
Graft Number  0.120 
1 - - 
2 -4.7% (-8.9%, -0.2%) 0.042 
>2 0.1% (-10.6%, 12.0%) 0.988 
CRF at Transplant (per 10 units) 0.6% (0.1%, 1.1%) 0.016 
CIT (per 10 hours) 4.2% (2.0%, 6.5%) <0.001 
Results are from a multivariable general linear model and bold p-values are significant at p<0.05. Due 
to the level of skew in the distribution, creatinine levels were log10-transformed, prior to analysis. The 
coefficients from the resulting model were then anti-logged, and converted into percentage 
differences. As such, the quoted values represent the estimated percentage difference in creatinine 
relative to the reference category for categorical variables, or for an increase of the stated number of 
units for continuous variables. All factors from Tables 1a-c were originally considered for inclusion, but 
recipient HCV, dialysis at transplant and donor terminal creatinine were subsequently excluded, due 
to a large quantity of missing data in these factors, and the fact that they were not selected for 





Supplementary Table 6 – Multivariable subgroup analysis of the association between CIT and 











CIT (per 10 hours) 1.08 (0.91 - 1.28) 0.366 0.76 (0.52 - 1.10) 0.142 
Donor Age (per Decade) 1.16 (1.09 - 1.23) <0.001 1.23 (1.08 - 1.40) 0.002 
Donor Sex (Male) 1.28 (1.08 - 1.51) 0.005 - - 
Donor BMI 1.03 (1.01 - 1.04) <0.001 - - 
Donor Terminal Creatinine 
(per 0.1 mg/dL) 1.03 (1.02 - 1.05) <0.001 1.07 (1.02 - 1.11) 0.002 
Recipient Diabetes 1.35 (1.02 - 1.77) 0.035 - - 
Dialysis at Transplant  <0.001  <0.001 
Haemodialysis - -   
Peritoneal Dialysis 0.42 (0.35 - 0.50) <0.001 0.30 (0.19 - 0.47) <0.001 
Not on Dialysis 0.22 (0.05 - 1.11) 0.068 NA* NA* 
Graft Number  0.005 - - 
1 - - - - 
2 1.38 (1.00 - 1.91) 0.051 - - 
>2 3.98 (1.46 - 10.81) 0.007 - - 
Year of Transplant  <0.001   0.147 
2007 – 2009 - -     
2010 – 2011 0.74 (0.57 - 0.96) 0.025 0.69 (0.41 - 1.16) 0.164 
2012 – 2013 0.54 (0.42 - 0.69) <0.001 0.72 (0.44 - 1.16) 0.177 
2014 – 2015 0.41 (0.32 - 0.52) <0.001 0.51 (0.29 - 0.91) 0.022 
Waiting Time  0.022 - - 
<18 Months - - - - 
18-35 Months 1.04 (0.85 - 1.28) 0.680 - - 
36-59 Months 1.36 (1.10 - 1.67) 0.004 - - 
60+ Months 1.18 (0.82 - 1.71) 0.369 - - 
HLA Mismatch Level - -   0.233 
1 - -     
2 - - 2.12 (0.70 - 6.40) 0.182 
3 - - 1.62 (0.55 - 4.72) 0.379 
4 - - 2.41 (0.76 - 7.62) 0.135 
Results are from multivariable binary logistic regression models produced separately for each cohort, 
and bold p-values are significant at p<0.05. All factors from Tables 1a-c were originally considered for 
inclusion, but recipient HCV was subsequently excluded, due to the large quantity of missing data and 
the fact that it was not selected for inclusion in either of the initial stepwise models. Factors identified 
as independent predictors of DGF in the resulting models were then entered into a model alongside 
CIT. The resulting analyses were based on N=2,593 for the SCS cohort, and N=577 for the HMP 
cohort. *Recipients not on dialysis were excluded from the analysis of the HMP cohort, as none of the 






Chapter 5 : Metabolic differences between 
kidneys preserved with hypothermic 
machine perfusion and those in static cold 
storage  
 
This study was performed early in my research degree using 1H-1D NMR and a paired 
porcine study design which formed the basis of later experiments.  
The study was designed in conjunction with my supervisor Jay Nath. I was responsible for 
performing experiments, analysing data and co-writing the manuscript which follows 
accompanied by additional commentary and supplementary figures and tables referred to 










Environmental temperature has a profound effect on the rate of biological processes 
including metabolism. The Arrhenius equation (203) describes the effect of temperature 
on a reaction at lower temperatures; reaction rates are reduced by 50% for every 10°C 
reduction in temperature. Southard and Belzer suggest that in ex-vivo organs preserved 
at 4°C, only 5-8% of normal metabolic function occurs (63). At such temperatures, demand 
for oxygen and substrates is also reduced. 
As discussed in Chapter 1, the characterising feature of HMP is the dynamic pulsatile 
recirculation of chilled perfusion fluid through renal vasculature. In contrast to static 
storage, machine perfusion permits constant delivery of substrates to renal parenchyma 
with washout of toxic metabolites.  
To date, few studies have explored metabolism within kidneys undergoing HMP. Bon et 
al. (172) used 1H-1D NMR to determine metabolic changes in circulating perfusate in an 
auto-transplantation porcine study. Functional outcome was assessed following standard 
HMP with a second group undergoing HMP with an experimental perfusion fluid. 
Concentrations of lactate, choline, valine, glycine and glutamate increased whilst the 
concentration of glutathione decreased. The rate of change was associated with graft 
function post-transplantation.  
Previous studies in our group have also used 1H-1D NMR to validate porcine kidneys as 
a metabolic model for human studies (174). The study compared changes in the perfusate 
concentration of metabolites in standard criteria deceased donor human and porcine 
kidneys.  Interestingly most metabolites seemed to increase in concentration at the same 




between this study and that of Bon et al. (172); the concentration of glutathione decreased 
over the perfusion period whilst the concentration of lactate, glycine, glutamate and valine 
increased significantly.  
Similar methodology was used in a clinical study in which the changing composition of the 
circulating perfusate of 26 cadaveric kidneys undergoing HMP was analysed prior to 
transplantation (173). The concentration of three metabolites at two different timepoints 
were associated with the onset of delayed graft function following transplantation. These 
metabolites, inosine, leucine and gluconate also increased significantly in concentration 
during the perfusion period in both human and porcine suggesting ongoing metabolism 
during the preservation period over time with the implication that metabolism influenced 
function post-transplantation.    
The aim of this study was to identify differences in metabolism between static and dynamic 
hypothermic preservation modalities to show how HMP promotes benefit. Differences in 
metabolism were detected by changes in metabolite accumulation in storage fluid and 
changes in metabolite concentration in end-point renal cortex using 1H-1D NMR in an 
established porcine cardiac death donor model using a paired study design.   
Methodology  
Perfusate was sampled from HMP kidneys whilst storage fluid was sampled for those 
kidneys in static storage. Of note, end-point tissue samples consisted solely of renal 






The use of porcine kidneys in organ preservation studies  
Organ preservation research benefits from an appropriate animal model which permits 
multiple replicates of the same experiment with change of one variable in order to study 
that variable in isolation. A cell line model may be useful to determine experimental 
conditions on isolated cell lines, such as the highly metabolically active proximal tubule, 
but such models lack relevance to the whole organ in addition to facing problems 
generating conditions of shear stress. A whole organ model is necessary to demonstrate 
the effects of therapeutic interventions on the ex vivo kidney. Ideally, the use of human 
kidneys in such a model would be preferable in terms of applicability but such discarded 
human kidneys are a very heterogenous group.  
Cadaveric kidneys differ due to many donor variables such as age, acute physiological 
insult due to donor cause of death and exposure to chronic disease such as 
atherosclerosis. Discard of cadaveric human kidneys occurs for multiple reasons including 
retrieval injury, unfavourable anatomy, cold ischaemic time. Aside from being a scare and 
unpredictable resource, it is evident that any cadaveric human kidneys available for 
preservation studies are a very heterogenous group, potentially resulting in experimental 
bias from the outset.   
Similarities between porcine and human kidneys  
Development of a robust, reliable and reproducible animal model is necessary to provide 
a homogenous set of organs, available at request, in which the effects of modifying 
isolated experimental variables can be explored.  In the past, canine organs have been 




preservation research for several reasons. The domestic pig is widely bred for human 
consumption thus animals and organs are readily available.   
From an anatomical perspective, porcine and human kidneys are similar. Both share a 
multi-lobar structure, contrasting with the unilobar structure of rodent and canine kidneys 
(205). In addition, intra-renal vasculature is similar between pigs and humans although 
extra-renal arterial supply differs. In one research study exploring the anatomical patterns 
of porcine kidneys, all kidneys were supplied by a single artery (205) contrasting with the 
higher proportions of multiple arteries seen in human kidneys (17-35%) (206). This 
contrast may in essence be a limitation as the prevalence of single vessel anatomy does 
remove multiple vessels, known to influence clinical outcome in the human setting (104), 
as a confounding factor in experimental groups.  
In addition to genetic similarities (207), pig kidneys display similar physiology to human 
kidneys (208).  Metabolism of pig kidneys in-vivo has been demonstrated to be 
comparable to human kidneys (209, 210). Using 1D-1H NMR spectroscopy, previous work 
within our group has validated the pig model for use in the HMP environment (174).  
Practical considerations  
In the context of organ preservation, large pig body sizes allows surgical procedures 
similar to humans (i.e donor nephrectomy, re-implantation). Such size-matched organs 
can therefore be used in place of human kidneys in perfusion circuits designed for the 
clinical setting.  
In the pig model used in this thesis, kidneys were removed from male English Large White 
pigs weighing between 80 and 85kg. This contrasts with the choice of pig breed and size 




(between 23-40 kg) (211-215) perhaps reflecting the relative ease of caring for such 
animals post-operatively. Pig breeds native to locality in which research is performed are 
commonly used; notably the Landrace pig and English Large White pig, also known as 
the Yorkshire pig, tend to predominate. Kidneys from larger pigs weighing 80-100kg are 
also used (216), but not in the case of auto-transplantation models.  
The relatively young age of pigs used in preservation studies reflects the nature in which 
domestic breeds are intensively fed, gaining muscle mass quickly prior to slaughter. The 
question remains over which demographic the pigs used in transplantation studies best 
represent although model design would suggest young, DCD donors with a high muscle 
bulk  
The extent to which porcine kidneys are well matched to human kidneys is referenced by 
continuing work exploring the use of pig kidneys in xenotransplantation to solve organ 
shortages (217). Porcine kidneys have demonstrated to have similar lobar and vascular 
anatomy, similar physiology and similar metabolism in the HMP environment compared 
with human kidneys. Such organs are readily available from one breed of pig within a 
designated weight range, resulting in a homogenous group of organs which can be used 
for experimental studies.  
Discussion 
As described in the manuscript, key findings included a greater total amount of central 
metabolites in kidneys preserved using HMP compared with those stored in static storage 
indicating HMP conditions promoted metabolic activity through delivery of metabolic 




preservation period were similar for all kidneys, contrasting with studies involving human 
cadaveric kidneys which are subject to an increased number of donor organ variables.  
The study model used a combination of metabolite concentration in circulating perfusion 
fluid and metabolite concentration within the renal cortex to show convincing evidence of 
ongoing metabolic activity during HMP with the suggestion that metabolism also occurs 
during static storage conditions. Metabolite calculations were based on a model with 
several assumptions including uniform distribution of metabolites throughout the kidney 
and complete extraction of metabolites from cells.  
An important consideration for subsequent studies is the use of metabolite concentration 
in perfusion fluid as a surrogate marker of tissue metabolic activity. Ideal characteristics 
include a timely and marked change in metabolite concentration which mimics such 
changes within renal tissue. However, such changes in perfusate metabolite concentration 
also occur due to processes such as cell damage or cell death. One notable consideration 
should be the means by which metabolites enter and leave cells.  
Following intra-cellular build up and accumulation, metabolites must either be actively 
transported across cell membranes, or leave by passive transport such as diffusion, 
osmosis and facilitated diffusion. All means of passive transport rely on permeability of the 
cell membrane which is affected by increases and decreases in temperature. Whilst 
permeability increases as temperature increases, in sub-zero temperatures ice crystals 
form which may pierce the cell membrane causing release of intra-cellular contents.  
As described in Chapter 1, hypothermia and hypoxia result in a reliance on anaerobic 
metabolism which results in lactate accumulation secondary to glycolytic pathway activity. 




accumulation within renal cortex without release into storage fluid. In contrast, during HMP 
there was a sequential rise in concentration of lactate in perfusion fluid secondary to 
homeostatic cellular mechanisms which coincided with lower concentrations of lactate 
within the renal cortex potentially reducing ischaemia reperfusion injury secondary to 
intracellular acidosis. This contrasts with static storage conditions, in which lactate 
accumulates in tissues, potentially worsening ischaemia reperfusion injury.  
Yet conclusions drawn are subject to the limitations of an untargeted metabolomics study. 
The origin of lactate maybe the result of preceding ischaemia during the retrieval process 
or secondary to the two hour period of static cold storage prior to designation to static or 
dynamic preservation modality. Alternatively it may be secondary to de novo metabolism 
during the preservation period itself, potentially increased during HMP due to delivery of 
glucose in perfusion fluid.   
Similar to lactate production, increased amounts of central metabolites may indicate 
tricarboxylic acid cycle activity although this is less likely given the largely hypoxic 
environment of HMP. Other origins of such metabolites are likely. For example, glutamate 
is more likely to increase in concentration as it is a degradation product of glutathione-s-
transferase (GST) detoxification reactions, a mark of ongoing oxidative stress during HMP 
(218).  
In addition to assumptions made when calculating total systems metabolite concentrations 
for both storage conditions, the method of using metabolite concentration in storage fluid 
for static storage conditions falsely assumed metabolites were present in the same 
concentration within all fluid surrounding the kidney including that of the major vasculature. 
This fluid is highly unlikely to represent the interstitial compartment over the course of the 




However, robust conclusions can still be drawn from tissue metabolite concentration alone 
as detailed in the manuscript.  
Concluding remarks  
In conclusion, experimental results demonstrate stark differences in metabolite levels in 
the renal cortex of kidneys preserved with HMP compared with those stored using static 
storage alone inferring more metabolic activity as a result of HMP. Results showing an 
increase in the concentration of lactate and glutamate over the perfusion period with a 
decrease in glutathione concentration were consistent with previous studies using 1H-1D 
NMR to assess the composition of circulating perfusate during HMP (172, 173). Perfusate 
analysis reveals an increase in the concentration of alanine and lactate indicating 
anaerobic metabolism is active during HMP. The depletion of glutathione and increase in 
glutamate concentration are a likely indication of oxidative stress which the kidney is 
exposed to during the hypothermic, largely hypoxic conditions of HMP.  
Continual supply of metabolic substrates during HMP may contribute to its clinical benefits 
whilst ongoing perfusion permits washout of toxic metabolites which may otherwise 
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a b s t r a c t
Hypothermic machine perfusion (HMP) and static cold storage (SCS) are the two methods used to
preserve deceased donor kidneys prior to transplant. This study seeks to characterise the metabolic
profile of HMP and SCS porcine kidneys in a cardiac death donor model.
Twenty kidneys were cold flushed and stored for two hours following retrieval. Paired kidneys then
underwent 24 h of HMP or SCS or served as time zero controls. Metabolite quantification in both storage
fluid and kidney tissue was performed using one dimensional 1H NMR spectroscopy. For each metabolite,
the net gain for each storage modality was determined by comparing the total amount in each closed
system (i.e. total amount in storage fluid and kidney combined) compared with controls.
26 metabolites were included for analysis. Total system metabolite quantities following HMP or SCS
were greater for 14 compared with controls (all p < 0.05). In addition to metabolic differences with
control kidneys, the net metabolic gain during HMP was greater than SCS for 8 metabolites (all p < 0.05).
These included metabolites related to central metabolism (lactate, glutamate, aspartate, fumarate and
acetate).
The metabolic environments of both perfusion fluid and the kidney tissue are strikingly different
between SCS and HMP systems in this animal model. The total amount of central metabolites such as
lactate and glutamate observed in the HMP kidney system suggests a greater degree of de novometabolic
activity than in the SCS system. Maintenance of central metabolic pathways may contribute to the clinical
benefits of HMP.
© 2016 Elsevier Inc. All rights reserved.
1. Introduction
Hypothermic Machine Perfusion (HMP) and Static Cold Storage
(SCS) are the two methods of kidney preservation that are used
widely in clinical practice during the time period between organ
retrieval and implantation [16]. A key concept for both preservation
modalities is that cellular metabolism, and therefore cellular
metabolic requirements, are minimised in these hypothermic
conditions and the rate of metabolism reported to be about 5e8% at
temperatures below 4 !C [29] with a similar decrease in oxygen
requirement [1].
The superiority of HMP over SCS is well documented
[4,17,22,23,27] but the mechanisms by which this occurs are not
clear. Improvement in flow dynamics, with fall in the intra-renal
resistance is likely to be one factor but the additional metabolic
support derived from the circulation of nutrient-containing
perfusion fluid may also help preserve organ function and have a
beneficial effect [7,30].
Metabolomic analyses of preservation fluid during HMP using
1D-1H NMR (One-dimensional proton nuclear magnetic resonance)
spectroscopy, by groups including our own, have demonstrated this
to be reproducible and highly specific for metabolite identification
and quantification [2,10,24]. However, surprisingly, to our knowl-
edge there are no studies that have sought to compare the
metabolomic profiles, or metabolome, of HMP and SCS kidneys.
Porcine kidneys are widely used in transplantation studies
owing to their similar physiological and anatomical properties to
human organs [9,11]. In addition, the metabolic profiles during
* Corresponding author.Department of Renal Surgery, University Hospitals Bir-
mingham, Birmingham, UK.
1 Authors contributed equally to this manuscript.
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periods of HMP for porcine and human kidneys are comparable
[24], with a correlation between metabolite profiles during storage
and post transplant outcome [2]. For HMP preserved human kid-
neys, the metabolic profile from perfusates of immediate graft
function kidneys differs from those with delayed function [10] and
reinforces the concept that significant metabolism occurs during
HMP and that metabolism reflects functional outcome.
The aims of this study were twofold. Firstly, to determine the
distribution of metabolites between the two different compart-
ments (fluid and tissue) during the organ preservation period.
Secondly, to determine the total amount of each metabolite within
HMP and SCS kidneys systems after 24 h of organ storage and




Abattoir/slaughterhouse pig kidneys (F.A. Gill, Wolverhampton,
UK) were used and no animals were sacrificed solely for the pur-
poses of this study, negating any need for ethical board approval.
Experiments were performed on 22e26 week old male ‘bacon
weight’ pigs, weighing 80e85 kg. All experiments were performed
following the principles of laboratory animal care according to NIH
standards. Animals were sacrificed by electrical stunning and
exsanguination. Initial organ preservationwas performed following
organ retrieval and occurred within 14 min of death, replicating
deceased cardiac death (DCD) donor conditions. Kidneys were cold
flushed (4 !C) with 1 L SPS-1 (UW) solution at a pressure of
100 mm Hg. Organs were then stored at 4 !C in SPS-1 for 2 h to
replicate the clinical period of organ transportation.
2.2. Experimental groups
Paired kidneys were randomly allocated to receive either HMP
or SCS for 24 h. HMP kidneys were perfused with 1 L of KPS-1 using
the LifePort Kidney Transporter 1.0 (Organ Recovery Systems, Chi-
cago, IL). (Perfusion pressure 30 mm Hg). SCS Kidneys were sub-
merged in 1 L of fresh chilled SPS-1 solution with a surrounding ice
bath. Preservation fluid was sampled for each kidney at baseline
and 2, 4, 8,12,18, and 24 h. After 24 h, organs were rapidly dissected
and tissue samples (1 cm3 sections) flash frozen and stored
("80 !C). All experiments were performed in a cold room (4 !C) to
ensure consistency.
2.3. Control kidneys
To ascertain metabolism during SCS or HMP storage conditions,
baseline values prior to storage conditions were needed (time 0).
Large volume tissue sampling precludes effective organ perfusion
and therefore ‘Control kidneys’ were used to establish baseline
metabolite levels. These were (n ¼ 6) flushed and cold transported
in identical fashion to experimental kidneys and tissue samples
obtained as described above (i.e. not subjected to 24 hr of SCS or
HMP).
2.4. Sample processing and metabolite quantification
NMR samples were prepared from storage fluid by mixing
150 mL of 400 mM (pH 7.0) phosphate buffer containing 2 mM DSS
(4,4-dimethyl-4-silapentane-1-sulfonic acid) and 8 mM imidazole
with 390 mL of each fluid sample and 60 mL of deuterium oxide
(D2O) to reach a final phosphate buffer concentration of 100 mM
and a final DSS concentration of 500 mM. After mixing, the 600 mL
samples were pipetted into 5 mm NMR tubes, sonicated and
centrifuged. Technical replicates of samples ($3) were prepared for
each timepoint.
For cell extract studies, 500 mg of renal cortex was manually
cryo-homogenised in liquid nitrogen. 5.1 ml of both methanol
("80 !C) and chloroform was added to the powdered tissue and
samples diluted with 4.65 ml of dH20 at 4 !C. Samples were
centrifuged to separate into polar and non-polar layers and 1.5 ml
of the upper polar layer was dispensed into a cryovial and dried.
Three technical replicates were performed for each tissue sample.
Dried polar residuewas then dissolved in 390 mL of dH20 and 210 mL
of buffer solution as described above.
The protocol used for 1H NMR analysis has been described
previously [10,24]. Briefly, this entailed processing on a Bruker AVII
500 MHz spectrometer, acquisition of one dimensional spectra and
then metabolite identification and quantification using Matlab
based ‘Metabolab’ software [18] and Chenomx 8.1 (ChenomxInc)
software respectively. Metabolites were deemed to be present if
they exhibited non-ambiguous spectral patterns or their presence
deemed biologically plausible and confirmed on ultra performance
liquid chromatography mass spectrometry. Any metabolites that
were present in different concentrations in the SCS and HMP fluid
(e.g. glucose, gluconate, mannitol, adenine, adenosine etc.) were
excluded from comparative analysis. Metabolite quantifications
were corrected to allow for sample dilution with sample buffer.
When determining concentrations of metabolites using Chenomx,
the researchers were blind to the storage group. Quantification of
the total amount of metabolite in the storage fluid, tissue and total
systemwas calculated based upon the weight of the kidney at time
of sample acquisition and final volume of storage fluid.
2.5. Statistical analysis
For each timepoint, three results were obtained (technical rep-
licates) and themedian value used. For comparison of SCS and HMP
conditions, analysis was performed using Wilcoxon paired signed
rank test (two tailed) as one kidney from each pair was subjected to
each condition and normality was not consistent on prior analysis.
When comparing SCS or HMPwith control kidneys, Mann-Whitney
u test (two tailed) was used, as these were non-paired samples.
Datawere reported as median concentrations and interquartile (IQ)
range. All analysis was performed using GraphPad Prism version
6.00 for Mac OS X, GraphPad Software, La Jolla California USA, with
p < 0.05 deemed to be indicative of statistical significance.
3. Results
Metabolic optimisation of cadaveric kidneys is a potential target
to improve the function of kidneys for transplantation. This study
seeks to establish the degree of metabolism, if any, that occurs in
the two widely used methods of kidney organ storage prior to
transplantation (HMP and SCS).
The total quantity of each metabolite after 24 h of either HMP or
SCS was calculated using 1H NMR methods and compared with
control organs to determine the net metabolic change during each
storage method.
We found evidence of metabolite production for both storage
modalities with 14 metabolites present in significantly greater
quantities in the HMP or SCS system compared with controls (all
p < 0.05) (Table 1) (Fig. 1, Fig 1(Suppl)). There were significantly
more metabolites with a net increase in the HMP system (13/14)
compared with the SCS system (7/14) (p ¼ 0.033).
Eight of the metabolites were significantly elevated in the HMP
system compared with both the control and SCS systems (all
p < 0.05), indicating a greater degree of metabolite production.
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These included lactate, glutamate, aspartate, fumarate, acetate,
myo-inisitol, niacinamide and formate (Fig. 1).
Despite the additional 24 h of organ preservation, albeit in static
conditions, the amount of lactate in the SCS systemwas comparable
to controls (1.37 vs 1.11 mmol p ¼ 0.138). However the amount in
the HMP system (2.13 mmol) was almost twice the amount of
either controls or SCS systems (p ¼ 0.002 and p ¼ 0.031). However,
despite greater amounts overall, the amount present in the HMP
tissue (0.76 mmol) was actually lower than SCS tissue (1.14 mmol)
or control tissue (1.11mmol) (p¼ 0.031 and p¼ 0.002 respectively),
reflective of lower intracellular concentrations for HMP kidneys.
The distribution of metabolites between the extracellular stor-
age fluid and tissue samples for both storage conditions are detailed
in Table 2. As expected, there were greater quantities of metabolites
in the circulating HMP fluid compared with the static conditions of
SCS at most time-points. After 24 h, the total amount of metabolite
in the perfusate for the HMP kidneys was significantly greater than
the SCS group for (21/26 ¼ 80.8%) of metabolites. Whilst concen-
trations rose most rapidly in the first 2 h of perfusion and therefore
may be in part due a metabolite washout phenomenon, there was
an increase in most metabolites over sequential timepoints as
would be expected with on-going production (Fig. 2aec).
Reduced glutathione is a constituent of both KPS-1 (used in
HMP) and SPS-1 (used in SCS) fluids at equal concentrations. Whilst
this remained at stable in the SCS environment, the glutathionewas
clearly consumed by the HMP group and after 8 h concentrations
were 17.6 fold higher in the SCS fluid (1.60 mM vs. 0.091 mM,
p ¼ 0.001) (Fig. 2d). Despite apparent organ uptake of reduced
glutathione, there was no evidence of this in the tissue samples
from either group.
4. Discussion
The aim of this study was to determine any metabolic differ-
ences between the two clinically used methods of organ storage in
this animal model.
Whilst the calculation of the total amount of metabolite within
the system does rely on several assumptions (complete metabolite
extraction from tissue and metabolite homogeneity within tissue),
we felt this was imperative to draw meaningful comparison be-
tween groups and enables the calculation of net metabolite pro-
duction/consumption in these two closed systems (HMP and SCS).
Although the storage fluid used in each experimental group
differs (most notably absence of glucose in the SCS fluid) and
therefore caution should be exercised in attributing any differences
merely to the parameters of storage (i.e. HMP or SCS), this study
was designed to assess metabolism during the two clinically used
organ preservation techniques, not merely the storage modality in
isolation.
This study clearly demonstrates the presence of major central
metabolites such as lactate, glutamate, fumarate, aspartate and
acetate at greater levels in the HMP system compared with both
controls and SCS (Fig. 1). This strongly suggests that these metab-
olites are being produced during HMP. Furthermore, the accumu-
lation of these metabolites into the circulating perfusion fluid
demonstrates effective homeostatic mechanisms are active to
prevent over accumulation within the local cellular environment.
The list of metabolites reported in this study is not exhaustive
and is a limitation of this study. Some interesting substrates (eg
glucose) were excluded as this is only present in one of the storage
fluids (KPS-1). For others the 1D 1H NMR spectral pattern is either
ambiguous or can be hidden under more domineering peaks from
other compounds.
The increased total lactate in the HMP system is likely to reflect
increased glycolysis in the HMP model. Although new glycolytic
activity of the glucose within the HMP fluid is one likely contrib-
utor, this is unlikely to the singular cause. This is supported by
evidence that the HMP fluid glucose concentrations did not
decrease during the study period and replicates findings from
previous human studies [10]. However conversion of a proportion
of perfusion fluid glucose into lactate through glycolytic pathways
has been corroborated by work demonstrating activity of these
pathways using 13C labelled glucose tracers [25].
The net gain of glutamate, fumarate, aspartate and acetate
during HMP is also intriguing. Whilst identification of responsible
metabolic pathways is difficult to ascribe solely with 1H NMR
studies, one explanation could be increased oxygen dependent
tricarboxylic acid (TCA) cycle activity. Although uniform upregu-
lation of TCA intermediates would support this theory, as discussed,
many are not easily identifiable using 1H NMR methods [6] and are
rarely found in equipoise even in vivo [14]. Several (13C) NMR
studies have reported glutamate as a valid marker of TCA activity
[3,5,20].
For some metabolites, the total system amounts for HMP and
SCS kidneys were comparable to the controls, suggesting that either
de novo production does not occur during the 24 h preservation or
that consumption mirrors production (Table 1 supplementary).
However, for metabolites with similar total amounts, the
compartment in which they were located varied per metabolite.
Some metabolites were entirely contained within the HMP kidney
Table 1
Total amount of metabolite present in each of the storage modalities at time zero (controls) or after 24 h of preservation (SCS or HMP). Data reported as Median (Interquartile
Range), unless stated otherwise. Statistical test: J Mann-Whitney u test (two tailed) #Wilcoxon paired signed rank test (two tailed). *Significant at p < 0.05.
Storage Modality p-Values
Control System (mmol) SCS System (mmol) HMP System (mmol) Control vs SCS J Control vs HMP J SCS vs HMP #
Glutamate 1.54 (1.12e1.84) 1.38 (1.11e1.66) 3.97 (3.69e4.71) 0.731 0.002* 0.031*
Myoinositol 1.18 (1.16e1.19) 1.29 (1.01e1.52) 2.16 (1.85e2.41) 0.731 0.002* 0.031*
Lactate 1.11 (0.976e1.23) 1.38 (1e1.75) 2.13 (1.67e2.71) 0.138 0.002* 0.031*
Hypoxanthine 0.454 (0.356e0.515) 0.710 (0.641e0.762) 1.05 (0.909e1.17) 0.001* 0.002* 0.156
Formate 0.442 (0.274e0.638) 0.643 (0.589e0.779) 0.842 (0.750e0.943) 0.101 0.004* 0.031*
Acetate 0.210 (0.206e0.212) 0.296 (0.253e0.301) 0.552 (0.494e0.654) 0.234 0.041* 0.031*
Alanine 0.302 (0.243e0.360) 0.486 (0.339e0.499) 0.501 (0.368e0.558) 0.035* 0.015* 0.313
Succinate 0.283 (0.267e0.297) 0.462 (0.312e0.52) 0.434 (0.307e0.541) 0.001* 0.015* 0.844
Inosine 0.588 (0.561e0.628) 1.08 (0.885e1.12) 0.185 (0.146e0.233) 0.001* 0.002* 0.031*
Aspartate 0.114 (0.104e0.118) 0.107 (0.0879e0.11) 0.165 (0.140e0.215) 0.234 0.041* 0.031*
Leucine 0.0476 (0.0441e0.0517) 0.0667 (0.0513e0.0820) 0.0693 (0.0495e0.0773) 0.014* 0.026* 0.688
Niacinamide 0.0196 (0.0181e0.0207) 0.0289 (0.0243e0.0319) 0.0490 (0.0420e0.0557) 0.001* 0.002* 0.031*
Tyrosine 0.0262 (0.0217e0.0302) 0.0434 (0.0339e0.0462) 0.0387 (0.0332e0.0431) 0.001* 0.013* 0.438
Fumarate 0.00412 (0.00339e0.00418) 0.00308 (0.00145e0.00348) 0.0133 (0.0077e0.0212) 0.064 0.002* 0.031*
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tissue (e.g. ADP, AMP, NADþ) and presumably in the intracellular
compartment. Other metabolites were evident in both the tissue
and storage fluid but at higher concentrations in the HMP fluid.
These discrepancies in metabolite location further highlight that
cellular transport processes are active in this environment but that
movement of metabolites into the extracellular fluid is not
Fig. 1. Metabolites significantly elevated in the HMP system compared with both SCS and control kidneys. Metabolite levels represent total amounts (mmol) in the storage fluid,
kidney tissue and entire system for porcine kidneys after 24 hr of HMP or SCS or time zero controls. Highly significant (**p < 0.01) and significant (*p < 0.05) differences between
HMP system versus both controls and SCS kidneys.
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indiscriminate.
Reduced glutathione is a constituent of the preservation fluid
KPS-1 and is thought to play a role in the removal of Reactive Ox-
ygen Species (ROS) generated duringmetabolism [19] In contrast to
the SCS kidney, there is a rapid decrease in the concentration of
glutathione in the preservation fluid of HMP stored kidneys and is
about 5% of the SCS values after 8 h (Fig. 2d.). The rate of glutathione
depletion observed in this study is similar to a previously reported
animal model [28] and is likely to reflect cellular uptake of this
protective antioxidant. Interestingly, glutathione concentration
remained relatively constant in the SCS kidney group. This further
reinforces the concept that HMP exerts its beneficial effects, at least
in part, by providing access to the cellular components of the kid-
ney during perfusion. Absence of reduced glutathione in tissue
demonstrates that not only is this protective antioxidant readily
absorbed by the kidney during perfusion but that even after a few
hours it is not longer available in the reduced state.
Although the number of organs in each experimental group is
small (n ¼ 7), it is comparable to other porcine kidney transplant
reports [8,12,15,21,26,30]. To improve validity, samples were pro-
cessed in triplicate at each timepoint and over 250 NMR spectra
were analysed. One strength of this study is that the kidneys stored
by HMP or SCS were paired, i.e. from the same pig, thus minimising
any metabolic differences arising from polymorphism in cellular
mediators of porcine metabolism. Although this approach does not
provide functional outcome information for the preserved organ,
previous studies have demonstrated good function for otherwise
healthy porcine organs stored by either SCS or HMP for similar time
periods [2,8,13,15,21,26].
This study demonstrates that in a porcine model, the distribu-
tion and amounts of metabolites vary significantly with the storage
method (HMP or SCS). The net gain of many central metabolites
during HMP conditions further supports the notion that significant
metabolism occurs during HMP and this may contribute to the
beneficial role of machine perfusion.
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Table 2
Metabolites present in tissue and storage fluid in HMP or SCS kidney systems at 24 h. Data reported as Median (Interquartile Range), unless stated otherwise. Statistical test:
#Wilcoxon paired signed rank test (two tailed). *Significant at p < 0.05.
Storage Total storage fluid amount (mmol) p-value# Total kidney tissue amount (mmol) p-Value#
Glutamate SCS 0.0812 (0.125e0.155) 0.0312* 0.952 (1.26e1.58) 0.6875
HMP 2.72 (2.75e2.89) 0.94 (1.24e1.68)
Myoinositol SCS 0.316 (0.399e0.879) 0.0625 0.596 (0.676e0.853) 0.5625
HMP 1.05 (1.25e1.38) 0.653 (0.816e1.3)
Lactate SCS 0.153 (0.205e0.245) 0.0312* 0.89 (1.14e1.59) 0.0312*
HMP 1.15 (1.38e1.82) 0.521 (0.755e0.895)
Hypoxanthine SCS 0.294 (0.328e0.404) 0.0312* 0.289 (0.407e0.424) 0.0625
HMP 0.705 (0.781e0.867) 0.189 (0.258e0.31)
Formate SCS 0.132 (0.136e0.186) 0.4375 0.434 (0.486e0.545) 0.0312*
HMP 0.151 (0.16e0.169) 0.688 (0.599e0.774)
Acetate SCS 0.073 (0.0808e0.0912) 0.0312* 0.167 (0.201e0.229) 0.0312*
HMP 0.239 (0.257e0.331) 0.252 (0.289e0.344)
Alanine SCS 0.0465 (0.0643e0.0815) 0.0312* 0.303 (0.415e0.435) 0.0312*
HMP 0.253 (0.306e0.358) 0.116 (0.187e0.207)
Succinate SCS 0.0104 (0.0155e0.0184) 0.0312* 0.298 (0.446e0.498) 0.0312*
HMP 0.104 (0.131e0.208) 0.203 (0.294e0.347)
Inosine SCS 0.703 (0.852e0.961) 0.0312* 0.145 (0.182e0.201) 0.0312*
HMP 0.0877 (0.108e0.128) 0.058 (0.0723e0.109)
Aspartate SCS e 0.0312* 0.0879 (0.107e0.11) 0.3125
HMP 0.039 (0.0452e0.0682) 0.0874 (0.115e0.155)
Leucine SCS 0.00442 (0.00506e0.00761) 0.0312* 0.0486 (0.0591e0.0775) 0.0312*
HMP 0.0285 (0.038e0.0468) 0.0222 (0.0304e0.0318)
Niacinamide SCS e 0.0312* 0.0243 (0.0289e0.0319) 0.0938
HMP 0.0221 (0.028e0.0282) 0.0194 (0.0221e0.0278)
Tyrosine SCS 0.00336 (0.0071e0.00843) 0.0312* 0.0306 (0.0371e0.0391) 0.0312*
HMP 0.0197 (0.0228e0.0276) 0.0112 (0.0143e0.0171)
Fumarate SCS e 0.0312* 0.00145 (0.00308e0.00348) 0.0312*
HMP 0.00456 (0.00737e0.00895) 0.00314 (0.00574e0.0126)
Fig. 2. Concentration of metabolites in the storage fluid of SCS and HMP kidneys over 24 h time period for four example metabolites. Values plotted as median (interquartile range).
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Supplementary Table 1 
 
 
 Storage Total storage fluid 
amount (mmol) 





SCS - 0.031* 0.094 (0.063-0.112) 0.031* 
HMP 0.048 (0.037-0.062)  0.055 (0.050-0.059)  
Choline SCS 0.039 (0.035-0.045) 0.031* 0.404 (0.329-0.423) 0.063 
HMP 0.102 (0.099-0.115)  0.267 (0.205-0.299)  
Creatinine SCS 0.032 (0.008-0.067) 0.031* 0.564 (0.127-0.699) 0.156 
HMP 0.196 (0.038-0.386)  0.228 (0.130-0.328)  
Hippurate SCS 0.002 (0.001-0.002) 0.031* 0.005 (0.003-0.007) 0.094 
HMP 0.006 (0.005-0.010)  0.001 (0.000-0.005)  
Isoleucine SCS 0.004 (0.003-0.005) 0.031* 0.036 (0.032-0.041) 0.031* 
HMP 0.026 (0.023-0.027)  0.019 (0.014-0.020)  
TMNO SCS 0.037 (0.031-0.047) 0.031* 0.152 (0.096-0.272) 0.219 
HMP 0.254 (0.165-0.266)  0.143 (0.099-0.218)  
Valine SCS 0.006 (0.006-0.010) 0.031* 0.068 (0.057-0.083) 0.031* 
HMP 0.041 (0.038-0.053)  0.035 (0.025-0.036)  
β-Alanine SCS 0.013 (0.010-0.021) 0.031* 0.101 (0.078-0.112) 0.031* 
HMP 0.085 (0.078-0.099)  0.038 (0.031-0.048)  
Taurine SCS 0.196 (0.136-0.227) 0.031* 0.981 (0.929-1.056) 0.063 
HMP 0.693 (0.640-0.821)  0.505 (0.437-0.554)  
ADP SCS 0.014 (0.013-0.015) 0.031* 0.013 (0.011-0.026) 0.438 
HMP -  0.024 (0.019-0.031)  
AMP SCS 0.003 (0.002-0.003) 0.031* 0.128 (0.105-0.169) 0.563 
HMP -  0.140 (0.131-0.166) 
NAD+ SCS - - 0.025 (0.022-0.031) 0.094 
HMP -  0.037 (0.033-0.049)  
S1 Table.  Distribution of metabolite quantity between extracellular storage fluid and 
entire kidney tissue for 12 metabolites detected in comparable total amounts to 
controls.  
 
Data reported as median (interquartile range), unless stated otherwise. Statistical test: 



















Chapter 6 : Oxygenation of ex vivo 
kidneys undergoing Hypothermic Machine 
Perfusion 
In this chapter a series of experiments were performed investigating the effects of 
oxygenation on ex vivo kidneys undergoing hypothermic machine perfusion. The 
experiments were written in the form of a manuscript with an accompanying commentary 
forming the remainder of the chapter.  
The manuscript was published in the Tissue Regeneration and Repair special edition of 
the journal Transplantation in February 2019 (219). Additional methods and data are 
described in Supplementary Information and in Chapter 2. 
I was responsible for experimental design, performing the experiments, processing and 
analysing tissue samples for NMR, Mass Spectrometry and immunohistochemistry in 









Following whole organ ischaemia inflicted during the retrieval process, ATP levels are 
quickly depleted as described in Chapter 1. As demonstrated in the previous chapter, 
hypothermic machine perfusion promotes metabolism by delivery of glucose to tissues 
(220). In these hypothermic conditions, in the absence of supplemental oxygen, 
hypothermic machine perfusion is largely anaerobic with only minimal evidence of TCA 
cycle activity. The was previously demonstrated by our group using modified UW-MPS 
supplemented with the metabolic tracer universally labelled glucose ([U-13C] glucose) 
(175).  
Several methods of oxygenation, during both normothermic and hypothermic preservation 
of ex vivo kidneys, have been described including oxygenation using a membrane 
oxygenator, retrograde oxygen persufflation and the use of a hyperbaric oxygen chamber 
(221). Whilst there is some evidence supporting the benefits of oxygenation during HMP 
in animal studies, there remains at present a lack of clinical evidence which use current 
perfusion fluids or methods of oxygenation making it difficult to compare outcomes to 
current practice (222).  
In a DBD auto-transplant porcine model comparing a 21 hour period of either anoxic or 
oxygenated HMP, there was no improvement in renal function post-transplantation (223) 
for the oxygenated group. This contrasts with findings of a similar study again using a 
porcine auto-transplant model, but in this case a DCD model of transplantation (224), with 
a 22-hour period of oxygenated HMP. Kidneys in the oxygenated HMP arm showed lower 
peak serum creatinine post-operatively and faster return to baseline creatinine levels 




In contrast, Lindell et al observed no difference in functional outcome in a similar DCD 
model when perfusing canine kidneys with oxygenated and non-oxygenated HMP for 24 
hours, although the type of device and running temperature differed between arms of the 
study (204). The study ascribed the lack of difference between oxygenated and non-
oxygenated arms to the low oxygen requirements of kidneys during hypothermic storage.  
Retrograde oxygen persufflation (ROP) has also been explored as a means of 
oxygenating kidneys during hypothermic storage (225) although it cannot be performed in 
conjunction with HMP due to the flow of gas. The renal vein is infused with gaseous 
oxygen whilst multiple pinpricks with an acupuncture needle permit escape of gases. In 
the most recent ROP studies, Treckmann et al (226, 227) observed superior functional 
outcomes with 4 hours of preservation with ROP compared to standard static cold storage 
and standard HMP conditions. However, no studies since have continued to explore this 
as a means of organ optimisation.  
Studies since 1968 have investigated the benefits of preserving kidneys in hyperbaric 
oxygen (228, 229). Most recently one study described the effects of a short three hour 
preservation period on ATP levels in 5 differing conditions; static and HMP conditions 
using non-oxygenated conditions and oxygenation using a hyperbaric chamber, in 
addition to a fifth group utilising a membrane oxygenator during HMP (230). A net increase 
in ATP levels was observed in groups of kidneys stored using hypothermic machine 
perfusion oxygenated with either hyperbaric oxygen or using a membrane oxygenator 
despite the three hour preservation period.        
Such aforementioned animal studies are limited by a small sample size and heterogenous 
conditions. Few studies have addressed the mechanisms by which oxygenation promotes 




metabolism. In this thesis so far we have discussed the metabolic products of glucose 
during HMP. In this series of experiments the effects of supplemental oxygen on ex vivo 
kidneys are explored using tracer-based metabolism applied to the porcine DCD model 
described in Chapter 2.  
Methods  
Preliminary work 
Unlike normothermic preservation conditions, hypothermic machine perfusion does not 
aim to mimic physiological conditions. Given that metabolism is reduced during 
hypothermia, any aerobic metabolism is also likely to be minimal raising the question of 
how beneficial supplemental oxygen is likely to be in an HMP circuit.  
Preliminary work for experiments in this chapter, reported in the results section of the 
manuscript, included measuring the oxygenation of arterial limb and venous effluent in a 
standard HMP circuit. Oxygen levels were quickly depleted in venous effluent showing an 
ongoing demand for oxygenation even in hypothermic conditions. A decrease in oxygen 
levels in the in-flow limb showed simple circulation of perfusion fluid is not adequate to 
oxygenate circulating perfusate. 
Methods of oxygenating perfusate 
In order to make the experiments relevant for the clinical setting, a means of oxygenation 
was selected which was sterile, non-traumatic to kidneys and could be used readily with 
standard UW-MPS perfusion fluid. The membrane oxygenator used in this series of 
experiments (Hilite 800 LT series hollow fiber oxygenator; Medos, Medizintechnik, AG) is 




documented use in other kidney preservation studies (82). The static priming volume of 
55ml is small enough to not displace a significant proportion of the 1L perfusion fluid used 
whilst the unit allows a flow rate of up to 800ml/min, exceeding the maximum flow rates 
commonly observed during HMP (78, 231).  
Unmodified UW-MPS does not include an oxygen carrier. An extra-cellular haemoglobin 
extract from the lugworm Arenicola Marina has been tested as an additive to preservation 
solutions for kidneys (232) whilst fluid containing extracted bovine haemoglobin has been 
successfully used to machine perfuse livers at sub-normothermic temperatures (233). For 
the purposes of experiments performed in this chapter, preliminary experiments 
suggested use of the membrane oxygenator resulted in a mean concentration of 68.7kPa.  
Discussion 
Despite a resurgence in interest in oxygenation during HMP, the mechanisms of action of 
oxygenation during HMP are perhaps suspected but not well understood. In our study, 
favourable changes in aerobic metabolism, higher ATP levels, improved perfusion 
parameters and less ultra-structural histological damage were observed in HMP/O2 
kidneys. This is in keeping with the improved functional outcomes seen with oxygenated 
HMP in a porcine DCD model (224) but contrasts with the equivalent outcomes seen in 
porcine DBD kidneys (223).  DCD kidneys are subject to a warm ischaemic insult during 
the retrieval process resulting in fast total depletion of ATP stores contrasting with the 
lesser insults suffered by DBD kidneys. Thus it may be the case that oxygenation is of a 
greater benefit to DCD kidneys compared with DBD kidneys, accounting for the non-





Metabolism and ATP levels  
Metabolite labelling patterns observed in the cortex of HMP/O2 kidneys indicated more 
TCA cycle activity with the observation of less U-13C labelled glycolytic pathway end-points 
compared with HMP/Air kidneys. Perfusate changes showed a consistent increase in the 
concentration of U-13C lactate and U-13C alanine over time in HMP/Air kidneys indicating 
continual glycolytic pathway cycle activity. However, in HMP/O2 kidneys this seemed to 
plateau after 8 hours. This may reflect the start of TCA cycle activity in HMP/O2 kidneys 
but this is difficult to prove as no tissue samples were taken during the perfusion period 
itself. The small increase in TCA cycle activity indicated by higher 4,5-13C glutamate levels 
is likely to account for the seven-fold increase in ATP levels observed in the renal cortex 
of HMP/O2 vs HMP/Air kidneys.    
The disparity in oxygen delivery and resultant reliance of the medulla on glycolytic 
pathway activity under normal physiological conditions is described in Chapter 1. One 
might suggest that simple aeration of perfusate is enough to meet oxygen requirements 
of the medulla, hence explaining why no significant differences were observed between 
labelled metabolites in the medulla of HMP/O2 and HMP/Air conditions.   
In this set of experiments the demonstration of aerobic respiration and higher ATP levels 
are used as outcome measures in the absence of a functional reperfusion or auto-
transplant model. As with all organ donation, the organ preservation process is simply 
preparation for reperfusion with the clinically relevant measure being restoration of 
function of the transplanted kidney thus avoiding the need for dialysis. As discussed in 
Chapter 1, metabolic dysfunction is one contributor to the development of ischaemia 




Wijermars et al observed the effect of post-reperfusion metabolic recovery on the 
development of delayed graft function in transplanted human kidneys, none of which were 
machine perfused (234). Changes in metabolites in the arterial circulation and transplant 
kidney renal vein were measured following reperfusion. Grafts with delayed graft function 
showed continual anaerobic metabolic activity as evidenced by continuing lactate 
production on reperfusion, contrasting with the cessation of lactate production in kidneys 
with immediate graft function. Such observations reflect the necessity for restoration of 
aerobic metabolism in order for kidneys to function.  
Observation of aerobic metabolism in HMP/O2 kidneys shows how even under 
hypothermic conditions, oxygenation of perfusate stimulates aerobic metabolic processes 
required for immediate graft function. The observation of higher ATP levels in HMP/O2 
kidneys, also seen in other studies (230, 235, 236), is a result of such aerobic metabolism. 
However, on reperfusion ATP levels are likely to be fast depleted. It is likely the rate of 
constant production of ATP due to aerobic respiration which promotes functional graft 
recovery.    
Further comments on flow parameters 
Our findings demonstrated a non-significant improvement in perfusion parameters with 
higher flow rates and lower resistance observed in HMP/O2 kidneys. These findings were 
consistent with other studies which observed a similar improvement of flow parameters 
during oxygenated HMP (223).  
One benefit of HMP is the vasodilatation of renal microvasculature. This has been shown 
to result in improved cortical microcirculation at reperfusion (87), reducing detrimental 




increased eNOS levels, central to vasorelaxation, following as little as 1 or 4 hours of non-
oxygenated HMP (82). Such oxygen dependent pathways (237) are likely to be further 
upregulated during oxygenated HMP showing further benefits of oxygenation in addition 
to the metabolic benefits observed.  
Mitochondrial damage 
As described in the manuscript, greater mitochondrial damage was noted in non-
oxygenated kidneys. As metabolic pathway activity central to aerobic metabolism occuring 
within mitochondria, damage to mitochondria may be the determinant of aerobic metabolic 
pathway activity. Conversely, mitochondrial damage may be an effect of ongoing 
ischaemia as a consequence of lower O2 availability. Much current research implicates 
mitochondrial dysfunction as a central process in AKI (238) manifesting as DGF in 
transplanted kidneys.  
Limitations 
As with both aforementioned animal studies determining the effects of oxygenated HMP 
on functional outcome post-transplantation (223, 224), the experiments described are 
limited by a small sample size. 
Experimental design did not permit acquisition of functional outcome data, limiting 
conclusions drawn from metabolic data. Tissue sampling prior to reperfusion may also 
have limited the relevance of our observation of a lack of demonstrable damage due to 
reperfusion injury; Given the majority of damage as a consequence of IRI occurs following 
reperfusion, data on tissue damage during the preservation period are of limited 
relevance. Further studies should investigate the extent of reperfusion injury in 




From a methodological perspective, further studies incorporating sequential tissue 
biopsies analysed using high resolution magic angle spectroscopy (HR-MAS) could inform 
decisions regarding the timing of oxygen delivery to kidneys.  
Concluding remarks  
This is the first study using an isotopic tracer to show the metabolic benefits of oxygenation 
during HMP with such changes consistent with measured ATP levels. Evidence for the 
clinical benefits following oxygenated HMP will be provided by two major multicentre trials 
currently being conducted by the COPE consortium (239).  
Current UK centres use several brands of HMP device, some of which have a means of 
oxygenation incorporated into the circuit, such as oxygen concentrators. A superior 
evidence base and demonstration of cost-effectiveness is required prior to widespread 
usage of oxygenation during HMP although results from this set of experiments and others 
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Background. Supplemental oxygenation of the standard hypothermic machine perfusion (HMP) circuit has the potential to in-
voke favorable changes in metabolism, optimizing cadaveric organs before transplantation.Methods.Eight pairs of porcine kid-
neys underwent 18 hours of either oxygenated (HMP/O2) or aerated (HMP/Air) HMP in a paired donation after circulatory death
model of transplantation. Circulating perfusion fluid was supplemented with the metabolic tracer universally labeled glucose. Per-
fusate, end-point renal cortex, andmedulla samples underwentmetabolomic analysis using 1-dimension and 2-dimension nuclear
magnetic resonance experiments in addition to gas chromatography-mass spectrometry. Analysis of 13C-labeledmetabolic prod-
ucts was combined with adenosine nucleotide levels and differences in tissue architecture. Results. Metabolomic analysis re-
vealed significantly higher concentrations of universally labeled lactate in the cortex of HMP/Air versus HMP/O2 kidneys
(0.056 mM vs 0.026 mM, P < 0.05). Conversely, newly synthesized [4,5-13C] glutamate concentrations were higher in the cortex
of HMP/O2 kidneys inferring relative increases in tricarboxylic acid cycle activity versus HMP/Air kidneys (0.013 mmol/L vs
0.003 mmol/L, P < 0.05). This was associated with greater amounts of adenoside triphosphate in the cortex HMP/O2 versus
HMP/Air kidneys (19.8mmol/mg protein vs 2.8mmol/mg protein, P < 0.05). Improved flow dynamics and favorable ultrastructural
features were also observed in HMP/O2 kidneys. There were no differences in thiobarbituric acid reactive substances and reduced
glutathione levels, tissue markers of oxidative stress, between groups. Conclusions. The supplementation of perfusion fluid
with high-concentration oxygen (95%) results in a greater degree of aerobic metabolism versus aeration (21%) in the
nonphysiological environment of HMP, with reciprocal changes in adenoside triphosphate levels.
(Transplantation 2019;103: 314–322)
Hypothermic machine perfusion (HMP) of kidneys hasbeen widely used as a modality of organ preservation
in clinical practice for over a decade. Hypothermic machine
perfusion involves the recirculation of chilled perfusion fluid
at subphysiological pressures through the renal vasculature
of the ex vivo kidney in the hours before transplantation.
The benefits of HMP have been reported for all subtypes of
cadaveric kidneys including improved short-term outcomes1,2
and graft survival3,4 compared with static cold storage. The
proposed mechanisms by which HMP exerts benefit include
decreased vasospasm,5 the protection of vascular endothe-
lium,6 the washout of toxic metabolites and supplementation
of metabolism7,8 with the potential for the metabolic profile
of the ex vivo kidney to predict early graft function.9
Oxygenation of circulating perfusate during HMP has re-
cently been revisited as ameans of optimizing cadaveric kidneys
before transplantation. Previous human and animal studies
have used a variety of methodologies yielding inconsistent but
promising results in terms of functional outcomes.10 Porcine
autotransplant studies have shown functional benefits when
the HMP circuit is modified to include oxygenation in a
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donation after circulatory death (DCD) model of transplan-
tation,11 but the same did not hold true for a donation after
brainstem death model.12
KPS-1 (Organ Recovery Systems, Itasca, IL), the kidney
perfusion solution commonly used in clinical practice, is a hy-
pertonic, acellular fluid with no designated oxygen carrier.
Any oxygenation of perfusion fluid is a result of passive diffu-
sion from the air containedwithin the perfusion fluid reservoir.
Supplemental oxygenation during HMP may be an effective
way to alter metabolic pathway activity, with the presumption
that oxygenation encourages aerobic metabolism and therefore
replenishes cellular adenoside triphosphate (ATP) stores.13 In
addition to potential functional benefits after reperfusion, in-
creased ATP stores prevent detrimental processes such as cellu-
lar swelling, apoptosis and necrosis.
Despite these proposed benefits of oxygenation, damage
due to reactive oxygen species (ROS), responsible for many
consequences of ischemia reperfusion injury (IRI) is a poten-
tial drawback.14 Any potential metabolic benefits of organ
oxygenation must, therefore, be tempered against the poten-
tially deleterious effects of ROS injury, and it would seem ratio-
nal that oxygen delivery should occur at the lowest therapeutic
concentration possible to achieve such benefits. In conditions
of oxidative stress leading to typical changes, such as oxida-
tive DNA modifications15,16 and lipid peroxidation,17 levels
of reduced glutathione (GSH) are depleted. Thiobarbituric
acid reactive substances (TBARS) provide a sensitive assay
for lipid peroxidation.18
Metabolic tracer studies using perfusion fluid supplemented
with universally labeled 13C glucose ([U-13C] glucose) have
been used to accurately demonstrate de novo metabolism
within biological systems, including the ex vivo HMP kid-
ney.19 In conjunction with adenosine nucleotide analysis,
the concentration and isotopic labeling patterns of central
metabolites enable description of aerobic/anaerobic path-
way activity in addition to their metabolic sequelae.
The aims of this study are to compare the metabolic conse-
quences, changes in perfusion dynamics, damage secondary
to oxidative stress, and histological changes between perfus-




Experiments were performed on 8 pairs of porcine kidneys
(n = 16). Porcine organswere procured from22- to 26-week-old
male English white pigs weighing 80 to 85 kg from a local ab-
attoir (F.A.Gill,Wolverhampton,UK) in a previously described
controlled model of DCD.20
Our model, similar to other well-reported controlled DCD
models in pigs,21 was designed to simulate a Maastricht cat-
egory III donor.22 Animals were sacrificed by electrical stun-
ning and exsanguination before in situ warm ischemia for
15 minutes, during which time, laparotomy and bilateral ne-
phrectomy were performed. After retrieval, all kidneys were
checked for damage and suitability for the study. To permit
fair comparison, pairs of kidneys were only included if both
kidneys were supplied by a single artery at the point of origin
from the abdominal aorta. Kidneys were initially flushed
with 1 L of Soltran solution (Baxter Healthcare) at 4°C at a
pressure of 120 mm Hg, supplemented with 0.93 g [U-13C]
labeled glucose (5mM) at 4°C and 5000 iU heparin to remove
any residual blood products and enable rapid cooling.
The purpose of adding 13C-enriched glucose to the cold flush
solution was to increase initial availability of glucose for gener-
ation of downstream labeled metabolic substrates later during
HMP.Organswere then stored in static conditions (1 L Soltran
with 1% PenStrep) for 2 hours before commencing HMP. All
experimentswere performed following the principles of labora-
tory animal care according to the National Institutes of Health
standards. No animal was slaughtered solely for the purpose
of experimentation.
Hypothermic Machine Perfusion
Machine perfusion was initiated using the LifePort Kidney
Transporter 1.0 (Organ Recovery Systems) at a pressure of
30 mm Hg. Kidneys were perfused with 1 L KPS-1 (Organ
Recovery Systems) supplementedwith 0.93 g [U-13C] glucose
(5 mM) giving a total glucose concentration of 15 mM.
Single arterial anatomy permitted cannulation with a 5 mm
T-connector to attach to the LifePort.
The standard LifePort perfusion circuit was modified
(Figure 1) to incorporate a pediatric membrane oxygenator
(Hilite 800 LT series hollow fiber oxygenator; Medos,
Medizintechnik, AG). One kidney from each pair was ran-
domly allocated to either the oxygenated or aerated perfu-
sion group with contralateral organ allocated to the other
perfusion group. In the oxygenated perfusion group (HMP/
O2) in which 95% O2, 5% CO2 (Carbogen, BOC Medical)
was passed through the oxygenator via a flow valve at
0.1 L/min. In the aerated perfusion fluid (HMP/Air) group,
sterile filtered room air (assumed 21% oxygen) was delivered
at the same rate (0.1 L/min).
During perfusion, the dissolved oxygen concentration in
the fluid entering the kidney via the in-flow limb was mea-
sured using an oxygen sensor (Oxygen Microsensor NTH-
PSt1; PresensGmbH,Germany) pairedwith amicrofiber optic
oxygen transmitter (Microx TX3; Presens GmbH). Before ex-
periments, this was calibrated using the oxygen-carrying ca-
pacity of deionized water at 4°C (100%, maximum) and
vigorously agitated 1% sodium sulphite solution (0%, mini-
mum). The negative control was validated against deionized,
nitrogenated water at room temperature. The mean concen-
tration of oxygen in the inflow limb of the HMP/O2 circuit
FIGURE 1. Schematic diagram of a modified LifePort circuit which
includes a pediatric membrane oxygenator. Perfusate is drawn from
the fluid reservoir containing the kidney (A) intro the perfusion circuit
via a peristaltic pump (B) and pushed through a pediatric membrane
oxygenator (C). The oxygenator allows for the gas supplied (either at-
mospheric air or 95% oxygen) to be dissolved in the fluid before it
passes through a bubble chamber and into the kidney (A) via the can-
nulated renal artery.
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was 68.7 kPa, whereas mean oxygen concentration in the in-
flow limb of the HMP/Air circuit was 21.0 kPa.
Kidneys were perfused for 18 hours. Perfusate samples
(2 mL) were frozen immediately after retrieval via the sam-
pling port of the LifePort cassette at multiple timepoints
(0, 1, 6, 12, 18 hours) with perfusion parameters also reported
at these times. At the end of the perfusion period, kidneys were
laterally bisectedwith cortex andmedulla samples snap frozen
in liquid nitrogen before storage at −80°C for metabolic anal-
ysis. Wedges of renal cortex and medulla and pieces of renal
artery were immersion fixed in 10% formalin for histology
and samples of cortex (2 ! 2 ! 5 mm) were immersion fixed
in glutaraldehyde in phosphate buffer for electronmicroscopy.
Sample Processing
Perfusate and tissue sample extraction was performed as
previously described.19 Perfusate samples for 1-dimension
(1D) 1H nuclear magnetic resonance (NMR), 2-dimension
(2D) 1H,13C HSQC NMR, and gas chromatography–mass
spectrometry (GC-MS) analysis were taken from the upper
layer of a biphasic solution containing polar metabolites, and
formed from a vigorously mixed solution of equal amounts of
neat perfusate, high-performance liquid chromatography
(HPLC) grademethanol (−80°C), andHPLC grade chloroform
(−20°C). Polar extracts were dried at 35°C in a vacuum drier.
Frozen cortex and medulla samples were powdered using
a Cryo-cup grinder (Biospec Products). From this, 0.5 g was
suspended in methanol (−80°C) and homogenized in Precellys
homogenization tubes using a Precellys 24 Dual homogenizer
(Bertin Technologies,Montigny-le-Bretonneux, France) at low
speeds in short intervals (5000 RPM for 8 ! 10 s) to prevent
samples fromheating. Cholorform (−20°C) and deionizedwa-
ter were then added and the resultant solution mixed vigor-
ously before sampling from the upper layer containing polar
metabolites. Samples were then dried at 35°C overnight in a
vacuum drier.
Nuclear Magnetic Resonance Spectroscopy
For NMRanalysis, dried perfusate and tissue extracts were
suspended in 100-mM phosphate buffer, containing 0.5-mM
dry sealing system, 2-mM imidazole, and 10% D2O.
Both 1D 1H and 2D 1H, 13C heteronuclear single quantum
coherence (HSQC) NMR, spectra were acquired using a 600-
MHz Bruker Avance III NMR spectrometer in 5-mm NMR
tubes. All 1D 1H NMR spectra were processed within the
MetaboLab software package version 1.0.0.1.23 After this,
0.5 Hz line broadening was applied with zero-filling the data
up to 131072 real data points before Fourier transformation.
The resulting spectra were referenced using dry sealing system
and manually phase corrected. Subsequently, the spectral
baselinewas corrected usingMetaboLab's spline baseline cor-
rection before the spectra were exported to Bruker format for
metabolites to be quantified using Chenomx 8.2 (Chenomx
INC, Edmonton, AB, Canada).
For 2D 1H,13C HSQC NMR, the 13C dimension was ac-
quired with a spectral width of 160 ppm using 25% of
8192 data points using a nonuniform sampling scheme. The
nonuniformly sampled spectra were reconstructed with com-
pressed sensing using the MDDNMR and NMRPipe soft-
ware.24-26 All spectra were processed without baseline
correction to avoid complications in the multiple-analysis
procedure. MetaboLab was used to combine data from 2D
1H,13CHSQCNMRandGC-MS using a previously described
model free approach27 to givemore accurate isotopomer distri-
butions for key metabolites of interest.
Gas Chromatography-mass Spectrometry
The dried polar extract was dissolved in 2%methoxyamine
HCl in pyridine (Sigma-Aldrich, Dorset, UK) followed
by incubation at 60°C and subsequently 60 μL N-
tertbutyldimethylsilyl-N-methyltrifluoroacetamide with
1% (w/v) tertbutyldimethyl-chlorosilane (Sigma-Aldrich,
Dorset, UK) derivatization reagent was added.
GC/MS was performed using an Agilent 7890B Series
GC/MSD gas chromatograph with a polydimethylsiloxane
GC column coupled, with a mass spectrometer (Agilent
Technologies UK Limited, Stockport, UK).
For determination of the mass isotopomer distributions,
spectra were corrected for natural isotope abundance. Data
processing from raw spectra to mass isotopomer distribu-
tion correction and determination was performed using
MetaboliteDetector software.28
HPLC: Adenosine Nucleotide Analysis
Concentrations of adenosine monophosphate (AMP),
adenosine diphosphate (ADP), and ATP were determined using
HLPC analysis of extracted kidney cortex and medulla samples
from the oxygenated and aerated experiments. Adenine nucleo-
tides were extracted from frozen powdered tissue with ice-cold
0.35 M perchloric acid and analyzed by ion-pair reverse phase
HPLC as described elsewhere.29
Biochemical Assays: Markers of Oxidative Stress
The GSH assay, as originally described by Hissin and
Hilf,30 was performed on samples of renal cortex to provide
an indication of oxidative stress. Quantification of cortical
malonaldehyde (MDA) was performed using TBARS assay.
Assay results for GSH and TBARS were normalized to pro-
tein content as per the Bradford assay.31 Full assay protocols
can be seen in the Supplemental Materials and Methods
(SDC, http://links.lww.com/TP/B660).
Light Microscopy
Wedges of renal cortex and medulla from 3 pairs of HMP/
O2 and HMP/Air kidneys and renal arteries were fixed in
formalin and processed to a paraffin block. After this,
4-μm sections of renal cortex andmedulla were stained with
hematoxylin and eosin and periodic acid Schiff, whereas re-
nal artery sections underwent staining with hematoxylin
and eosin alone.
Photomicrographs of 10 random glomeruli (40! magnifica-
tion), 10 random areas containing predominantly tubules (5 sub-
capsular and5midcortex at 20!magnification) and5 transverse
sections of intraparenchymal arteries (20! magnification) were
assessed. Image J 1.05i software (National Institutes of Health,
Bethesda, MD) was used for morphometric assessment.
Images were assessed for evidence of injury using glomeru-
lar shrinkage, interstitial edema, and perivascular edema as in-
dicators of damage. The extent of injury of extraparenchymal
renal arteries was semiquantitatively graded. Further informa-
tion on grading of injury can be seen in Supplemental Mate-
rials and Methods (SDC, http://links.lww.com/TP/B660).
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Electron Microscopy
Standard protocols of the ElectronMicroscopy Laboratory,
University Hospitals Birmingham, Birmingham, UK, were
followed. Forelectronmicroscopy(EM),biopsies (2!2!5mm)
of renal cortexwere fixed in 2.5%glutaraldehyde in 0.1Mphos-
phate buffer, pH 7.4 then postfixed in osmium tetroxide and en-
bloc stained with uranyl acetate before being processed by
standard techniques to an epon araldite block. Thick sec-
tions were stained with toluidine blue and ultrathin sections
stained with lead citrate and examined by a Joel
JEM1200-EX 11 electron microscope.
Random photomicrographs were taken of glomeruli, tu-
bules, and arteries/arterioles at 6800! to include mesangial
areas and glomerular capillary loops. Of the total mitochon-
dria present, the percentage of glomeruli of normal morphol-
ogy, condensed, and containing flocculent densities were
determined for each kidney. Both the pathologist and techni-
cian who acquired and analyzed images with light and elec-
tronmicroscopywere blinded to the kidney allocation groups.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
version 6.00 for Mac OS X (GraphPad Software, La Jolla,
CA). Analyses were deemed to be statistically significantwhen
P is less than 0.05. HMP/O2 and HMP/Air groups were com-
pared using Mann-Whitney U test.
RESULTS
Preliminary Studies
Using previously described methodology, a porcine kidney
was perfused using a standard unmodified LifePort circuit8
which does not provide oxygenation or aeration of perfusate.
After 2 hours of storage in static conditions, oxygen levels in
the in-flow limb dropped by over 90% in 2 hours from an ini-
tial PaO2 of 20.58 to 1.77 kPa, whereas the venous effluent
declined from 2.15 kPa, approximately 10% of that in the
in-flow limb at T0, to absolute anoxia within 80 minutes.
Perfusion Parameters
Mean resistance readings were lower, and therefore flow
readings higher, for all timepoints in HMP/O2 kidneys.
However, the difference did not reach statistical signifi-
cance at 6, 12, or 18 hours (P values 0.063, 0.278, 0.063,
respectively) (Figure 2).
1D 1H-NMR: Quantification of
Metabolites Concentrations
1D 1H-NMR analysis was used to determine the concen-
tration of unlabeledmetabolites within the circulating perfus-
ate at 6, 12, and 18 hours (Table S1, SDC, http://links.lww.
com/TP/B660). The concentrations of unlabeled metabolites
in renal cortex and medulla (Table S2, SDC, http://links.
lww.com/TP/B660) were also determined. No significant dif-
ferences were observed between circulating metabolites in the
perfusate of HMP/O2 compared with HMP/Air kidneys.
2DNMR andGC-MS Analysis: Isotopomer Distributions
for 13C-labeled Metabolites
Using 2DNMR, isotopomer combinations were determined
for the metabolites alanine, glutamate, and lactate in the perfu-
sion fluid and tissues of both HMP/O2 and HMP/Air kidneys,
indicating de novometabolism (Table 1). For these metabolites,
2D NMR data were combined with GC-MS data to determine
isotopomer distributions in Table 1.
FIGURE 2. Perfusion parameters for oxygenated hypothermic machine perfusion (HMP/O2) and aerated hypothermic machine perfusion
(HMP/Air) porcine kidneys.
TABLE 1.
Isotopomer distributions for isolated labeledmetabolites in the
perfusate and tissue of HMP/O2 and HMP/Air porcine kidneys
Isotopomer HMP/O2, % HMP/Air, % P
Lactatea +3 Perfusate 5.43 9.85 0.0078b
Cortex 6.36 8.73 0.0078b
Medulla 13.80 15.70 0.0312b
Alaninea +3 Perfusate 4.05 8.54 0.0078b
Cortex 6.07 8.09 0.0078b
Medulla 6.78 8.39 0.0312b
Citrate +2 Perfusate 0.00 0.00 >0.9999
Cortex 0.48 0.33 0.6250
Medulla 0.00 0.36 0.2500
Glutamatea +2 Perfusate 1.80 0.27 0.1250
Cortex 1.60 0.50 0.0312b
Medulla 3.13 0.40 0.0312b
Succinate +2 Perfusate 1.01 0.26 0.2500
Cortex 1.46 0.41 0.0156b
Medulla 2.54 0.36 0.0312b
Malate +2 Perfusate 0.38 0.34 0.6250
Cortex 1.09 0.87 0.4688
Medulla 2.80 0.00 0.0312*
a Combined NMR/MS analysis used to calculate isotopomer distributions.
*P < 0.05.
HMP/Air, aerated hypothermic machine perfusion; HMP/O2, oxygenated hypothermic machine
perfusion.
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Absolute Quantification of Labeled Metabolites
Using a combination of 1D, 2DNMRandGC-MS, concen-
trations of [U-13C] alanine and [U-13C] lactate were quantified
for extracted perfusate samples at each timepoint (Figure 3).
Labeled isotopomers of glutamate were absent in early per-
fusate samples, thus continuous data is not reported for glu-
tamate. Absolute concentrations of [U-13C] alanine, [U-13C]
lactate and [4,5-13C] glutamate were determined for end-
point perfusate, cortex, and medulla samples (Figure 4).
Microscopy: LightMicroscopy and ElectronMicroscopy
Glomeruli
Glomeruli were shrunken but otherwise appeared normal
on light microscopy in both groups. There was significantly
more shrinkage of glomeruli in the HMP/Air 52% (range,
40-70) versus HMP/O2 67% (range, 47-83) (P < 0.001).
Therewas no ultrastructural difference between the 2 groups;
epithelial and endothelial cells appeared condensed with
preservation of podocyte foot processes and an intact endo-
thelial lining with retained fenestrations.
Tubules and Interstitium
Changes consistent with acute tubular injury were present
up to a similar extent in bothHMP/O2 andHMP/Air kidneys
on light microscopy. Ultrastructural changes include edema/
separation between the basolateral infoldings, focal areas of
denuded basement membranes, and moderate numbers of
exfoliated epithelial cells within the lumen. The brush border
was largely intact.
Abnormal mitochondrial morphology consisted of either
condensedmitochondria ormitochondria containing flocculent
densities, an indication of irreversible injury. Examples are
FIGURE 3. Absolute concentrations of universally labeled 13C ([U-13C]) alanine and [U-13C] lactate in circulating perfusate. *
0.01 < P < 0.05, ** 0.001 < P <0.01, *** P< 0.001.
FIGURE 4. Absolute concentrations of universally labeled 13C ([U-13C]) alanine, [U-13C] lactate and [4,5-13C] glutamate determined using 1-
dimensional 1H nuclear magnetic resonance, 2-dimensional heteronuclear single quantum coherence nuclear magnetic resonance, and gas
chromatorgraphy-mass spectometry data. * 0.01 < P < 0.05, ** 0.001 < P < 0.01, ***P < 0.001. HMP/O2, oxygenated hypothermic machine
perfusion; HMP/Air, aerated hypothermic machine perfusion.
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shown in Figure 5. Swelling of mitochondria was not ob-
served. There was evidence of increased injury in HMP/
Air kidneys with 29% (24-61%) of mitochondria display-
ing normal morphology compared with 72% (49-78%) of
HMP/O2 kidneys (P = 0.200). The percentage of mitochondria
containing flocculent densities was similar in both groups;
16% (14-23%) HMP/Air versus 20% (13-28%) HMP/O2.
Interstitial edema was similar in both groups with a median
of 17 (11-34) pixels in HMP/O2 compared with 20 (13-24)
pixels in HMP/Air group (P = 0.184).
Arteries
Although endothelium was intact in intraparenchymal renal
arteries and arterioles, there was at least moderate denudation
of the extraparenchymal renal arteries in both groups. Patchy
medial edema was seen between medial smooth muscle cells
in both groups. Periarterial edemawas similar in both groups
with a median of 26% (13-66%) HMP/O2 versus 34%
(20-88%) HMP/Air (P = 0.211).
HPLC: Adenosine Nucleotide Analysis
Tissues samples from4 pairs of porcine kidneys underwent
analysis byHPLC. ATP levels in the cortex ofHMP/O2 kidneys
were over sevenfold greater than for HMP/Air kidneys (mean,
19.8 mmol/mg protein vs 2.8 mmol/mg protein, P = 0.029).
AMP levels were higher in both the cortex and medulla of
HMP/O2 versus HMP/Air kidneys although the results did
not reach statistical significance, whereas ADP levels were
significantly higher in the cortex of HMP/O2 kidneys
(Table S3 SDC, http://links.lww.com/TP/B660; Figure 6).
TBARS: MDA Quantification
Hypothermicmachineperfusion/O2had slightly lower levels of
MDAcontent but thiswas nonsignificant (7.26 ± 0.99 nmol/mg
protein vs 8.07 ± 0.61 nmol/mg protein, P = 0.486).
GSH: Tissue GSH Concentrations
There was no significant difference in mean GSH concen-
tration in the cortex of HMP/Air and HMP/O2 groups at
the end of the perfusion period (7.22 ± 0.72 nmol/mg pro-
tein vs 7.80 ± 0.96 nmol/mg protein, P = 0.200).
DISCUSSION
Supplemental oxygenation during the HMP of kidneys in-
vokes a multitude of changes which have scope to improve
outcomes after transplantation. Our results show pronounced
metabolic differences between HMP/O2 and HMP/Air kid-
neys in addition to significant consequences for tissue architec-
ture, mitochondrial morphology, and cellular ATP levels.
The Role of Oxygenation in Supporting Metabolism
Cessation of blood supply during organ retrieval is the
start of a period of hypoxia leading to a depletion in cellular
ATP stores and a resultant switch to anaerobicmetabolism,32
reflected in the build-up of the products of glycolysis, such as
lactate and alanine in both tissue and perfusate.8 Hypother-
mia during this period, whether in static conditions or
FIGURE 5. Electron micrographs of a tubular epithelial cell from A, aerated hypothermic machine perfusion (HMP/Air) and B, oxygenated hy-
pothermic machine perfusion (HMP/O2). The mitochondria within the HMP/Air group have a mixture of appearances: normal (white arrow),
condensed (purple arrow) and contain multiple flocculent densities (yellow arrow). The mitochondria in the HMP/O2 group are of normal ap-
pearance (white arrow) with a rare flocculent density (yellow arrow). Part of the nucleus (N) is apparent in both. Original magnification, !18 500;
bar, 500 nm.
FIGURE 6. Adenoside monophosphate (AMP), adenoside diphosphate (ADP), adenoside triphophate (ATP), and overall energy levels in the
cortex and medulla of oxygenated hypothermic machine perfusion (HMP/O2) and aerated hypothermic machine perfusion (HMP/Air) kidneys.
* 0.01 < P < 0.05.
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HMP, leads to a reduction in metabolism33 and consequen-
tially, a decrease in oxygen requirement.34
Historically, this decrease in oxygen requirement has led to
the acceptance that the hypoxic environment of a standard
HMP circuit is adequate to meet the oxygen demands of ex
vivo kidneys.Our results show that oxygenation promotes aer-
obic metabolism, as reflected in significantly higher concentra-
tions of [4,5-13C] glutamate in the cortex of HMP/O2 kidneys
versus HMP/Air kidneys. The reciprocal outcome is a decrease
in de novo glycolytic activity in HMP/O2 kidneys which is
reflected in lower cortical concentrations of universally labeled
alanine and lactate compared with HMP/Air kidneys.
We have previously observed small (<0.5%) proportions
of [4,5-13C] glutamate during standard HMP in the cortex
of porcine kidneys after a 24-hour period.19 However, the
percentage of [4,5-13C] glutamate observed in the cortex of
both HMP/Air and HMP/O2 conditions was higher, even
with a reduced perfusion period and a lower concentration
of [U-13C]-labeled glucose, indicating that both conditions
promote tricarboxylic acid (TCA) cycle activity compared
with standard HMP.
Within the perfusate, changes in the absolute concentra-
tion of [U-13C] alanine and [U-13C] lactate mirrored a poten-
tial metabolic switch after several hours of HMP/O2,
resulting in a reduction in the production of glycolytic end-
points. This was in contrast to HMP/Air kidneys where a
steady rate of production of [U-13C] alanine and [U-13C] lac-
tate was observed.
Significantly higher proportions of labeled TCA cycle inter-
mediates, in addition to [4,5-13C] glutamate, an indication of
TCA cycle activity, were observed in the cortex ofHMP/O2 kid-
neys compared with HMP/Air kidneys. Our results show oxy-
genation during HMP promotes TCA cycle activity, with ATP
regeneration seen within cells as a result. In comparison, perfus-
ate aeration seems to result in a metabolic phenotype, depen-
dent on glycolytic pathway activity to produce ATP (Figure 7).
Other studies have also observed an increase in tissue ATP
levels as a result of oxygenatedHMP. In a small study using a
porcine model of HMP, high levels of dissolved oxygen
(100 kPa) using a membrane oxygenator increased tissue
ATP resynthesis as detected by 13P NMR spectroscopy.13
Similarly, enzymatic analysis of tissue samples showed signif-
icantly higher levels of ATP after oxygenated machine perfu-
sion compared to cold storage.35 The relative increase in ATP
levels in HMP/O2 within the renal cortex is likely to be of
benefit to graft function posttransplantation.
In contrast to the changes seen in the renal cortex, no signif-
icant changes inmetabolic profile (Figure 4) or adenosine nucle-
otide levels (Figure 6) were observed in themedulla of HMP/O2
and HMP/Air kidneys. This may reflect reduced perfusion of
the medulla due to shunting of cortical blood flow seen in nor-
mal physiological conditions, with reduced medullary perfu-
sion likely exaggerated in conditions of HMP, resulting in
anaerobic metabolism.36-38 Thus, the usual preponderance to-
ward anaerobic metabolism is likely to be unaffected by oxy-
genated perfusion fluid if perfusion of the medulla is poor.
Changes in Perfusion Parameters
The effects of oxygenation are not limited to metabolism
within the parenchyma. As a result of flow-related shear
stress during nonmodified HMP, vascular endothelium may
be protected by modulation of Kruppel-like factor 2 and
subsequent upregulation of endothelial nitric oxide syn-
thase signaling pathways,39 even as a result of short dura-
tions of HMP.6
The observation of improved flow dynamics in HMP/O2
kidneys did not reach statistical significance. This was likely
a limitation of sample size as such improvement in renal flow
dynamics has previously been observed during oxygenated
HMP in other studies.12,40 This may occur secondary to up-
regulation of endothelial nitric oxide synthase pathways, an
oxygen-dependent process,41 leading to increased renal ar-
tery nitric oxide–dependent vasodilation. Renal artery
nitric oxide–dependent vasodilation is associated with im-
proved early microcortical circulation after reperfusion of
HMP kidneys39 which may play a role in the prevention of
FIGURE 7. Differences in isotopic labeling patterns in the cortex of aerated hypothermic machine perfusion (HMP/Air) (blue) and oxygenated
hypothermic machine perfusion (HMP/O2) (red) kidneys. Thick black arrows indicate upregulated pathways interpreted from metabolite
isotopomer combinations and metabolite concentrations indicating de novo activity.
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delayed graft function. However, an alternative mechanism
may be vasodilatation secondary to dissolved CO2, a constitu-
ent of carbogen.
Given notable changes inmetabolic profile betweenHMP/O2
and HMP/Air kidneys in addition to a sevenfold increase in
ATP levels in the renal cortex, small differences in flow are
unlikely to be the sole determinant of the observed changes
between the 2 groups. The localized use of the vasodilator pa-
paverine has been explored in the setting of live donor ne-
phrectomy with favorable clinical effect.42 With HMP
lending itself to delivery of drugs throughout the ex vivo kid-
ney, such vasodilator administration in an unmodified HMP
circuit would determine the extent towhich flow effects alone
promote beneficial changes in hypoxic conditions.
Structural Changes as a Result of Oxygenation
The benefits of oxygenation are reflected in the histology
seen on light microscopy and electron microscopy. The in-
creased shrinkage of glomeruli within theHMP/Air group in-
dicates acute changes due which are likely due to lower
perfusion pressures, in keeping with worse perfusion charac-
teristics detected in this group. This diminished flow, together
with the lower oxygen content of the perfusate produces rel-
ative ischemia evidenced by the increased injury to the tu-
bules in this group with a higher percentage of
morphologically abnormal mitochondria. However, the de-
gree of change is still compatiblewith tubular epithelial cell re-
covery with well less than half the mitochondria containing
flocculent densities, suggesting avoidance of irreversible cell
injury.43 Chromatin condensation of nuclei was seen in both
groups and is a sign of reversible cell injury.44 This degree of
injury would suggest that, despite the cells being able to re-
cover, the time to recovery may be increased, resulting in pro-
longed delayed or poor graft function.
Changes in mitochondrial architecture have been noted as
a result of IRI during renal transplantation process.45 Yet de-
spite recent interest, no study has assessed the changes in mi-
tochondrial morphology using EM in kidneys undergoing
oxygenated HMP. Mitochondrial changes have been studied
during HMP of hearts. Preserved architecture of mitochon-
dria during oxygenated HMP of hearts has been observed
with damage in those organs in static storage manifesting as
mitochondrial flattening.46
Metabolic pathway activity central to aerobic metabolism,
namely TCA activity cycle and oxidative phosphorylation,
occur within mitochondria. Hence preservation of mitochon-
drial architecture may facilitate such aerobic metabolism con-
tributing to higher levels of ATP in HMP/O2 kidneys.
Harmful Effects of Oxygenation
Our results showed equivalence of damage due to ROS in
both experimental conditions, suggesting that delivery of high
concentrations of O2 via perfusate during HMP is nondetri-
mental. However, conclusions drawn from such results may
be limited due to both sample size and timing of IRI; our
model does not take into account injury as a consequence
of reperfusion.
Functional Outcomes
To date, 2 autotransplantation porcine studies have shown
short-term functional benefits of perfusate oxygenation com-
pared with a nonoxygenated control, both for prolonged pe-
riods (>20 hours) using DCD models.11,47
Potential functional benefits of the changes we have dem-
onstrated are yet to be explored in the clinical setting. Clinical
trials are currently underway investigating the use of oxygen-
ation in HMP of kidneys in differing scenarios. The POMP
trial seeks to compare outcomes of oxygenatedHMPkidneys
compared with static cold storage in high-risk donor organs,
whereas the COMPARE trial is assessing the value of oxy-
genated versus nonoxygenated HMP.48 We await the results
of these trials to ascertain whether the differences we have
observed translate into clinical benefit.
Limitations
While describing the metabolic profile and tissue adenine
nucleotide levels of HMP/O2 and HMP/Air kidneys, our pre-
clinical large animal perfusion model used slaughterhouse
kidneys with limitations inherent to such models.
Conclusions drawn from histology and HPLC data were
limited due to sample size because not all pairs of kidneys
underwent analysis. The significant differences noted be-
tween HMP/O2 and HMP/Air kidneys should be reproduced
in further research.
Oxygenation of the HMP/O2 circuit was provided using a
membrane oxygenator resulting in concentrations in the “ar-
terial limb” of the circuit of 68.7 kPa. Arguably, such high
concentrations are not required to supplement metabolism
during hypothermia. Carbogen, used in the HMP/O2 arm
of the study, contains supraphysiological (5%) levels of car-
bon dioxide. When dissolved in the solution, it is likely to
have resulted in a lower pH, changing the acid-base balance
of interstitial fluid. However, KPS-1 contains pH buffers,
such as HEPES which counteracts this acidity.
CONCLUSIONS
With increasing numbers of transplants from high-risk do-
nors being performed to address organ shortage,49 strategies
to optimize donor organs have the potential to improve out-
comes and increase utilization of such marginal organs. Ox-
ygenation of circulating perfusion fluid during HMP is 1
potential method of optimization with a multitude of benefi-
cial sequelae demonstrated by evidence of aerobic respiration
using tracer-based metabolism, regeneration of ATP stores
and improved perfusion characteristics with reciprocal histo-
logical changes in the absence of demonstrable damage sec-
ondary to oxidative stress.
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Supplementary methods: Light Microscopy  
Grading of injury  
To calculate glomerular shrinkage, the percent glomerular area occupied by glomerular 
tuft was determined for each glomerulus. The mean distance between 25 random tubules 
for each photomicrograph was used as a surrogate marker of interstitial oedema. The 
proportion (%) of vessel area to adventitia was calculated to determine the extent of 
perivascular oedema; lower percentages indicated more perivascular oedema. 
 
The injury of extra-parenchymal renal arteries were semi-quantitatively graded: 
endothelial denudation: 0 nil, 1 minimal, 2, moderate, 3 extensive; Intimal oedema: 0 nil, 
1 focal, 2 moderate to extensive; medial oedema and vacuolation of smooth muscle cells: 





Supplementary Table 1. Concentrations of metabolites in circulating perfusion fluid in 
HMP/Air and HMP/O2 kidneys at three time-points. Data reported as the mean with 95% 
confidence intervals. No differences were detected using Wilcoxon signed rank test. 
  HMP Air  HMP O2  
Metabolite Timepoint 
(hours) 
Mean concentration (mM) Mean concentration (mM) p-value 























































































































































Supplementary Table 2. Concentration of unlabelled metabolites in the renal cortex and 
medulla of HMP/O2 and HMP/Air kidneys at the end of the perfusion period. Data reported 
as the mean with 95% confidence intervals. *- denotes statistical significance (p<0.05). 
  HMP Air HMP O2  




















































































































































































































































Supplementary Table 3. Mean Adenine nucleotide concentrations for HMP/O2 and HMP/Air 










Cortex AMP 102.7 98.3 0.485 
ADP 14.6 4.6 0.029* 
ATP 19.8 2.8 0.029* 
Total (AMP+ADP+ATP) 137.2 105.7 0.029*      
Medulla AMP 205.6 164 0.057 
ADP 16.2 8.9 0.057 
ATP 5.1 2.5 0.114 





Chapter 7 : Metabolic characterisation of 
machine perfused cadaveric kidneys for 
transplantation using 13C enriched glucose 
 
In this chapter a clinical study was performed involving human cadaveric kidneys prior to 
transplantation. Organs were perfused with specially formulated UW-MPS solution in 
which all 10mmol glucose comprised of the metabolic tracer [U-13C] glucose. Whilst 
initially referred to as a study entitled “Metabolic characterisation of machine perfused 
cadaveric kidneys for transplantation using 13C enriched glucose,” the study was re-




Figure 43. Champion study logo 
Ethical approval for the study, along with local NHS trust Research and Development 
committee approval were gained by my supervisor Jay Nath prior to commencing patient 
recruitment. I was involved in study design and was responsible for all experimental work 
including local implementation of protocols, patient recruitment, preparation of all kidneys 
prior to perfusion, sampling, sample processing and analysis. A laboratory technician 
Thomas Smith assisted with performing biochemical assays. Study consumables relating 
to machine perfusion including customised perfusion fluid were provided by Organ 









Analysis of metabolites within perfusion fluid: studies to date  
The 10mmol of glucose contained within each litre of UW-MPS provides a metabolic 
substrate to kidneys undergoing HMP. Metabolism of this glucose has been illustrated by 
supplementing perfusion fluid with 5mmol [U-13C] glucose, a metabolic tracer, 
demonstrating de novo metabolism in porcine and discarded human kidneys (175). In this 
proof of concept study performed by our unit, unequivocal evidence of de novo anaerobic 
metabolism was observed as evidenced by the presence of [U-13C lactate] and [U-13C 
alanine] in perfusate and renal cortex samples. The presence of glutamate with 13C 
enrichment in the 4 and 5 carbon positions indicated limited de novo aerobic activity.  
Similarly in Chapter 6, the supplementation of perfusion fluid with an additional 5mmol of 
isotopic [U-13C] glucose showed in both aerated and oxygenated porcine kidneys, 
anaerobic metabolism dominated in the first 8 hours of HMP as evidenced by increasing 
concentrations of [U-13C] lactate and [U-13C] alanine in circulating perfusion fluid during 
HMP (240). In addition, labelling patterns of glutamate indicative of aerobic metabolism 
were detected in both perfusion fluid and renal cortex at the study endpoint.    
In these porcine experimental studies, 5mmol of [U-13C] glucose was added to the UW-
MPS solution containing 10mmol unlabelled 12C glucose. This was performed for simplicity 
as there was no easy way to remove the existing glucose in a sterile manner. In both 
studies, supplementing perfusion fluid with additional glucose increased its osmolarity, 
changing the biological properties of the perfusion fluid with possibilities of such a change 




In a previously described human metabolic study of circulating perfusate, Guy et al used 
1D 1H NMR (173) to determine changes in metabolite concentrations in circulating 
perfusate, with ROC curves indicating glucose, inosine and leucine may predict the 
development of DGF. In this study both alanine and lactate concentrations increased over 
between 45 minutes and four hours. Using a porcine model, Bon et al (172) utilised 1D 1H 
NMR to show how changes in several metabolites including lactate may be associated 
with graft function following auto-transplantation, with the suggestion that changes in 
biomarker levels were less marked in those kidneys with a better functional outcome. In 
both studies, the increase in concentration of metabolites in perfusion fluid cannot be 
attributed to de novo metabolism alone. Cell damage during preceding static cold storage, 
in addition to anaerobic metabolism during these periods likely contributes to metabolite 
concentrations observed in perfusion fluid as they are simply washed out of the kidney 
when HMP is commenced, one of the beneficial mechanisms of HMP.     
Hence, ongoing metabolism, in particular de novo metabolism as evidenced by use of [U-
13C glucose] as a metabolic tracer, reflects changing conditions such as oxygenation. De 
novo metabolism during HMP may therefore be influenced by demographic variables such 
as donor sub-type and cold ischaemic time as a reflection of pre-HMP warm and cold 
ischaemic insults respectively. Description of the metabolic profile of a cadaveric kidney 
during HMP, as described by changes in the concentration of de novo metabolites, may 
be a useful tool in determining organ viability with the potential to predict clinical outcome.  
Proteomic biomarkers in the setting of HMP 
Studies continue to explore associations between perfusate proteomic biomarkers and 
post-transplantation outcome (95) as evidence of the potential utility of HMP to assess 




2012 (95) identifying 3 perfusate biomarkers predictive of the development of DGF 
although recency, lack of good study design and the identification of only weak 
inconsistent correlations are the main reasons for lack of widespread use. These cytosolic 
proteins, lactate dehydrogenase (LDH), glutathione s transferase (GST) and aspartate 
transaminase (AST), leak into the interstitia and intra-vascular space through the cell 
membranes of ischaemically injured cells.  
Lactate dehydrogenase (LDH), the enzyme which catalyses the conversion of pyruvate 
both to and from lactate, is a non-specific marker of cellular injury. Perfusate LDH 
concentrations have been found to be significantly higher in kidneys which develop DGF 
in several studies, with Moers et al reporting an area under the curve of 0.60 in the cohort 
of patients from the Machine Preservation Trial (96, 241).  
Glutathione S-transferases (GST) are a family of enzymes which play a major role in 
detoxification, protecting cells from oxidative stress. Given the significance of urinary GST 
levels as a marker of renal injury in cardiac surgery (242) and other clinical settings, it is 
perhaps unsurprising given in the closed circuit of HMP, several studies have shown a 
potential role of perfusate GST as a biomarker (96). More specifically, perfusate levels of 
isoenzyme p-GST have been shown to be associated with delayed graft function (97).   
Aspartate transaminase, an enzyme more commonly associated with the liver, is also 
expressed by damaged renal parenchymal cells, with one study demonstrating an AUC 
0.61 (96).  
More recent studies have identified further promising biomarkers including neutrophil 
gelatinase–associated lipocalin. The small polypeptide NGAL is expressed primarily in 




siderophores involved in cell growth and survival (243) whilst also enhancing the delivery 
of iron and protecting kidney tubule cells by upregulating haem oxygenase-1 (244).  
As serum and urine NGAL concentrations rise in proportion to the grade of kidney injury 
(245) it is perhaps unsurprising that both pre-clinical (246) and clinical (247) studies have 
suggested that perfusate concentration of the molecule may predict graft function at 6 
months. The same study by Parikh et al (247) identified liver-type fatty acid-binding protein 
(L-FABP) as another biomarker of graft function at 6 months.  
Due to the promise of LDH, GST-Pi and NGAL as potential biomarkers of organ damage, 
biochemical assays for these proteomic markers were performed on perfusate samples.  
Study aims  
The aim of this study was to describe the de novo metabolism occurring in the ex vivo 
cadaveric kidney during HMP and to determine whether such metabolism correlated with 
functional outcomes following transplantation. A study was designed using [U-13C] 
glucose as a metabolic tracer. Such use of a metabolic tracer in the clinical setting to 
describe metabolic activity during HMP is a novel, non-invasive, sensitive method of 
describing de novo metabolism in whole organs. 
Secondary aims were to determine associations between demographic and transplant 
variables, and metabolic profile. Biochemical assays were also performed in order to 
determine correlation between the proteomic biomarkers LDH, GST-Pi and NGAL, and de 









Ethical approval for the study was sought from the National Research Ethics Service 
(NRES) Committee East Midlands – Leicester, NHS Health Research Authority 
(15/EM/0328) on 07/09/15 (Appendix B). The research protocol and accompanying 
documentation were approved by the trust’s Research and Development department on 
24/11/15 (Appendix C). Documentation, including a study log, recruitment log, delegation 
of duties, confirmation of ethical approval, University Hospitals Birmingham Research and 
Development department approval and copies of study documentation including data 
collection tools were kept securely in the study site file.  
The decision to use HMP as a method of preservation was decided by the on-call 
consultant depending on donor-recipient issues and theatre availability. During the study 
period all recipients of cadaveric kidneys where donor kidney was likely to be preserved 
with machine perfusion were approached for inclusion in the study. All patients were 
consented in line with Good Clinical Practice guidance (248), asked to sign a consent form 
(Appendix D) and were given a patient information sheet (Appendix E). Paediatric donor 
kidneys and those as part of a multi-organ transplant were excluded.    
Following recipient recruitment and arrival of donor organ into centre, arrangements were 
made for an emergency theatre to be made available for the purpose of preparing the 
kidney for machine perfusion. Following receipt of cadaveric organs, ‘back-bench’ 






Hypothermic Machine Perfusion 
The kidney was fully prepared for transplantation excluding lengthening of vasculature. 
The LifePort® provides arterial pulsatile perfusion regulated at 30mmHg via either a 
RingSeal connector or a T-connector as described in Chapter 2, Figure 32. The decision 
was made to avoid using T-connectors unless necessary as tying a suture to secure the 
connector damages the artery making it more susceptible to arterial thrombosis.  
All kidneys were perfused with one litre of a custom formulation of KPS-1 (Organ Recovery 
Systems, USA) stored at 4°C (Figure 34). In this modified KPS-1, biologically identical to 
industry standard UW-MPS, perfusion fluid had been formulated to include 10mmol [U-
13C] glucose instead of conventional 12C glucose. Kidneys were perfused in either v1.0 or 
v1.1 LifePort® Kidney Transporters (Organ Recovery Systems (Itasca, IL, USA) used in 
standard clinical practice at our unit. Perfusion pressure was set at 30mmHg. This was 
not changed for the duration of HMP in line with normal unit practice. Temperature and 
perfusion parameters were recorded at each sampling timepoint.    
No kidney was discarded as a result of machine perfusion parameters (flow, resistance). 
All patients received standard post-operative care with peri-operative and post-operative 
immunosuppression as per the unit’s standardised protocol. Due to the unpredictable 
nature of theatre availability and logistics of organ transplantation, kidneys were not 
perfused for a predetermined time period.  
Perfusate Sampling  
Perfusate was sampled prior to commencing machine perfusion in addition to the following 
times following commencement of machine perfusion: 5 minutes, 1 hour, 4 hours then at 




was taken where machine perfusion was ceased greater than half an hour following the 
previous perfusate sample.  
At each timepoint 5ml circulating perfusion fluid was removed from the Lifeport® sampling 
port under aseptic conditions as described in Chapter 2. One ml of fluid was used for Point 
of Care (POC) analysis (Cobasâ b221, Roche Diagnostics Limited) to provide pH, pO2, 
pCO2, lactate and glucose level in real time. The remaining 4ml of fluid was divided into 2 
x 2ml cryovials. The cryovials were immediately placed in dry ice prior to transport to a -
80oC freezer.    
Determination of metabolite concentrations using NMR and Mass 
Spectrometry 
Perfusate samples were thawed before vortexing for 30 seconds. Following this, 430µL of 
perfusate was removed from each 2ml cryovial in preparation for NMR processing. This 
involved mixing with 200µL NMR buffer with further mixing via vortexing and centrifugation 
prior to placing 600µL in a 5mm NMR tube. Both 1D 1H NMR and 2D 1H, 13C HSQC NMR 
spectra were acquired using a 600-MHz Bruker Avance III NMR spectrometer. From each 
sample cryovial, 43µL was also removed for analysis by mass spectrometry.  
The resulting output NMR spectra were referenced and manually phase corrected before 
the spectral baseline was corrected using MetaboLab's spline baseline correction (177). 
The spectra were then exported to Bruker format for metabolites to be quantified using 
Chenomx 8.2 (Chenomx INC, Edmonton, AB, Canada). Final metabolite concentrations 




The complex 1D 1H NMR spectral pattern of glucose results in difficulties when 
determining glucose concentrations using NMR due to overlapping of spectral peaks of 
other metabolites at multiple positions along the chemical shift axis. Therefore glucose 
concentrations were determined in real time using point of care analysis.  
MetaboLab was used to combine data from 2D 1H,13C HSQC NMR and GC-MS using a 
model free approach (158) as discussed in Chapter 1 in order to give more accurate 
isotopomer distributions for key metabolites of interest. The total concentrations of alanine 
and lactate were determined by adjusting 1H NMR concentrations taking into account 
isotopomer distributions as determined by 2D 1H,13C HSQC NMR. More in-depth 
commentary and explanation of sample processing methods and analysis is described in 
Chapter 2.  
Biochemical Assays 
Once thawed and mixed via vortexing for 30 seconds, perfusate samples were removed 
for analysis using three biochemical assays; lactate dehydrogenase (LDH), neutrophil 
gelatinase-associated lipocalin (NGAL) and glutathione s transferase Pi (GST-Pi) as 
described in Chapter 2.  
Clinical outcomes 
Clinicians were not blinded to the use of HMP during the preservation period. However, 
this is not thought to have influenced clinical decision making. Delayed graft function was 
defined by the need for dialysis in the first 7 days following transplantation. Serum 
creatinine values were recorded at 1 week, 1 month, 6 months and 1 year post-operatively. 
Creatinine values were excluded from statistical analyses for patients with DGF until graft 




Statistical analysis  
Fisher’s exact test and Mann-Whitney U test were used to compare groups. Unless 
specified, a two-tailed Spearman’s rank correlation was used to determine whether there 
was a correlation existed for continuous data as datasets were assumed to be non-
normally distributed. For continuous data, median values are reported along with range of 
values.  
Statistical analysis was performed using GraphPad Prism version 8.00 for Mac OS X 
(GraphPad Software, La Jolla, CA). Analyses were deemed to be statistically significant 











Firstly, baseline demographics are reported for the kidneys perfused as part of this study 
including donor, recipient and transplant specific variables. Following this, clinical 
outcomes are reported for the cohort.  
Changes in metabolite concentrations and flow parameters during HMP are described 
before possible associations are sought between such changes and clinical outcomes. 
Data relating to the timing of machine perfusion is also described for the cohort with a 
similar analysis relating to clinical outcome. Metabolite analysis according to donor 
subtype is then described. Biochemical assay results for the cohort follows with a search 
for an association between assay results and clinical outcome.  
Finally, the effect of anaerobic metabolite concentrations on pH is described in addition to 
the composition of neat KPS-1 and accuracy of sample processing.   
Baseline demographics  
Between October 2016 and July 2018, 16 deceased donor kidneys were recruited for 
inclusion in the study and subsequently underwent perfusion with [U-13C] glucose KPS-1. 
Following assessment after a period of HMP, one kidney was deemed unsuitable for 
transplantation due to anatomical reasons relating to the recipient. This kidney was 
transplanted at another centre following a further four-hour period of SCS. Due to this 
additional period of SCS and lack of consistency of clinical care between centres following 
transplantation, this kidney was excluded from further analysis.  
One further kidney was excluded from analyses as graft failure was attributed solely to 




post-operatively with hypotension not responding well to vasopressor support. This 
caused graft hypoperfusion and subsequent renal vein thrombosis leading to graft 
explantation after 4 days.  
Fourteen kidneys were included in the analysis. Table 5 shows baseline demographics 
including donor variables, recipient variables, and transplant timings including and within 
the total CIT. The cohort was divided by donor subtype and according to incidence of 
delayed graft function to determine whether donor factors differed in these groups. 
Differences between groups often lacked statistical significance although this was due to 
the small numbers involved in each group. DCD organs were retrieved from older donors 
compared to DBD kidneys (36.6yrs vs 33.2yrs) and were transplanted into older recipients 
(46.4yrs vs 33.5yrs).  
Clinical outcomes 
Following transplantation, recipients of four (28.6%) of the remaining 14 kidneys 
experienced delayed graft function which lasted between 4 and 42 days. Two of these 
kidneys which experienced DGF were from DCD donors, resulting in an incidence of DGF 
of 50% in the four DCD organs in the study. Of the 10 DBD kidneys in the study population, 
two recipients experienced DGF resulting in an incidence of DGF of 20% for DBD kidneys 
(p=0.5205).  
Male gender was associated with inferior serum creatinine at 1 year but not at any other 
follow-up timepoint (Table 6, Table 7). No other demographic variable was associated with 
serum creatinine at any follow-up timepoint.  Table 6 also shows serum creatinine values 
for sub-groups of the cohort including analysis by donor sub-type. No graft loss occurred 




Median serum creatinine values were 168µmol/L at one week (range 89-488µmol/L, 
n=11), 123µmol/L at one month (range 56-233µmol/L, n=13), 122 µmol/L at six months 






Table 5. Description of demographic variables of study population with subgroup analysis according to development of 
DGF and donor sub-type. For categorical variables, data reported as N (%), with p-value from Fisher’s exact test. For 
continuous variables, median values (range) are reported, with p-value from Mann-Whitney test. P-values significant at 
p<0.05. 
 All IGF DGF p-value DBD DCD p-value 
 n=14 n=10 n=4  n=10 n=4  
Donor demographics        
Male 50.0% (n=7) 40.0% (n=4) 75% (n=3) 0.5594 40% (n=4) 75% (n=3) 0.5594 






(18.1 - 65.5) 
36.6 
(21.5 - 73.3) 0.8392 
DCD donor 28.6% (n=4) 20.0% (n=2) 50% (n=2) 0.5205 n/a n/a n/a 
Caucasian 100% (n=14) 100% (n=10) 100% (n=4) >0.9999 100% (n=10) 100% (n=4) >0.9999 
Traumatic brain 
injury 21.4% (n=3) 30% (n=3) 0% (n=0) 0.5055 30.0% (n=3) 0% (n=0) 0.5055 
History of 
hypertension 21.4% (n=3) 10% (n=1) 50% (n=2) 0.1758 20% (n=2) 25% (n=1) >0.9999 
History of diabetes 0% (n=0) 0% (n=0) 0% (n=0) >0.9999 0% (n=0) 0% (n=0) >0.9999 






(17.1 - 28.1) 
28.0 
(23.3 - 43) 0.1419 
 
       
Recipient demographics       
Male 71.4% (n=10) 60.0% (n=6) 100% (n=4) 0.2507 70% (n=7) 75% (n=3) >0.9999 






(17.6 - 56.4) 
46.4 
(31.4 - 62.6) 0.1419 






(18.2 - 33.8) 
30.4 
(21.9 - 33.8) 0.4535 
Caucasian 57.1% (n=8) 80.0% (n=8) 0% (n=0) 0.015* 60.0% (n=6) 50% (n=2) >0.9999 
History of 
hypertension 42.9% (n=6) 30.0% (n=3) 75.0% (n=3) 0.2448 30.0% (n=3) 75% (n=3) 0.2448 
History of diabetes 21.4 (n=3) 20.0% (n=2) 25.0% (n=1) >0.9999 20.0% (n=2) 25.0% (n=1) >0.9999 
CMV positive  42.9% (n=6) 30% (n=3) 75% (n=3) 0.2448 30.0% (n=3) 75% (n=3)  0.2448  
Transplant demographics       




(14.7- 24.4) 0.8392 
19.6 
(14.7 - 24.4) 
21.5 
(15.3 - 23.3) 0.3736 









(5.58 - 13.6) 
10.8 
(7.92 - 11.8) 0.2398 









(34.3 - 65.5) 
50.1 
(48.4 - 54.7) 0.3736 
Outcome        





Table 6. Correlation between categorical demographic variables and serum creatinine. P-values calculated using 
Mann-Whitney test. P-values significant at p<0.05. 
  
1 week creatinine  
(µmol/L) 
1 month creatinine 
(µmol/L) 
6 month creatinine 
(µmol/L) 
12 month creatinine  
(µmol/L) 

















(range) p-value  































































































































































Table 7. Correlation between continuous demographic variables and serum creatinine. R-values (95% confidence 
interval) represent a correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, as datasets 
were assumed to be non-normally distributed. P-values significant at p<0.05. 





















































Recipient demographics            


































Transplant demographics          

























































Changes in metabolite concentrations and renal resistance during 
machine perfusion  
Table 8 shows metabolite concentrations for the cohort at one hour, four hours and at the 
endpoint of machine perfusion. Figure 44 shows the increase in all anaerobic metabolite 





Table 8. Changes in metabolite concentrations and renal resistance over time. All metabolite concentrations units 
mmol/L unless otherwise stated. Median values (range) are reported for 1 hour, 4 hour sampling timepoints and 
Tend, the endpoint of perfusion period which varied for each kidney.   
 
  1 hour  4 hours  T End  
  Median (range) Median (range) Median (range) 
3-Methylxanthine 0.0266 (0.023-0.033) 0.0269 (0.0236-0.0347) 0.0271 (0.0238-0.0364) 
Acetate 0.21 (0.0398-0.388) 0.194 (0.0493-0.386) 0.172 (0.0511-0.345) 
Adenine 5.8 (5.05-6.15) 5.55 (5.02-6.62) 5.78 (5.09-6.5) 
Alanine 0.0672 (0.0273-0.11) 0.117 (0.07-0.26) 0.152 (0.0844-0.268) 
Ethanolamine 7.07 (5.71-8.34) 7.18 (6.24-10.6) 7.55 (5.58-10.2) 
Formate 0.182 (0.043-0.348) 0.199 (0.0422-0.402) 0.207 (0.0405-0.366) 
Fumarate 0.0021 (0.00061-0.0060) 0.0039 (0.00092-0.0075) 0.00545 (0.002-0.0121) 
Gluconate 76.4 (59.5-80.8) 78.1 (66.4-86.5) 79.7 (67.2-88.7) 
Glutamate 0.303 (0.152-0.497) 0.943 (0.496-1.47) 1.61 (0.792-2.66) 
Glutathione 1.34 (1.16-1.77) 0.767 (0.591-1.52) 0.554 (0.0476-0.924) 
Glycine 0.57 (0-0.971) 1.85 (0.579-2.79) 3.02 (1.12-4.27) 
Hippurate 0.00169 (0-1.34) 0.00361 (0-0.0149) 0.00391 (0-0.0118) 
Hypoxanthine 0.104 (0-0.222) 0.175 (0.0972-0.447) 0.184 (0.0749-0.474) 
Inosine 0.0207 (0-0.0889) 0.0301 (0-0.121) 0.0233 (0.00491-0.0832) 
Isopropanol 0.0141 (0-0.0173) 0.0149 (0.0127-0.0201) 0.0158 (0.013-0.0246) 
Lactate 0.829 (0.371-1.12) 1.3 (0.558-1.78) 1.58 (0.655-2.13) 
Leucine 0.0079 (0.00322-0.0163) 0.0164 (0.00414-0.0333) 0.0144 (0.00261-0.043) 
Oxypurinol 0.293 (0.257-0.35) 0.31 (0.274-0.378) 0.312 (0.262-0.431) 
Ribose 1.59 (1.51-2.03) 1.59 (1.38-1.99) 1.64 (1.55-2.28) 
Succinate 0.0177 (0.00813-0.0262) 0.0195 (0.0135-0.0382) 0.0254 (0.0155-0.0625) 
Trimethylamine N-oxide 0 (0-0.0275) 0 (0-0.0411) 0.00813 (0-0.0783) 
Tyrosine 0.00629 (0-0.292) 0.0099 (0-0.486) 0.0117 (0-0.424) 
Valine 0.00821 (0.00399-0.016) 0.0129 (0.00767-0.0313) 0.015 (0.00952-0.0413) 
      
Total concentration of lactate 0.937 (0.406-1.2) 1.54 (0.641-2.13) 1.91 (0.907-3.88) 
Concentration of [U-13C] 
lactate  0.0371 (0.0134-0.353) 0.149 (0.0835-0.962) 0.258 (0.163-2.14) 
% [U-13C] lactate  6.04 (1.26-30.7) 10.8 (5.54-47.1) 16.1 (8.7-55) 
      
Total concentration of alanine  0.07 (0.027-0.11) 0.128 (0.073-0.278) 0.165 (0.098-0.279) 
Concentration of [U-13C] 
alanine  0 (0-0.012) 0.01 (0-0.047) 0.0125 (0.004-0.106) 
% [U-13C] alanine  0 (0-14) 7.13 (0-29.2) 8.26 (2.67-39.7) 
      
POC lactate 1.4 (0.9-2.14) 2.05 (1.2-2.82) 2.4 (1.7-3.9) 
POC glucose  9.15 (8.6-10) 8.6 (8-9.4) 8.44 (8-9.31) 
POC pH 7.17 (7.07-7.23) 7.12 (7.02-7.18) 7.1 (6.97-7.14) 
      
Renal Resistance 
(mmHg/ml/min) 






Figure 44. Graphs showing changes in the concentration of perfusate lactate and alanine during machine 
perfusion at 1 hour, 4 hours and T End. Median concentrations (mM) are shown along with interquartile 
range and range of values.  
























































































































Associations between metabolite concentrations, renal resistance and 
clinical outcomes 
No metabolite concentration was associated with the development of delayed graft 
function (Supplementary Information, Table 17). Multiple correlation analyses were 
performed to determine whether there was a consistent correlation between metabolite 
concentration and serum creatinine at 1 week (Supplementary Information, Table 18), 1 
month (Supplementary Information, Table 19), 6 months (Supplementary Information, 
Table 20) and 12 months (Supplementary Information, Table 21).  
A negative correlation was observed between both labelled and unlabelled anaerobic 
metabolite concentrations at 4 hours and perfusion endpoint, and serum creatinine at 1 
month, 6 months and 12 months with such correlation investigated further with analysis 
according to DBD donor (Table 10) and DCD donor (Supplementary Information, Table 
22) subtype. Further correlations between metabolite concentration and serum creatinine 
were identified but few were consistently statistically significant across sampled timepoints 
or serum creatinine values. Of these, formate concentrations at 1 hour, 4 hours and 
perfusion endpoint were negatively correlated with 12-month creatinine.   
There was no correlation between change in oxygen levels over the perfusion period and 
point of care lactate (p=0.924), concentration of de novo [U-13C] lactate (p=0.727) or total 






Timing of machine perfusion 
Duration of SCS prior to HMP, duration of HMP, total CIT and HMP as a % of CIT were 
not associated with renal resistance at the end of the perfusion period (Supplementary 
Information, Table 23). Of these 3 time periods relevant to the initiation of HMP, none 
were associated with perfusate concentration of anaerobic metabolites at 1 hour, 4 hours 
or T End (Supplementary Information; Table 25, Table 26, Table 27). 
An analysis was performed to determine if correlations were present between endpoint 
metabolite concentrations and duration of SCS, duration of HMP and total CIT to 
determine whether metabolite concentrations increased as a result of an increase in each 
time period (Supplementary Information, Table 24). There was no correlation between any 
anaerobic metabolite concentration and duration of SCS, HMP or total CIT. Endpoint 
glutamate and glycine concentrations were positively correlated with duration of HMP 





Differences between DBD and DCD donor kidneys  
Analysis of labelled anaerobic metabolites yielded consistent differences between DBD 
and DCD kidneys.  Significant differences in the proportion of U-13C labelled alanine and 
U-13C labelled lactate were evident as soon as 1 hour after commencing HMP (Table 9). 
This contributed to the observation that concentrations of U-13C lactate and U-13C alanine 
were proportionally higher in DCD kidneys at all timepoints, although differences were 
only significantly at T End (Figure 45). The same changes were not observed in 1H-1D 
NMR alanine and lactate concentrations. POC lactate concentrations were higher in DCD 
vs DBD kidneys at all timepoints although the difference in concentrations did not reach 
statistical significance. Changes in anaerobic metabolite proportions and concentrations 
for each kidney in the cohort are displayed in Figure 46.  
Following initial analysis suggesting a negative correlation between some anaerobic 
metabolites and serum creatinine, a sub-group analysis according to donor sub-type was 
performed to see if the relationship was consistent. On first appearance, there was a 
significant correlation between several anaerobic metabolite concentrations and serum 
creatinine with r-value suggesting de novo anaerobic metabolism correlates with lower 
serum Cr. However, on observation of data this observed trend was due to outlying Cr 






Table 9. Differences in metabolite concentration and renal resistance between DBD and DCD donor kidneys. All 
metabolite concentrations units mmol/L unless otherwise stated. P-values are reported for Mann-Whitney tests. P-
values significant at p<0.05. 













(n=4) p-value  
3-Methylxanthine 0.02717 0.02571 0.3566 0.02793 0.02548 0.1988 0.02678 0.02747 0.8392 
Acetate 0.2098 0.1853 0.9451 0.1942 0.172 0.9451 0.1723 0.1704 0.9181 
Adenine 5.77 5.869 0.6354 5.495 5.727 0.3736 5.846 5.32 0.2398 
Alanine 0.07014 0.05694 0.3736 0.1295 0.08073 0.024* 0.1534 0.1132 0.1059 
Ethanolamine 7.35 6.54 0.024* 7.122 7.669 0.5395 7.532 7.776 0.5395 
Formate 0.1824 0.1557 0.8392 0.1992 0.1769 0.9451 0.2066 0.1503 0.7333 
Fumarate 0.001688 0.00376 0.2897 0.0033 0.005449 0.1778 0.004605 0.007521 0.0839 
Gluconate 76.23 76.65 0.8392 76.98 78.94 0.8392 79.7 78.74 >0.9999 
Glutamate 0.3031 0.3503 0.5395 0.9433 1.113 0.7333 1.518 2.033 0.4535 
Glutathione 1.344 1.297 0.4535 0.8348 0.7477 0.6583 0.5757 0.1162 0.3037 
Glycine 0.4302 0.7827 0.9451 1.543 2.149 0.5395 2.791 3.312 0.3736 
Hippurate 0.003607 0 0.0509 0.004758 0.0006907 0.1279 0.009133 0 0.033* 
Hypoxanthine 0.1044 0.1013 0.7283 0.1753 0.2005 >0.9999 0.1838 0.1902 0.9451 
Inosine 0.02617 0.01435 0.5395 0.03361 0.009977 0.1968 0.02448 0.005372 0.0719 
Isopropanol 0.01412 0.01427 0.9161 0.01535 0.01481 0.4775 0.01566 0.01581 0.7572 
Lactate 0.8852 0.6404 0.2398 1.348 1.009 0.1878 1.723 1.228 0.1878 
Leucine 0.01005 0.005142 0.1878 0.01742 0.00112 0.1518 0.0188 0.01105 0.3736 
Oxypurinol 0.2929 0.2828 0.5395 0.3218 0.3084 0.3906 0.3123 0.31 0.6354 
Ribose 1.594 1.594 0.2498 1.594 1.594 0.999 1.594 1.723 0.5415 
Succinate 0.01773 0.01757 0.7333 0.01803 0.02333 0.1878 0.02533 0.0254 0.8392 
Trimethylamine N-oxide 0 0 0.5055 0 0 0.8801 0 0.03108 0.2797 
Tyrosine 0.005986 0.0145 0.0519 0.0109 0.008826 0.2887 0.01167 0.0119 0.969 
Valine 0.008365 0.007291 0.3966 0.01289 0.01151 0.5395 0.01504 0.01589 0.4346 
          
Total concentration of 
lactate 0.9372 0.8463 >0.9999 1.528 1.787 0.5395 1.907 2.062 0.9451 
Concentration of U-13C 
lactate  0.03286 0.1536 0.0759 0.1444 0.6402 0.0939 0.232 0.8194 0.024* 
% U-13C lactate  3.359 15.77 0.036* 9.626 35.11 0.008* 13.71 39.85 0.002* 
          
Total concentration of 
alanine  0.07014 0.06011 0.7333 0.1365 0.0955 0.2398 0.168 0.1542 0.5395 
Concentration of U-13C 
alanine  0 0.003169 0.2567 0.0055 0.0165 0.1159 0.01023 0.04097 0.036* 
% U-13C alanine  0 4.437 0.2567 3.361 17.52 0.023* 5.249 27.02 0.008* 
          
POC lactate 1.25 1.5 0.8551 1.8 2.475 0.3966 2.25 3.81 0.1768 
POC glucose  8.895 9.48 0.0709 8.45 8.935 0.1129 8.3 8.75 0.1399 
POC pH 7.164 7.173 0.9451 7.131 7.1 0.6354 7.121 7.036 0.5185 
          
Renal Resistance  





Table 10. Correlation between creatinine values and T End concentration of anaerobic metabolites for DBD kidneys. 
R-values represent a correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test for 
continuous data, as datasets were assumed to be non-normally distributed. P-values significant at p<0.05. 
 1-week Cr 1-month Cr 6-month Cr 12-month Cr 
 r value p-value r value p-value r value p-value r value p-value 
         
Total concentration of lactate -0.5667 0.1206 -0.5667 0.1206 -0.2675 0.4529 -0.4146 0.233 
Concentration of U-13C lactate  -0.5333 0.1475 -0.6667 0.0589 -0.7052 0.0272* -0.6464 0.0485* 
% U-13C lactate  0.03333 0.9484 -0.15 0.7081 -0.4559 0.1864 -0.3171 0.3693 
POC lactate -0.4979 0.1763 -0.6667 0.057 -0.4616 0.1791 -0.5216 0.1244 
         
Total concentration of alanine  -0.7 0.0433* -0.6667 0.0589 -0.383 0.2732 -0.5183 0.1283 
Concentration of U-13C alanine  -0.5774 0.1101 -0.5774 0.1101 -0.6728 0.0374* -0.6411 0.0502 
% U-13C alanine  
-






Figure 45. Difference in anaerobic metabolites concentrations between DBD and DCD kidneys at 1 hour, 4 
hours and T End. Median concentrations are shown along with interquartile range and range of values. *- 
indicates statistical significance where p-value <0.05 
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Figure 46. Changes in percentage U-13C labelled lactate(a), absolute concentrations of U-13C lactate(b), 
percentage concentration of U-13C alanine(c), absolute concentration of U-13C alanine(d) and 1D-1H NMR 
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Biochemical assays  
Preliminary analysis of donor variables and transplant timings were performed to 
determine whether these impacted on biochemical assay results (Table 11, Table 12). 
Male gender was significantly associated with LDH concentration at all timepoints. Donor 
BMI correlated with increasing LDH concentration at all sampling timepoints. However, 
LDH, GST-Pi and NGAL concentrations at any timepoint, were not associated with the 
development of DGF (Supplementary Information, Table 28) or serum creatinine values 
(Supplementary Information, Table 29).   
NGAL concentration at 4 hours positively correlated with endpoint 1H 1D NMR lactate 
concentrations whilst NGAL concentrations 1 hour and 4 hours positively correlated with 
1H 1D alanine and total alanine concentrations (Table 13). On observation of the 
concentration of [U-13C] metabolites, the converse was true and an inverse correlation 
was suggested. Both endpoint concentrations of [U-13C] lactate and [U-13C] alanine were 
negatively correlated with endpoint concentrations of NGAL. 
Endpoints LDH concentrations were positively correlated with all anaerobic metabolite 
concentrations at all timepoint but only reached statistical significance for U-13C lactate 
concentrations at 4 hours and at the endpoint of machine perfusion, in addition to total 
alanine concentrations at 1 hour and 4 hour (see Table 13). No consistent, or significant 








Table 11. Association between donor categorical variables and biochemical assays. Data reported as Median 
(range), with p-value from Mann-Whitney test. P-values significant at p<0.05. 
 1 hour  4 hours  T End  
















         




















































         




















































         




















































Table 12. Association between donor continuous variables and biochemical assays. R-values represent a correlation 
co-efficient calculated using a two-tailed Spearman’s rank correlation test for continuous data, as datasets were 
assumed to be non-normally distributed. P-values significant at p<0.05. 
 1 hour  4 hours  T End  
 r 95% CI p-value r 95% CI p-value r 95% CI p-value 
NGAL          
Donor Age 0.3099 
-0.2803 to 
0.7301 0.2806 0.1209 
-0.4751 to 
0.6408 0.696 0.03297 
-0.5193 to 
0.5659 0.9155 
Donor BMI 0.2132 
-0.3730 to 
0.6777 0.4636 0.06593 
-0.5169 to 
0.6070 0.8347 -0.1297 
-0.6284 to 
0.4447 0.6595 
          
SCS time prior 
to HMP 0.2088 
-0.3770 to 
0.6752 0.4731 0.3022 
-0.3151 to 
0.7398 0.3155 0.2615 
-0.3281 to 
0.7045 0.3656 
HMP duration 0.3275 
-0.2622 to 
0.7391 0.253 0.2967 
-0.3205 to 
0.7371 0.3247 0.2659 
-0.3238 to 
0.7069 0.3573 
Total CIT 0.2659 
-0.3238 to 
0.7069 0.3573 0.3132 
-0.3041 to 
0.7453 0.2975 0.3407 
-0.2483 to 
0.7457 0.2335 
% HMP of total 
CIT  0.006593 
-0.5383 to 







          
GST-Pi          
Donor Age 0.4901 
-0.07209 to 
0.8160 0.0779 0.522 
-0.05899 to 
0.8388 0.0707 0.2838 
-0.3064 to 
0.7164 0.3226 
Donor BMI 0.3582 
-0.2294 to 
0.7545 0.209 0.4451 
-0.1583 to 
0.8064 0.1299 0.297 
-0.2933 to 
0.7234 0.2999 
          
SCS time prior 






0.5088 0.8064 0.1892 
-0.3943 to 
0.6640 0.5142 
HMP duration 0.4637 
-0.1060 to 
0.8042 0.0973 0.3242 
-0.2930 to 
0.7506 0.28 0.4422 
-0.1326 to 
0.7945 0.1143 
Total CIT 0.3758 
-0.2101 to 
0.7631 0.1862 0.1099 
-0.4837 to 
0.6342 0.7231 0.4466 
-0.1272 to 
0.7965 0.1104 
% HMP of total 
CIT  0.1385 
-0.4374 to 
0.6338 0.6375 0.1044 
-0.4879 to 
0.6309 0.737 0.1078 
-0.4623 to 
0.6148 0.7122 
          
LDH          
Donor Age 0.4769 
-0.08919 to 
0.8101 0.0872 0.4725 
-0.1242 to 
0.8182 0.1057 0.5297 
-0.01873 to 
0.8331 0.0544 
Donor BMI 0.6396 
0.1479 to 
0.8777 0.0161* 0.7143 
0.2522 to 
0.9111 0.0079* 0.7363 
0.3220 to 
0.9139 0.0037* 
          
SCS time prior 
to HMP 0.178 
-0.4041 to 
0.6575 0.5423 0.1758 
-0.4304 to 
0.6728 0.5659 0.2044 
-0.3809 to 
0.6727 0.4827 
HMP duration 0.1736 
-0.4078 to 
0.6549 0.5526 0.1923 
-0.4164 to 
0.6820 0.5293 0.0989 
-0.4693 to 
0.6092 0.7385 
Total CIT 0.1516 
-0.4265 to 
0.6418 0.6051 0.04396 
-0.5329 to 
0.5929 0.8917 0.1121 
-0.4589 to 
0.6175 0.7043 
% HMP of total 













Table 13. Association between key metabolites of interest and biochemical assays. R-values represent a correlation 
co-efficient calculated using a two-tailed Spearman’s rank correlation test for continuous data, as datasets were 
assumed to be non-normally distributed. P-values significant at p<0.05. 
 1 hour  4 hours  T End 
 r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value 
NGAL       
       
1D lactate 0.4857 (-0.07783 to 0.8140) 0.0809 
0.7088 (0.2418 to 
0.9092) 0.0086* 
0.4681 (-0.1004 to 
0.8062) 0.0938 
Total NMR Lactate  0.3319 (-0.2576 to 0.7413) 0.2464 
0.5385 (-0.03612 
to 0.8455) 0.0611 
0.1473 (-0.4302 to 
0.6392) 0.6158 
U-13C lactate -0.222 (-0.6827 to 0.3650) 0.4448 
-0.3846 (-0.7793 to 
0.2285) 0.1955 
-0.5824 (-0.8550 to 
-0.05763) 0.0318* 
POC lactate 0.1569 (-0.4221 to 0.6450) 0.5895 
0.1685 (-0.4366 to 
0.6686) 0.5791 
-0.07956 (-0.5968 
to 0.4844) 0.7867 
       
1D alanine 0.5429 (-0.0002240 to 0.8387) 0.0479* 
0.6703 (0.1715 to 
0.8956) 0.0147* 
0.4813 (-0.08353 
to 0.8121) 0.084 
Total NMR alanine 0.5824 (0.05763 to 0.8550) 0.0318* 
0.6374 (0.1151 to 
0.8836) 0.0221* 
0.3275 (-0.2622 to 
0.7391) 0.253 
U-13C alanine -0.1916 (-0.6654 to 0.3922) 0.5087 
-0.3934 (-0.7833 to 
0.2187) 0.1834 
-0.5749 (-0.8519 to 
-0.04634) 0.0341* 
       
TMNO 0.2042 (-0.3811 to 0.6726) 0.4821 
0.2568 (-0.3587 to 
0.7167) 0.3956 
0.2183 (-0.3684 to 
0.6806) 0.4516 
       
GST-Pi       
       
1D lactate 0.1253 (-0.4482 to 0.6257) 0.6706 
0.3077 (-0.3096 to 
0.7425) 0.3063 
-0.1628 (-0.6485 to 
0.4171) 0.5756 
Total NMR Lactate  0.06374 (-0.4965 to 0.5865) 0.8319 
0.1209 (-0.4751 to 
0.6408) 0.696 
-0.2354 (-0.6902 to 
0.3527) 0.4145 
U-13C lactate 0.1912 (-0.3926 to 0.6652) 0.5121 
-0.005495 (-0.5674 
to 0.5599) 0.9929 
0.1144 (-0.4570 to 
0.6190) 0.6956 
POC lactate 0.05525 (-0.5029 to 0.5808) 0.8517 
0.1519 (-0.4502 to 
0.6591) 0.6175 
-0.2223 (-0.6829 to 
0.3647) 0.4403 
       
1D alanine 0.1648 (-0.4154 to 0.6497) 0.5733 
0.2802 (-0.3366 to 
0.7287) 0.3535 
-0.2662 (-0.7070 to 
0.3236) 0.3545 
Total NMR alanine 0.2703 (-0.3196 to 0.7092) 0.3492 
0.3297 (-0.2873 to 
0.7533) 0.2715 
-0.2596 (-0.7035 to 
0.3299) 0.3673 
U-13C alanine 0.1233 (-0.4498 to 0.6245) 0.6726 
-0.1018 (-0.6293 to 
0.4899) 0.7402 
0.002205 (-0.5415 
to 0.5446) 0.9956 
       
TMNO 0.2277 (-0.3598 to 0.6859) 0.4319 
-0.07168 (-0.6106 
to 0.5126) 0.82 
0.1386 (-0.4373 to 
0.6339) 0.6341 
       
LDH       
       
1D lactate 0.3231 (-0.2667 to 0.7368) 0.2597 
0.1813 (-0.4258 to 
0.6759) 0.5537 
0.244 (-0.3447 to 
0.6949) 0.3998 
Total NMR Lactate  0.4549 (-0.1170 to 0.8003) 0.1044 
0.4451 (-0.1583 to 
0.8064) 0.1299 
0.4725 (-0.09482 
to 0.8082) 0.0905 
U-13C lactate 0.4462 (-0.1278 to 0.7963) 0.1119 
0.5604 (-0.004644 
to 0.8542) 0.0499* 
0.5824 (0.05763 to 
0.8550) 0.0318* 
POC lactate 0.4 (-0.1827 to 0.7747) 0.1564 
0.4503 (-0.1519 to 
0.8087) 0.1236 
0.3956 (-0.1878 to 
0.7726) 0.1614 
       
1D alanine 0.4154 (-0.1648 to 0.7820) 0.1413 
0.2912 (-0.3259 to 
0.7343) 0.3342 
0.2791 (-0.3110 to 
0.7139) 0.3332 
Total NMR alanine 0.6527 (0.1700 to 0.8828) 0.0136* 
0.5824 (0.02799 to 
0.8628) 0.0402* 
0.5341 (-0.01260 
to 0.8349) 0.0521 
U-13C alanine 0.3546 (-0.2333 to 0.7527) 0.2124 
0.4512 (-0.1508 to 
0.8091) 0.1228 
0.4714 (-0.09630 
to 0.8077) 0.0905 
       
TMNO 0.4905 (-0.07156 to 0.8161) 0.0779 
0.2748 (-0.3418 to 
0.7260) 0.3623 





Associations between pH and lactate concentrations 
Anaerobic metabolite concentrations, labelled and unlabelled, were negatively correlated 
with pH (Table 14).  
Table 14. Associations between pH and anaerobic metabolites. R-values represent a correlation co-efficient calculated 
using either a two-tailed Spearman’s rank correlation test or Pearson's correlation co-efficient as specified. a- denotes 
use of Pearson's correlation co-efficient which was used when values were normally distributed. b- denotes use of 
Spearman's correlation test. P-values significant at p<0.05. 
Metabolite r value  95% CI R squared p-value 
     
Lactate Point of Carea -0.8974 -0.9337 to -0.8429 0.8054 <0.0001 
1D Lactatea -0.7045 -0.8019 to -0.5705 0.4963 <0.0001 
Total concentration lactate using 
NMRa -0.759 
-0.8402 to -
0.6446 0.5761 <0.0001 
Concentration U13C labelled lactateb -0.6283 -0.7501 to -0.4653 0.3948 <0.0001 
   
 
 
1D Alanineb -0.6951 -0.7977 to -0.5533 0.4832 <0.0001 
Total concentration alanine using 
NMRa -0.7256 
-0.8168 to -
0.5989 0.5264 <0.0001 
Concentration U13C labelled 
alanineb -0.6592 
-0.7723 to -






Composition of Neat KPS  
For six kidneys, KPS-1 was sampled prior to commencing perfusion. The median 
concentration of constituent metabolites as detected by 1H 1D-NMR is reported in Table 
15.  
Table 15. Metabolites contained within sampled Neat KPS-1 prior to 
commencing perfusion. Mean concentrations (mM) are reported along with 








Known constituent  
Adenine 6.38 0.506 0.207 
Gluconate 76.1 4.35 1.78 
Glutathione 1.39 0.42 0.171 
Ribose 1.56 0.0951 0.0388 
    
Not known constituent 
3-Methylxanthine 0.027 0.00166 0.00068 
Acetate 0.326 0.137 0.0559 
Alanine 0.0134 0.00172 0.000701 
Ethanolamine 6.63 0.422 0.172 
Formate 0.258 0.107 0.0438 
Fumarate 0.00046 0.000713 0.000291 
Glutamate 0.0467 0.0562 0.0229 
Glycine 0 0 0 
Hippurate 0 0 0 
Hypoxanthine 0 0 0 
Inosine 0.009 0.0106 0.00431 
Isopropanol 0.012 0.00161 0.000655 
Lactate 0.011 0.00211 0.000861 
Leucine 0 0 0 
Oxypurinol 0.304 0.0131 0.00537 
Succinate 0.0198 0.00341 0.00139 
Trimethylamine N-oxide 0 0 0 
Tyrosine 0.0947 0.147 0.0599 
Valine 0 0 0 





Precision of sample processing  
In order to determine the precision of sample processing and analysis, six replicates of 
the same end-point sample for one kidney were processed and analysed as separate 
samples from the point of thawing. The mean concentration, standard deviation and 
standard error of the mean are reported in Table 16.  
Table 16. Analysis of sample replicates. Mean concentrations (mM) are reported along with standard deviation 
and standard error of mean.  
 Mean (mM) Standard Deviation Standard error of mean 
% [U-13C] lactate  12.6 0.073 0.0326 
NMR Lactate total 1.26 0.147 0.0659 
Concentration [U-13C] 
labelled lactate 0.16 0.0194 0.00869 
% [U-13C] alanine 5.58 1.54 0.689 
NMR Alanine total 0.129 0.00313 0.0014 
Concentration [U-13C] 
labelled alanine 0.00725 0.00219 0.00098 
    
3-Methylxanthine 0.0258 0.000287 0.000128 
Acetate 0.273 0.00355 0.00159 
Adenine 6.08 0.853 0.381 
Alanine 0.122 0.00103 0.000459 
Ethanolamine 6.53 0.152 0.0678 
Formate 0.267 0.0303 0.0136 
Fumarate 0.0015 0.000128 0.0000574 
Gluconate 80 0.361 0.161 
Glutamate 0.826 0.00639 0.00286 
Glutathione 0.792 0.0767 0.0343 
Glycine 1 0.0441 0.0197 
Hippurate 0.00792 0.00196 0.000874 
Hypoxanthine 0.1 0.0629 0.0281 
Inosine 0.0258 0.00347 0.00155 
Isopropanol 0.0139 0.000128 0.0000574 
Lactate 1.1 0.128 0.0571 
Leucine 0.00976 0.000385 0.000172 
Oxypurinol 0.297 0.00598 0.00267 
Ribose 1.61 0.0356 0.0159 
Succinate 0.0215 0.000168 0.0000752 
Trimethylamine N-oxide 0.00089 0.00199 0.00089 
Tyrosine 0.007 0.000385 0.000172 
Valine 0.0116 0.000206 0.0000921 






Tracer based metabolism provides unequivocal evidence of de novo metabolism. These 
experiments apply such methodology to ex vivo cadaveric kidneys prior to transplantation 
in order to improve understanding of metabolism during the organ preservation period. 
Here we describe the first study to use tracer-based metabolism to describe de novo 
metabolism in human cadaveric kidneys prior to observation of clinical outcome following 
transplantation.  
Metabolism 
Overall kidneys underwent HMP for a median of 8.7 hours, a relatively short duration 
which contrasts with the 18-hour duration of HMP used in previous metabolomic studies 
in our group (175, 219, 220).  
Increased durations of HMP correlated with decreasing glutathione concentrations likely 
reflecting its role as a scavenger of free radicals. Decreases in perfusate glutathione over 
time have been observed in several other studies (219, 220). The concentration of most 
labelled and unlabelled metabolites did not correlate significantly with duration of HMP, 
suggesting metabolite build up was not simply related to exposure of organs to metabolic 
substrate alone.   
The absence of correlation between any endpoint anaerobic metabolite concentration and 
duration of SCS, HMP or total CIT suggests it is too simplistic to suggest anaerobic 
metabolism occurs at a consistent rate in all kidneys. Analysis of DBD and DCD subgroups 
suggest donor subtype is a dominant factor in the metabolic phenotype of kidneys 
undergoing HMP; even with such relatively short perfusion durations, stark differences in 




The concentration of [U-13C] lactate was higher in DCD kidneys by a magnitude of 4.7, 
4.4 and 3.5 at 1 hour, 4 hours and at the endpoint of machine perfusion although this only 
reached statistical significance for endpoint samples. The concentration of [U-13C] alanine 
was also higher by a magnitude of 3.0 and 4.0 at 4 hours and at the endpoint of perfusion, 
although this also only reached statistical significance at T End. Differences are 
represented graphically in Figure 45. Such differences in T endpoint concentration of 
labelled metabolites may in part be accounted for by the increased duration of HMP in 
DCD vs DBD kidneys (10.8 vs 8.1hrs) resulting in longer perfusion period in which de 
novo metabolism can occur. However, changes in de novo metabolite composition and 
concentration were evident early in the perfusion period.    
No labelled glutamate was observed in any perfusate sample in the study at any timepoint. 
This was unsurprising given the relatively short duration of HMP compared with previous 
studies in which [4,5-13C] glutamate was observed (175, 219). In addition, porcine kidneys 
are larger and are retrieved from relatively young subjects compared with human kidneys 
included in this study. However, the absence of [4,5-13C] glutamate does not evidence that 
de novo aerobic metabolism is not ongoing. In contrast to products of glycolysis which can 
appear within minutes, TCA cycle intermediates do not appear for several hours (249).  
As differences in the concentration of U13C lactate were evident as early as 1 hour after 
commencing machine perfusion, one would suspect that DCD kidneys are reliant on 
anaerobic metabolism, with a relative thirst for glucose to fuel such metabolism early in in 
the perfusion period, unsurprising given the yield of ATP per glucose molecule when cells 
utilise anaerobic vs aerobic metabolism. This may be due to depletion of intra-cellular 
glucose stores during organ retrieval and static storage. Such a difference in preference 




of organ retrieval. Such warm ischaemia results in a switch to anaerobic metabolism which 
likely continues once the organ is cooled, with anaerobic metabolism ongoing during HMP. 
In comparison, one would suspect that DBD kidneys utilise both anaerobic and aerobic 
metabolism. Cold perfusion of DBD kidneys without preceding warm ischaemia may serve 
to slow the rate of aerobic metabolism, with anaerobic metabolism occurring following this 
due to lower oxygen availability during conditions of static storage.    
If DCD kidneys are indeed reliant on anaerobic metabolism due to the manner in which 
they are retrieved, there may be a role for normothermic regional perfusion to revert 
organs to a state of aerobic metabolism prior to organ cooling.  
As expected, a correlation was observed between increasing lactate concentrations and 
a decrease in pH suggesting changes in acid-base balance were a result of anaerobic 
metabolism (Table 14) A lower rate of anaerobic metabolism may be beneficial for cells 
as it results in less lactate accumulation, and maintenance of a more physiological pH.  
Glutathione concentrations were negatively correlated with duration of HMP suggesting 
the anti-oxidant continued to scavenge free radicals during the perfusion period. Such 
change in concentration would suggest ongoing ischaemic injury during HMP despite the 
provision of metabolic substrate and washout of toxic metabolites.  
Having identified differences between DBD and DCD groups, one would suspect that 
these differences in de novo metabolism may be responsible for the development of 
delayed graft function. Yet no metabolite was identified as predictive of DGF, perhaps 
reflecting the difference needed between groups to be statistically significant. Correlations 




suggest a relationship between de novo metabolism and functional outcome. However, 
given the small sample size, such correlation proved to be spurious once data for one 
kidney was removed.  
In a study using venous samples obtained via a cannulated renal vein and paired arterial 
following reperfusion, Wijermars et al demonstrated an association between continuing 
anaerobic metabolism in kidneys, evidenced by continuing lactate production on 
reperfusion, and the development of delayed graft function (234). The study did not 
investigate functional differences in DGF and IGF groups by means of observing 
creatinine values.  
Demographics  
Recruitment for the study was lower than expected resulting in a sample size of 14 
kidneys. There was a stark contrast between donor and recipient ethnicity, with diverse 
local ethnicity reflected in the demographics of the cohort. Ethnicity was the only 
demographic variable to differ between DGF and IGF groups (Table 5). The higher 
incidence of DGF in non-Caucasians did not appear to be related to a higher prevalence 
of diabetes or hypertension with the association likely due to chance given the small 
sample size.   
In the study population, kidneys underwent HMP for less than half of the total CIT with a 
median delay of 8.4 hours in initiating HMP during the preservation period. In conjunction 
with the extended total CIT observed in the cohort, a delay in the initiation of HMP, with 
kidneys remaining in static storage, is likely to limit its benefits as several beneficial 
mechanisms of action, such as preservation of endothelium via exertion of shear stress 




conditions. The delay in initiation contrasts with timings of the Machine Preservation Trial 
(70) and provides a small insight into the variation in delay in initiation of HMP in the UK. 
Such information was lacking from the NHSBT registry analysis discussed in Chapter 4.  
Biochemical assays 
Observed positive correlations between unlabelled alanine and lactate concentrations and 
NGAL concentration in perfusate may infer ongoing kidney damage leads to cell damage, 
and release of intra-cellular metabolites following cell death. In contrast, the negative 
correlation observed between endpoint NGAL concentrations and endpoint 
concentrations of U-13C lactate and U-13C alanine suggests preservation of organs is 
associated with higher de novo metabolism, albeit anaerobic.   
An increase in LDH concentrations correlated with increasing concentrations of anaerobic 
metabolites at all timepoints suggesting increasing anaerobic metabolism is associated 
with cell death. 
The search for a metabolic biomarker  
Donor, recipient and transplant specific factors influence graft function following 
implantation (35, 70, 186). Most studies measuring changes in metabolites and protein 
levels (95, 96, 173, 247) aim to identify biomarkers of organ damage and consequently 
predict graft function. Despite the identification of more novel biomarkers in recent years 
including the lysosomal enzyme N-acetyl-D-glucosaminidase (96), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (250), leptin (250) and micro RNAs 
(251), no perfusate biomarker is routinely used in clinical practice. The complexities of 
transplantation are reflected in this inability for researchers to identify one sensitive and 




Reperfusion Injury inflicts much of the damage organs sustain during organ preservation 
and following reperfusion, with changes in metabolism playing a key role in such injury.    
Number of variables  
Small scale animal studies (212, 220, 252) are conducted in a controlled environment in 
which animals are of a similar age, same gender and often identical genetic strain. 
Whether auto-transplant, reperfusion model or benchtop set-up alone, the experimental 
design of these studies dictates that only one variable is examined in isolation. This is a 
stark contrast to the number of variables which cannot be controlled for in our ‘real world’ 
setting.  
As such, the small sample size and large number of variables did not permit a multivariate 
analysis, limiting analyses to univariate analyses alone. The large number of statistical 
tests performed also increased the likelihood of both type 1 and type 2 errors occurring.  
Limitations  
There are several limitations of the study in addition to sample size and experimental 
methodology itself.   
This non-interventional study is novel as patient care did not change as a result of the 
study and in the absence of taking renal biopsies, kidneys were in no way damaged as a 
result of the study. Original ethical approval was sought to include biopsies taken from 
machine perfused organs at the end of the period of HMP. However, biopsies pose a risk 
of damaging organs and it is not unit policy to perform routine tissue biopsies. At the time 
of commencing the study, a national study was under way which included a punch biopsy 




formation of iatrogenic arterio-venous fistulae were attributed to these retrieval biopsies in 
other kidneys implanted in the centre thus biopsies were not taken from kidneys included 
in our study due to reluctance of transplant surgeons. Ideally punch biopsies would have 
been taken following the perfusion period enabling direct observation of renal cortex 
metabolites.  
The sampling of circulating perfusate was non-invasive and can be performed frequently 
with biochemical assays and 1D 1H NMR samples (172) processed and analysed within 
hours. However, as they are non-invasive several inferences must be made in order to 
draw conclusions regarding de novo metabolism within tissues themselves. Referring 
back to Chapter 6, a strong correlation was observed between end-point perfusate and 
renal cortex concentrations for the unlabelled metabolites alanine (r=0.82, p=0.01), lactate 
(r=0.750, p=0.005) and glutamate (r=0.86, p<0.001). Hence one limitation is the extent to 
which changes in perfusate mimic changes in metabolism within tissue.  
With respect to clinical outcome measures, delayed graft function as a binary outcome 
was less useful for sub-group analysis given the small sample size. Large differences in 
measured outcomes were required to show differences in IGF and DGF groups. Serum 
creatinine was a better functional measure of outcome however, as an outcome measure 
this was influenced in the short-term by development of DGF. As creatinine values for 
patients requiring haemodialysis do not indicate graft function, those values were deemed 
‘missing’ for purpose of analysis. However, kidneys which had regained graft function had 






Final comments  
By the time of HMP initiation, DCD kidneys are likely to be starved of oxygen with the 
likelihood that intra-cellular glucose levels have been continually decreasing due to 
reliance on anaerobic metabolism in the hypoxic conditions of static storage.  
Our data shows how donor sub-type is a key determinant of the extent of de novo 
anaerobic metabolism as evidenced by significantly higher proportions and absolute 
concentrations of U-13C alanine and lactate in DCD kidneys compared with DBD kidneys 
at end timepoints. Importantly the same differences would not have been apparent without 
employment of a metabolic tracer.  
Such description of de novo metabolism adds to our understanding of biological processes 
which continue during HMP in DCD kidneys and would not be possible without the use of 
tracer-based metabolism analysis. Anaerobic metabolism resulting in a higher lactate 
concentration contributes to higher rates of DGF in these kidneys in keeping with research 
showing anaerobic metabolism is higher in kidneys which experience DGF post-
implantation (234). Subsequent studies should confirm this association with a larger 
sample size and aim to correlate increasing warm ischaemic time with the amount of 
anaerobic metabolism to see if such a dose response relationship is present.  
If such an association is consistent amongst DCD kidneys, therapeutic efforts should seek 
to promote aerobic metabolism in near physiological conditions using normothermic 
regional perfusion prior to HMP. Alternatively, oxygenated HMP should be considered as 
a means of organ reconditioning by promoting aerobic metabolism as described in 





Supplementary tables  
Table 17. Association between development of DGF and measured outcomes including metabolite concentration and 
renal resistance. All metabolite concentrations units mmol/L unless otherwise stated. Data reported as median (range), 
with p-value from Mann-Whitney test. P-values significant at p<0.05. 














                    
3-Methylxanthine 0.0273 0.0266 0.9151 0.0275 0.0267 0.969 0.0283 0.0268 0.6354 
Acetate 0.185 0.21 0.8392 0.172 0.194 0.7333 0.168 0.172 0.972 
Adenine 6.09 5.63 0.1878 5.7 5.5 0.5395 5.85 5.66 0.8392 
Alanine 0.0599 0.0672 0.7333 0.116 0.129 0.4535 0.142 0.153 0.4535 
Ethanolamine 6.87 7.23 0.4535 6.89 7.39 0.2398 7.26 7.77 0.5395 
Formate 0.156 0.182 0.9451 0.177 0.199 >0.9999 0.15 0.207 0.9451 
Fumarate 0.00238 0.00207 0.8142 0.00391 0.00353 >0.9999 0.00614 0.0046 0.3926 
Gluconate 76.3 76.6 0.8392 79.8 76.3 0.3736 79.9 77.7 0.4535 
Glutamate 0.324 0.303 0.9451 0.939 0.943 0.9451 1.35 1.61 0.6354 
Glutathione 1.33 1.34 0.9451 0.767 0.817 0.9211 0.486 0.554 0.6354 
Glycine 0.554 0.57 0.9451 1.46 1.85 0.8392 2.25 3.02 0.7333 
Hippurate 0.00169 0.00215 0.9441 0.00384 0.00215 0.4505 0.0053 0.00391 0.8332 
Hypoxanthine 0.125 0.104 0.7283 0.182 0.175 >0.9999 0.18 0.193 0.6354 
Inosine 0.012 0.034 0.1059 0.0177 0.0348 0.2517 0.0145 0.0237 0.2278 
Isopropanol 0.0136 0.0146 0.2008 0.0144 0.0158 0.4775 0.0147 0.0175 0.2258 
Lactate 0.64 0.888 0.1878 1.09 1.37 0.1878 1.5 1.61 0.3736 
Leucine 0.00545 0.0102 0.1419 0.0129 0.0174 0.5205 0.0122 0.0188 0.5395 
Oxypurinol 0.297 0.293 0.9451 0.318 0.31 0.8152 0.319 0.312 0.9451 
Ribose 1.59 1.59 0.7762 1.59 1.59 0.8342 1.64 1.67 0.9291 
Succinate 0.0153 0.018 0.1878 0.0177 0.0226 0.3037 0.0216 0.0286 0.1878 
Trimethylamine N-oxide 0 0 0.6703 0.0185 0 0.2567 0.028 0 0.4126 
Tyrosine 0.00553 0.00668 0.8362 0.0099 0.0102 0.979 0.0103 0.0124 0.8142 
Valine 0.00729 0.00837 0.3566 0.0122 0.0134 0.4535 0.014 0.0177 0.2897 
                    
NMR Total concentration of 
lactate 0.752 0.940 0.5395 1.36 1.56 0.3736 1.7 1.98 0.6354 
Concentration of U-13C 
lactate  0.044 0.037 0.9451 0.118 0.154 0.5395 0.236 0.276 0.6354 
% U-13C lactate  7.07 6.04 0.5395 12.1 10.4 0.7333 21 15.9 0.7333 
                    
NMR Total concentration of 
alanine  0.06 0.07 0.8651 0.118 0.137 0.5395 0.149 0.174 0.5395 
Concentration of U-13C 
alanine  0 0 0.6703 0.003 0.014 0.5504 0.01 0.017 0.7053 
% U-13C alanine  0 0 >0.9999 4.01 7.13 0.9471 9.13 8.26 0.7333 
                    
POC lactate  1.35 1.4 0.6124 1.95 2.1 0.9181 2.15 2.55 0.6623 
POC glucose  9.4 8.995 0.4376 8.75 8.55 0.2567 8.55 8 0.7343 
                
Renal Resistance  





Table 18. Association between metabolite concentration and serum creatinine 1 week following transplantation. R-
values represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported 
alongside 95% confidence interval. P-values significant at p<0.05. 
 1 hour  4 hours  End point  
 r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value 
3-Methylxanthine 0.1048 (-0.5429 to 0.6743) 0.7601 -0.1636 (-0.7057 to 0.4993) 0.6337 0.05455 (-0.5776 to 0.6458) 0.8812 
Acetate -0.5455 (-0.8681 to 0.1012) 0.0876 -0.6091 (-0.8898 to 0.005963) 0.0519 -0.5455 (-0.8681 to 0.1012) 0.0876 
Adenine 0.4909 (-0.1744 to 0.8485) 0.1294 0.01818 (-0.6013 to 0.6241) 0.9673 -0.04545 (-0.6404 to 0.5836) 0.9033 
Alanine -0.4273 (-0.8243 to 0.2514) 0.1928 -0.5727 (-0.8775 to 0.06179) 0.0708 -0.3818 (-0.8060 to 0.3016) 0.2483 
Ethanolamine -0.2909 (-0.7670 to 0.3918) 0.3863 -0.6818 (-0.9131 to -0.1185) 0.0251 -0.2636 (-0.7546 to 0.4165) 0.4348 
Formate -0.6091 (-0.8898 to 0.005963) 0.0519 -0.5636 (-0.8744 to 0.07515) 0.0761 -0.5545 (-0.8713 to 0.08829) 0.0818 
Fumarate -0.1364 (-0.6914 to 0.5199) 0.6937 -0.2733 (-0.7590 to 0.4078) 0.4128 0.2785 (-0.4031 to 0.7614) 0.4034 
Gluconate -0.2818 (-0.7629 to 0.4001) 0.4023 0.1091 (-0.5398 to 0.6767) 0.7545 -0.4455 (-0.8313 to 0.2302) 0.173 
Glutamate -0.1636 (-0.7057 to 0.4993) 0.6337 -0.3636 (-0.7985 to 0.3206) 0.2731 0.02727 (-0.5955 to 0.6296) 0.9462 
Glutathione -0.1364 (-0.6914 to 0.5199) 0.6937 0.164 (-0.4990 to 0.7059) 0.6278 -0.3091 (-0.7751 to 0.3747) 0.356 
Glycine -0.2455 (-0.7461 to 0.4324) 0.4684 -0.3636 (-0.7985 to 0.3206) 0.2731 -0.06364 (-0.6511 to 0.5715) 0.8603 
Hippurate 0.07909 (-0.5609 to 0.6599) 0.8179 0.3107 (-0.3732 to 0.7758) 0.3489 0.1907 (-0.4779 to 0.7195) 0.5704 
Hypoxanthine -0.004598 (-0.6157 to 0.6099) 0.9948 -0.4364 (-0.8278 to 0.2409) 0.1826 -0.2273 (-0.7374 to 0.4479) 0.5034 
Inosine -0.4364 (-0.8278 to 0.2409) 0.1826 -0.4 (-0.8134 to 0.2819) 0.225 -0.1636 (-0.7057 to 0.4993) 0.6337 
Isopropanol -0.3371 (-0.7873 to 0.3475) 0.3082 -0.5968 (-0.8857 to 0.02525) 0.0569 -0.5 (-0.8518 to 0.1627) 0.1217 
Lactate -0.3091 (-0.7751 to 0.3747) 0.356 -0.2545 (-0.7503 to 0.4245) 0.4511 -0.4182 (-0.8207 to 0.2617) 0.203 
Leucine -0.2182 (-0.7330 to 0.4556) 0.5208 -0.3052 (-0.7734 to 0.3784) 0.3591 -0.1455 (-0.6962 to 0.5131) 0.6731 
Oxypurinol 0.2364 (-0.4402 to 0.7417) 0.4854 -0.3508 (-0.7931 to 0.3338) 0.2886 0.009091 (-0.6071 to 0.6185) 0.9895 
Ribose 0.3718 (-0.3122 to 0.8019) 0.2639 -0.3668 (-0.7998 to 0.3174) 0.271 0.143 (-0.5149 to 0.6949) 0.68 
Succinate -0.7909 (-0.9455 to -0.3456) 0.0055 -0.09091 (-0.6666 to 0.5527) 0.7964 0.2545 (-0.4245 to 0.7503) 0.4511 
Trimethylamine N-
oxide 0.1079 (-0.5407 to 0.6760) 0.7636 0.1156 (-0.5351 to 0.6803) 0.7333 0.4001 (-0.2818 to 0.8135) 0.224 
Tyrosine -0.2661 (-0.7557 to 0.4143) 0.4291 0.1093 (-0.5396 to 0.6768) 0.7487 -0.03189 (-0.6324 to 0.5925) 0.9302 
Valine -0.4055 (-0.8156 to 0.2759) 0.2159 -0.3182 (-0.7791 to 0.3660) 0.3415 -0.2961 (-0.7693 to 0.3869) 0.374 
       
NMR Total 
concentration of lactate -0.1182 (-0.6816 to 0.5333) 0.7345 -0.01818 (-0.6241 to 0.6013) 0.9673 -0.5727 (-0.8775 to 0.06179) 0.0708 
Concentration of U-13C 
lactate  0.3455 (-0.3392 to 0.7909) 0.2993 -0.1364 (-0.6914 to 0.5199) 0.6937 -0.1727 (-0.7104 to 0.4922) 0.6147 
% U-13C lactate  0.5091 (-0.1508 to 0.8551) 0.1142 0.1818 (-0.4851 to 0.7150) 0.595 0.2364 (-0.4402 to 0.7417) 0.4854 




-0.3818 (-0.8060 to 0.3016) 0.2483 -0.6909 (-0.9159 to -0.1354) 0.0226 -0.5182 (-0.8584 to 0.1387) 0.1072 
Concentration of U-13C 
alanine  0.2023 (-0.4687 to 0.7252) 0.5636 -0.5242 (-0.8606 to 0.1306) 0.1011 -0.2916 (-0.7673 to 0.3911) 0.3813 
% U-13C alanine  -0.1158 (-0.6804 to 0.5350) 0.7432 -0.3762 (-0.8037 to 0.3076) 0.255 0.03636 (-0.5896 to 0.6350) 0.9241 
       
POC lactate  -0.4966 (-0.8506 to 0.1671) 0.1229 -0.4545 (-0.8348 to 0.2194) 0.1635 -0.1053 (-0.6746 to 0.5426) 0.7584 
POC glucose  0.2621 (-0.4179 to 0.7538) 0.4341 -0.02278 (-0.6269 to 0.5984) 0.9516 0.1321 (-0.5231 to 0.6891) 0.6984 
       





Table 19. Association between metabolite concentration and serum creatinine 1 month following transplantation. R-
values represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported 
alongside 95% confidence interval. P-values significant at p<0.05. 
 1 hour  4 hours  End point  
 r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value 
3-
Methylxanthine -0.1018 (-0.6293 to 0.4899) 0.7403 -0.1953 (-0.6837 to 0.4139) 0.5198 -0.0989 (-0.6275 to 0.4921) 0.7506 
Acetate -0.456 (-0.8112 to 0.1448) 0.1198 -0.4725 (-0.8182 to 0.1242) 0.1057 -0.2558 (-0.7162 to 0.3596) 0.3959 
Adenine 0.3901 (-0.2224 to 0.7818) 0.1889 0.1484 (-0.4532 to 0.6570) 0.6298 -0.2582 (-0.7174 to 0.3574) 0.3939 
Alanine -0.5055 (-0.8321 to 0.08128) 0.0812 -0.5549 (-0.8521 to 0.01262) 0.0525 -0.5824 (-0.8628 to -0.02799) 0.0402* 
Ethanolamine -0.3516 (-0.7639 to 0.2644) 0.2392 -0.4011 (-0.7868 to 0.2100) 0.1759 -0.5769 (-0.8607 to -0.01972) 0.0425* 
Formate -0.4176 (-0.7943 to 0.1910) 0.1574 -0.3681 (-0.7716 to 0.2467) 0.2167 -0.456 (-0.8112 to 0.1448) 0.1198 
Fumarate -0.5055 (-0.8321 to 0.08128) 0.0812 -0.4374 (-0.8031 to 0.1675) 0.1359 0.2562 (-0.3593 to 0.7164) 0.395 
Gluconate -0.2912 (-0.7343 to 0.3259) 0.3342 0.02198 (-0.5484 to 0.5784) 0.9493 -0.4725 (-0.8182 to 0.1242) 0.1057 
Glutamate -0.533 (-0.8433 to 0.04381) 0.0642 -0.6923 (-0.9034 to -0.2110) 0.0109* -0.3901 (-0.7818 to 0.2224) 0.1889 
Glutathione 0.1374 (-0.4620 to 0.6506) 0.6561 0.4897 (-0.1021 to 0.8255) 0.0913 0.1264 (-0.4708 to 0.6441) 0.6827 
Glycine -0.7198 (-0.9130 to -0.2628) 0.0073* -0.6319 (-0.8815 to -0.1060) 0.0236* -0.2692 (-0.7231 to 0.3470) 0.3734 
Hippurate 0.3448 (-0.2716 to 0.7606) 0.2482 0.4613 (-0.1383 to 0.8134) 0.114 0.2996 (-0.3177 to 0.7385) 0.3187 
Hypoxanthine -0.3945 (-0.7838 to 0.2175) 0.1836 -0.3846 (-0.7793 to 0.2285) 0.1955 -0.6593 (-0.8916 to -0.1523) 0.0169* 
Inosine -0.3736 (-0.7742 to 0.2407) 0.2095 -0.2586 (-0.7176 to 0.3571) 0.3902 0.02751 (-0.5445 to 0.5821) 0.9311 
Isopropanol -0.3995 (-0.7861 to 0.2119) 0.176 -0.5041 (-0.8315 to 0.08309) 0.0812 -0.4292 (-0.7994 to 0.1774) 0.1439 
Lactate -0.4011 (-0.7868 to 0.2100) 0.1759 -0.4121 (-0.7918 to 0.1974) 0.1635 -0.4066 (-0.7893 to 0.2037) 0.1695 
Leucine -0.3681 (-0.7716 to 0.2467) 0.2167 -0.564 (-0.8556 to -0.0005061) 0.0476* -0.4066 (-0.7893 to 0.2037) 0.1695 
Oxypurinol 0 (-0.5636 to 0.5636) >0.9999 -0.3329 (-0.7549 to 0.2840) 0.2648 -0.1538 (-0.6602 to 0.4487) 0.6167 
Ribose 0.5576 (-0.008835 to 0.8531) 0.0493* -0.08457 (-0.6187 to 0.5030) 0.7876 0.1445 (-0.4563 to 0.6548) 0.6363 
Succinate -0.5495 (-0.8499 to 0.02052) 0.0553 -0.3077 (-0.7425 to 0.3096) 0.3063 0.1703 (-0.4351 to 0.6697) 0.5786 
Trimethylamine 
N-oxide -0.01747 (-0.5754 to 0.5516) 0.9744 0.1745 (-0.4316 to 0.6720) 0.5719 0.0657 (-0.5171 to 0.6068) 0.8355 
Tyrosine -0.03867 (-0.5894 to 0.5366) 0.9055 -0.07153 (-0.6105 to 0.5128) 0.8166 -0.07703 (-0.6140 to 0.5087) 0.8025 
Valine -0.5427 (-0.8472 to 0.03013) 0.058 -0.5165 (-0.8366 to 0.06649) 0.0741 -0.5805 (-0.8621 to -0.02505) 0.0406* 




-0.467 (-0.8159 to 0.1311) 0.1103 -0.4286 (-0.7992 to 0.1781) 0.146 -0.5714 (-0.8585 to -0.01152) 0.0449* 
Concentration 
of U-13C lactate  0.1484 (-0.4532 to 0.6570) 0.6298 -0.5275 (-0.8411 to 0.05144) 0.0673 -0.456 (-0.8112 to 0.1448) 0.1198 
% U-13C lactate  0.3132 (-0.3041 to 0.7453) 0.2975 -0.08791 (-0.6208 to 0.5005) 0.7784 -0.03297 (-0.5857 to 0.5407) 0.9205 
       
NMR Total 
concentration 
of alanine  




-0.2489 (-0.7126 to 0.3660) 0.4184 -0.5679 (-0.8572 to -0.006280) 0.046* -0.3906 (-0.7821 to 0.2218) 0.1864 
% U-13C 
alanine  -0.52 (-0.8380 to 0.06174) 0.0714 -0.3149 (-0.7461 to 0.3024) 0.2941 -0.08242 (-0.6174 to 0.5046) 0.7926 
       
POC lactate  -0.675 (-0.8973 to -0.1797) 0.0135* -0.6217 (-0.8778 to -0.08947) 0.0261* -0.5055 (-0.8321 to 0.08123) 0.0804 
POC glucose  0.3292 (-0.2878 to 0.7531) 0.2705 0.1568 (-0.4462 to 0.6619) 0.6068 0.01376 (-0.5542 to 0.5729) 0.9677 
       
Renal 




Table 20. Association between metabolite concentration and serum creatinine 6 months following transplantation. 
R-values represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, 
reported alongside 95% confidence interval. P-values significant at p<0.05. 
 1 hour  4 hours  End point  
 r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value 
3-Methylxanthine 0.0871 (-0.4785 to 0.6017) 0.765 -0.0793 (-0.5966 to 0.4846) 0.7866 0.09901 (-0.4692 to 0.6093) 0.7351 
Acetate -0.4598 (-0.8025 to 0.1108) 0.0994 -0.4708 (-0.8074 to 0.09696) 0.091 -0.2775 (-0.7131 to 0.3126) 0.3335 
Adenine 0.363 (-0.2242 to 0.7569) 0.2011 0.09681 (-0.4710 to 0.6079) 0.7413 -0.1672 (-0.6511 to 0.4133) 0.5653 
Alanine -0.352 (-0.7514 to 0.2361) 0.216 -0.2728 (-0.7106 to 0.3172) 0.3427 -0.3938 (-0.7718 to 0.1898) 0.1634 
Ethanolamine -0.08141 (-0.5980 to 0.4830) 0.7815 -0.4576 (-0.8015 to 0.1136) 0.1013 -0.5325 (-0.8343 to 0.01486) 0.0524 
Formate -0.3696 (-0.7601 to 0.2169) 0.1928 -0.3806 (-0.7654 to 0.2047) 0.1789 -0.418 (-0.7833 to 0.1617) 0.1375 
Fumarate -0.4119 (-0.7804 to 0.1689) 0.1434 -0.413 (-0.7809 to 0.1676) 0.1417 0.1876 (-0.3957 to 0.6631) 0.5163 
Gluconate -0.1628 (-0.6485 to 0.4171) 0.5757 0.2992 (-0.2911 to 0.7245) 0.2965 -0.286 (-0.7176 to 0.3042) 0.3191 
Glutamate -0.3366 (-0.7437 to 0.2525) 0.2376 -0.473 (-0.8084 to 0.09415) 0.0892 -0.2332 (-0.6890 to 0.3547) 0.4194 
Glutathione 0.209 (-0.3768 to 0.6754) 0.47 0.2445 (-0.3442 to 0.6952) 0.396 0.09241 (-0.4744 to 0.6051) 0.7529 
Glycine -0.3784 (-0.7644 to 0.2071) 0.1818 -0.4202 (-0.7843 to 0.1591) 0.1351 -0.121 (-0.6231 to 0.4517) 0.6784 
Hippurate 0.4906 (-0.07151 to 0.8162) 0.077 0.5936 (0.07467 to 0.8596) 0.0279* 0.405 (-0.1769 to 0.7771) 0.1507 
Hypoxanthine -0.2819 (-0.7154 to 0.3083) 0.326 -0.1166 (-0.6203 to 0.4552) 0.6897 -0.473 (-0.8084 to 0.09415) 0.0892 
Inosine -0.3388 (-0.7448 to 0.2502) 0.2347 -0.0837 (-0.5995 to 0.4812) 0.7748 0.1498 (-0.4280 to 0.6407) 0.6061 
Isopropanol -0.3252 (-0.7379 to 0.2645) 0.2538 -0.2958 (-0.7227 to 0.2945) 0.3011 -0.3076 (-0.7289 to 0.2826) 0.2816 
Lactate -0.2882 (-0.7188 to 0.3021) 0.315 -0.165 (-0.6498 to 0.4152) 0.5701 -0.209 (-0.6754 to 0.3768) 0.47 
Leucine -0.3058 (-0.7280 to 0.2844) 0.2853 -0.2181 (-0.6805 to 0.3686) 0.4502 -0.1452 (-0.6379 to 0.4319) 0.6183 
Oxypurinol 0.07921 (-0.4847 to 0.5966) 0.7878 0.02974 (-0.5217 to 0.5636) 0.9192 0.07261 (-0.4897 to 0.5923) 0.805 
Ribose 0.5178 (-0.03511 to 0.8280) 0.0594 0.1109 (-0.4598 to 0.6168) 0.7057 0.2874 (-0.3029 to 0.7183) 0.3157 
Succinate -0.4532 (-0.7995 to 0.1191) 0.105 -0.2838 (-0.7164 to 0.3064) 0.3227 0.1804 (-0.4020 to 0.6589) 0.5344 
Trimethylamine N-
oxide 0.1868 (-0.3965 to 0.6626) 0.5266 0.1667 (-0.4138 to 0.6508) 0.5675 0.05404 (-0.5038 to 0.5800) 0.8558 
Tyrosine -0.03536 (-0.5675 to 0.5176) 0.9059 0.00882 (-0.5368 to 0.5492) 0.9774 -0.03084 (-0.5644 to 0.5209) 0.9176 
Valine -0.3863 (-0.7682 to 0.1983) 0.1715 -0.4092 (-0.7791 to 0.1720) 0.1466 -0.3932 (-0.7715 to 0.1905) 0.1632 




-0.4708 (-0.8074 to 0.09696) 0.091 -0.407 (-0.7781 to 0.1746) 0.1488 -0.4268 (-0.7874 to 0.1512) 0.1288 
Concentration of 
U-13C lactate  -0.1672 (-0.6511 to 0.4133) 0.5653 -0.5919 (-0.8588 to -0.07198) 0.0282* -0.5941 (-0.8597 to -0.07535) 0.0276* 
% U-13C lactate  -0.07481 (-0.5937 to 0.4880) 0.7995 -0.3586 (-0.7547 to 0.2290) 0.2069 -0.3498 (-0.7503 to 0.2385) 0.2188 




-0.4366 (-0.7919 to 0.1395) 0.1191 -0.5787 (-0.8535 to -0.05197) 0.0327* -0.5765 (-0.8526 to -0.04868) 0.0335* 
Concentration of 
U-13C alanine  -0.4439 (-0.7952 to 0.1306) 0.1186 -0.7024 (-0.9015 to -0.2576) 0.0066* -0.5667 (-0.8486 to -0.03422) 0.037* 
% U-13C alanine  -0.6385 (-0.8773 to -0.1461) 0.0163* -0.4575 (-0.8014 to 0.1138) 0.1014 -0.3124 (-0.7314 to 0.2777) 0.2749 
       
POC lactate  -0.6102 (-0.8662 to -0.1005) 0.0227* -0.5469 (-0.8403 to -0.005466) 0.0453* -0.5243 (-0.8308 to 0.02611) 0.0564 
POC glucose  -0.06416 (-0.5867 to 0.4961) 0.8271 -0.01544 (-0.5538 to 0.5320) 0.9592 -0.1105 (-0.6165 to 0.4601) 0.7056 
       




Table 21. Association between metabolite concentration and serum creatinine 12 months following transplantation. R-
values represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported 
alongside 95% confidence interval. P-values significant at p<0.05. 
 1 hour  4 hours  End point  
 r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value 
3-
Methylxanthine 0.08609 (-0.4793 to 0.6010) 0.7678 -0.01544 (-0.5538 to 0.5320) 0.9593 0.2048 (-0.3805 to 0.6730) 0.4794 
Acetate -0.6388 (-0.8774 to -0.1466) 0.0161* -0.6454 (-0.8800 to -0.1576) 0.0148* -0.452 (-0.7989 to 0.1206) 0.1055 
Adenine 0.5264 (-0.02322 to 0.8317) 0.0555 0.03084 (-0.5209 to 0.5644) 0.9183 -0.1167 (-0.6204 to 0.4551) 0.6896 
Alanine -0.2885 (-0.7189 to 0.3017) 0.3146 -0.3502 (-0.7505 to 0.2381) 0.2185 -0.4626 (-0.8037 to 0.1074) 0.0973 
Ethanolamine -0.2137 (-0.6780 to 0.3726) 0.4603 -0.7137 (-0.9057 to -0.2786) 0.0054* -0.4824 (-0.8126 to 0.08215) 0.0825 
Formate -0.5463 (-0.8401 to -0.004609) 0.0458* -0.5485 (-0.8410 to -0.007754) 0.0448* -0.5595 (-0.8456 to -0.02364) 0.04* 
Fumarate -0.1841 (-0.6610 to 0.3988) 0.5244 -0.2326 (-0.6887 to 0.3553) 0.4192 0.3702 (-0.2163 to 0.7603) 0.1912 
Gluconate -0.2974 (-0.7235 to 0.2930) 0.2996 0.1938 (-0.3903 to 0.6667) 0.5037 -0.3326 (-0.7417 to 0.2568) 0.2437 
Glutamate -0.06608 (-0.5880 to 0.4947) 0.8226 -0.3392 (-0.7450 to 0.2498) 0.234 -0.1982 (-0.6692 to 0.3864) 0.4938 
Glutathione 0.01982 (-0.5289 to 0.5568) 0.9486 0.28 (-0.3101 to 0.7144) 0.3287 0.1366 (-0.4390 to 0.6327) 0.6395 
Glycine -0.326 (-0.7383 to 0.2637) 0.2536 -0.3502 (-0.7505 to 0.2381) 0.2185 -0.1233 (-0.6245 to 0.4498) 0.6727 
Hippurate 0.4168 (-0.1632 to 0.7827) 0.1385 0.6191 (0.1146 to 0.8697) 0.0209* 0.3469 (-0.2416 to 0.7489) 0.2224 
Hypoxanthine -0.1333 (-0.6307 to 0.4417) 0.6474 -0.3128 (-0.7315 to 0.2773) 0.2742 -0.3546 (-0.7527 to 0.2333) 0.2124 
Inosine -0.5242 (-0.8308 to 0.02626) 0.0567 -0.2723 (-0.7103 to 0.3177) 0.3423 -0.086 (-0.6009 to 0.4794) 0.7681 
Isopropanol -0.415 (-0.7818 to 0.1652) 0.1399 -0.516 (-0.8272 to 0.03750) 0.0609 -0.5397 (-0.8373 to 0.004640) 0.0486* 
Lactate -0.2643 (-0.7060 to 0.3254) 0.3583 -0.2577 (-0.7024 to 0.3317) 0.3709 -0.4251 (-0.7866 to 0.1533) 0.1304 
Leucine -0.2841 (-0.7166 to 0.3061) 0.3223 -0.2018 (-0.6712 to 0.3832) 0.4848 -0.1432 (-0.6367 to 0.4335) 0.6232 
Oxypurinol 0.1476 (-0.4299 to 0.6394) 0.6124 -0.108 (-0.6150 to 0.4621) 0.7107 0.1498 (-0.4280 to 0.6407) 0.6069 
Ribose 0.5366 (-0.008991 to 0.8360) 0.0491* 0.009757 (-0.5361 to 0.5499) 0.9753 0.2843 (-0.3060 to 0.7167) 0.3211 
Succinate -0.6872 (-0.8959 to -0.2301) 0.0082* -0.2996 (-0.7247 to 0.2907) 0.2958 0.1035 (-0.4657 to 0.6121) 0.7237 
Trimethylamine 
N-oxide 0.1318 (-0.4429 to 0.6297) 0.6589 0.2824 (-0.3078 to 0.7157) 0.3257 0.247 (-0.3419 to 0.6966) 0.3905 
Tyrosine -0.1571 (-0.6451 to 0.4219) 0.5888 0.05629 (-0.5021 to 0.5815) 0.8477 0.03087 (-0.5209 to 0.5644) 0.917 
Valine -0.3282 (-0.7394 to 0.2614) 0.2494 -0.3767 (-0.7635 to 0.2091) 0.1839 -0.3881 (-0.7690 to 0.1963) 0.1695 




-0.2687 (-0.7084 to 0.3212) 0.3501 -0.3392 (-0.7450 to 0.2498) 0.234 -0.6145 (-0.8679 to -0.1073) 0.0217* 
Concentration of 
U-13C lactate  0.1145 (-0.4569 to 0.6191) 0.6951 -0.4559 (-0.8007 to 0.1157) 0.1027 -0.4912 (-0.8164 to 0.07068) 0.0765 
% U-13C lactate  0.2093 (-0.3765 to 0.6755) 0.4698 -0.152 (-0.6420 to 0.4262) 0.6016 -0.1278 (-0.6273 to 0.4462) 0.6615 




-0.3102 (-0.7302 to 0.2800) 0.2776 -0.5947 (-0.8600 to -0.07636) 0.0274* -0.5308 (-0.8336 to 0.01711) 0.0532 
Concentration of 
U-13C alanine  -0.07049 (-0.5909 to 0.4913) 0.8182 -0.5514 (-0.8422 to -0.01193) 0.0435* -0.4338 (-0.7906 to 0.1429) 0.1216 
% U-13C alanine  -0.3517 (-0.7512 to 0.2365) 0.2166 -0.3296 (-0.7402 to 0.2599) 0.2478 -0.1564 (-0.6447 to 0.4225) 0.591 
       
POC lactate  -0.6574 (-0.8846 to -0.1779) 0.0124* -0.6071 (-0.8650 to -0.09554) 0.0236* -0.515 (-0.8268 to 0.03895) 0.0615 
POC glucose  0.02769 (-0.5232 to 0.5622) 0.9254 0.05188 (-0.5054 to 0.5786) 0.8596 0.02212 (-0.5272 to 0.5584) 0.9423 
       
Renal 





Table 22. Correlation between creatinine values and T End concentration of anaerobic metabolites for DCD 
kidneys. R-values represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation 
test. P-values significant at p<0.05. 
 1 month Cr 6 month Cr 12 month Cr 
 r value p-value r value p-value r value p-value 
       
Total concentration of lactate -0.8 0.3333 -0.8 0.3333 -0.4 0.75 
Concentration of U-13C lactate  -0.8 0.3333 -0.8 0.3333 -0.8 0.3333 
% U-13C lactate  -1 0.0833 -1 0.0833 -0.8 0.3333 
POC lactate -0.9487 0.1667 -0.9487 0.1667 -0.3162 0.6667 
       
Total concentration of alanine  -1 0.0833 -1 0.0833 -0.4 0.75 
Concentration of U-13C alanine  -0.8 0.3333 -0.8 0.3333 -0.8 0.3333 
% U-13C alanine  -0.8 0.3333 -0.8 0.3333 -0.8 0.3333 
 
Table 23. Association between timings of HMP and renal resistance. R-values represent the correlation co-
efficient calculated using a two-tailed Spearman’s rank correlation test. P-values significant at p<0.05. 
   Renal resistance r 95% CI p-value 
          
Duration of SCS prior to HMP RR at 1 hour 0.3113 -0.2789 to 0.7308 0.2785 
  RR at 4 hours  0.286 -0.3042 to 0.7176 0.3191 
  RR at Tend 0.37 -0.2165 to 0.7603 0.1921 
          
Duration of HMP RR at 1 hour 0.2627 -0.3270 to 0.7051 0.3636 
  RR at 4 hours  0.4224 -0.1565 to 0.7853 0.1331 
  RR at Tend 0.348 -0.2404 to 0.7494 0.2214 
          
Total CIT RR at 1 hour 0.2539 -0.3354 to 0.7003 0.3805 
  RR at 4 hours  0.3388 -0.2502 to 0.7448 0.2347 
  RR at Tend 0.3348 -0.2545 to 0.7428 0.2404 
          
HMP as a % of CIT RR at 1 hour 0.09492 -0.4724 to 0.6067 0.749 
  RR at 4 hours  0.1826 -0.4001 to 0.6602 0.529 





Table 24. The influence of perfusion timing on endpoint metabolite concentration. R-values represent the correlation co-
efficient as per two-tailed Spearman’s rank correlation test, reported alongside 95% confidence interval. P-values 
significant at p<0.05. 
 Duration of SCS prior to HMP Duration of HMP Total CIT  




0.6418 0.6051 0.1824 
-0.4002 to 





0.04213 0.0352* -0.3168 
-0.7336 to 





0.2848 0.2878 0.1385 
-0.4374 to 





0.5446 >0.9999 -0.04176 
-0.5718 to 





0.3153 0.3411 0.1824 
-0.4002 to 





0.07773 0.0274* -0.3275 
-0.7391 to 





0.7507 0.2178 0.2249 
-0.3624 to 





0.3447 0.3998 0.04176 
-0.5129 to 





0.7368 0.2597 0.6747 
0.2079 to 





0.2713 0.2666 -0.7143 
-0.9059 to -





0.7278 0.2878 0.5473 
0.006029 to 





0.4386 0.6401 -0.06968 
-0.5904 to 





0.5129 0.8915 0.1648 
-0.4154 to 





0.6258 0.6672 -0.297 
-0.7234 to 





0.6135 0.7179 0.1894 
-0.3941 to 





0.6120 0.727 0.03297 
-0.5193 to 





0.5352 0.9758 0.09011 
-0.4762 to 





0.7045 0.3656 0.1648 
-0.4154 to 





0.5116 0.884 0.3203 
-0.2697 to 





0.5836 0.8438 0.1473 
-0.4302 to 






0.7090 0.3491 0.3309 
-0.2586 to 





0.7415 0.2441 0.07481 
-0.4880 to 





0.5336 0.9669 0.2288 
-0.3588 to 
0.6865 0.4284 0.07481 
-0.4880 to 
0.5937 0.7995 





0.6876 0.4265 0.1648 
-0.4154 to 




U-13C lactate  0.1121 
-0.4589 to 
0.6175 0.7043 0.2615 
-0.3281 to 
0.7045 0.3656 0.05495 
-0.5031 to 
0.5806 0.8557 
% U-13C lactate  -0.08132 
-0.5979 to 
0.4830 0.7849 0.222 
-0.3650 to 




Total concn of 
alanine  0.08132 
-0.4830 to 








U-13C alanine  0.1209 
-0.4518 to 
0.6230 0.6818 0.1956 
-0.3887 to 
0.6677 0.5022 0.05055 
-0.5064 to 
0.5777 0.8676 
% U-13C alanine  0.0989 
-0.4693 to 
0.6092 0.7385 0.2791 
-0.3110 to 
0.7139 0.3332 0.1033 
-0.4658 to 
0.6120 0.727 
          
POC lactate 0.1193 
-0.4530 to 
0.6220 0.6829 0.3072 
-0.2830 to 
0.7287 0.283 0.2122 
-0.3739 to 
0.6772 0.4634 






0.5383 0.9879 -0.06402 
-0.5866 to 
0.4962 0.8312 
POC pH 0.07277 
-0.4896 to 
0.5924 0.8047 -0.07718 
-0.5952 to 






Table 25. Correlation between total CIT duration and T End anaerobic metabolite levels. R-values represent the 
correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported alongside 95% 
confidence interval. P-values significant at p<0.05. 
Metabolites Timepoint r 95% CI p-value 
1D lactate 1 hour 0.1165 -0.4553 to 0.6203 0.693 
 4 hours 0.07692 -0.4864 to 0.5951 0.7966 
 T End 0.1033 -0.4658 to 0.6120 0.727 
     
POC Lactate 1 hour -0.146 -0.6384 to 0.4312 0.6162 
 4 hours 0.04626 -0.5096 to 0.5748 0.8763 
 T End 0.1193 -0.4530 to 0.6220 0.6829 
     
% U-13C lactate 1 hour 0.156 -0.4228 to 0.6445 0.5944 
 4 hours 0.01538 -0.5321 to 0.5538 0.9638 
 T End -0.08132 -0.5979 to 0.4830 0.7849 
     
Total amount of lactate detected 
on NMR 1 hour 0.2132 -0.3730 to 0.6777 0.4636 
 4 hours 0.3099 -0.2803 to 0.7301 0.2806 
 T End 0.2308 -0.3570 to 0.6876 0.4265 
     
Concentration U-13C lactate 1 hour 0.2835 -0.3067 to 0.7163 0.3253 
 4 hours 0.2264 -0.3610 to 0.6852 0.4356 






Table 26. Correlation between duration of HMP and T End anaerobic metabolite levels. R-values represent the 
correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported alongside 95% 
confidence interval. P-values significant at p<0.05. 
Metabolites Timepoint r 95% CI p-value 
1D lactate  1 hour -0.07253 -0.5922 to 0.4898 0.8083 
 4 hours -0.002198 -0.5446 to 0.5415 >0.9999 
 T End 0.03297 -0.5193 to 0.5659 0.9155 
     
POC Lactate 1 hour -0.2102 -0.6760 to 0.3757 0.4678 
 4 hours -0.03304 -0.5659 to 0.5193 0.9124 
 T End 0.3072 -0.2830 to 0.7287 0.283 
     
% U-13C lactate 1 hour 0.1692 -0.4116 to 0.6523 0.5629 
 4 hours 0.09011 -0.4762 to 0.6036 0.7616 
 T End 0.222 -0.3650 to 0.6827 0.4448 
     
Total amount of lactate detected 
on NMR 1 hour 0.06374 -0.4965 to 0.5865 0.8319 
 4 hours 0.2659 -0.3238 to 0.7069 0.3573 
 T End 0.1648 -0.4154 to 0.6497 0.5733 
     
Concentration U-13C lactate  1 hour 0.2703 -0.3196 to 0.7092 0.3492 
 4 hours 0.1121 -0.4589 to 0.6175 0.7043 






Table 27. Correlation between period of SCS prior to HMP and T End anaerobic metabolite levels. R-values 
represent the correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported 
alongside 95% confidence interval. P-values significant at p<0.05. 
Metabolites Timepoint r 95% CI p-value 
1D lactate  1 hour 0.3363 -0.2529 to 0.7435 0.2399 
 4 hours 0.05055 -0.5064 to 0.5777 0.8676 
 T End 0.1033 -0.4658 to 0.6120 0.727 
     
POC Lactate 1 hour 0.1637 -0.4163 to 0.6490 0.5734 
 4 hours 0.1608 -0.4188 to 0.6473 0.5804 
 T End 0.1193 -0.4530 to 0.6220 0.6829 
     
% U-13C lactate 1 hour 0.178 -0.4041 to 0.6575 0.5423 
 4 hours 0.08132 -0.4830 to 0.5979 0.7849 
 T End -0.08132 -0.5979 to 0.4830 0.7849 
     
Total amount of lactate detected 
on NMR 1 hour 0.4286 -0.1492 to 0.7882 0.1281 
 4 hours 0.1868 -0.3964 to 0.6626 0.5221 
 T End 0.2308 -0.3570 to 0.6876 0.4265 
     
Concentration U-13C lactate  1 hour 0.367 -0.2198 to 0.7588 0.1974 
 4 hours 0.3846 -0.2002 to 0.7674 0.1755 
 T End 0.1121 -0.4589 to 0.6175 0.7043 
 
Table 28. Association between biochemical assay concentrations and development of DGF. Data reported as 
Median (range), with p-value from Mann-Whitney test. P-values significant at p<0.05. 
  All (n=14) DGF (n=4) IGF (n=10) p-value  
NGAL 
(ng/ml) 1 hour 3.81 (1.48-14.4) 3.65 (1.48-14.4) 3.81 (1.62-11.0) 0.9451 
 4 hours  4.61 (2.58-18.9) 4.52 (2.71-18.9) 4.61 (2.58-11.5) 0.9399 
 T End 5.02 (2.25-25.5) 5.33 (2.25-13.9) 4.40 (2.71-25.5) 0.8392 
      
GST Pi 
(ng/ml) 1 hour 32.1 (14.1-36.7) 33.0 (14.1-33.2) 30.2 (19.6-36.7) 0.8392 
 4 hours  31.0 (21.6-32.2) 31.6 (27.2-32.2) 29.6 (21.6-31.1) 0.0755 
 T End 28.7 (21.2-32.8) 26.9 (21.6-31.2) 28.9 (21.2-32.8) 0.4725 
      
LDH 
(Nmol) 1 hour 12.0 (1.00-32.0) 12.5 (1.00-32.0) 13.3 (3.01-26.8) 0.8392 
 4 hours  17.7 (3.77-35.7) 17.4 (3.77-35.7) 17.7 (5.66-28.9) 0.9399 






Table 29. Association between biochemical assay concentrations and serum creatinine. R-values represent the 
correlation co-efficient calculated using a two-tailed Spearman’s rank correlation test, reported alongside 95% 
confidence interval. P-values significant at p<0.05. 
 1 week Cr 1 month Cr 6 month Cr 12 month Cr 










































































































































































































Chapter 8 : Discussion 
 
 
The French surgeon Alexis Carrel, considered the father of solid organ transplantation, 
made significant contributions to the field of organ preservation (254). In his sentinel paper 
entitled ‘the preservation of tissues and its applications in surgery’ published in 1912, he 
stated ‘a tissue is in latent life when its metabolism becomes so slight that it can hardly 
been detected, and also when its metabolism is completely suspended’ (255). As a 
hypothermic modality of preservation, such reduction in metabolism is a key mechanism 
by which hypothermic machine perfusion acts. Additional mechanisms include simple 
mechanistic amelioration of vasospasm, protective endothelial pathways and a limited role 
of resuscitation including the reversal of ischaemia reperfusion injury.  
Research conducted forming the contents of this thesis adds to current understanding of 
the clinical utility and metabolic mechanisms by which HMP is beneficial in addition to 
discussing one method of optimisation of cadaveric kidneys during hypothermic machine 
perfusion. Exploration of such metabolism with employment of [U-13C] glucose as a 
metabolic tracer forms the basis of work contained in this thesis.  
However, given the lack of explicit guidance for its usage and a lack of clinical trials within 
the UK showing any benefit to the use of HMP, the first aim of the thesis addressed in 
Chapter 4 was to determine whether HMP does in fact influence clinical outcomes in this 
population via registry analysis of a national cohort of patients. Such examination of 
outcomes for DBD and DCD kidneys was important given the results of the only UK based 
RCT for DCD kidneys contradicted the results of the Machine Preservation Trial. Results 
showed a reduction in the incidence of DGF for recipients of DCD kidneys which 




Importantly, the study highlighted graphically for DCD kidneys how the incidence of DGF 
changes for kidneys undergoing HMP with increasing durations of CIT.   
With the suggestion clinical outcomes differ between kidneys stored in HMP and SCS, as 
a preliminary study, the aim of the study described in Chapter 5 was to determine changes 
in metabolism between HMP and SCS conditions using 1D-1H NMR. This chapter along 
with Chapter 6 utilises an established porcine DCD model with significant advantages but 
also inherent limitations.  
With limitations associated with non-utilisation of tracer-based metabolism, it was still 
evident that metabolism differed in those organs undergoing HMP compared those stored 
using SCS alone. It was evident that such differences could and should indeed be 
investigated with use of a metabolic tracer; research has shown tracer-based metabolism 
using 2D NMR spectroscopy has a role in describing de novo metabolism in discarded 
human cadaveric kidneys and porcine kidneys during HMP (175). Chapter 3 describes 
refinements in NMR methodology which permit a more accurate determination of 
isotopomers in a shorter time period using 13C spectral filters and J-coupling based 
splitting enhancement in 2D-NMR spectra.  
Given that hypoxia initiates IRI, and with changes in metabolism central to ongoing 
ischaemic insult during the preservation period, supplemental oxygenation during HMP 
may serve to reduce injury. Using a multi-modality approach, the aim of Chapter 6 was to 
determine the changes effected by supplementation of circulating perfusion fluid with 
oxygen. Results showing a greater degree of aerobic metabolism and higher ATP levels 
in kidneys undergoing oxygenated HMP compared with aerated HMP suggest 
oxygenation has a limited role in resuscitation during HMP although the results of clinical 




Application of tracer-based NMR and MS methodology to human cadaveric kidneys during 
HMP prior to transplantation allows for description of de novo metabolism during the 
ischaemic phase of IRI. However, such methodology has never been applied to human 
kidneys prior to transplantation. The results of the CHAMPION study described in Chapter 
7 showed stark differences in de novo metabolism with DCD kidneys displaying higher 
rates of anaerobic metabolism. The extent of anaerobic metabolism may be associated 
with duration of initial warm ischaemic insult. Such changes in metabolism for DCD organs 
are perhaps unsurprising but provide an explanation of why the incidence of DGF is higher 
in DCD kidneys and provides a focus for resuscitation of such organs.  
Optimal duration 
The benefits of HMP in the wider context are due to hypothermia, but in comparison to 
static storage, benefits are due to changes in metabolism as a driving force for reduction 
of IRI, simple mechanistic amelioration of vasospasm and upregulation of protective 
endothelial pathways.  
The duration of HMP after which each of these mechanisms of action exerts clinical benefit 
is likely to differ. For example, endothelial protective methods likely occur as a result of 
upregulation of protective endothelial pathways such as KLF-2 and eNOS, some of which 
also result in vasodilation. Such pathways are unlikely to be upregulated within minutes, 
and likely require several of hours of HMP to take effect. Similarly, in Chapter 6, deviation 
from anaerobic metabolism as a result of oxygenation seemed to occur at 8 hours. Simple 
mechanistic amelioration of vasospasm which occurs during hypothermia is likely to occur 
within the first hour of machine perfusion and it is this mechanism which is likely 
responsible for the change in perfusion parameters in the first instance. As such, the 




duration is likely to differ per mechanism of action and also for each kidney according to 
donor subtype amongst other variables.  
The resuscitative potential of HMP 
The basic principle of hypothermic modalities of organ preservation is a reduction in the 
rate of metabolic reactions. Whilst this reduces organ damage otherwise seen in warm 
ischaemia, it seems rational that the extent to which organs can be resuscitated swiftly is 
limited as deviation towards a different metabolic phenotype is also limited by 
hypothermia. For example, even with oxygenated HMP, 8 hours of perfusion were 
required before differences in de novo metabolites in circulating perfusate were evident. 
However, technologies such as oxygenation (212) alongside the addition of additives such 
as haemoglobin (256) have shown promise in organ resuscitation.  
The limited role of standard HMP in the resuscitation of kidneys is evidenced by the 
predominance of CIT as an independent risk factor for adverse long-term outcomes 
regardless of hypothermic preservation modality in several studies (70, 186, 187, 200).  
Normothermic modalities of organ preservation  
The results of the CHAMPION study (Chapter 7) suggested DCD organs rely on anaerobic 
metabolism compared to DBD organs. Such a switch to anaerobic metabolism likely 
occurs due to initial warm ischaemic insult. Normothermic regional perfusion has the 
potential to reduce this initial warm ischaemic insult in situ prior to cold-flush and 
subsequent preservation in hypothermic conditions.  
Restoration of blood in DCD donors following asystole using the patient’s own blood 




perfusion, considered a form of pre-conditioning as organs remain in situ whilst perfusion 
is commenced. A study by Antoine et al (257) described clinical outcomes of uncontrolled 
DCD donors in France where uncontrolled DCD donors form part of the donor pool, unlike 
the UK. In this study, organs perfused using NRP displayed lower rates of PNF compared 
with those cooled in situ.  
Ex vivo normothermic perfusion (EVNP), first described by Carrel and Lindbergh in 1935 
(50), attempts to simulate the in vivo environment by supplementing explanted organs 
with oxygenated blood whilst maintaining homeostasis. Similar to hypothermic perfusion, 
normothermic perfusion aims to preserve organs ex vivo whilst also providing 
opportunities to assess viability and repair damage. However, whilst hypothermic 
conditions aim to reduce metabolic processes, both types of normothermic perfusion 
preserve and facilitate these processes.  
The benefits of EVNP, whilst shown to be promising in preliminary animal studies (258) 
and those in discarded human kidneys (259), are yet to be reported in randomised trials 
although one such trial is currently underway.  
Future studies and technologies 
Future studies relating to this thesis should explore the relationship between warm 
ischaemia and predominance of anaerobic metabolism further. If, as suggested by data 
in Chapter 7, warm ischaemic insult determines the extent of anaerobic metabolism, there 
may be a greater role for resuscitative technologies in such organs such as oxygenated 




Tracer-based metabolism should easily be applied to the setting of ex vivo normothermic 
perfusion in order to guide its usage and optimise outcome. The results of such studies 
are likely to show a greater degree of aerobic metabolism.  
Recently, the role of mesenchymal stem cells has been explored within the field of renal 
transplantation (260) with evidence that the infusion of such cells has the potential to 
promote an immunomodulatory effect (258, 261, 262) in addition to promoting 
angiogenesis (263) and improving the function of glomeruli and tubuli (264). Studies 
should continue to investigate the role of mesenchymal stem cell infusion on organ 
regeneration. 
Final comments  
Regardless of the method of preservation, the primary aim is to preserve structure and 
function of the kidney with secondary aims of resuscitation and assessment of donor 
kidneys prior to implantation. The organ preservation period is a crucial period in which 
cadaveric kidneys lie dormant, classically in static hypoxic ischaemic conditions. However, 
hypothermic machine perfusion is an alternative established, dynamic method of 
preserving kidneys with observed clinical benefits in well-designed major randomised 
control trials. This thesis aids understanding of its clinical utility and mechanism of action 
with reference to metabolism in addition to showing the benefits of oxygenating circulating 
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Conclusion: Our data suggest that treating kidneys with MitoQ during cold
preservation ameliorates the detrimental effects of IRI and can potentially
improve graft and patient outcomes after kidney transplantation.
Translational Kidney Ischemia-reperfusion and preservation
OS331 HYPOTHERMIC MACHINE PERFUSION FOLLOWING
STATIC COLD STORAGE IN DONATION AFTER
CARDIAC DEATH CADAVERIC KIDNEYS: A UK
POPULATION-BASED COHORT STUDY
Kamlesh Patel, James Hodson, Adnan Sharif, Melanie Field, Jay Nath, Nick
Inston, Andrew Ready
Queen Elizabeth Hospital Birmingham, United Kingdom
Background: Previous systematic reviews have demonstrated the reduction
in delayed graft function (DGF) rates when hypothermic machine perfusion
(HMP) is used to preserve kidneys prior to transplantation. However,
heterogeneity in design of randomised controlled trials, such as the timing of
the start of HMP, may explain why reduction in DGF rates in a Eurozone
population were not demonstrated in a UK study in Donation after Cardiac
Death (DCD) donors.
The aim was to assess the outcome of DCD donor kidneys which undergo a
period of HMP following SCS compared to those which are preserved with SCS
alone.
Methods: A population based cohort study was performed using prospec-
tively collected data from the National Health Service Blood and Transplant
service in the United Kingdom. All adult recipients of single organ DCD kidneys
transplanted between 2007 and 2015 were included.
Results: A total of 4529 DCD kidneys were included in the study with HMP
used in 19.1% of cases (N = 864). HMP usage was found to be in decline over
the period of the study (p < 0.001), from 25.6% of transplants in 2007–2010, to
14.4% of transplants in 2014–2015. Cases where HMP was used had
significantly longer CIT than SCS organs (median: 14.8 vs. 14.1 h,
p < 0.001), and HMP was most commonly used in organs that were re-
perfused with the recipients’ blood during the daytime (8:00–16:59, p < 0.001).
The rate of DGF was found to be significantly lower in organs where HMP
was used, compared to SCS (34.2% vs. 41.9%, p < 0.001). This remained
significant after accounting for potentially confounding factors in a multivariable
analysis, with an odds ratio of 0.64 (95% CI: 0.53–0.78, p < 0.001) for HMP vs.
SCS. Neither patient (p = 0.610) nor graft (p = 0.664) survival were found to
differ significantly between the HMP and SCS cohorts.
Discussion: Our UK population-based study demonstrates the incidence of
delayed graft function can be significantly reduced by a period of HMP in DCD
kidneys, even after a period of SCS.
OS332 EVALUATION OF OUTCOMES IN RENAL
TRANSPLANTATION USING MACHINE PERFUSION
FOR THE PRESERVATION OF KIDNEYS FROM
EXPANDED CRITERIA DONORS
Emilie Savoye1, Marie-Alice Macher1, Michel Videcocq2, P Gatault3, M.
Hazzan4, I Abboud5, Antoine Thierry6, Isabelle Etienne7, S Drouin8, J Sayegh9,
Olivier Bastien1, Christian Lamotte1, H!el"ene Logerot1, Camille Legeai1,
Corinne Antoine1
1Agence De La Biom!edecine, France; 2Chu Nantes, France; 3Chu Tours,
France; 4Chu Lille, France; 5Chu Saint Louis Paris, France; 6Chu Poitier,
France; 7Chu Rouen, France; 8Chu La Piti!e Salp!etri"ere Paris, France; 9Chu
Anger, France
Introduction: The shortage of kidney grafts led to retrieve organs from old
donors with one or more co-morbidities, considered as “expanded criteria
donors” (ECD). In France, since 2012, the Agency of biomedicine (ABM) has
recommended the use of machines perfusion (MP) to preserve kidneys from
this donor population to improve kidney preservation and the transplantation
outcomes, with the creation of a specific lump sum financing the additional
costs of this strategy. This study evaluates the impact of MP vs. cold storage
(CS), for the period 2011–2014 with kidneys from ECD.
Methods: From the ABM database (Cristal), the effect of MP on the delayed
graft function (DGF) was analyzed using a multivariate logistic model excluding
pre-emptive transplants and primary non functions (PNF). In addition, trans-
plants from the same donor, whose one kidney preserved by MP and the other
by CS (population of twins), were analyzed using a mixed model.
Results: Co-morbidities of recipients are more frequent and the age of donors
and recipients is significantly higher for kidney preserved by MP (n = 801) vs.
CS (n = 3515). With 16% of DGF for MP vs. 29% for CS, MP has a protective
effect on the DGF (OR adjusted = 0.45, CI [0.36, 0.56]). In the population of the
twins (84 pairs, 168 grafts), we observed 7% of DGF for MP vs. 33% for CS and
an adjusted OR 0.19 (CI [0.06; 0.58]). The durations of hospitalization and
dialysis after transplantation are shorter with fewer sessions of dialysis.
Discussion: Our results confirm the reduction in the incidence of the DGF of
ECD kidneys preserved by machines, with 2.2 times less risk despite a
population more at risk in this group, and a lower 5.2 times risk in the population
of the kidneys “twins”. It remains to assess the impact of the DGF in the long
term survival and measure the cost effectiveness of this strategy.
Clinical Kidney Ischemia-reperfusion and preservation
OS333 EXTENDED EX-VIVO NORMOTHERMIC HUMAN KIDNEY
PERFUSION USING AN ARTIFICIAL OXYGEN CARRIER
Fermin Fontan, Mohamed Aburawi, Negin Karimian, Heidi Yeh, Korkut Uygun,
James Markmann
Harvard Medical School Massachusetts General Hospital, United States
Background: Hypothermic machine perfusion (HMP) is commonly used in
kidney preservation, providing some advantage over static cold storage. How-
ever, the low temperature offers little opportunity to improve organ quality or to
obtain functional data. We therefore established an oxygenated normothermic
machine perfusion (NMP) system to investigate the possibility of rescuing
discarded kidneys.
Methods/materials: Pressure and temperature controlled NMP with an
enriched media and Hemopure (bovine hemoglobin-based oxygen carrier)
was used to perfuse 9 human kidneys deemed un-transplantable by all
transplant centers. The average cold ischemia time (CIT) was 21 h. The grafts
were discarded for different reasons, including poor performance on the HMP
pump, concerning biopsy results, poor flush, fail to allocate the organ, and
surgical damage to the hilum. Organs from donation after circulatory and brain
death were accepted. Kidneys were perfused for up to 12 hrs. Different
metabolic markers, functional parameters and macroscopic assessment mea-
surements were recorded throughout the perfusion session.
Results: Renal artery flow/resistance showed a sustained improvement
throughout the perfusion period. The maintenance of a relatively physiologic
pH/bicarbonate level and the arterio-venous oxygen difference showed
evidence of significant metabolic activity. Only the last three kidneys in our
series produced significant amounts of urine; this correlated with removing the
albumin aiming to assess the implications of decreasing the oncotic pressure of
the perfusate.
Conclusions: Our ongoing series results are notable for a significant
metabolic activity, favorable functional parameters and macroscopic charac-
teristics; in addition to urine production suggesting that some of these kidneys
could have been used for transplantation. ATP and pathology results are
pending, which will likely add more information for us to more accurately
catalog these grafts and theorize which ones could be implanted.
Translational Kidney Ischemia-reperfusion and preservation
OS334 DEVELOPMENT OF AN AUTOMATIC REGULATED
NORMOTHERMIC KIDNEY PRESERVATION DEVICE
FOR LONG-TERM PERFUSION
Annemarie Weissenbacher1, Letizia Lo Faro2, Olga Boubriak3, James Hunter1,
Rutger Ploeg1, Nikolay Mikov4, Andrew Cook4, Daniel Voyce4, Constantin
Coussios3, Peter Friend1
1Oxford Transplant Centre Nuffield Department of Surgical Sciences, United
Kingdom; 2Oxford Transplant Centre, Nuffield Department of Surgical
Sciences, Oxford University, United Kingdom; 3Institute of Biomedical
Engineering Department of Engineering Science University of Oxford, United
Kingdom; 4Organox Limited Oxford Science Park Magdalen Centre, United
Kingdom
Background: Normothermic kidney perfusion for a period of 24 h or longer
could offer significant clinical advantages. It would enable clinicians to
investigate the condition of renal parenchyma during the warm preservation
period and provide a platform for repairing kidneys that are currently discarded.
This would enlarge the donor pool and enable more successful renal
transplants.
Methods: We have established an automated closed circuit normothermic
kidney perfusion (NKP) prototype, with the objective of perfusing human
kidneys for 24 h.
Results: Twenty-one discarded human kidneys from DBD (donation after
brain death) and DCD (donation after cardiac death) donors were perfused and
functional parameters were proven stable and physiological. Median perfusion
time was 15 h (1.5–24.4). Eight kidneys were perfused for 24 h. Cold ischemia
time (CIT) was significantly longer in DCD compared to DBD; p = 0.033.
Median CIT was 25.3 h (8.1–106). DCD kidneys (601.7 ! 150 ml) produced
more urine than DBDs (285 ! 95.74 ml) but this was not significant; p = 0.17.
Urinary output was significantly correlated with warm ischemia time in DCD;
p = 0.018. Measured biochemical parameters included glucose, lactate,
NGAL, KIM-1 and L-FABP. All but one perfused kidneys showed clear
Oral Presentations Abstracts of the 18th Congress of the European Society for Organ Transplantation
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NRES Committee East Midlands - Leicester 
The Old Chapel 




Telephone: 0115 8839436 
07 September 2015 
 
Mr Jay Nath 






Dear Mr Nath  
 
Study title: A study to determine the metabolic effects of machine 
perfusion on cadaveric kidneys for transplantation.   
REC reference: 15/EM/0328 
Protocol number: 1 
IRAS project ID: 184195 
 
Thank you for your letter of 28 August 2015, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information,  please contact 
the REC Assistant,  Joanne Unsworth, nrescommittee.eastmidlands-leicester@nhs.net. 
Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the study.  
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website.   
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 






The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Covering letter on headed paper [Covering letter explaining changes 
to PIS]  
  26 August 2015  
IRAS Checklist XML [Checklist_08072015]    08 July 2015  
IRAS Checklist XML [Checklist_28082015]    28 August 2015  
Participant consent form [Consent form]  1  01 June 2015  
Participant consent form [Revised consent form]  V1.1  20 August 2015  
Participant information sheet (PIS) [Information Sheet]  1  01 June 2015  
Participant information sheet (PIS) [Revised PIS]  V1.1  20 August 2015  
Participant information sheet (PIS) [PIS with changes explained]    20 August 2015  
REC Application Form [REC_Form_08072015]    08 July 2015  
Research protocol or project proposal [Protocol]  1  01 June 2015  
Summary CV for Chief Investigator (CI) [CV Jay Nath]  1  06 July 2015  
Summary CV for student [CV Jay Nath]  1  06 July 2015  
Summary CV for supervisor (student research) [CV Supervisor]  1  06 July 2015  
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language [Protocol Flowsheet]  
1  01 June 2015  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 




We are pleased to welcome researchers and R&D staff at our training days – see details at 
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Copy to: Mr Jay Nath 
Dr Chris Counsell, Research and Development Office 
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Head of R&D Governance: Dr Christopher Counsell 
Head of R&D Operations: Joanne Plumb 
R&D Office, 1st Floor, ITM, Heritage Building, Queen Elizabeth Hospital Birmingham, Edgbaston 
Birmingham B15 2WG 
Tel: 0121 371 4185 Fax:0121 371 4204 Email: R&D@uhb.nhs.uk 
Website: www.research.uhb.nhs.uk 






Mr N. Inston 
Consultant Surgeon 
Department of Renal Transplantation & Nephrology 
Queen Elizabeth Hospital 
UHB 
 
UHB Research Governance Office 
1st Floor, Institute of Translational Medicine 
Heritage Building 
Queen Elizabeth Hospital Birmingham 
Mindelsohn Way 
Edgbaston 
Birmingham B15 2WG 
Tel. 0121 371 4185 
Fax 0121 371 4204 
 
 
Research Project Authorisation 
Project reference:RRK 5478 
Main Ethics 
Committee Reference 
15/EM/0328    
IRAS Project ID      
 
 
24 November 2015 
 
Dear Mr Inston 
 
A Study to Determine the Metabolic effects of Machine Perfusion on Cadaveric Kidneys for Transplantation 
 
Thank you for submitting details of your proposed research project, which I am happy to authorise on behalf of 
University Hospitals Birmingham. The following main document versions were reviewed (note this is not a complete 
list of all documents submitted):  
 
Protocol - version: V1 01/06/15 
Participant information sheet (main) - version: V1 20/08/15 




University Hospitals Birmingham NHS Trust has agreed to act as sponsor for this study. We believe this is a single site 
study. If you wish to include sites outside University Hospitals Birmingham then you must provide details of potential 
sites to the R&D Office, the main research ethics committee, and if necessary to the regulatory authorities. Note, 
however, that sites outside University Hospitals Birmingham must not start recruiting into the study until there has been 
formal authorisation from the R&D Office at University Hospitals Birmingham. We will require a copy of the approval 
letter from the R&D Department of the relevant Trust. If the study is a clinical trial of a medicine then we will also 
require a signed clinical trial agreement which we will draw up between UHB and the other Trust; for other types of 
study a clinical study agreement would not normally be required. 
 
Indemnity arrangements. 
Researchers who hold substantive or honorary contracts with University Hospital Birmingham (UHBT) will be covered 
against claims of negligence by patients of UHBT under the Clinical Negligence Scheme for Trusts (CNST). This 
scheme does not cover ‘no fault’ compensation and the Trust is precluded from taking out separate insurance to cover 
this. Any patient or volunteer taking part in the study is entitled to know that if they suffered injury as a result of 






Head of R&D Governance: Dr Christopher Counsell 
Head of R&D Operations: Joanne Plumb 
R&D Office, 1st Floor, ITM, Heritage Building, Queen Elizabeth Hospital Birmingham, Edgbaston 
Birmingham B15 2WG 
Tel: 0121 371 4185 Fax:0121 371 4204 Email: R&D@uhb.nhs.uk 
Website: www.research.uhb.nhs.uk 
Projects database: //uhb/userdata/R & D/R&D database/distributed database 2002.mdb 
 
 
participating in the study they would first have to prove negligence in a court of law before they could gain 
compensation. 
 
If the study involves patients of any other Trust or healthcare organisation, you will need to confirm the indemnity 
arrangements with that organisation. 
 
Pharmacy 




Any medical devices used specifically for this study, whether purchased, loaned or borrowed must be registered with 
the Medical Engineering Department. Equipment must not be used until it has completed formal acceptance testing by 
Medical Engineering. A calibration and maintenance schedule must be drawn up and agreed with Medical Engineering 
in accordance with the manufacturer’s recommendations. There should be a formal maintenance contract in place if 
maintenance is to be carried out by external contractors (including the equipment manufacturers). If, at the end of the 
study, the equipment is transferred or disposed of, details must be sent to Medical Engineering to amend the equipment 
asset register.    
 
Reporting Adverse Events 
If this study involves an intervention in the treatment of patients then you must ensure that any serious adverse events, 
regardless of whether you believe the event is related to the research or the intervention, are reported according to 
the Trust’s policy on reporting research-related adverse events.  Please see attached memo. Note that you must also 
follow any SAE reporting requirements stipulated by the sponsor. 
 
A copy of the Trust policy may be obtained from the R&D office and is also available on the R&D section of the 
Trust’s intranet and internet sites. A copy of a blank SAE form is enclosed, this may be used if it is not possible to 
report the event through the Trust’s online reporting system. 
 
Drugs and Treatment outside the study 
Approval for the study to commence cannot be taken to imply approval for the same form of treatment to continue 
beyond the end of the study, or for patients who are not part of the study. If it is likely that continuing treatment is 
required at the end of the study, then it is the Principal Investigator’s responsibility to ensure that study participants are 
fully aware of the types of treatment that would be available to them. 
 
Research Governance 
You should ensure that you and your research team abide by the Trust policies on research governance. These are 




You must set up and maintain a study file containing the essential documents needed to facilitate a full audit of the 
conduct of the study. The minimum requirements for the content and layout of the study file are set out in the enclosed 
documents. This file may be audited at short notice by the R&D Office, the sponsor, or regulatory authorities. 






Head of R&D Governance: Dr Christopher Counsell 
Head of R&D Operations: Joanne Plumb 
R&D Office, 1st Floor, ITM, Heritage Building, Queen Elizabeth Hospital Birmingham, Edgbaston 
Birmingham B15 2WG 
Tel: 0121 371 4185 Fax:0121 371 4204 Email: R&D@uhb.nhs.uk 
Website: www.research.uhb.nhs.uk 




Delegated Duties Log 
You must maintain a list of all those people who have responsibility for delivering any study-related tasks set out in the 
protocol. The log must list the names of the individuals, their roles and responsibilities, the date they started working on 
the study, and, if appropriate, the date they finished. Each entry must be signed by the person accepting the 
responsibilities. Note that anyone who is involved in the direct care of patients must hold a substantive or honorary 
contract with University Hospitals Birmingham. 
 
Accrual Records 
It is essential that you maintain up-to-date and accurate records of recruitment and participation in your study. You will 
be asked to provide these figures as part of the annual reporting and on request at other times during the year. For 
studies registered on the UKCRN portfolio, you are expected to provide regular accrual data to the Chief Investigator 
who will submit them to the UKCRN. You should keep an anonymised record, with dates, of patients approached, 
consented, screened, recruited, completed, and dropped out as appropriate. 
 
PICS 
Research studies are now listed on a separate research tab on the trust’s Prescribing, Information and Communication 
System (PICS). When a participant is screened or recruited into this study you must ensure that this is promptly 




The R&D Office will request information about progress with the study in 6 months, 12 months and annually thereafter. 
Approval for this study may be withdrawn if you do not complete and return reports when requested. 
 
Protocol Breaches 
Serious protocol breaches must be reported to the R&D office as soon as possible and must be notified to the Chief 
Investigator and Sponsor immediately you become aware of them. If you are the Chief Investigator you must notify the 
Ethics Committee within 7 days and, for CTIMP studies, you must notify the MHRA within 7 days. A serious breach is 
one that is likely to affect to a significant degree the mental or physical integrity of the research participants or the 
scientific value of the study. A report of a serious breach should identify measures taken to correct the consequences of 
the breach and measures to prevent future similar breaches ( a so-called ‘CAPA’ log). Minor protocol breaches should 
be recorded in your study file. 
 
Urgent Safety Measure 
If necessary, appropriate urgent safety measure to protect clinical trial subjects from any immediate hazard to their 
health and safety can be taken immediately without waiting for Ethics Committee, Regulatory Authority or R&D 
approval. However you must inform the R&D Office, Chief Investigator, Sponsor, Ethics Committee and MHRA, as 
appropriate, in writing within 3 days. 
 
Protocol Amendments 
Trust approval will usually automatically cover minor protocol amendments but you must send details to the R&D 
office for information. Details of all substantial amendments must be sent to the R&D Office for authorisation together 
with copies of the ethics approval and/or regulatory approval for the amendments and any revised documentation. The 
R&D office will acknowledge all amendments. A substantial amendment is defined by NRES (the National Research 
Ethics Service) and would include any change that could affect the safety, conduct or the resource implications of the 
study. 
 






Head of R&D Governance: Dr Christopher Counsell 
Head of R&D Operations: Joanne Plumb 
R&D Office, 1st Floor, ITM, Heritage Building, Queen Elizabeth Hospital Birmingham, Edgbaston 
Birmingham B15 2WG 
Tel: 0121 371 4185 Fax:0121 371 4204 Email: R&D@uhb.nhs.uk 
Website: www.research.uhb.nhs.uk 




It is expected that the study will begin at University Hospital Birmingham within 12 months of Trust authorisation. If 
there is a long delay in starting the study, the Trust may consider withdrawing authorisation for the study. Unless 
explicitly withdrawn, Trust approval lasts for as long as the study has valid ethics committee and regulatory approval. 
 
End of Study 
According to information you have provided, this study is expected to end in August 2018 and the minimum 
recruitment target is 75. The R&D Office will request a final report shortly after this date. If the study ends for any 
reason before this date you must notify the R&D Office. Note that the Chief Investigator for the whole study is required 
to provide an end of study report to the main research ethics committee and regulatory authorities. 
 
Archiving 
For studies designated as a Clinical Trial of an Investigational Medicinal Product (CTIMP), it is a legal requirement to 
retain essential documents for at least 5 years after the declared end of the study. The sponsor or regulatory authorities 
may insist on a longer retention period for a particular study. For all other types of study there are no statutory 
requirements but generally accepted good practice guidelines recommend that documents are retained for at least 5 
years. Documents must be archived in a way such that they can be readily accessed (24 hours notice) if required for 
audits or regulatory purposes. The costs of archiving is borne by the Principal or Lead Investigator and should be taken 
into account when applying for research grants or seeking other forms of funding. For CTIMPs, there must be a named 
archivist, approved by the sponsor, who is responsible for setting up and controlling the archive. 
 
Health Records Labelling 
The Health Records of study subjects are retained according to the Trust’s “Health Records Management Policy”; for 
patients in research studies the retention period is 15 years after the last treatment or consultation related to the study. 
The Principal Investigator must ensure that all records for patients involved in a study are clearly labelled to ensure that 
the retention policy can be followed. 
 
Cover for absence 
If the Principal Investigator is likely to be absent and out of contact for a prolonged period (> 2 weeks), the PI must 
either explicitly suspend patient recruitment and patient-related activity in the study, or explicitly delegate the 
responsibilities of Principal Investigator to a named deputy. The PI must be satisfied that their deputy is sufficiently 
qualified through education, training and experience to take on the role of PI. These periods of absence and delegation 
must be recorded in the study file. 
 
Website entry 




The Trust R&D Office has developed a Powerpoint-based tool summarising some of the regulations relevant to clinical 
research. This is available at \\uhb\userdata\R & D\R&D Shared Docs\Guide to Responsibilities\Guide to Investigator 
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Dr Christopher Counsell 
Head of R&D Governance 
 
Enclosed: Sample study file layout 
  Incident Reporting & Serious Adverse Event Form 
 
Copies to: }Dr Nath  
 Relevant Service Departments 
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CONSENT FORM FOR RESEARCH STUDY 
 
 
Effects of Machine Perfusion on Cadaveric Kidneys for Transplantation 
 
 
Name of researchers: Mr Nicholas Inston,,Mr Jay Nath, Mr Kamlesh Patel  
 
             
 
• I confirm that I have read and understood the information sheet version ……….….Date…….…….. 











• I understand that my participation is voluntary and that I am free to withdraw at any time, without giving 





• I understand that relevant sections of any of my medical notes and data collected during the study may be 
looked at by researchers, from regulatory authorities or from the NHS Trust, where it is relevant to my 
















 Date  Signature 
Name of Person taking consent (if 
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It	 has	 been	 standard	 practice	 to	 flush	 transplant	 kidneys	 with	 fluid	 using	 a	
specialised	 machine	 for	 over	 five	 years	 and	 is	 recommended	 in	 national	
guidelines.	 	We	 are	 undertaking	 this	 research	 to	 help	 us	 understand	 how	 the	
flushing	process	benefits	the	kidney	at	a	metabolic	level.	
To	better	understand	this,	one	of	 the	components	of	 the	 fluid	used	to	 flush	the	










We	 need	 your	 permission	 to	 take	 part	 in	 the	 study.	 This	 will	 include	 using	














The	 risk	 associated	 with	 kidney	 biopsy	 is	 very	 small	 and	 is	 a	 test	 performed	
routinely	for	non-research	purposes.	We	have	had	no	serious	problems	with	this	
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Funding	




All	 you	 need	 to	 do	 to	 take	 part	 is	 to	 agree	 and	 sign	 the	 consent	 form.	 It	 is	
important	 to	 take	 the	 time	 to	 read	 this	 information	and	ask	any	questions	you	
have.	Once	you	have	agreed	to	be	in	the	study	the	information	will	be	collected.	
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